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Abstract  
 
Working as agents for their patients, health care providers often make treatment decisions 
on the patient’s behalf. By establishing common standards, clinical guidelines are central 
to efforts to improve patient care and can expedite the introduction of new technologies. 
Each year considerable resources are used to disseminate clinical guidelines, though 
conventional public health interventions often have a limited effect in changing providers’ 
practice.  
Using economic theory and methods, research was undertaken to design and evaluate 
interventions to support the roll-out of malaria rapid diagnostic testing. This thesis 
contains five research papers on providers’ knowledge, preference and practice in treating 
patients with malaria symptoms in Cameroon and Nigeria. In this setting, uncomplicated 
malaria is routinely diagnosed and treated by health workers in outpatient departments 
and primary health centres, or self-treated using antimalarials purchased at pharmacies 
and drug stores.  
Major problems with malaria diagnosis and treatment were identified. Relatively few 
febrile patients were tested for malaria, many did not receive the recommended 
antimalarial, and when patients were tested for malaria the test result was often ignored 
when treatment was prescribed. Moreover, there was no significant relationship between 
providers’ knowledge and their practice, and preferences over alternative antimalarials 
were similar among providers working in the same facility or locality.   
The results of a cluster randomized trial in Cameroon demonstrated that introducing rapid 
diagnostic tests with enhanced training, which targeted providers’ practice, was more 
cost-effective than introducing rapid diagnostic tests with basic training, when each was 
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compared to current practice. Since the trial concluded, the Ministry of Health has 
incorporated the enhanced training in the nationwide roll-out of rapid diagnostic testing. 
The findings are also relevant for policy makers elsewhere, and highlight the value in 
developing strategies to improve providers’ adherence to malaria treatment guidelines 
when expanding access to malaria testing.
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Useful terminology 
 
Febrile illness 
Malaria is clinically suspected on the basis of fever or a history of fever since the signs and 
symptoms of malaria are nonspecific. In settings where the risk of malaria is high (which 
includes Cameroon and Nigeria), malaria should be suspected in patients that present with 
a fever or history of fever in the past 24 hours. Diagnosis based on clinical features alone 
has very low specificity and results in over-treatment. The World Health Organization 
(WHO) recommends parasitological confirmation of malaria in all patients before 
treatment is prescribed. Other possible causes of fever and the need for alternative or 
additional treatment should be carefully considered.  
Uncomplicated Malaria 
Malaria is caused by infection of red blood cells with protozoan parasites of the genus 
Plasmodium. The parasites are inoculated into the human host by a feeding female 
anopheles mosquito. The WHO defines uncomplicated malaria as a symptomatic infection 
with malaria parasitaemia without signs of severity and/or evidence of vital organ 
dysfunction.  
National Malaria Treatment Guidelines 
In many countries (including Cameroon and Nigeria), national governments develop 
malaria treatment guidelines to advise how malaria should be diagnosed and what 
treatment is recommended. National guidelines are usually based on guidance published 
by the WHO and the local epidemiological setting. The guidelines establish a common 
standard which providers are expected to adhere to.  
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Malaria Diagnosis 
Malaria can be confirmed using microscopy, which involves examining thick and thin 
blood slides under a microscope, or using a rapid diagnostic test (RDT), which is an 
antigen-based stick in which a coloured line indicates that plasmodial antigens have been 
detected. The WHO recommends prompt parasitological confirmation by microscopy or 
alternatively by RDT in all patients suspected of malaria before treatment is started. 
Treatment solely on the basis of clinical suspicion should only be considered when a 
parasitological diagnosis is not accessible.  
Malaria Treatment 
Malaria is treated using medicines known as antimalarials. There are different types of 
antimalarials, and the artemisinin combination therapy (see below) is the recommended 
first-line treatment for uncomplicated malaria through sub-Saharan Africa. Other types of 
antimalarial include: amodiaquine, chloroquine, sulphadoxine-pyrimethamine, quinine 
and artemisinin-monotherapy. 
Artemisinin Combination Therapy (ACT) 
ACT is the recommended first-line treatment for uncomplicated malaria. It is a 
combination of artemisinin or one of its derivatives with an antimalarial or antimalarials 
of a different class. The different generic types of ACT are: artemether-lumefantrine (AL); 
artesunate-amodiaquine (ASAQ); artesunate-mefloquine (ASMQ); artesunate-
sulphadoxine-pyrimethamine (ASSP); and dihydroartemisinin-piperquine (DHAPQ). For 
each type there are multiple brands available. The most widely used brands include 
Coartem and Coarsucam.  
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Preface  
 
This PhD thesis includes a collection of research papers. These papers are related, though 
they have been published, or submitted, as independent research contributions. As a 
result some information has been repeated and the terminology used is not uniformly 
consistent. The term ‘provider’ is used in many of the papers to refer to the individual 
health worker providing treatment, though in some instances health worker, clinician, 
doctor, nurse, pharmacist, patent medicine dealer and medicine retailer have been used. 
Similarly, facility and outlet have been used to refer to an organization where malaria 
treatment may be obtained, and may collectively include hospital outpatient departments, 
health centres, clinics, pharmacies and drug stores. However, in some instances, facility 
refers to public and mission hospitals and health centres. The term medicine retailer has 
also been used to refer collectively to private sector retail outlets, including pharmacies, 
drug stores, and patent medicine dealers. I should also add that having married in 2012 I 
changed my name, and my thesis includes papers authored as Lindsay Mangham and as 
Lindsay Mangham-Jefferies.
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1. Introduction 
1.1 Malaria diagnosis and treatment in sub-Saharan Africa  
Malaria is a major cause of mortality and morbidity in sub-Saharan Africa and an 
integrated strategy is recommended that combines preventive measures with prompt 
access to effective treatment [1]. Malaria places an enormous burden on the health system, 
and in areas of medium-to-high transmission, malaria should be suspected in all 
individuals who present with a fever, or had a fever in the past 24 hours. In sub-Saharan 
Africa, antimalarials may be obtained from a variety of facilities and outlets, including 
government and mission hospitals and health centres, private clinics, pharmacies, drug 
stores, general stores and itinerant medicine vendors. Individuals may also seek treatment 
from herbalists and traditional healers.  
Uncomplicated malaria is routinely treated by health workers in outpatient departments 
and at the primary care level, though severe cases should be referred and admitted for 
inpatient care. Responsibilities for prescribing malaria treatment span a range of cadres, 
and nurses and junior staff often prescribe treatment in primary care facilities [2].  
Self-treatment of uncomplicated malaria is also common, and many cases are treated at 
home using antimalarials left-over from previous illness or bought at retail outlets. Retail 
outlets are a major source of antimalarials [3-5]. Pharmacies are regulated and licensed to 
sell both prescription-only and over-the-counter medicines under the supervision of a 
qualified pharmacist, though clients may be served by staff without formal pharmacy 
training [6-8]. The legal status of drug stores varies; they are often permitted to sell a 
limited range of products, and can be owned and managed by someone without clinical or 
pharmacy qualifications [7, 9-12]. In some settings, antimalarials can also be purchased at 
general stores, or obtained from itinerant medicine sellers [5]. 
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The resources available for diagnosing malaria vary by type of facility. Parasitological 
testing is available at hospitals and larger facilities, though health workers at many 
primary care facilities routinely diagnose malaria on the basis of clinical symptoms [13]. 
1.2 Clinical guidelines for the diagnosis and treatment of malaria 
The World Health Organization (WHO) publishes clinical guidelines for the diagnosis and 
treatment of malaria based on biomedical evidence on the efficacy and safety of diagnostic 
methods and antimalarial medicines [1, 14].  There have been two major changes to 
malaria treatment guidelines over the last decade. First, artemisinin combination therapy 
(ACT) became the recommended treatment for uncomplicated malaria following evidence 
of resistance to older alternative antimalarials, such as chloroquine and sulphadoxine-
pyrimethamine (SP). ACT has been widely adopted, and it is now the first-line treatment 
for uncomplicated malaria throughout sub-Saharan Africa. It comes in five generic 
combinations: artemether-lumefrantrine, artesunate-amodiaquine, artesunate-
mefloquine, artesunate-sulphadoxine-pyrimethamine, and dihydroartemisinin-
piperquine. Quinine and artemisinin-monotherapy can also be used to treat malaria, 
though they should be reserved for cases of severe malaria. 
Second, in 2010 the WHO updated malaria treatment guidelines to recommend 
parasitological testing of all febrile patients before treatment is prescribed and confirm 
rapid diagnostic tests (RDTs) are a valid alternative to microscopy [1]. Parasitological 
testing was previously encouraged, since clinical symptoms are non-specific and the fever 
may have other causes [1], however, access to microscopy testing was limited by the 
availability of laboratory equipment and technicians able to prepare and read blood slides. 
In the absence of a malaria test presumptive malaria treatment is advised for febrile 
patients [13, 14]. As a result, it is common for antimalarials to be consumed based on 
symptoms alone.  
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RDTs offer considerable potential to expand access to malaria testing and reduce the over-
consumption of antimalarials, since they require minimal infrastructure and training [15]. 
Interest in RDTs has grown substantially in recent years and governments across sub-
Saharan Africa are now deciding how to expand access to malaria testing and whether to 
introduce RDTs in health facilities that already offer microscopy testing. These policy 
decisions will require governments to revise national malaria treatment guidelines, and 
consider what interventions could be used to expedite the introduction of RDTs and 
ensure policy changes are accompanied by changes in providers’ practice. 
1.3 Providers’ knowledge, preference and practice in diagnosing and 
treating uncomplicated malaria  
Ensuring providers adhere to clinical guidelines is essential for delivering high quality 
patient care. National malaria treatment guidelines can be used to assess the quality of 
malaria case management and the performance of health care providers. Although many 
studies describe access to clinical guidelines and in-service training, relatively few report 
on providers’ knowledge of malaria treatment. Similarly, limited attention has been given 
to understanding providers’ preferences, such as how they prefer to diagnose malaria and 
what treatment they prefer to give. Economic theory suggests providers frequently act as 
agents and make decisions on behalf of their patients. This agency relationship arises 
when patients lack information to diagnose the illness and select treatment. It is 
important, therefore, to understand providers’ preference over different diagnostic 
methods or which antimalarial they prefer to supply, and who and what influences their 
preference. It can also be helpful to distinguish between providers’ stated and revealed 
preference. Their stated preference would reflect the providers’ choice in the absence of 
constraints, such as the resources available at the facility, the patients’ ability to pay or 
specific information about the patient. In contrast, their revealed preference reflects their 
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actual choice given the prevailing constraints, and is more commonly referred to as their 
practice. 
Available evidence indicates considerable variation in providers’ knowledge across 
geographies and types of facility within sub-Saharan Africa. In Kenya, six months after ACT 
became the first-line antimalarial, 70% of government health workers were aware of the 
new drug policy, while in Cameroon more than a year after the policy change less than 
15% of health workers knew the recommended antimalarial [16-18]. Concerns have been 
expressed about the knowledge of medicine retailers [10, 19-23]. In a recent study from 
Kenya, 65% of medicine retailers correctly identified artemether-lumefantrine (AL) as the 
first-line treatment, though only 48% would recommend AL to adults and 37% would 
recommend AL to children [23]. Also, medicine retailers in Nigeria have expressed 
confusion over antimalarials and antipyretics, and the correct antimalarial doses for 
children [11]. 
For many years, the literature on malaria case management was dominated by studies that 
described treatment following a symptomatic diagnosis and demonstrated problems with 
the choice of antimalarial [16, 24-35]. Studies undertaken since ACT became the first-line 
antimalarial have shown providers in government and mission facilities were slow to 
change their practice and prescribe ACT [16, 32, 35]. Providers’ practice tends to improve 
over time, though surveys undertaken up to four years after the policy change found not 
all febrile children were prescribed the recommended antimalarial [16, 32, 36, 37]. There 
were also problems with ACT dispensing, with under-dosing common among children 
weighing 15-24kg and inadequate advice on the regimen [16, 32, 35]. Problems with the 
treatment supplied were also found at medicine retailers in Kenya, Nigeria, Tanzania, and 
Uganda, where less than half of mystery clients seeking malaria treatment were advised to 
buy the type of antimalarial recommended by the government [11, 22, 29, 30, 38-45]. 
Similarly, in 2010 only 39% of febrile patients at drug shops in Uganda received an ACT 
[38].  
1. INTRODUCTION 
23 
 
Several recent studies on malaria case management have focused on treatment following a 
malaria test [33, 36, 46-54].  The emphasis given to appropriate treatment reflects 
advanced in rapid diagnostic testing and concerns about the cost of ACT, as well as 
possible risks associated with missing non-malaria causes of febrile illness, and the 
potential to accelerate artemisinin resistance [55]. While these are powerful arguments 
for testing for malaria before supplying antimalarials, studies have shown diagnostic 
testing is often underused and antimalarials are often prescribed to patients with a 
negative malaria test. For example, in Kenya, only 43% of febrile patients attending 
government facilities with microscopy available were tested for malaria, and antimalarials 
were prescribed to 61% of cases with a negative blood slide [33]. Evidence of providers 
prescribing antimalarials to test-negative patients also occurred in Malawian, Tanzanian 
and Zambian health facilities that had diagnostic testing available (either with microscopy 
or RDT) and had ACT in stock [52-54]. However, there is some evidence of improvement 
over time, as cross-sectional surveys conducted at health facilities in Tanzania showed the 
national roll-out of RDTs was associated with an increase (from 16% to 55%) in the 
percentage of febrile patients tested for malaria, and a significant reduction (from 43% to 
18%) in the overuse of ACT in patients without malaria parasites [56]. 
To design effective interventions and improve the quality of malaria case management, it 
is important to understand the influences on providers’ practice. Qualitative methods have 
been used to study the practice of health workers and medicine retailers [57-65]. For 
instance, Kenyan nurses were interviewed to investigate why ACT was infrequently 
prescribed [59]. The nurses expressed positive perceptions about the efficacy and safety of 
ACT, though explained they would reserve ACT for patients under five years or with more 
severe symptoms because of concerns about the government’s ability to sustain supply. 
Nurses also mentioned that patients may have preferences over different antimalarials, 
and with staff shortages and a busy workload there may be insufficient time to explain the 
treatment regimen. Other qualitative studies focused on providers’ perceptions of RDTs 
and reasons why providers prescribed antimalarials to test-negative patients [57, 58, 62]. 
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Many providers recognised the advantages of malaria testing, though they also expressed 
a lack of trust in test results and explained it would indefensible to miss a malaria case 
[57]. Providers’ preferences were shaped by their initial training and their peers, but also 
by their patients, as providers noted a malaria diagnosis was often expected and readily 
accepted by their patients [58]. 
Influences on providers’ practice has also been explored using quantitative methods, and 
logistic regression has been used to determine whether the treatment prescribed to febrile 
patients was associated with patient, provider or health facility characteristics [22, 24, 25, 
31, 33-35, 38, 46, 66-69]. The presence of a fever or high temperature was positively 
associated with decisions to undertake a malaria test, treat for malaria, and prescribe the 
recommended treatment. Access to in-service training, malaria treatment guidelines, wall 
charts, and supervision were positively associated with the choice of antimalarial in some 
but not all studies. The effect of pre-service training, work experience, case load, 
consultation time, the age of the patient, and the level of facility also had mixed results on 
providers’ decision to test for malaria and their choice of treatment.  
While the evidence available on the quality of malaria case-management at different types 
of health facility and by different types of provider is reasonably extensive, some 
questions remain. The relationship between providers’ knowledge and practice is not well 
understood; although some evidence suggests access to in-service training, job aids and 
clinical guidelines can have a positive effect on choice of treatment, the overall findings 
were mixed. We also have very little information on providers’ stated preference, and 
understanding their preference may help to explain differences between providers’ 
knowledge and practice and identify new approaches to intervention. Thus, we cannot 
assume efforts to disseminate malaria treatment policy will necessarily change providers’ 
knowledge of the guidelines, the type of treatment that providers’ prefer to supply, or the 
treatment actually supplied to febrile patients. It is also important to understand the 
degree to which providers are constrained resources available at the health facility or 
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outlet, the patient’s ability to pay for treatment, or aspects of the institutional environment 
in which they work. 
1.4  Aims and objectives  
In this thesis I examine the care received by febrile patients seeking treatment at different 
types of facility in Cameroon and Nigeria. The research focuses on providers’ knowledge, 
preference and practice and approaches a common public health problem, how to improve 
providers’ adherence to clinical guidelines, from an economics perspective. This 
perspective has considerable potential to offer new insights, though alternative theories 
are available from other disciplines that could be applied to examine the practice of health 
care providers. For instance, psychology has a range of theories on behaviour change, such 
as the expectancy-value theory, theory of reasoned behaviour, attitude-behaviour-context 
theory and normative conduct theory [70-72]. Some of these theories focus on individual 
motivation and are based on expectations and values, while others emphasize social 
influences and external contextual factors. There are also theories on human behaviour in 
sociology, such as those that consider the role of social expectations and trust [73-75], and 
anthropological models of behaviour change, such as social learning theory in which 
behaviour change results from observing and imitating others [76]. 
Within the economics literature, analysis of human behaviour is often founded on rational 
choice theory, which assumes individuals make deliberative choices between distinct 
courses of action [77, 78]. Individuals are presumed to weigh up the expected benefits and 
costs of different actions and make choices that maximize their expected utility. This 
underpins my research, though I also emphasize that providers often make decisions in 
the context of the agency relationships. For example, a provider’s interaction with a 
patient can be characterized as a principal-agent relationship when the patient relies on 
the provider to diagnose the condition and select treatment. I also acknowledge that 
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providers’ preference and practice may reflect multiple agency relationships, and 
providers may be influenced by additional principals, such as their employer or supplier.  
Moreover, my thesis draws on thinking from behavioural economics and new institutional 
economics. As explained further in Chapter 2, these theories suggest providers may be 
bounded in their ability to make rational decisions, or constrained by the prevailing social, 
cultural or institutional environment. While these theories tend to be located within the 
economics literature they have been heavily influenced by thinking in other disciplines. 
For example, the notion of informal institutions, which is central to new institutional 
economics, builds on work from sociology and cultural theory [79, 80] and behavioural 
economics integrates economics with psychology as it incorporates concepts such as 
habits, framing and social norms of behaviour [81].    
The research on providers’ preference and practice was used to design interventions to 
improve providers’ adherence to the malaria treatment guidelines, and the cost-
effectiveness of the interventions implemented in Cameroon were evaluated as part of this 
thesis. 
The aim of the thesis was to analyse providers’ stated and revealed preferences for 
treating febrile patients, when providers have imperfect information and are agents in 
multiple agency relationships, and to evaluate the cost-effectiveness of interventions that 
were designed to improve providers’ adherence to clinical guidelines.  
Specific objectives are: 
 To describe the treatment supplied to febrile patients at health facilities and 
medicine retailers in Cameroon and Nigeria.  
 To assess providers’ knowledge of the national malaria treatment guidelines and 
investigate the determinants of providers’ stated preference for treating 
uncomplicated malaria.  
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 To examine the determinants of providers’ revealed preference (i.e. their practice) 
for treating patients with malaria symptoms. 
 To evaluate the cost-effectiveness of interventions to improve providers’ practice 
in diagnosing and treating uncomplicated malaria at public and mission facilities in 
Cameroon. 
1.5 Structure of the thesis  
The thesis is structured in three parts. Part I contains the introduction, literature review 
and an overview of the study setting, Part II contains five research papers, and Part III 
discusses the research findings and the overall contribution of the thesis.  
Chapter 2 summarises conceptual and empirical literature. Providers’ practice has been 
considered from an economics perspective, founded in agency theory and thinking from 
new institutional economics and behavioural economics. The empirical literature was 
reviewed to identify possible interventions to improve providers’ ability to diagnose and 
treat uncomplicated malaria. 
Chapter 3 provides overview of the study sites, and introduces the Research on the 
Economics of ACT (REACT) project, which was the context for the research included in this 
thesis. This chapter contains the trial protocol for the evaluation in Cameroon. The 
protocol describes the interventions that were developed following extensive formative 
research, and how they would be evaluated using a cluster-randomized trial. 
Chapters 4 to 8 contain the five research papers:  
I. Treatment of uncomplicated malaria at public health facilities and medicine 
retailers in south-eastern Nigeria.  
II. Malaria prevalence and treatment of febrile patients at health facilities and 
medicine retailers in Cameroon. 
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III. What determines providers’ stated preference for the treatment of uncomplicated 
malaria? 
IV. Mind the gap: knowledge and practice of providers treating uncomplicated malaria 
at health facilities and medicine retailers in Cameroon and Nigeria.  
V. Economic evaluation of a cluster randomized trial of interventions to improve 
health workers’ practice in diagnosing and treating uncomplicated malaria in 
Cameroon. 
Four of these papers report on findings arising from the formative research undertaken to 
inform the design of interventions to improve diagnosis and treatment of patients who 
present with symptoms of uncomplicated malaria. The first two papers describe the 
results of patient exit surveys undertaken at health facilities and medicine retail outlets in 
Nigeria and Cameroon and highlight problems with the treatment of uncomplicated 
malaria (Chapters 4 and 5).  
As providers are often responsible for treatment decisions, providers’ knowledge, 
preference and practice in treating uncomplicated malaria was the focus of further 
investigation. The paper in Chapter 6 reports on the determinants of providers’ stated 
preference for the treatment of uncomplicated malaria, and thus examines their 
preference when not constrained by the resources available, information about the patient 
or the patient’s ability to pay. Chapter 7 contains a research paper on the relationship 
between providers’ knowledge and their practice. The knowledge-practice gap was 
examined by restricting the analysis to the subset of patients who relied on the provider to 
select treatment and were supplied an antimalarial, and by linking exit survey responses 
to the individual provider who supplied treatment.  
The final research paper is presented in Chapter 8. This is the economic evaluation of 
training interventions that were implemented in Cameroon to support the introduction of 
malaria RDTs and encouraged providers to test febrile patients for malaria and to provide 
treatment that adhered to the test result. Two training interventions were designed, based 
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on the formative research: one-day ‘basic’ training that sought to ensure providers knew 
how to use malaria RDTs and the recommendations in the national malaria treatment 
guidelines; and three-day enhanced’ training that explicitly focused on changing providers’ 
practice.  
Chapter 9 contains the discussion. The overall findings from the thesis are summarized 
and contribution of the thesis is discussed. The limitations of the thesis are acknowledged 
and areas for further research are outlined. The thesis concludes by considering the 
implications of the research for the design and evaluation of interventions to encourage 
providers to adhere to malaria treatment guidelines and on malaria treatment policy in 
Cameroon. 
Finally, an appendix has been included. This contains the appendix to the empirical review 
included in Section 2.2 and two further research papers for which I am a co-author. The 
first presents findings from qualitative research in Cameroon, which was undertaken as 
part of the formative research. This paper complements the quantitative research 
reported in Chapters 5-7 and contributed to the design of interventions in Cameroon. The 
second paper reports on the effectiveness of the interventions evaluated in Cameroon. 
This paper complements the economic evaluation as it includes detail on the 
implementation and effectiveness of the training interventions. 
1.6 Contribution of the candidate  
The thesis was undertaken in the context of the Research on the Economics of ACT 
(REACT) project, which sought to improve the diagnosis and treatment of uncomplicated 
malaria in Cameroon and Nigeria. The project was implemented in four phases: formative 
research; intervention design; evaluation; and dissemination. By taking a phased approach 
the project sought to design interventions to address problems identified during the 
formative research and respond to the interests of policy-makers. As such, the project 
evolved differently in each country. An overview of REACT is provided in Section 3.2. 
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REACT was conceived by the principal investigators: Dr Virginia Wiseman, Professor 
Wilfred Mbacham, and Professor Obinna Onwujewke. I joined the project as a co-
investigator after funding had been secured, though before any research commenced.  I 
made a substantial scientific contribution to the project, and coordinated research 
activities and managed research teams in Cameroon and Nigeria.  
The research contained in this thesis includes work conducted in the context of REACT, 
but for which I had a lead responsibility and undertook with considerable independence. I 
led the design and analysis of patient exit surveys and provider surveys in Cameroon and 
Nigeria, which included the development of research instruments, training of field teams 
to pilot and administer the surveys, and analysis of the survey data. Chapters 4 and 5 
present the main findings of the exit surveys. These findings identified priorities for 
intervention.  
From my reading on theory-based evaluation, I wanted to ensure the selection and design 
of interventions was founded on a conceptual and empirical understanding of the patient-
provider interaction. This included a literature review on interventions to improve 
providers’ practice in diagnosing and treating malaria (Section 2.2). I independently 
developed the search strategy, identified relevant papers, synthesized the evidence and 
interpreted the findings. The review was written up as a working paper for REACT and 
was approved by the principal investigators. Chapters 6 and 7 contain additional analyses 
on the knowledge, stated and revealed preferences of providers. For each, I led the 
conception of the research question, undertook the analysis, and prepared the research 
paper. I received support from my PhD supervisor, though the work was conducted with 
considerable independence and my co-authors understood this research was intended to 
contribute to a PhD. 
My research was particularly pertinent to the selection and design of interventions in 
Cameroon as a decision was made to focus on malaria case management at public and 
mission facilities, where providers are routinely responsible for diagnosis and the choice 
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of treatment. In discussions with the National Malaria Control Programme (NMCP), it was 
agreed REACT should develop training interventions that not only sought to improve 
providers’ knowledge of the malaria treatment guidelines, but also explicitly sought to 
change their practice. I led workshops with the Cameroon study team to develop the 
content of the training. During this design phase, I also prepared a logic model to articulate 
the causal mechanisms by which the training was expected to change providers’ 
knowledge and practice (Section 3.2).  
The trial design was led by the principal investigators, with support from co-investigators, 
including myself, Bonnie Cundill, a statistician, and Clare Chandler, social scientist. The 
trial protocol is included in Section 3.3. 
Chapter 8 presents the economic evaluation I conducted in Cameroon. I led the design and 
analysis of the economic evaluation. I oversaw the collection of patient exit surveys and 
managed a Research Assistant, Tom Drake, who collected data on the cost of the 
interventions and the facility costs of malaria diagnosis and treatment. I worked 
independently on the cost-effectiveness and prepared the research paper. Co-authors 
provided feedback on a full draft and approved the final paper.  
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2. Literature Review  
 
This Chapter contains a review of conceptual and empirical literature and presents a 
conceptual framework. Section 2.1 presents economic theories relevant to understanding 
providers’ practice and the patient-provider interaction. This includes agency theory and 
concepts from new institutional economics and behavioural economics. Section 2.2 
contains a comprehensive literature review on interventions that had been used to 
improve providers’ ability to diagnose and treat uncomplicated malaria. This literature 
review is a working paper undertaken for REACT and was used to identify potential 
interventions that could be used to improve the practice of providers diagnosing and 
treating uncomplicated malaria in Cameroon and Nigeria. Section 2.3 contains a 
conceptual framework I developed to inform the research and it illustrates who or what 
may influence providers’ preference and their practice. Section 2.4 summarises the 
current evidence and rationale for further research. 
2.1 Conceptual literature  
2.1.1  Agency theory 
Economics is concerned with the decisions that people make, and offers a perspective 
from which to consider the actions of providers supplying health care [1]. Agency theory is 
often used to provide a conceptual framework for examining the interaction between 
health care providers and their patients [2, 3]. The theory applies to situations where 
there is an asymmetry of information, and in the context of health care it is assumed that 
patients lack the knowledge to make rational decisions about the health care they require, 
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and once at a facility they rely on the provider to diagnose the condition and recommend 
treatment [3]. 
The information held by providers and patients is likely to depend on the nature of the 
illness and the complexity of treatment [4]. The degree of imbalance is likely to be greater 
when the patient’s symptoms are severe, there are many treatment options, and clinical 
interventions require more advanced technology. In these situations the provider will 
have information that is complementary to that held by the patient, while for more 
familiar illnesses, such as the common cold, providers’ information will largely substitute 
that held by the patient, since the patient may know the treatment options from previous 
care seeking. There may also be limits on the providers’ information, which bounds their 
ability to make rational decisions, and provider’s practice may be constrained by the 
resources available at the facility or by the patient’s ability to pay for health care. 
A perfect agent has been defined as someone who would use her superior knowledge to 
select the best good or service for the principal that is consistent with his preferences [5, 
6]. In other words, the perfect agent would make the same choices as the principal, if the 
principal held all the necessary information from which to make a rational decision over 
the set of choices available [6]. However, agency theory contends that the agent will have 
her own preferences and has an incentive to exploit the information asymmetry for her 
benefit. Thus, both the principal and his agent want to maximize their individual utility 
functions. In standard agency theory, the utility functions are entirely independent of each 
other, and it follows that the self-interested agent would make choices for her own benefit, 
irrespective of the principal’s preferences. 
The economics literature typically assumes that the agent’s utility function depends on her 
preferences over income and leisure time, and that the agent has a financial incentive to 
induce demand in order to increase her income until she has obtained her optimal 
combination of income and leisure, or at least achieved a threshold income [2, 7]. It can be 
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argued, therefore, that the provider’s effort in diagnosis and the choice of treatment will 
depend on the monetary benefits she accrues, and that she may supply additional 
unnecessary medicines or services in order to increase her income. Supplier induced 
demand is said to occur when the agent supplies more of a good than would be demanded 
by the fully-informed principal. Redressing the information imbalance between providers 
and patients may mitigate supplier-induced demand, though there may be practical limits 
to the amount of technical knowledge and skills that can be transferred to the patient [6, 
8]. 
Agency theory has traditionally focused on the bilateral relationship between the principal 
and their agent, however, the situation may be complicated further as the provider may be 
serving multiple principals [9, 10]. For instance, in addition to the provider’s agency 
relationship with the patient, she may also be acting as an agent on behalf of her employer, 
policy-makers or programme managers in the Ministry of Health, or suppliers of 
pharmaceutical products. In some instances the provider will have a formal contract with 
the principal, though often the contractual relationship will be an implicit understanding 
in which the provider perceives a responsibility to act on behalf of the principal. For 
example, while it may be unusual for the patient and provider to have a written agreement 
for the health care transaction, the provider’s actions in treating the patient may reflect a 
pledge to the Ministry of Health to practice ethically, or an intrinsic motivation to meet the 
patient’s needs and supply effective treatment. 
2.1.2 Financial incentives  
The health economics literature on agency theory has concentrated on the providers’ 
financial incentives under different types of organization and remuneration schemes [11]. 
In theory profit-maximising firms are more likely than government or NGOs to exploit the 
information advantage and induce demand, though provider practices will also depend on 
the method of remuneration [12]. Providers that receive income directly determined by 
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the services supplied have a financial incentive to provide treatment. These fee-for-service 
remuneration schemes are common in the private sector, and tend to apply to providers 
that own or part-own the clinic, pharmacy or drug store [13]. In contrast, providers paid a 
salary have no financial incentive to provide care and are presumed to work the minimum 
required to sustain their employment. These are two distinct provider payment methods, 
though there are also many complex employment and remuneration arrangements [14]. 
Allowances or bonuses may be provided in addition to a basic salary, dual employment is 
common, and there may be informal arrangements, in which providers receive 
commission from drug sales, or under-the-counter payments from patients [15, 16]. 
2.1.3 Contractual arrangements 
Provider and patient incentives may be aligned if the payment received by the provider is 
contingent on the patient’s health outcome rather than health care inputs [1]. Thus, the 
provider has an incentive to exert effort when diagnosing the patient’s condition and 
provide effective treatment if her income depends on an observable improvement in the 
patient’s health. There are, however, considerable challenges and costs involved in 
devising incentive-compatible contracts and expertise is required to monitor the agent’s 
actions and enforce penalties should the contract be breached [2, 3, 17]. Consequently, 
outcome-contingent contracts are rare in modern medicine, though they have been used 
by traditional healers in some African countries [18, 19]. Input-based contracts are also 
problematic when the relationship between health care consumption and health outcomes 
is uncertain, health care inputs are difficult to measure and medical experts disagree on 
what is best for the patient [3, 19].  
2.1.4 Dynamic relationships & reputation effects 
Contractual difficulties may be overcome if the relationship is considered from a longer-
term perspective since providers who are concerned about their ability to generate 
income in the future will want to establish and maintain a good reputation to encourage 
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repeat business. The provider’s reputation is important because health care is an 
experience good and the quality of health care cannot be assessed in advance of 
consumption [20, 21]. Providers may also use advertising or observable attributes to 
signal the quality of their services. Reputation effects can incentivize providers to exert 
greater effort, offer effective care and achieve patient satisfaction. Providers are usually 
more responsive to reputation effects when there is considerable competition, while 
reputation is less important when patients have little choice over where they seek care 
[20]. 
2.1.5  Intrinsic motivation and patient attributes 
It is argued that providers not only respond to financial incentives but also have an 
intrinsic motivation to provide care and improve the health of others [3, 22]. Economists 
do not consider agents to be altruistic, but argue that they remain self-interested, derive 
satisfaction from their work and enjoy the esteem that is associated with their profession 
[3, 23, 24]. Agency theory incorporates intrinsic motivation by extending the provider’s 
utility function to include the utility derived from the anticipated improvement in the 
patient’s health [3, 25, 26]. The degree of intrinsic motivation is likely to vary between 
providers and may depend on patient or facility characteristics. For example, providers at 
mission facilities may derive some intrinsic motivation from their faith, though factors 
such as improved supervision or greater job security may also be relevant [18]. Providers 
may distinguish between patients, and Ryan (1994) identified several sociological studies 
that report differential levels of care depending on the patients’ gender, education or 
ethnicity [27]. Similarly, remarkable differences were observed in an ethnographic study 
on the treatment of patients attending a Ghanaian hospital that related to the patients’ 
socioeconomic background and communication style [28]. 
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2.1.6 Institutional & Social Context 
Individual behaviour takes place within an institutional and social context [29]. This is 
well understood by anthropologists and sociologists, and authors from these disciplines 
have explored various dimensions including societal expectations that influence the role of 
doctors and patients in the medical consultation, power dynamics and the symbolic and 
social value of medicines, and potential for shared treatment-decision making [30-34].   
Economists have also considered how social, cultural and political factors may influence 
behaviour by considering the role of institutions [35, 36]. Formal institutions, such as 
regulation, can constrain the providers’ actions or medicines available at the facility [37], 
though the term institution has been defined broadly to include any form of constraint 
that may shape human interaction [38]. Thus, provider-patient interactions are 
considered embedded within social structures, cultural norms and values [39, 40]. Social 
networks were found to be an important source of information for individuals in rural 
Tanzania making choices about their health care consumption, and explained patterns of 
treatment seeking over time [41]. Providers’ preferences and practices may also be 
shaped by others working at the facility, as social networks not only affect the flow of 
information but can be a source of reward and punishment [36].  
2.1.7 Economic psychology 
The growing literature on behavioural economics highlights limitations and 
inconsistencies in individuals’ ability to make rational utility-maximizing decisions [42]. 
Individuals tend to assess choices with reference to the current situation, be reluctant to 
change preferences, and be risk averse [43]. Moreover, individuals prefer to make choices 
that conform to expectations and behavioural norms which may explain why providers 
are often slow to respond to changes in treatment policies. In the context of health and 
health care, these issues have been explored by sociologists, though the economics 
research has so far focused on influences over individual lifestyle choices, rather than 
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provider behaviour within an agency relationship [44]. Nevertheless, social and 
psychological factors are also likely to influence providers’ preference and practice. 
2.1.8 Summary 
Agency theory provides a useful framework to consider the relationship between 
providers and their patients, and highlights many factors that may influence providers’ 
knowledge and practice. Standard agency theory emphasizes the financial incentives that 
result from information asymmetry, though extensions to the theory recognise intrinsic 
motivation. The interaction may also depend on organization, social, cultural and 
psychological factors and may be constrained by the resources available, institutional 
environment and social structures. 
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2.2 Empirical literature: A review of interventions to improve 
providers’ ability to diagnose and treat uncomplicated malaria 
A review of the empirical literature was undertaken to identify studies that report on 
interventions that were intended to improve the ability of providers to diagnose and treat 
uncomplicated malaria. The introduction summarises common problems with providers’ 
practice, including the type of antimalarial supplied, the under-use of malaria testing, and 
the provision of antimalarials to patients who test negative for malaria. Various 
intervention have been developed to improve the ability of providers to diagnose and 
treat malaria. 
This comprehensive literature review was undertaken to understand what interventions 
had been tried and tested, and to synthesize evidence on their effectiveness. The literature 
review synthesizes evidence from 27 studies and 32 different interventions. The different 
types of interventions were categorized using a pre-defined typology, based on the 
information provided about the intervention or intervention package. The majority of the 
studies included provider training or an educational process that sought to enhance the 
providers’ knowledge and skills of malaria diagnosis and treatment. 
The review concludes that provider training can have a significant effect on providers’ 
knowledge and practice, though synthesis was limited by the amount of information 
available on the intervention and variation within each intervention category, as well 
differences in the setting, research methodology and outcome indicators used. Moreover, 
it was difficult to ascertain the merits of supplementary activities such as refresher 
training or supervision when they were included within an intervention package. 
The findings from this literature review, along with quantitative and qualitative research 
conducted in Cameroon and Nigeria, were used to inform the design of interventions for 
the REACT project.  
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The literature was written up as a working paper for the REACT and has been published 
on the ACT Consortium website. The working paper has a relatively lengthy appendix, and 
this is included as an appendix to the thesis (Appendix A). 
 
Authors: Lindsay Mangham(1) 
(1) Department of Global Health and Development, London School of 
Hygiene and Tropical Medicine, UK 
Status: Working Paper for REACT Project, published on the ACT Consortium 
website (www.actconsortium.org/REACTliteraturereview). The working 
paper was reviewed by colleagues, but was not subject to academic peer-
review. 
Copyright: The author retained copyright. 
Contribution: I am the sole author of the literature review. Colleagues reviewed the 
report and provided comments. 
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Executive Summary 
Prompt access to effective malaria treatment is important, and many individuals rely on providers to 
diagnose malaria and dispense the recommended treatment. Whether the emphasis is on 
presumptive or parasitological diagnosis, ensuring that providers are able to supply treatment in line 
with national guidelines is critical for patient care.  There are, however, longstanding problems with 
the care available at many public health facilities and private sector outlets. Given these problems 
and the recent interest in the use of RDTs, there is a need for interventions that improve the ability 
and practice of providers to treat patients that present at a health facility with a fever. This literature 
review examines the evidence available on interventions to improve providers’ ability to diagnose or 
treat uncomplicated malaria. 
A comprehensive search of the published literature was undertaken using bibliographic databases. 
Relevant publications in the grey literature were identified from review articles, reference lists of 
relevant publications and from websites of development agencies. Publications since 1990 were 
eligible if they met all of the following inclusion criteria: 
 The intervention was intended to improve providers’ ability to diagnose or treat 
uncomplicated malaria.  
 The population exposed to the intervention are providers.  
 The study design included a comparison group.  
 The effect was reported on a malaria-related outcome.  
 The study setting was an area of endemic malaria transmission in sub-Saharan Africa or Asia. 
Evidence on effectiveness was synthesized using three types of outcome: i) presumptive treatment 
of uncomplicated malaria; ii) appropriate treatment of uncomplicated malaria (following a diagnostic 
test); and iii) the accuracy of prescribing antimalarial treatment regimens.  
Twenty-nine publications were eligible for the review, which report on 27 studies and 32 different 
interventions. The majority of the studies were from Africa, with 8 from Kenya, 5 from Tanzania, 4 
from Uganda and 3 from Nigeria. The majority of the interventions were designed to focus on 
malaria, though several included malaria within the Integrated Management of Childhood Illnesses 
(IMCI). Provider training was dominant, and the principal activity in 21 of 32 interventions. The 
training interventions included studies focusing on presumptive treatment of malaria, and studies on 
diagnostic testing.  
Most interventions had a significant positive effect on the presumptive treatment of uncomplicated 
malaria, and the accuracy of the doses and advice given. The provision of RDTs and training on 
diagnostic tests improved the appropriate treatment of malaria, though the proportion of test-
negative patients receiving antimalarials often remained relatively high. No studies compared an 
intervention in both public and private sector providers and only two programmes reported on the 
cost-effectiveness of the intervention. 
Further work on interventions to improve the appropriate treatment of febrile patients would be 
valuable. The studies show that provider training and the provision of RDTs can be beneficial, though 
suggest that conventional approaches may have only a limited effect. 
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Abbreviations 
ACT   Artemisinin Combination Therapy 
AL   Artemether Lumefantrine 
AM   Antimalarial 
AQ  Amodiaquine 
ASAQ   Artesunate Amodiaquine 
BCC   Behaviour Change Campaign 
CQ   Chloroquine 
HW   Health Worker 
IMCI   Integrated Management of Childhood Illnesses 
NGO   Non-Governmental Organization 
N/A   Not Applicable 
OTC    Over the Counter  
RCT    Randomized Control Trial 
RDT    Rapid Diagnostic Test 
SP    Sulphadoxine Pyrimethamine 
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1. Background  
Malaria is a major cause of mortality, and the majority of the disease burden falls in sub-Saharan 
Africa [1]. There are approximately 250 million episodes of malaria each year, and about one million 
malaria-related deaths, mostly in children under five years of age [1]. Prompt access to effective 
malaria treatment is important, and many individuals rely on providers to diagnose malaria and 
dispense the recommended treatment. The most effective treatment for uncomplicated malaria is 
artemisinin combination therapy (ACT) and this medicine is the first-line recommended antimalarial 
across sub-Saharan Africa [2]. ACT replaced less effective antimalarials, such as sulphadoxine-
pyrimethamine (SP) and guards against drug resistance by combining the artemisinin derivative with 
another type of antimalarial, such as lumefantrine or amodiaquine (as in artemether-lumefantrine 
and artesunate-amodiaquine).  
The introduction of ACT has, however, brought new challenges. The treatment regimen for ACT is 
more complex than the former first-line treatment SP, which was taken as a single dose, and should 
be taken twice daily for three days in a dose suitable for the patient’s weight or age. ACT is also 
considerably more expensive than alterative antimalarials, and as it can cost up to ten times more 
than SP, affordability is a key concern. The high cost of ACT also brought into question the 
widespread use of presumptive treatment in areas of low to medium malaria transmission. A revived 
an interest in parasitological diagnosis also coincided with the release of rapid diagnostic tests (RDTs) 
for malaria. Malaria RDTs have been shown to have high specificity and sensitivity, and have the 
potential to transform access to malaria testing since they are suitable for use in resource-
constrained settings and do not require laboratory equipment or specialist skills. 
Whether the emphasis is on presumptive or parasitological diagnosis, ensuring that providers are 
able to supply treatment in line with national guidelines is critical for patient care.  However, there 
are longstanding problems with the care available at many public health facilities and private sector 
outlets [3, 4]. For example, despite the efforts of the Zambian malaria control programme to 
disseminate guidance on the change in first-line treatment from sulphadoxine pyrimethemine (SP) to 
artemether lumefantrine (AL), two years after AL (a type of ACT) had been adopted as the first-line 
antimalarial only 42% of children under five years received treatment in line with national guidelines 
[5]. Ensuring patients receive the recommended type of antimalarial is the first step, though it is also 
important that they receive the appropriate dose and understand how to take the full course of 
treatment. In terms of the dosage, recent studies from Kenya and Uganda reported more than 90% 
of children received ACT in the recommended dose, however such accuracy in dosing has not always 
been the case [5, 6].  For example, a study on treatment in government health centres in Nigeria 
found that 39% of antimalarials were in the correct dose, with 30% receiving an insufficient dose and 
a further 30% receiving more than required [7]. The same study showed even greater problems in 
the private sector, with 28% of patients at patent medicine dealers obtaining the correct dose, while 
half of the patients received an inadequate amount [7].  The advice given by providers to patients on 
how to administer the medicine may be a further source of problem [8]. 
Given the problems with the delivery of ACTs in several settings, as well as the relatively recent 
interest in the use of RDTs, there is a need for interventions that improve the ability and practice of 
providers to treat patients that present at a health facility with a fever. This literature review 
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examines the evidence available on interventions to improve providers’ ability to diagnose or treat 
uncomplicated malaria. The review has been undertaken as part of the Research on the Economics of 
ACTs (REACT) project. The objective of REACT is to design and evaluate interventions to improve the 
treatment of uncomplicated malaria in Cameroon and Nigeria.  This literature review has been 
undertaken to inform intervention selection and design. 
This is not the first paper to review the literature on interventions to improve malaria treatment. 
Smith et al (2009) recently reviewed interventions to improve provider practice and user behaviour 
in relation to prompt and effective malaria treatment in sub-Saharan Africa [9]. Goodman et al 
(2007) and Brieger et al (2005) both review the literature on the role of private practitioners and 
interventions that have been used to improve their practice [4, 10]. Other related review articles 
have focused on interventions to improve home-based management of malaria or on improving 
prescribing practices [11-14]. This review of interventions to improve providers’ ability and practice 
in treating malaria is distinct insofar as it includes papers that report on a wider range of malaria-
related outcomes and from settings across both Africa and Asia. The literature in this area is 
constantly evolving, and even since the review by Smith et al, there have been several new 
publications. 
2. Objectives 
The aim of the literature review is to synthesize evidence on interventions to improve the ability of 
providers to diagnose and/or treat uncomplicated malaria. Specific objectives of the review are:  
a) to identify the range of interventions evaluated that sought to improve providers’ ability to 
diagnosis or treat uncomplicated malaria;  
b) to review the characteristics of the studies in terms of the approach and research methods 
used to evaluate the intervention; and  
c) to compare the effectiveness of the interventions. 
3. Methods 
3.1 Literature Search Strategy 
A comprehensive search of the published literature was undertaken using the following databases: 
Medline, Embase, Global Health, International Bibliography of Social Sciences (IBSS), CAB Abstracts 
and International Network for the Rational Use of Drugs (INRUD). The databases were last accessed 
on 26 November 2009. 
From the research question four concepts were derived and underpin the search. The concepts were: 
malaria; treatment; intervention; and provider (as shown in Box 1 with their synonyms). The 
synonyms were used as keywords for title and abstract searches in Medline, Embase, Global Health, 
IBSS and CAB Abstracts. Truncation search terms were used to make the search inclusive. The 
outputs from the title and abstract searches for all the synonyms in each concept were combined 
using the Booliean operator “or”. The four concepts were then brought together using the “and” 
operator. The search of the INRUD database was less restrictive, and used the keywords “malaria” or 
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“fever” or “febrile” in all indexed fields. The citations obtained from each of the databases were 
exported to Endnote reference management database, and all duplicates were removed.  
Box 1. Search strategy 
Concept: malaria  Concept: treatment Concept: intervention Concept: provider 
fever diagnos* intervention public 
febrile management education private 
malaria knowledge training personnel 
 practice  clinician* 
 treatment*  health worker* 
 test*  retailer* 
   seller* 
   provider* 
Within each concept terms were combined with the operator “or” 
Results from each concept were combined using the operator “and” 
Search was limited to publications since 1 January  1990 
 
The search focused on publications available in peer-review academic journals since we are primarily 
interested in evaluation studies grounded in a rigorous study design. Relevant publications in the 
grey literature were identified from review articles, reference lists of relevant publications and from 
websites of development agencies.  
3.2 Inclusion Criteria 
Publications were eligible if they met all of the following inclusion criteria: 
 The publication reports on an intervention that was intended to improve the ability or 
practice of providers to diagnose or treat uncomplicated malaria. Improving providers’ ability 
or practice to treat uncomplicated malaria could be the primary focus, or contained within a 
range of objectives.  
 The population exposed to the intervention are providers. The providers may be from any 
cadre, with any or no qualification and from any type of health facility or outlet. This 
population can therefore include individuals working in government, mission and private 
facilities, pharmacies and drug retail outlets as well as community-based actors. 
 The study design was defined as a (cluster) randomized control trial, pre-post design with a 
control group, repeated cross-sectional studies, pre-post design without control, or a post-
only evaluation which included a comparison group. One-time cross-sectional studies and 
post-only designs without a comparison were excluded as they lack a comparison group.  
 The study reports the effect of the intervention on malaria-related outcomes. It can use any 
outcome measure for provider knowledge, provider competence, or treatment outcomes in 
relation to the care received by patients or their health status. The term malaria-related is 
defined to include confirmed and unconfirmed malaria cases, since it is common for malaria 
diagnoses to be based solely on febrile symptoms. 
 The study population depends on the outcome reported, though may be patients for whom 
treatment is sought, mystery clients that seek treatment, or providers. 
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 The study setting was an area of endemic malaria transmission in sub-Saharan Africa or Asia. 
Studies were excluded if the abstract was not available in the English language and if it was published 
before 1990.  
Characteristics of publications that failed to meet the inclusion criteria include: interventions that 
directly target patients, caregivers or the community (e.g. home management of malaria 
interventions to educate mothers, or mass-media campaigns); interventions that introduce as well as 
train community based agents (e.g. recruit and train village malaria assistants); and interventions 
that focused on malaria prevention strategies (e.g. bednets or intermittent preventive treatment). 
3.3 Data extraction and synthesis 
The title and abstract of each citation were reviewed to identify publications for the full-text review. 
The full-text of identified publications were read to determine it if met all the inclusion and none of 
the exclusion criteria.  
For each eligible publication summary details were extracted in a tabular form, capturing the nature 
of the intervention, study context, study design, research methods and outcomes reported. Based on 
the description of the intervention it was categorized both in terms the principal element of the 
intervention package, and any supplementary activities. The categories used in this review are listed 
and defined below and based on a recent World Health Organization report (Box 2) [15]. 
Box 2. Different categories of intervention 
Consumer Education:   activities to improve the knowledge or awareness of patients, their 
caregivers or the community. These range from mass-media campaigns to displaying a poster 
or leaflets at a health facility. 
Economic Intervention:   economic incentives are created to change the practice of health 
providers. 
National Policy Initiative:   the intervention is part of a national programme of activities, or 
closely aligned to a government initiative. 
Pre-packaged Antimalarials:   drugs are repackaged and as such presented in age-specific 
packs or with additional information. 
Provider Educational Process:   providers are educated using an approach that differs to 
conventional workshop-based provider training. 
Printed Educational Materials:   participants receive written or pictorial documents, such as a 
training manual, clinical algorithm or another form of job aid. 
Provider Training:   participants attend workshop-based training, possibly including practice 
sessions. A variety of learning techniques may be used within the workshop-format including 
lectures, seminars, role-play and assessment. 
Rapid Diagnostic Testing (RDT) Provision:   providers have RDTs available to use. 
Refresher Training:   participants have the opportunity to attend a second training workshop. 
Enhanced Supervision:   providers receive additional supervision or support visits. 
   
To compare the effectiveness of the interventions on the ability of provider to diagnose and treat 
malaria we have focused on three types of outcome: 1) presumptive treatment of uncomplicated 
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malaria in febrile patients; 2) appropriate treatment of uncomplicated malaria in febrile patients 
(following a diagnostic test); and 3) the accuracy of prescribing antimalarial treatment regimens. 
Thus for synthesis, outcomes have also been assigned to the following categories: 
1) Presumptive treatment of uncomplicated malaria in febrile patients: 
 Provider knowledge of how to diagnose and/or treat malaria 
 Proportion of patients who were presumptively prescribed or treated with an antimalarial 
 Proportion of patients who were presumptively prescribed or treated with the 
recommended antimalarial 
2) Appropriate treatment of uncomplicated malaria in febrile patients: 
 Provider ability to conduct malaria diagnostic testing 
 Proportion of patients who were prescribed or treated with an antimalarial following a 
malaria diagnostic test 
3) Accuracy of prescribing antimalarial treatment regimens: 
 Provider ability to prescribe or dispense an antimalarial in the correct dose 
 Provider ability to prescribe or dispense an antimalarial with correct advice on the regimen 
For those outcomes that report on the treatment prescribed or received we distinguish between 
outcomes obtained from simulated mystery client visits and outcomes from real-world patient-
provider interactions. The latter, by definition, entail patient variation in terms of their symptoms, 
demographic and socio-economic characteristics. In contrast, the outcomes from the simulated 
mystery client visits present a standardized case with which to measure the competence of the 
provider. The providers’ ability to conduct diagnostic testing is also considered a measure of their 
competence. 
4.  Results 
4.1 Search results and selection of publications 
The process for selecting publications is shown in Figure 1. A total of 1918 publications were 
identified from the database and reference lists, searches once duplicates were removed. From the 
title and abstract 53 publications were selected for full-text review. After the review of the full text, 
26 publications were rejected as they did not meet the inclusion criteria (Appendix A). Sixteen were 
rejected because the intervention does not seek to improve the ability of providers, predominately 
because the intervention involved introducing a community-based agent, such as village health 
volunteer. Other publications were rejected because the study was descriptive (2 publications), there 
was no comparison group (4 publications) or because the publication did not report on malaria-
related outcomes (4 publications). Twenty-six publications [16-41] were eligible and a further 3 
publications [42-44] were identified from review articles and the reference lists of eligible articles.  
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Figure 1: Flow chart for selection of studies 
 
 
4.2 Overview of the selected publications  
Thirty publications were eligible for the review. These publications report on 27 studies, since some 
publications report on the same studies [17, 19, 20, 24, 31-33] and other publications report on 
multiple studies [20, 33]. Moreover, the publications report on a total of 32 interventions as 5 studies 
evaluate multiple interventions [21, 25, 29, 33, 35]. For instance, Harvey et al (2008) use a 3-arm 
intervention trial to consider the impact of provider training and job aid, a job aid alone in 
comparison to a control group[21].  
The characteristics of the selected studies are summarized in Table 1 and Appendix B. The majority of 
the studies (17 of 27) were set in three countries in East Africa, with 8 from Kenya, 5 from Tanzania 
and 4 from Uganda [16, 17, 23-27, 29, 31-38, 40, 42]. A further 8 were from West Africa (of which 3 
were from Nigeria) [18, 28, 30, 39, 41-44]. The remaining three studies were from Ethiopia, Zambia 
[21] and India [22]. 
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The studies were reasonably balanced between public and private sector facilities. Fifteen studies 
were located in public facilities, predominately focusing on malaria diagnosis and treatment at the 
primary care level. Eleven studies engaged private sector actors; primarily drug retailers with no or 
little formal training though a few were from private health clinics. A couple of studies involved 
wholesalers of malaria treatment in addition to retail outlets [32, 37]. One study evaluated training 
of community health workers [21].  
 
4.3 Different types of intervention 
Thirty-two interventions were evaluated within the 27 studies. The majority of the interventions 
were designed to focus on malaria (21 of 32 interventions or 16 of 27 studies) (Appendix B). In the 12 
remaining interventions, improving malaria diagnosis and treatment was part of a broader objective, 
often the management of a range of common childhood illnesses. There was one exception, in which 
the objective of the intervention was to improve the quality of laboratory services [18]. 
In 21 of the 32 interventions (or 19 of 27 studies), the principal activity was categorized as provider 
training, and in total provider training was used in 27 of the interventions (Box 3). The different types 
of studies and interventions are summarized in Box 3 and described in Appendix B. Within the 
category of provider training there was considerable variation. Improving diagnosis and treatment of 
malaria was the focus in the majority of the training interventions, though in some instances this was 
a component of a child health training programme. For example, 4 interventions were training 
implemented as part of the Integrated Management of Childhood Illnesses (IMCI) initiative [17, 22, 
31, 39]. The use of malaria diagnostic tests, either using microscopy or rapid diagnostic tests, was 
covered in 6 training interventions [18, 25, 29, 35, 36, 40]. The training workshops used a range of 
learning techniques, and many sought active participation by including practical sessions and role-
playing, in addition to seminars and presentations. The training workshops also varied in length, with 
courses lasting from one-hour to 11 days. 
Box 3. Categorization of the studies and interventions 
CATEGORY INTERVENTION STUDY 
 Principal 
activities 
Principal & 
supplementary 
activities 
Principal  
activities 
Consumer Education - 7 - 
Economic Intervention 3 3 2 
National Policy or Initiative  - 4 - 
Pre-packaged Antimalarials 1 4 1 
Provider Educational Process 3 3 3 
Printed Educational Materials 1 24 - 
Provider Training 21 27 19 
Provision of Rapid Diagnostic Testing 2 2 2 
Refresher Training 1 3 - 
Enhanced Supervision - 9 - 
TOTAL  32  27 
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Three interventions were categorized as a provider educational process, since they sought to 
improve providers’ knowledge and practice but without taking a workshop-based training approach 
[37, 42, 44]. Two interventions used self-assessment in order to encourage participants to reflect on 
the quality of the services provided, and discussion with colleagues [42, 44]. The other educational 
intervention focused on peer-to-peer learning, with wholesalers trained and encouraged to educate 
their customers from drug retail outlets on new malaria treatment guidelines [37]. 
Nine interventions (within 7 studies) focused on conducting tests to diagnose malaria [18, 21, 25, 29, 
35, 36, 40]. Three studies evaluated the impact of provider training on the ability of health workers 
to accurately conduct diagnostic tests [18, 21, 29]. Two studies evaluated the impact of training in 
microscopy, in addition to training in malaria management, on the treatment received by febrile 
patients [25, 36]. Finally two studies evaluated the impact of providing RDTs on the treatment 
received by febrile patients [35, 40].  
Two studies focused on changing provider practices by adjusting economic incentives [32, 33]. These 
two interventions were country case studies undertaken in the context of preparatory work on the 
Affordable Medicines Facility – malaria (AMFm) [32, 33]. The AMFm proposes to subsidize ACT, with 
the aim of increasing the availability and affordability of ACT, whilst also crowding out artemisinin 
monotherapies whose use can contribute to drug resistance. One study reports on the impact of a 
price subsidy, shopkeeper training, and behaviour change communication activities in Tanzania, with 
an additional arm also evaluating the impact of including a suggested retail price [32]. The other case 
study was a franchise scheme in Kenya [33]. 
As the studies range from the early 1990s until 2009, they have been undertaken in the context of 
different national policies for the first-line recommended treatment for uncomplicated malaria. Only 
6 of the 27 studies report on an intervention that has been undertaken in the context of ACT, and of 
these 4 focus on improving malaria diagnosis in public sector facilities, either by training on 
microscopy or RDTs or by making RDTs available [21, 35, 36, 40]. The remaining 2 studies are the 
AMFm case studies, which consider improving the availability and affordability of ACTs though 
private sector distribution channels [19, 32, 33]. 
While the interventions have been described by focusing on their principal component, it should be 
noted that the vast majority of the interventions involved a package of activities. For instance, 
provider training and provider educational process interventions were typically supplemented by 
printed educational materials such as training manuals, guidelines or wall charts displaying clinical 
algorithm for treating malaria. In 9 instances the interventions referred to an enhanced level of 
supervision [16, 23-25, 35, 38, 39] and in three of interventions there were opportunities for 
refresher training [23, 24, 29]. Activities that sought to enhance consumer awareness were 
mentioned in 7 interventions [16, 23, 24, 32, 33, 37, 43], while 4 interventions involved the 
distribution of repackaged antimalarials [32, 41, 43]. Finally, 4 of the interventions were closely 
aligned to a national government programme or initiative, such the dissemination of change of first-
line treatment [16, 18, 35]. 
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4.4 Evaluation methods 
Studies were eligible to be included in the literature review if they adopted a study design which 
permitted the intervention to be evaluated with reference to a comparison group. Three studies 
applied a cluster randomized or individual randomized control design [16, 25, 41]. Ten studies used a 
pre-post design with a control group [18, 22-24, 26, 27, 30, 32, 33, 35] and 7 studies used a pre-post 
design without a control group [28, 29, 36, 38-40, 43]. The remaining 7 studies evaluated post 
intervention with a comparison group [17, 21, 31, 34, 37, 42, 44]. 
The studies used a variety of research methods to evaluate the impact of the intervention. They also 
tended to employ several methods of data collection to validate and contextualize their findings. The 
main methods used to assess the impact of the intervention on providers’ ability to treat according 
to guidelines were direct observation of the patient consultation (in 10 studies) [17, 21, 23, 31, 34, 
35, 39, 41, 42, 44] and exit surveys with patients or their caregiver (in 9 studies) [17, 25, 31, 32, 34, 
35, 40-42]. The latter sometimes involved a re-examination of the patient, re-reading of blood slides 
or independent testing for malaria parasites. Mystery clients were used in 6 studies [16, 24, 26, 37, 
38, 43], as an alternative method for assessing provider competence in delivering treatment, and 
with the advantage that the same scenario is presented in each case in order to control for variation 
in patient characteristics, such as their age or symptoms. In two studies patient records were 
consulted, though there were concerns about the reliability of these data [28, 35], and in two studies 
patients were followed up either on day 4 to obtain information on patient adherence to treatment 
or on day 7 to know the health status of patients [25, 41]. 
Additional research methods were used to assess the impact of the intervention. For instance, 
household surveys were used in 3 studies to examine the treatment seeking behaviour and 
treatment received by febrile patients [20, 24, 33]. Five studies used methods of assessing health 
worker knowledge of malaria treatment [18, 22, 27-29], and 5 studies involved a health facility 
survey or retail audit to determine, amongst other things, the availability of diagnostic services and 
medicines [16, 37, 40, 42, 43]. Qualitative research was undertaken in 8 studies, usually interviews or 
focus group discussions with the health care providers, though 2 studies sought the views of patients 
or caregivers[17, 33, 40-42, 44]. The objective of the qualitative work also varied, in some cases it 
sought to obtain a deeper understanding of the effect and acceptability of the intervention. In other 
cases, however, qualitative methods were used during the development stage, such as in the design 
of activities or materials, or more generally to explore the feasibility of the intervention. Finally, only 
two studies reported on the cost-effectiveness of the intervention [19, 22]. 
 
 4.5 Effect of intervention  
The evaluation studies report a range of different outcome measures, as summarized in Table 1. The 
outcome measures have been grouped to determine the effect of the intervention on the providers’ 
ability to deliver presumptive treatment, appropriate treatment following a diagnostic test, and the 
accuracy of the treatment provided in terms of dosage and advice on regimen. These results are 
presented in Tables 2, 3 and 4, respectively. Evidence across the studies has been synthesized, 
though it is important to note direct comparison is limited by variation in the specific indicators used 
as well as differences in other dimensions such as the methods of data collection and the study 
context.  
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In the majority of cases the intervention had a significant positive effect on the presumptive 
treatment of uncomplicated malaria (Table 2). Three studies show provider training had a positive 
impact on providers’ knowledge of how to treat malaria [22, 30, 37]. A further 8 studies show that 
provider training had a significant positive impact on whether febrile patients received either any 
antimalarial or the recommended antimalarial, and these studies cover interventions with providers 
in both public and private sector facilities [16, 23, 24, 26, 35, 37, 38, 43]. Studies that used mystery 
clients to assess provider competence consistently show that training is effective in improving 
presumptive treatment. However, in two instances was the effect was not significant [25, 39]. The 
first compares training on a clinical algorithm to diagnose malaria as has having no significant impact 
on whether the patient receives an antimalarial, though the proportion of febrile patients receiving 
an antimalarial is very high in the intervention and control arms [25]. The other study shows that 
provider training has no significant effect on proportion of febrile patients without malaria that 
receive an antimalarial, and as desired the proportion is relatively low in both groups [35]. 
Provider training and job aids designed to improve the accuracy of diagnostic testing show a positive 
effect, with the studies by Harvey and Ohrt reporting improvements in conducting the test and in 
understanding the test results (as in Table 3) [21, 29].  The appropriateness of the treatment received 
by febrile patients following a diagnostic test is also reported in Table 3. Treatment with an 
antimalarial is considered appropriate following a positive test result for the presence of malaria 
parasites, and inappropriate following a negative test result. The results from two interventions that 
introduced RDTs show that the introduction of RDTs reduced the proportion of RDT negative patients 
that received an antimalarial, though only in one of the two studies was the reduction statistically 
significant [35, 40]. In the two studies that evaluated the impact of provider training, it was found 
that the proportion of parasite negative patients that received an antimalarial was significantly 
reduced [25, 36]. 
Several studies assessed the accuracy with which health workers deliver treatment in the correct 
dose and with advice on how the treatment should be administered (Table 4). Overall the 
interventions had a significant positive effect on the proportion of patients that received an 
antimalarial in the correct dose or with correct advice on the treatment regimen. Only in one study 
was the effect not significant, and in this case prior to the intervention more than three-quarters of 
the patients were prescribed an antimalarial in the correct dose [36]. 
The other interventions which are not reported in these tables are the two AMFm cases studies 
which introduced an economic incentive. The study from Tanzania, which introduced a price subsidy 
and rolled out supporting interventions including shopkeeper training and behaviour change 
communication in the community showed a significant positive impact on the availability of ACTs in 
retail outlets and in the use of ACTs [32]. The inclusion of a suggested retail price also had a positive 
impact, though caution was noted in setting the price since the mean price charged was slightly 
higher in that district. Finally the results of a household survey in Kenya show an increase in the use 
of ACTs, though it is not possible to determine the source of the ACT and therefore the effect of the 
franchise scheme on their use. 
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5. Discussion 
The review identified studies that have evaluated interventions to improve the ability of providers to 
diagnose malaria and treat patients. In total 30 publications met the eligibility criteria and these 
contained 27 studies and evaluated 32 different interventions. In the majority of studies the 
intervention involved provider training or an educational process intended to enhance providers’ 
knowledge and skills when treating febrile patients, either specifically in the context of malaria or for 
a wider range of childhood illnesses. The most recent studies were undertaken since ACT was 
adopted, and included studies that sought to improve malaria diagnosis in the public sector facilities 
as well as others that promoted the availability and affordability of ACT in the private sector. This 
reflects the concerns about the higher price of ACTs and the need to limit resistance to artemisinin 
derivatives. 
Overall the studies were found to have a positive effect on presumptive treatment of febrile patients, 
and the accuracy of the doses and advice given. This shows that provider training (and other 
interventions) can change the knowledge, competence and practice of providers working in the 
public and private sectors. The results also show that the provision of RDTs and training on diagnostic 
tests led to improvements in the appropriate treatment of malaria, with reductions in the 
proportions of patients receiving an antimalarial if they were found to be test negative. Despite the 
reductions, the proportions of test-negative patients receiving antimalarials were still relatively high, 
suggesting that more would be needed to prevent inappropriate treatment with antimalarials in 
patients who tested negative for malaria. The overprescribing of antimalarials following parasitic 
diagnosis has been the focus of research in Tanzania, which highlights the considerable change in 
mind-set required to influence the prescribing behaviour of public sector health workers [45, 46].  
In synthesizing the effect of the interventions it is important to be cognizant of the differences in the 
context, actors, and research methodology, as well as the variations in the outcome indicators used. 
There was also variation in the study designs used. The more rigorous approaches employed a 
randomized, or cluster randomized design or alternatively a pre-post design with a control group. 
These designs mitigate bias, by controlling for comparatively more potential confounders, though are 
used in only 13 of the 27 studies. 
None of the studies compared the implementation of an intervention across public and private 
sector providers. This may reflect the need to tailor the intervention to the type of provider, and 
what makes sense in the public sector may not be readily transferred to the private sector and vice 
versa. It might be useful to know the relative impact of, say, a training intervention with providers in 
the public and private sectors to know where best to direct efforts to improve treatment of 
uncomplicated malaria. However, such decisions ought also to take into account the patterns of 
treatment seeking and the relative cost-effectiveness of the interventions. In that vein, it was 
noteworthy that only two programmes reported on the cost-effectiveness of the intervention. The 
impact of the intervention from an equity perspective was also a notable gap in the research. 
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6. Conclusion 
The review of the interventions to improve the ability of provider to diagnose and treat 
uncomplicated malaria provides valuable background to the design of interventions for the REACT 
project. It is useful to know what approaches have been tried and tested, as well as the methods 
used to evaluate their effect. The review also highlights areas for further work. For instance, while it 
has been shown that provider training and other educational processes can have a significant effect 
on providers’ knowledge and practice, the magnitude of the effect varies considerably. Moreover, in 
developing a training package, it is clear the following aspects would benefit from further 
consideration: the length of the programme, learning techniques, importance of supervision and 
benefits of refresher training.  
The studies also suggest that further work on interventions to improve the appropriate treatment of 
febrile patients would be valuable. The studies show that provider training and the provision of RDTs 
can be beneficial, though suggest that conventional approaches may have only a limited effect. The 
findings also indicate the focus of the REACT project on analysing the cost-effectiveness and equity 
implications of an intervention will be important since these perspectives have received limited 
consideration. Thus, REACT should demonstrate the feasibility and importance of bringing an 
economic perspective to evaluation of interventions targeting service delivery improvements. 
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Table 1. Overview of selected studies 
Intervention Country,  
Year 
Facility or Outlet First-line 
AM 
Study Design Research instruments Outcome Measures Study 
Provider Training 
(malaria) 
Kenya,  
2005 
60 Private sector 
drug retailers 
AQ / SP 
for OTC 
Cluster RCT   Mystery clients 
 Retail audit 
 
 
 % mystery clients sold (any) AM 
 % mystery clients sold 
recommended AM  
 % mystery clients sold 
recommended AM with correct 
advice on regimen 
[16] 
Provider Training (IMCI) Tanzania, 
2000 
20 Primary health 
facilities 
Not 
specified 
Post + control 
(up to 3 years 
after training) 
 Observation of 
consultation   
 Exit survey of febrile <5yrs 
(including re-examination) 
 Interviews with providers 
 % febrile <5yrs observed that were 
correctly treated for malaria 
[17, 
20] 
Provider Training 
(laboratory tests) 
Ghana, 
2000 
205 Public sector 
peripheral 
laboratories  
Not 
specified 
Pre-Post (after 18 
months) 
 Provider survey  % of laboratories surveyed with 
accurate results for malaria 
microscopy 6-months after training 
[18] 
Educational Process  
(self- assessment) 
Guinea 
and 
Kenya, 
2001 
8 Primary care 
clinics in each 
country 
Not 
specified 
Post  + control 
(after 15 months) 
 Health facility survey 
 Observation of patient 
consultations 
 Exit survey of febrile <5yrs 
 Interviews & FDGs with 
staff 
 % febrile <5yrs observed that were 
correctly prescribed malaria 
treatment 
[42] 
Provider Training & Pre-
packaged AMs 
Nigeria, 
2003 
200+ Private drug 
retailers 
CQ and 
SP 
Pre-post  Mystery clients 
 Retail audit  
 % of mystery clients sold the 
recommended AM 
[43] 
A) Provider Training 
(RDT) & Job Aid 
B) Job Aid 
Zambia 79 Community 
health workers 
Not-
specified 
3-arm study 
 
 Observation of CHW 
performance using 16-
item checklist 
 Responses to 10 standard 
test results 
 % steps in using RDT performed 
correctly 
 % RDTs read correctly 
[21] 
Educational Process  
(self- assessment & 
peer feedback) 
Mali, 
2001 
Public health 
facilities 
Not 
specified 
Post + control  Observation of provider-
client interaction;  
 Interviews with study 
participants 
 % provider that comply to fever 
care standards 
[44] 
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Intervention Country,  
Year 
Facility or Outlet First-line 
AM 
Study Design Research instruments Outcome Measures Study 
Provider Training (IMCI) India Public health 
facilities (85 
health workers) 
Not 
specified 
Pre-Post 
(immediately 
after) 
 Multiple choice and 
problem-based  
questionnaire 
 Malaria knowledge score  [22] 
Provider Training 
(malaria) 
Kenya, 
1995-
1997 
23 Private sector 
drug retailers 
CQ Pre-Post (after 
1yr and after 
2yrs) 
 Observations of patient 
consultations 
 % of those seeking treatment for 
fever that were sold an AM  
 % of AMs sold in correct dose 
 % of AMs sold with advice on use 
[23] 
Provider Training 
(malaria) 
Kenya 
1999-
2000 
 Private sector 
drug retailers 
CQ / SP Pre-Post + 
control in two 
study sites*  
 
 Mystery shoppers  
 Household survey 
(children <5yrs reporting 
fever in past two weeks) 
 % mystery clients advised to buy an 
AM 
 % mystery clients sold CQ / SP that 
were given advice on regimen 
 % AM users taking adequate dose 
[19, 
24] 
A) Provider Training 
(microscopy + clinical 
diagnosis)  
B) Provider Training 
(clinical diagnosis) 
Tanzania 
2003-
2004 
16 public health 
centres & 13 
dispensaries 
SP Cluster RCT (3 
arms) 
 Exit survey of febrile <5yrs 
(including re-examination 
and microscopy test) 
 Follow up on day-7 
 % febrile children attending facility 
that receiving AM prescription 
[25] 
Provider Training 
(childhood illness) 
 
Tanzania, 
2004 
40 private sector 
drug retailers 
SP Pre-Post with 
control (after 6 
months) 
 Mystery clients  % mystery clients sold the 
recommended AM (SP) 
 % mystery clients sold the 
recommended AM with correct 
advice on regimen 
[26] 
Provider Training 
(rational drug use) 
Uganda, 
Not 
specified 
private providers Not 
specified 
Pre-Post with 
control 
 Mystery clients  % mystery clients sold an AM 
 % mystery clients sold an AM and 
given advice on the regimen 
[27] 
Provider Training 
(malaria) 
 
Ghana, 
Not 
specified 
Medical assistants 
from 40 public 
health centres 
CQ Pre-Post, no 
control (after 3-9 
months) 
 Prescription survey from 
outpatient records 
  Knowledge assessment  
 FGDs 
 % providers know correct dose for 
3yr old 
 % providers know correct dose for 
5yr old 
[28] 
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Intervention Country,  
Year 
Facility or Outlet First-line 
AM 
Study Design Research instruments Outcome Measures Study 
Provider Training 
(microscopy) + 
Refresher Training 
(microscopy) 
Kenya Kenyan & 
international 
microscopists 
Not 
specified 
Pre-Post  Pre-post examination / 
assessment (including 
reading slides) 
 % point improvement on knowledge 
of microscopy 
  % point improvement on slide 
sensitivity and specificity 
[29] 
Provider Training 
(childhood illnesses) 
Nigeria 28 private sector 
drug retailers 
CQ Pre-Post with 
control 
 provider knowledge 
assessment 
 Mean knowledge score [30] 
Provider Training (IMCI) Uganda, 
2000, 
2001, 
2002 
public and NGO 
facilities 
Not 
specified 
Post + Control  Observation of patient 
consultation 
 Exit survey of febrile >5yrs 
(including re-examination) 
 Interviews with providers 
 % febrile <5yrs observed that were 
given an AM in the correct dose 
[31]  
[20] 
Economic Incentive  
A) Price subsidy, BCC, 
training, & suggested 
retail price 
B) Price subsidy, BCC & 
training 
C) No intervention 
Tanzania, 
2007-08 
private sector 
drug retailers 
AL Pre-Post with 
control (after 6 
months)  
 
 Patient Exit Interviews   % of consumers purchasing AMs 
that bought AL 
[32, 
33] 
Economic Incentive 
(Franchise scheme) 
Kenya, 
2007 
9 Community & 
family wellness 
shops that joined 
franchise  
AL Pre-Post (after 9 
months) 
 Household survey 
(reporting fever in past 2 
weeks) 
 Interviews with franchisee 
 FGDs with caregivers 
 Use of AL (but cannot be attributed 
to franchise scheme) 
[33]  
Provider Training Ethiopia 3 public health 
facilities without 
laboratories (6 
nurses) 
CQ Post + 
comparison  
 Observation of patient 
consultation 
 Exit survey of febrile >5yrs 
(including re-examination) 
 No. of children that providers 
diagnosed with fever compared to 
control (clinical diagnosis by study 
paediatrician) 
[34] 
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Intervention Country,  
Year 
Facility or Outlet First-line 
AM 
Study Design Research instruments Outcome Measures Study 
A) RDT provision vs No 
RDTs 
B) Pre vs post training, 
guidelines, supervision 
Kenya, 
2006 
60 government 
health facilities 
(hospitals, health 
centres, 
dispensaries)  
AL Pre-Post with 
control  
 
 
 Observation of patient 
consultation 
 Exit survey of febrile >5yrs 
(including re-examination 
and microscopy test) 
 % febrile >5yrs with and without 
uncomplicated malaria that 
received recommended AM 
 % febrile >5yrs who were RDT test 
positive and received recommended 
AM 
 % febrile >5yrs who were RDT test 
negative and received ACT 
[35] 
Provider Training 
(microscopy)  
Uganda 
2006 
8 public facilities 
with microscopy 
services (also  
malaria 
surveillance sites) 
AL Pre-Post (after 4 
months) 
 Patient-level surveillance 
data from health facility 
(febrile patients, all ages) 
 Gold standard microscopy 
to determine diagnostic 
accuracy 
 
 % febrile <5yrs / >5yrs who were 
parasite positive and received AM 
 % febrile <5yrs / >5yrs who were 
parasite negative and received AM 
 % <5yrs / >5yrs prescribed AM who 
were prescribed a correct dose 
[36] 
Provider Educational 
Process (peer 
educators) 
 
Kenya, 
2000 
Private sector 
wholesalers and 
drug retail outlets 
SP Post & Control 
 
(Intervention 
arm if poster was 
visible) 
 2 mystery clients per 
facility.  
 Retail audit 
 Mean malaria knowledge score 
(based on 10-question true/false 
quiz) 
 % mystery clients that were sold 
recommended AM (SP) 
 % outlets with the recommended 
AM in stock 
[37] 
Provider Training 
(childhood illness) 
Uganda, 
2002-
2003 
Private clinics and 
drug shops 
CQ + SP Pre-Post (after 3 
months) 
 Mystery clients  % mystery clients supplied 
recommended AM 
 % mystery clients supplied 
recommended AM in the correct 
dose 
 % mystery clients supplied 
recommended AM with correct 
advice on regimen 
[38] 
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Intervention Country,  
Year 
Facility or Outlet First-line 
AM 
Study Design Research instruments Outcome Measures Study 
Provider Training (IMCI) Nigeria, 
Not 
specified 
4 urban public 
health centres (32 
health workers) 
Not 
specified 
Pre-post (after 3 
months) 
 Observation of patient 
consultation (for children 
<5yrs) 
 % of children <5yrs correctly 
(clinically) diagnosed for malaria 
 % of children <5yrs observed that 
received an AM 
 % of children <5yrs observed 
correctly prescribed an AM 
[39] 
Provision of RDTs 
(including training) 
 
Tanzania, 
2005 
6 rural public 
dispensaries 
(without 
microscopy 
services) 
AL Pre-Post (after 8 
weeks) 
 Health facility survey 
 Patient exit survey (incl. 
microscopy and RDT) 
 Qualitative exit interviews 
with patients  
 Qualitative interviews 
with providers 
 % of AM prescriptions that were 
RDT test negative 
[40] 
Pre-packaged AMs 
(compared to routine 
prescription) 
Ghana, 
Not 
specified 
6 public health 
facilities  
CQ Cluster RCT  
(3 facilities as 
intervention, 3 
facilities as 
control) 
 Observations of patient 
consultations 
 Patient exit survey  
 Follow up on day-4 on 
adherence to AM 
 FGDs on perception of 
packaging 
 % of clinical diagnosed malaria cases 
that were given the correct 
prescription 
[41] 
 
* First study site:  no training 1998 vs CQ training 1999 vs SP trained 2000 and 2001; Second study site:  no training 1998 and 1999 vs SP training 2000 and 2001 
Abbreviations: ACT = artemisinin-based combination therapy; AL = artemether lumefantrine; AM = antimalarial; ARI = acute respiratory infection; AQ = amodiaquine; ASAQ 
= artesunate amodiaquine; BCC = behaviour change campaign; CQ = chloroquine; HW = health worker; IMCI = Integrated Management of Childhood Illnesses; NGO = 
nongovernmental organization; N/A = Not applicable; OTC = over the counter; RCT = randomized controlled trial; RDT = rapid diagnostic test; SP = sulphadoxine 
pyrimethamine
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Table 2. Effect of interventions on providers’ ability to presumptively treat uncomplicated malaria 
Intervention Outcome Indicator Pre-Intervention or 
Control Arm 
Post-Intervention or 
Intervention Arm 
Significance Study 
Effect on providers’ knowledge of how to treat malaria 
Provider Training Mean knowledge score (out of 100) 43.2 (n=33) 71.6 (n=37) P<0.001 [30] 
Provider Training (8-day IMCI) Mean knowledge score (out of 100) 28.5 (n=35) 80.0 (n=35) P<0.05 [22] 
Provider Training (5-day IMCI) Mean knowledge score (out of 100) 20.0 (n=50) 80.0 (n=50) P<0.001 [22] 
Provider Educational Process 
(Peer Educators) 
Mean malaria knowledge score (10-question true/false 
quiz) 
7.1 8.7 P<0.001 [37] 
Effect on ability of providers to clinically diagnose malaria 
Provider Training (IMCI) No. of children providers diagnosed with fever compared to 
control (clinical diagnosis by study paediatrician) 
39 248 33% sensitivity 
99% specificity 
[34] 
Effect on proportion of patients that were prescribed or treated with any antimalarial (AM) 
Provider Training  % mystery clients that were sold an AM 58% (n=135)  78% (n=143)  OR:2.6, Not 
specified 
[16] 
Provider Training % mystery clients that were advised to buy an AM 2% (n=224) 54% (n=183) Significant [24] 
Provider Training % mystery clients that were sold an AM 33% (n=78) 27% (n=30) Not significant [27] 
Provider Training (IMCI) % febrile <5yrs observed that received an AM 87% (n=32) 100% (n=46) Not specified [39] 
Provider Training (clinical 
diagnosis) 
% febrile children attending facility that receiving AM 
prescription 
control: 
99% (n=1100) 
algorithm only:  
95% (n=1058) 
Not significant [25] 
Provider Training % of those seeking treatment for fever that were sold an 
AM 
34% (n=289) Post 1yr: 84% (n=237) 
Post 2yr: 79% (n=150) 
P<0.001 
P<0.001 
[23] 
Effect on proportion of patients that were prescribed or treated with the recommended antimalarial (AM) 
Provider Educational Process 
(Peer Educators) 
% mystery clients sold the recommended AM (SP) 5% (n=302) 29% (n=202) P<0.001 [37] 
Provider Training % mystery clients sold the recommended AM (SP) 55% (n=20) 85% (n=20) P<0.01 [26] 
Provider Training % mystery clients sold the recommended AM 21% (n=135) 52% (n=143)  OR: 5.0, P<0.001 [16] 
Provider Training % mystery clients given or recommended correct AM 2% (n=57) 73% (n=66) P<0.001 [38] 
Provider Training + Pre-
packaged antimalarial 
% of mystery clients sold the recommended AM 48% (n=112) 87% (n=100) P<0.01 [43] 
Provider Training + Materials + 
Supervision 
% of febrile patients >5yrs with uncomplicated malaria that 
received recommended treatment 
7% (n=27)  48% (n=13)  P=0.05 [35] 
Provider Training + Materials + 
Supervision 
% of febrile patients >5yrs without uncomplicated malaria 
that received ACT 
13% (n=401) 14% (n=297) P=0.86 [35] 
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Table 3. Effect of interventions on providers’ ability to appropriately treat malaria by improving malaria diagnosis  
Intervention Outcome Indicator Pre-Intervention or 
Control Arm 
Post-Intervention or 
Intervention Arm 
Significance Study 
Effect on providers’ competence in malaria diagnostic testing 
Provider Training (laboratory 
tests) 
% of laboratories surveyed with accurate results for 
malaria microscopy 6-months after training 
84% (n=58) 
 
91% (n=54) 
 
Not specified [18] 
Provider Training (microscopy) Pre-test score and % point improvement following 
training: written examination on knowledge of 
microscopy 
62% (n=77) + 27% (n=77) P<0.001 [29] 
Provider Training (microscopy) Pre-test score and % point improvement following 
training: sensitivity and specificity of slide readings 
74% (n=77) 
76% (n=77) 
+ 14% (n=77) 
+ 17% (n=77) 
P<0.001 
P<0.001 
[29] 
Refresher Training (microscopy) Pre-test score and % point improvement following 
training: written examination on knowledge of 
microscopy 
82% (n=23) + 15% (n=23) P<0.001 [29] 
Refresher Training (microscopy) Pre-test score and % point improvement following 
training: sensitivity and specificity of slide readings 
89% (n=23) 
 
94% (n=23) 
+ 6% (n=23) 
 
+ 3% (n=23) 
Not significant 
Not significant 
[29] 
Provider Training (RDTs) % steps in using RDT performed correctly 
 
80% (n=21) 92% (n=26) P<0.05 [21] 
Provider Training (RDTs) % RDTs read correctly 
 
80% (n=21) 93% (n=26) P<0.05 [21] 
Printed Educational Materials 
(Job Aid on RDTs) 
% steps in using RDT performed correctly 
 
57% (n=32) 80% (n=21) P<0.05 [21] 
Printed Educational Materials 
(Job Aid on RDTs) 
% RDTs read correctly 54% (n=32) 80% (n=21) P<0.05 [21] 
Effect on treatment with antimalarial 
RDT Provision + Provider 
Training 
% of AM prescriptions who were RDT test negative 55% (n=365) 16% (n=168);  Significant [40] 
RDT Provision % of febrile >5yrs who were RDT test positive and 
received recommended treatment 
48% (n=13) 36% (n=13) P=0.04 [35] 
RDT Provision % of febrile >5yrs who were RDT test negative and 
received ACT  
14% (n=297) 11% (n=346)  P=0.30 [35] 
Provider Training % febrile <5yrs who were parasite positive (from 
microscopy) and receiving AM 
95.0% 96.7% P=0.06 [36] 
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Intervention Outcome Indicator Pre-Intervention or 
Control Arm 
Post-Intervention or 
Intervention Arm 
Significance Study 
Provider Training % febrile >5yrs who were parasite positive (from 
microscopy) and receiving AM  
90.4% 90.8% P=0.87 [36] 
Provider Training % febrile <5yrs who were parasite negative (from 
microscopy) and receiving AM 
47.9% 19.6% P<0.001 [36] 
Provider Training % febrile >5yrs who were parasite negative (from 
microscopy) and receiving AM  
38.8% 15.6% P<0.001 [36] 
Provider Training % febrile children attending facility who received AM 
prescription 
algorithm only:  
95% (n=1058)  
algorithm & 
microscopy training  
61% (n=973) 
Significant [25] 
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Table 4. Effect of the interventions on providers’ ability to give accurate dose and advice on regimen 
Intervention Outcome Indicator Pre-Intervention or 
Control Arm 
Post-Intervention or 
Intervention Arm 
Significance Study 
Effect on providers’ ability to provide correct dose of antimalarial 
Provider Training  % providers who know correct dose for 3yr old 25% (n=32) 58% (n=33)  Not specified [28] 
Provider Training  % providers who know correct dose for 5yr old 12.5% (n=32) 30% (n=33) Not specified [28] 
Provider Training (IMCI) % febrile <5yrs observed given an AM in the correct dose 25% (n=135)  88% (n=169) P<0.001 [17] 
Provider Training (IMCI) % febrile <5yrs observed given an AM in the correct dose In 2000: 24% (n=224) 
In 2001: 38% (n=73) 
In 2002: 30% (n=105) 
48% (n=142) 
47% (n=138) 
52% (n=378) 
P<0.001 
Not significant 
P<0.05 
[20, 
31] 
Provider Training (IMCI) % febrile <5yrs observed given an AM in the correct dose 36% (n=32) 84% (n=46) Not specified [39] 
Pre-packaged drugs % of clinically diagnosed malaria cases who were received 
an AM in the correct dose 
74% (n=340) 93% (n=314).  P<0.001 [41] 
Provider Training % patients <5yrs prescribed AM treatment who were 
prescribed a correct dose 
86.3% 89.0% P=0.39 [36] 
Provider Training % patients >5yrs prescribed AM treatment who were 
prescribed a correct dose 
78.6% 79.5% P=0.86 [36] 
Provider Training % mystery clients given or recommended correct AM in 
the correct dose 
 0% (n=57) 50% (n=66) P<0.001 [38] 
Provider Training % of AMs sold in correct dose 
 
32% (n=99); 
 
Post 1yr: 83% (n=199) 
Post 2 yr:90% (n=119) 
P<0.001 
P<0.001 
[23] 
Provider Education Process  
(self-assessment) 
% febrile children observed prescribed AMs in the correct 
dose 
51% (n=160)  62% (n=160); P<0.001 [42] 
Effect on providers’ ability to provide advice on treatment regimen 
Provider Training % mystery clients who were sold the recommended AM 
with correct advice on regimen 
 5% (n=135) 
 
31% (n=143)  
 
OR: 8.8, 
P<0.001 
[16] 
Provider Training % mystery clients who were sold SP who were given 
appropriate advice on regimen 
0% (n=2) 98% (n=98) Significant [24] 
Provider Training % mystery clients who were sold the recommended AM 
with correct advice on regimen 
13% (n=20) 40% (n=20) P<0.01 [26] 
Provider Training % mystery clients who were given or recommended 
correct AM with correct advice on how to administer 
 8% (n=57) 49% (n=66) P<0.001 [38] 
Provider Training % of AMs sold with advice on use 
 
2% (n=99) Post 1yr: 94% (n=199) 
Post 2 yr: 98% (n=119) 
P<0.001 
P<0.001 
[23] 
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2.3 Conceptual framework  
A conceptual framework was developed to integrate insights from the conceptual and 
empirical literature reviews and illustrate what factors may influence providers’ 
preference over alternative antimalarials for uncomplicated malaria and their practice 
when treating patients with malaria symptoms (Figure 1).  
The framework is founded in the agency theory and applies to patient-provider 
relationships that are characterised by information asymmetry in which the provider 
makes treatment decisions on behalf of the patient. The conceptual framework 
distinguishes between the treatment that the provider prefers to supply for a given illness 
and the treatment the provider actually supplies to an individual patient. Thus, it is 
acknowledged that there may be differences between the provider’s stated preference and 
their revealed preference (i.e. practice). Preferences may also be shaped by the prevailing 
institutional and social environment. 
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Figure 1. Conceptual framework on providers’ preference and practice 
 
INSTITUTIONAL AND SOCIAL ENVIRONMENT 
(regulation, taxation, social structures, roles, culture, values,  
psychology, peer expectations, norms, risk preferences) 
 
MULITPLE PRINCIPALS 
EMPLOYER 
ANTI-
MALARIAL 
SUPPLIERS 
MINISTRY 
OF HEALTH 
PATIENTS 
PATIENT-SPECIFIC 
INFORMATION 
* About illness: symptoms, 
examination & tests 
* Consumer demand 
PROVIDERS’ 
(STATED) 
PREFERENCE 
INFORMATION 
* From policy documents, 
training, other actors 
RESOURCES AVAILABLE 
* Equipment & medicines 
* Patient’s finances 
FINANCIAL 
INCENTIVES 
(includes any potential 
future income) 
NON-FINANCIAL 
INCENTIVES 
(includes motivation to 
improve patient’s 
health & satisfy others) 
PROVIDERS’ 
PRACTICE 
2. LITERATURE REVIEW 
 
84 
 
In summary, the framework shows that the provider’s preference depends on financial 
and non-financial incentives, subject to the information she has available. The 
provider’s financial and non-financial incentives are determined by the contractual 
relationships the provider has with the patient and also with other principals for whom 
the provider acts as an agent. These may include her employer, policy makers in the 
Ministry of Health or suppliers of pharmaceutical products. The multiple principals 
may also influence the information the provider has about different treatment options. 
The providers’ practice (the treatment supplied) is expected to reflect the provider’s 
stated preference, though may be constrained by information the provider acquires 
about the patient, explicit demands of their patients, the resources available at the 
facility, or the patient’s ability to pay for treatment.  Finally, the framework includes the 
institutional environment, which recognizes that there may be other factors that 
influence the provider’s preference and her practice. 
The empirical literature review showed that most interventions to improve providers’ 
ability to diagnose and treat malaria focused on the information and resources 
available. For example, the vast majority of the interventions involved training, often 
using conventional methods to disseminate information about the malaria treatment 
guidelines, or introduced RDTs. However, there were some interventions where the 
mechanism of effect would reflect the role of multiple principals. For instance, peer-
education or supervision may shape providers’ preference through non-financial 
incentives by appealing to the provider’s desire to please or satisfy others. 
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2.4  Summary 
The introduction outlined the changes to the WHO malaria treatment guidelines that 
have taken place over the past decade:  first, the recommendation that ACT became the 
first-line treatment for uncomplicated malaria, and second, the recommendation that 
all febrile patients are tested for malaria before treatment is supplied. The introduction 
also noted that the care received by febrile patients often falls short of the standard set 
out the in the malaria treatment guidelines: not all febrile patients receive the 
recommended antimalarial, relatively few febrile patients are tested for malaria, and it 
was common for patients who tested negative for malaria to be given an antimalarial. 
As providers are often responsible for the care received, we need a better 
understanding of what determines their practice, and what interventions could be used 
to improve providers’ adherence to malaria treatment guidelines.  
Economic theory offers a perspective from which to explore providers’ practice. The 
review of the conceptual literature indicated how agency theory and thinking from new 
institutional economics and behavioural economics may help us understand both their 
preference and their practice, and identify potential mechanisms for changing provider 
behaviour. The review of the empirical literature on interventions to improve 
providers’ ability to diagnose and treat malaria indicated interventions can have a 
positive effect. For example, training was widely used and often effective in changing 
the knowledge, competence and practice of providers treating febrile illness, though 
the magnitude of effect varied considerably. The review also indicated that introducing 
RDTs can reduce the over-consumption of antimalarials, though in several studies the 
proportion of test-negative patients who received an antimalarial remained relatively 
high. 
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 The evidence summarised in the introduction and literature reviews suggest areas for 
further research. Studies on the care provided to febrile patients highlighted 
considerable variation between geographic settings and type of provider, and this 
suggests that it would be important to understand the environment in which providers 
work and the prevailing policy context before making decisions on how to expand 
access to malaria testing, and what interventions could be used to change providers’ 
practice. The review indicated training can be an effective intervention, though it also 
highlighted several design considerations. These include the content, length and style 
of the training, the potential for interactive and participatory sessions, the 
supplementary educational materials required, and also the role for refresher training 
and supervision. Moreover, if training is to be considered as in intervention, it would be 
valuable to understand the extent to which providers’ preference and practice are 
consistent with their knowledge of the malaria treatment guidelines. This may indicate 
where conventional approaches to training, which focus on providers’ knowledge of the 
clinical guidelines, are likely to achieve a change in providers’ practice, or whether 
additional intervention may be needed.
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3.  Study Setting 
 
This Chapter describes the setting for the research contained in this thesis, which for the 
purposes of this chapter refers to describes both the geographic context and also the 
larger project in which the PhD was situated. Section 3.1 introduces the study sites, 
including the national malaria treatment guidelines and the types of facility from which 
malaria treatment can be obtained. Section 3.2 provides an overview of the REACT project 
and its implementation. Section 3.3 is the published trial protocol for the REACT study in 
Cameroon. It contains a detailed description of the interventions and the study design 
used to evaluate their effect on the treatment received by febrile patients. 
3.1 Study sites in Cameroon and Nigeria 
The research was undertaken at public and mission health facilities, pharmacies and 
medicine retailers in urban and rural areas of Cameroon and Nigeria.  
Cameroon 
In Cameroon the two sites were Yaoundé in the Centre region, and Bamenda and 
surrounding areas in the Northwest region. The Yaoundé study site encompasses seven 
urban health districts and has an estimated population of 2.5 million, who are 
predominantly French-speaking. The Bamenda study site consists of an urban health 
district and seven rural health districts that lie within a 21 km radius. The region has a 
population of approximately 2 million, and English and pidgin-English are widely spoken. 
Malaria is endemic in both study sites and they both have a long rainy season, which lasts 
between March and November. In Yaoundé the heaviest rains are in April-May and 
September-October, while in Bamenda there are heavy rains between June and October.  
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The health system in Cameroon is divided into three levels: i) central services of the 
Ministry of Public Health including management of tertiary hospitals, ii) regional 
delegations who manage the referral hospitals and oversee the distribution of 
pharmaceutical products and medical supplies to all public facilities within each region, 
and iii) health districts who are responsible for operational services at the peripheral 
level, including district hospitals and primary health care centres.  
Service delivery in the public health system is adversely affected by a shortage of trained 
staff in rural health facilities; inadequate staff supervision; insufficient equipment and 
medical supplies; a weak health management information system; and limited community 
involvement, which has resulted in low utilization of health services[1].   
As Cameroon has one of the highest densities of doctors and nurses in sub-Saharan Africa, 
the main issue on human resources is not the number of workers, but their distribution 
[2]. The majority of staff are concentrated in urban areas and it is estimated that almost 
40% of the doctors work in the Centre region, which is home to 18% of the population [2]. 
Absenteeism is also a key issue and signals a lack of motivation. This has been attributed 
to the working conditions, including the inadequate availability of equipment, drugs and 
other medical supplies, limited supervision and few opportunities for career progression. 
The health system also includes facilities owned and operated by mission organizations, 
such as the Catholic Church, and private sector providers. There are mission facilities at all 
three levels of the health system, and they operate in rural as well as urban areas. Like the 
government system, mission facilities receive supplies from a central pharmaceutical 
agency and they charge user fees for the services provided. Private sector clinics and 
private pharmacies operate with the permission of the regional delegation of the Ministry 
of Public Health and tend to be found in urban and semi-urban areas. Other actors in the 
health system are not formally recognized, and these include drug stores who retail over-
the-counter medicines in the two Anglophone regions of Cameroon; itinerant medicine 
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vendors; common initiative groups registered under the Ministry of Agriculture who offer 
some basic health care; traditional healers; and herbalists. Nigeria 
The Nigerian study sites were in Enugu State in south-east Nigeria. The two sites were 
urban communities in Enugu and rural communities in Udi. Enugu State has a population 
of 3.3 million people, the majority of whom are of Igbo ethnicity and speak the Igbo 
language. The study sites are similar in terms of language and culture, though as a rural 
setting, there are fewer public health facilities and pharmacies in Udi. Malaria is endemic 
in Enugu state, and occurs all year round. The rainy season is between May and October. 
In Nigeria, the Federal Ministry of Health is responsible for health policy decisions, though 
much of the system is decentralized to the State and Local Government Levels. The district 
health system in Enugu operates with health posts, health dispensaries, and health centres 
at the primary level, and with cottage and district hospitals at the secondary level [3]. 
There is also a university teaching hospital in Enugu which provides referral services. The 
health system is structured so that district hospitals should supervise the primary health 
centres and cottage hospitals in their district, though in practice supervision is limited and 
there are weak or non-existent referral mechanisms between health centres and hospitals 
[3]. There are also major problems with the resources available at the primary care level, 
and shortages of basic drugs and supplies are relatively common. 
Service delivery in the public health system is severely constrained by the availability of 
trained health workers. Doctors are rare at the primary care level and most health centres 
are ran by nurses and community health extension workers, who are semi-skilled and 
have received one or two years of training. In addition, health workers tend to be 
concentrated in urban areas, while more than 70% of the population in Enugu State 
resides in rural areas [3]. Supervision and monitoring of health workers is largely 
ineffective as many health workers lack motivation and are frustrated by resource 
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constraints absenteeism is common and it is not unusual for health posts and health clinics 
to be closed [3]. Public sector strikes also interrupt the provision of primary care. 
There are, however, also a wide range of private sector providers operating in Enugu 
State. These include a private hospital and private clinics operating in urban Enugu as well 
as private sector pharmacies and drug stores, known as patent medicine dealers. 
Pharmacies tend to be located in urban areas, while drug stores can be found in both 
urban and rural settings, and these are often the first point of contact for many individuals 
seeking treatment. In Nigeria, pharmacies and patent medicine dealers are formally 
recognised in the health care system and are governed by professional organizations, 
namely the Pharmaceutical Association of Nigeria and the Association of Patent Medicine 
Dealers. Finally, there are traditional providers of health care, including traditional birth 
attendants, and herbalists operating in Enugu State. 
Malaria diagnosis and treatment in Cameroon and Nigeria 
In both countries, malaria treatment guidelines advise malaria should be suspected in all 
patients presenting with fever or a history of fever in the previous 24 hours [4, 5]. Malaria 
testing is recommended though not always available, and in the absence of a confirmed 
diagnosis antimalarials should be taken presumptively, based on symptoms alone. ACT 
has been the first-line treatment for uncomplicated malaria (in all patients except 
pregnant women) since 2004 in Cameroon and since 2005 in Nigeria. Antimalarials, 
including ACT, have over-the-counter status in Cameroon and Nigeria and can be obtained 
from pharmacies and drug stores as well as public, mission and private facilities. Malaria 
treatment may also be sought from mobile medicine vendors, herbalists and traditional 
healers. Patients pay for treatment at all types of facility, though both countries have 
exemptions for children under five and pregnant women attending public facilities.  
In Cameroon, public and mission facilities, and private pharmacies are the main source of 
treatment for uncomplicated malaria. Most public and mission hospitals and health 
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centres in the Cameroon sites have a pharmacy and a laboratory for simple diagnostic 
procedures and are staffed by nurses, pharmacy attendants and laboratory technicians. 
Some larger facilities also have a medical doctor. In the private sector, pharmacies are 
legally required to employ a qualified pharmacist and licensed to sell prescription and 
over-the-counter medicines. In addition, antimalarials are available at drug stores in the 
North-West region, which are typically owned and staffed by providers with no or few 
qualifications.  
In Enugu State, Nigeria, treatment for uncomplicated malaria is most frequently obtained 
at public health centres, pharmacies and drug stores (known locally as patent medicine 
dealers). Malaria diagnostic testing is not widely available at the primary care level and 
public facilities are staffed by nurses, community health officers and extension workers. 
For-profit pharmacies and drug stores are formally recognised in the health system and 
have professional associations. Licensed pharmacies are required to have a qualified 
pharmacist, while patent medicine dealers are not required to have specific qualifications 
or training and are formally restricted from selling prescription-only medicine.  
3.2 Research on Economics of ACT (REACT) Project 
The aim of the REACT project was to improve the diagnosis and treatment of 
uncomplicated malaria in Cameroon and Nigeria. The project commenced in 2009 and 
continued until 2013. REACT was financed by the ACT Consortium, which was supported 
through a grant from the Bill & Melinda Gates Foundation to the London School of Hygiene 
and Tropical Medicine (www.actconsortium.org).   
REACT was founded on the principle that the project should respond to policy priorities in 
each country and take an evidence-based approach. This required close collaboration with 
the National Malaria Control Programme in Cameroon and the Enugu State Malaria 
3. STUDY SETTING 
 
92 
 
Control Programme in Nigeria. Extensive formative research was also critical to identify 
priorities and design interventions tailored to each study setting.  
REACT was implemented in four phases: 
1. Formative research to understand how malaria was diagnosed and treated at 
different types of facility. 
2. Design interventions to support the introduction of malaria rapid diagnostic tests 
and improve providers’ adherence to malaria treatment guidelines. 
3. Implement interventions and evaluate their effectiveness and cost-effectiveness. 
4. Disseminate research findings. 
The formative research involved quantitative and qualitative research in all four study 
sites. Patient exit surveys were conducted at different types of health facility to determine 
the proportion of febrile patients tested for malaria, and the proportion of febrile patients 
who received an ACT, the first-line antimalarial. The patient exit surveys were 
accompanied by provider and facility surveys. Survey results highlighted the limited 
availability of malaria testing, and treatment practices that did not adhere to the malaria 
treatment guidelines (Research Papers I and II) [6, 7]. The findings led to additional 
research:  
 Secondary analysis of the survey data to examine the providers’ knowledge, 
preference and practice for treating uncomplicated malaria (Research Papers III 
and IV) [8, 9]. 
 Focus group discussions with community members and in-depth interventions 
with providers in Nigeria to explore the potential for malaria rapid diagnostic 
testing [10].  
 Focus group discussions with health workers at public and mission facilities in 
Cameroon to explore their perceptions of malaria testing and the reasons why 
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antimalarials were prescribed to patients who tested negative for malaria 
(Appendix B) [11]. 
The findings from the formative research in Cameroon and Nigeria were shared with 
representatives from their respective Malaria Control Programmes in 2010, shortly after 
the WHO had published revised malaria treatment guidelines that confirmed RDTs are a 
valid alternative to malaria microscopy [12]. In these discussions it was agreed REACT 
should design interventions to support the introduction of malaria RDTs and address 
problems with providers’ practice. However, the interventions needed to be tailored to the 
country context since the formative research had demonstrated substantial differences 
between the two countries.  
In Nigeria, the State Malaria Control Programme (SMCP) indicated they wanted REACT to 
intervene in primary health facilities, private sector pharmacies and drug stores, as these 
types of facilities are often the first point of contact individuals seeking treatment for 
febrile illness. The formative research showed that malaria treatment was often 
presumptive since access to malaria testing was extremely limited, and there were major 
problems with the type of antimalarial supplied, with less than a quarter of febrile patients 
receiving an ACT. The formative research also highlighted the extent to which patients and 
caregivers at pharmacies and drug stores asked for a specific medicine.  
As a result it was agreed that an intervention in Nigeria would need to address the 
knowledge and practice of providers, and also the knowledge and preferences of those 
seeking treatment. Following discussions between the SMCP and the REACT team, it was 
agreed that RDTs would be introduced in all facilities and medicine retail outlets 
participating in the trial and the project would evaluate the effectiveness of a provider 
training intervention that sought to improve the knowledge and practice of providers and 
the combined effectiveness of a provider and community intervention, with the latter 
engaging school teachers and school-children to raise awareness about malaria testing 
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with RDTs and also that ACT is the recommended treatment for confirmed cases of 
uncomplicated malaria [13]. Interventions were designed and evaluated in Nigeria, though 
I have not included this research in my thesis. 
My thesis does, however, include research undertaken to evaluate the cost-effectiveness of 
the interventions implemented in Cameroon since the study was closely aligned to my 
interests on providers’ knowledge, preference and practice and I had a lead role in 
economic evaluation. The remainder of this section explains the rationale and design of 
the REACT study in Cameroon, and includes a copy of the published trial protocol [14]. 
The National Malaria Control Programme (NMCP) in Cameroon indicated they wanted 
REACT to focus on introducing RDTs at public and mission health facilities. Having found 
that malaria testing was underused and it was common for febrile patients who tested 
negative to be prescribed an antimalarial, it was agreed that the intervention would need 
to encourage providers to test for malaria before prescribing treatment and to ensure that 
the treatment prescribed should be based on the test result [6]. Also for the intervention 
to be accepted by the NMCP, it was important for the intervention to be relatively 
inexpensive, easy to replicate on a larger scale and tested in a setting as close to the ‘real-
world’ as possible. On this basis financial incentives were ruled out since the NMCP had 
indicated they had concerns about their affordability and sustainability over the longer 
term. Similarly, it was agreed that the project would not intervene to control the supply of 
ACT and that the process by which RDTs were supplied to facilities would need to be 
agreed by the NMCP. 
A training intervention was considered since the literature review had shown training can 
improve providers’ practice, though we were also aware training was not identified as a 
significant predictor in either the primary analysis (Research Paper II) or the secondary 
analysis on the relationship between providers’ knowledge and practice (Research Paper 
IV). On the other hand, there was evidence that providers’ stated preference (Research 
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Paper III) may depend on the source and method of communication and literature review 
had emphasized the importance of considering not only the content and length of the 
training but also the difference between passive and active learning. It was finally agreed 
two different training interventions would be evaluated. 
Figure 2 summarizes the development of REACT in Cameroon. It illustrates the key steps 
that followed formative research, including the selection and design of interventions, 
implementation and evaluation. For example, it shows how the literature review on 
interventions to improve providers’ ability to diagnose and treat uncomplicated malaria 
informed the selection of interventions.  
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Figure 2. Development of REACT in Cameroon 
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The trial protocol, which contains detail on the interventions designed and evaluated by 
REACT in Cameroon, has been included in the Section 3.3 [14]. In summary, two types of 
training interventions were selected: one-day ‘basic’ training that sought to ensure 
providers knew the malaria treatment guidelines and were able to use an RDT; and 
‘enhanced’ training over three days that covered the basic training and included additional 
activities that focused on changing providers’ practice. The activities included in the 
enhanced training were intended to reinforce key messages about malaria diagnosis and 
treatment, and were based on findings from the formative research. For example, small-
group exercises were used, in which providers worked together to discuss challenges and 
identify possible solutions because we had learnt providers can be influenced by other 
health workers. A module on communicating with patients was also included because 
providers were found to be influenced by their patients and role-playing was used to 
generate ideas and skills for how providers could better manage patient expectations. 
Training modules and materials were designed and piloted, and the final versions were 
endorsed by the National Malaria Control Programme. In addition, I developed a logic 
model to depict how we expected the training interventions to change providers’ 
knowledge and practice, and used the logic model to identify what data would be needed 
to evaluate their effect (Figure 3).  
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Figure 3. Logic Model for REACT Cameroon 
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The final study design was a three-arm cluster-randomized trial and this was used 
evaluate the effect of the interventions on providers’ practice. Clusters were public and 
mission health facilities in the study sites which had microscopy available. The three arms 
of the trial were: 
 Basic intervention: RDTs supplied monthly to health facilities. One-day training for 
up to 3 participants per facility. Lectures on malaria diagnosis and treatment and a 
practical session on using RDTs. Participants received the malaria treatment 
guidelines, a training manual and job aids. Participants were also encouraged to 
conduct peer-to-peer ‘in-facility’ training for their colleagues. 
 Enhanced intervention: All aspects of the basic intervention, plus two-days of 
supplementary training using participatory methods, such as small-group work 
with problem-solving exercises, games, and drama.  
 Control: Current practice (microscopy testing was available) 
The effect of the intervention was measured using a composite indicator that required 
patients to be tested for malaria, receive an ACT if the test result was positive, and receive 
no antimalarial if the test result was negative. Thus, the primary outcome measures 
whether the provider adheres to the malaria treatment guidelines, and allows us to assess 
whether the interventions were effective in changing how they diagnose and treat patients 
who present with a fever.  
While this primary outcome does allow us to evaluate the effect of the intervention, we 
also recognised it has limitations. The outcome does not capture whether cases of non-
malaria febrile illness (i.e. patients who tested negative for malaria and whose fever has 
other causes) were appropriately treated and does not report the effect of the intervention 
on the patient’s health outcome. Given the uncertainty surrounding the non-malaria 
causes of febrile illness and the resources available for the REACT project it was agreed 
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the project should focus on whether providers’ adhered to the malaria treatment 
guidelines rather than the appropriate management of febrile illness. Similarly, the REACT 
team agreed it was not a priority to evaluate the specificity and sensitivity of malaria tests 
conducted since requiring all patients to be independently tested for malaria could 
influence the uptake of malaria testing and make it difficult to assess whether the 
intervention had any effect on the proportion of patients who were tested during their 
consultation. The project also lacked the financial resources required to follow up patients 
and ascertain whether subsequent care was sought for the illness episode and their final 
health outcome. 
The cost-effectiveness of the two training interventions was evaluated compared to 
current practice and the incremental cost per febrile patient correctly treated (according 
to the malaria treatment guidelines) was estimated. The analysis uses statistical methods 
suitable for individual patient data on costs and effects obtained from a cluster 
randomized trial [15, 16]. This involved taking into account the potential for correlation 
between costs and effects at the individual-level and cluster-level, intra-cluster 
correlation, and imbalance in selected baseline characteristics across the study arms.  Two 
scenarios were analysed: a base-case which estimated the cost-effectiveness of the 
interventions compared to current practice as implemented for the trial, and a ‘scale-up 
scenario’ in which the start-up costs were treated as a sunk cost, and it was assumed the 
training would be held every two years. The estimates from the latter should be useful for 
policy makers in Cameroon deciding whether to scale-up the introduction of RDTs with 
health worker training. The economic evaluation focused on the treatment supplied in a 
single consultation, rather than the health outcome of the illness episode, since it would 
not have been possible to estimate the number of deaths (or disability-adjusted life-years) 
averted without making several assumptions about the specificity and sensitivity of each 
diagnostic methods, causes of non-malaria febrile illness, patient adherence to medication, 
or the costs and effects of subsequent treatment seeking. This is a limitation, though there 
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are plans to synthesize findings across multiple cost-effectiveness studies undertaken 
within the ACT Consortium, which will include data on the accuracy of microscopy and 
RDTs in routine use and data from following up febrile patients. 
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3.3 Trial protocol for REACT study in Cameroon 
The trial protocol describes the interventions and the study design used to evaluate their 
effect on malaria diagnosis and treatment in Cameroon. The trial was designed following 
extensive formative research (described in Research Papers II, III and IV and Appendix B) 
and sought to increase the use of malaria testing in public and mission facilities and 
encourage providers to prescribe treatment based the test result. The trial evaluated the 
effectiveness and cost-effectiveness of introducing RDTs with either basic or enhanced 
provider training, where the basic training sought to improve providers’ knowledge of the 
malaria treatment guidelines and the enhanced training focused on changing providers’ 
practice. 
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Abstract
Background: Governments and donors all over Africa are searching for sustainable, affordable and cost-effective
ways to improve the quality of malaria case management. Widespread deficiencies have been reported in the
prescribing and counselling practices of health care providers treating febrile patients in both public and private
health facilities. Cameroon is no exception with low levels of adherence to national guidelines, the frequent
selection of non-recommended antimalarials and the use of incorrect dosages. This study evaluates the
effectiveness and cost-effectiveness of introducing two different provider training packages, alongside rapid
diagnostic tests (RDTs), designed to equip providers with the knowledge and practical skills needed to effectively
diagnose and treat febrile patients. The overall aim is to target antimalarial treatment better and to facilitate
optimal use of malaria treatment guidelines.
Methods/Design: A 3-arm stratified, cluster randomized trial will be conducted to assess whether introducing
RDTs with provider training (basic or enhanced) is more cost-effective than current practice without RDTs, and
whether there is a difference in the cost effectiveness of the provider training interventions. The primary outcome
is the proportion of patients attending facilities that report a fever or suspected malaria and receive treatment
according to malaria guidelines. This will be measured by surveying patients (or caregivers) as they exit public and
mission health facilities. Cost-effectiveness will be presented in terms of the primary outcome and a range of
secondary outcomes, including changes in provider knowledge. Costs will be estimated from a societal and
provider perspective using standard economic evaluation methodologies.
Trial Registration: ClinicalTrials.gov: NCT00981877
Keywords: Cost-effectiveness, malaria, Rapid Diagnostics tests (RDTs)
Background
Governments and donors all over Africa are searching for
sustainable, affordable and cost-effective ways to improve
the quality of malaria case management. Widespread
deficiencies have been reported in the prescribing and
counselling practices of providers (by which we mean
health workers) responsible for treating febrile patients
attending public and private facilities [1-8]. Similar pro-
blems have been reported in Cameroon where malaria
accounts for 35%-40% of all deaths, 50% of morbidity
among children under the age of five, 40%-45% of medi-
cal consultations and 30% of hospitalizations [9,10].
Despite widespread availability of malaria testing using
microscopy in public and private facilities in Cameroon
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and recent guidelines from the World Health Organiza-
tion (WHO) recommending parasitological confirmation
of suspected malaria cases in all patients before treat-
ment where testing facilities are available [11], sympto-
matic diagnosis of malaria remains routine in more than
50% of consultations [12]. There is, however, increasing
interest in scaling up the use of rapid diagnostic tests
(RDTs) to expand access to parasitological diagnosis and
improving malaria case management. The Government
of Cameroon is piloting the introduction of RDTs into
communities in 50 health districts in the national terri-
tory [13]. This policy initiative is based on the premise
that making RDTs available will make it quicker and
easier to test and in turn, promote the rational use of
artemisinin-based combination therapy (ACT).
The appeal of RDTs lies in their high specificity and
sensitivity. They are relatively simple to use compared
with microscopy and do not require specialised skills or
laboratory equipment and reagents that are often una-
vailable in rural or resource poor settings [14]. RDTs are
also seen as the solution to malaria over-diagnosis, a
practice that can be costly [15] and result in poorer
health through delays in access to treatment of the cor-
rect diagnosis and repeated treatment seeking costs [16].
Misdiagnosis may also contribute to increasing antima-
larial drug pressure and thus resistance, thereby speeding
up the ineffectiveness of available and affordable drugs
[17]. Hence there is both a human and an economic case
for introducing RDTs compared with existing presump-
tive treatment. However, in order for the full benefits of
RDTs to be realised, supporting interventions that encou-
rage health workers to deliver treatment that is consistent
with malaria guidelines are likely to be needed.
The diagnosis and subsequent treatment of malaria is a
complex decision making process [18]. Interventions
must be sympathetic to a wide range of issues that provi-
ders face including a lack of training in the use of RDTs
especially among more junior staff [19], a distrust of test
results particularly negative ones [6,20,21], lack of alter-
native drugs with which to treat fever patients [19,22]
and patient demand for inappropriate medicines
[8,19,23]. All of these issues have been shown to affect
whether a malaria test is done and in turn acted upon.
If diagnostic and prescribing practices of providers are
to be improved through the large-scale procurement and
deployment of RDTs and ACTs in countries such as
Cameroon, some level of supporting interventions are
likely to be needed, or the intended benefits of these
investments may be seriously undermined. The WHO
recommends that a number of conditions are in place
before integrating and scaling up the use of RDTs in
malaria control and primary health care services includ-
ing provider training, monitoring how the test is used
and the establishment of clear guidelines that incorporate
a diagnosis and treatment algorithm that includes RDTs
[24]. To date, the most cost-effective composition of
training for providers is not known. There are arguments
for both a basic introduction to the tests that will require
few resources to implement, and for a more comprehen-
sive programme that not only equips providers with the
knowledge of the malaria guidelines and skills to use
RDTs, but also strives to improve the quality of malaria
case management by supporting providers to change
their practice and manage patient expectations, especially
when the malaria test is negative. This study will use a
cluster randomized controlled trial to help identify, in
routine health facility scenarios, which of these options is
most effective and cost-effective in equipping providers
with the knowledge and practical skills needed to effec-
tively diagnose and treat febrile patients. It is important
to compare these options for supporting RDT introduc-
tion with current practice in the absence of RDTs but
where microscopy is widely available, in order to identify
whether there is a value to introducing these new tests
at all.
A strength of this trial is that the chosen provider
interventions target several specific problems identified
through our own formative research that undermine the
implementation of malaria treatment guidelines in
Cameroon. Between May and November 2009, a cross-
sectional cluster survey and series of focus group discus-
sions were conducted to understand current practices in
delivering malaria treatment in the two sites targeted for
the evaluation. It was revealed that all mission and
almost 90% of public health facilities have microscopy
testing available, though only about a third used it. Qui-
nine, which should be reserved only for cases of severe
malaria, was often used for the treatment of uncompli-
cated malaria. Factors affecting providers’ choice of
treatment appeared to be broader than simple consid-
eration of the test result, with many patients receiving
antimalairals they do not need. Some of the issues iden-
tified were unique to the local setting while others
reflect problems experienced across the country and
elsewhere. A description of the methods and results of
the formative research have been published elsewhere
[12,25].
Finally, this study also makes an important contribu-
tion to the pursuit of efficiency. While evaluations of a
wide range of provider training interventions have been
reported in the literature [26-28] using an equally wide
range of methods, few of these enable the assessment of
the relative value for money of these interventions. This
study will provide much needed information on the
cost-effectiveness of the selected provider training inter-
ventions which will aid health care planners in their
decisions over how to allocate scarce health care
resources.
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Methods/design
This study is a 3-arm stratified cluster randomised con-
trolled trial across 47 health facilities in two areas of
Cameroon. The intervention is being delivered at the facil-
ity level and therefore this will be the unit of randomisa-
tion with study site as the stratum. Outcomes will be
assessed through exit interviews with patients as well as
health facility surveys. Economic and financial costs will
also be measured to enable the calculation of incremental
cost-effectiveness ratios. Ethical approval for this study
was obtained from the Cameroon National Ethics Com-
mittee and the London School of Hygiene and Tropical
Medicine.
Study area and participants
The two study sites are Yaoundé and Bamenda in the
Centre and Northwest regions respectively. The Bamenda
study site consists of an urban health district and seven
rural health districts that lie within a 21 km radius. It is
predominantly an English and pidgin-English speaking
region with an estimated population of 2 million. The
Yaoundé study site encompasses seven urban health dis-
tricts and has an estimated population of 2.5 million that
is predominantly French-speaking.
Although both study sites lie within the forest ecological
zone of Cameroon favorable for the development of the
Plasmodium parasite and Anopheles vector, they have dif-
ferent climatic patterns. The Yaoundé study site has two
main seasons: the long wet season that lasts from February
to November (with more intense rains between September
and November) and a short dry season from December to
January. Transmission in this site is perennial with an
inoculation rate of over 100 infected bites per person per
month. The Bamenda study site is characterized by one
long rainy season (March - October) of intense transmis-
sion with inoculation rates of 20 infected bites per person
per month. In 2004, the forest ecological zone accounted
for 40.6% of the total malaria morbidity (40.1%) recorded
in the general population [29,30].
All public and mission health facilities have been enum-
erated and GPS mapped. Health facilities were informed
of the proposed study and asked to give verbal consent
before GPS coordinates were obtained. They include pub-
lic district hospitals and health centres, mission hospitals
and mission health centres. The health centres are staffed
by nurses and sometimes medical doctors. Each of these
health facilities has a propharmacy with a pharmacy atten-
dant and a laboratary for simple diagnostic procedures
including microscopy testing.
Facilities will be selected at random within each stratum
from those that are not included in the Government pilot
roll-out of RDTs, do not solely offer specialist services, see
4 or more febrile patients per day, and are accessible by
road throughout the wet season. Selected facilities will be
asked to give written consent prior to randomisation. If
facility-level consent is not provided replacement facilities
will be randomly selected from the remaining list of
eligible facilities.
Contamination may occur if providers that have
received basic or enhanced training meet to discuss
their training or if they meet with providers from the
control facilities. This may result in information or stra-
tegies being shared, the effect of the intervention
spreading to control clusters and possible dilution of
differences between treatment arms. In order to reduce
the risk of contamination, the different intervention and
control facilities are separated by a buffer area. Specifi-
cally, facilities within the same health area will be
selected if they are ≥ 2 km from another facility in
Bamenda and ≥ 1 km in Yaoundé.
All patients (or their caregiver) attending the health
facilities will be approached on exit for consent to parti-
cipate in an exit survey and screened for their eligibility.
Patients will be eligible if they are present at the facility
and they (or their caregiver) report seeking treatment
for fever or suspected malaria. Patients will be excluded
if they are pregnant, less than 6 months old or have
signs and symptoms of severe malaria. All providers that
are responsible for diagnosis and treatment of suspected
cases of malaria will be eligible to participate in the pro-
vider survey.
Interviewers will explain to all participants that invol-
vement in the study is voluntary and they have the right
to withdraw at any point in time and ask any questions.
Information about the study will be read to all partici-
pants and provided in hard copy. All participants will be
asked if they give their consent to take part in the study
and if so, asked to sign the standard consent form.
Interventions
Health facilities will be randomised to either current
practice or one of the two provider interventions. The
basic intervention is the introduction of RDTs with basic
provider training on malaria diagnosis and treatment
while the enhanced intervention will be the introduction
of RDTs with enhanced provider training. The enhanced
training covers the material in the basic training and also
strives to improve the quality of care by supporting pro-
viders to adapt their practice by encouraging further dis-
cussion of the malaria guidelines, interactive self-
awareness, improve their ability to communication with
patients and colleagues.
Supply of RDTs
Facilities randomised to either the basic intervention or
the enhanced intervention will be supplied with RDTs
for use in diagnosing malaria. The RDT that will be
Wiseman et al. Trials 2012, 13:4
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used is SD Bioline Malaria Ag Pf/Pan which is able to
detect P. falciparum, P.vivax, P. malariae or P.ovale.
This test was chosen in conjunction with the National
Malaria Control Programme and is reported to have a
minimum detection rate of for P. falciparum of 97.5%
even at low levels of parasitaemia (200 parasites/μl) [31].
The supply of RDTs is intended to be relatively stable
in order to assess the impact of the two provider inter-
ventions in the context of a reliable supply system.
RDTs will be provided by the study team, free of charge,
on a four-weekly rotation basis. Estimates of RDTs
required will be determined in discussion with the facil-
ity head and based on routine records of the number of
febrile patients that a facility can expect during a month
(taking into account seasonal variations). Members of
the research team will deliver RDTs to the facilities at
the start of each month with the option for replenish-
ment between delivery dates. Stock management records
will be kept by the study team to monitor the distribu-
tion of these RDTs.
Facilities will be requested not to charge for the use of
an RDT in children <5 years, but will be able to charge
a token fee of at most 100CFA (0.2USD) for all patients
above 5 years of age. Currently there is no national pol-
icy for the cost of RDTs in health facilities. Facilities are
routinely supplied with ACTs and we will not alter the
current distribution of medicines by the government or
mission authorities. Our formative research found that
more than 80% of public and mission facilities had
ACTs in stock. In the analysis we will take into account
that stock-outs of ACTs would prevent patients from
receiving ACTs by also considering a secondary out-
come which allows either prescription or receipt of an
ACT.
Basic Provider Training (BT)
Facilities randomised to the basic intervention will be
supplied RDTs and receive basic provider training on
malaria diagnosis and treatment. This training is
intended to mimic the style of workshop that is routinely
implemented as in-service health worker training. The
training will be conducted over one day and contain
three training modules: 1) Malaria Diagnosis; 2) Rapid
Diagnostic Testing; 3) Malaria Treatment. Together
these three training modules will provide health workers
with the knowledge and skills on why malaria testing is
recommended, how to use an RDT, the treatment algo-
rithm and details contained in the malaria guidelines.
The malaria guidelines state how confirmed cases of
uncomplicated malaria should be treated, including
advice on dosing and treatment regimens for different
types of ACT. The training also provides advice on other
causes of febrile illness which should be investigated if
the malaria test is negative. The module on RDTs
includes a practical session in which all health workers
will get hands-on experience of the steps involved in
using an RDT.
The training will be conducted in conference halls of
health districts located in both study sites. The following
types of providers will be invited to the training: medical
doctors, nurses, laboratory technicians and pharmacy
attendants. Each facility will be invited to select 3 provi-
ders to attend the training. The training will be con-
ducted jointly by medical doctors, representatives of the
national malaria control programme and the research
team. The trainers will receive extensive briefing by the
research team and given a trainer’s manual which pro-
vides detail of the material for each module and how it
should be delivered. The training manual also includes
standardized power-point presentations. In addition, the
trainers will be trained in presentation and communica-
tions skills.
Each basic training workshop will train 25-30 provi-
ders. The training primarily takes a didactic seminar
style in which the trainer delivers the training material,
though there is scope for questions and discussion. A
participant’s training manual will be given to providers
that attend the training course and includes all essential
reference material including the malaria treatment
guidelines. Participants will also be provided with job
aids for RDTs and a treatment algorithm to be placed
on their tables while in their health facilities.
All participants of the basic training will be strongly
encouraged to train others at their facilities using copies
of the training materials including manuals, copies of
presentations and table top flip charts. This will not be
mandatory or enforced, but as an incentive only those
that train their colleagues will be given a certificate of
completion.
Enhanced Provider Training (ET)
All facilities randomized to the enhanced intervention
will be supplied RDTs and receive enhanced provider
training. Enhanced provider training covers all the mate-
rial contained in the basic provider training but also
additional material targeting improvements in quality of
care. The enhanced provider training will last for a total
of three days (one day on basic training modules and an
extra two days for the additional material). This training
is more resource-intensive than routine in-service train-
ing, but intends to tackle some of the ingrained factors
affecting health worker prescribing in relation to
malaria, as identified in Cameroon and elsewhere.
The enhanced provider training contains three addi-
tional training modules: 4) Adapting to Change; 5) Pro-
fessionalism; 6) Communicating Effectively. A specific
focus of these modules is to address challenges posed by
RDTs for interactions between the health workers and
patients. The modules take an interactive and supportive
approach to training with the majority of the material
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covered using small-group work. There are several exer-
cises in each module based on games and puzzles, testi-
monials on the use of RDTs, self-developed participatory
drama and role-playing. In these additional modules the
role of the trainer is to direct and facilitate the learning
process rather than provide technical information. The
participants will be given training materials to accom-
pany these modules.
The adapting to change module seeks to provide health
workers with the opportunity to reflect and discuss the
clinical guidelines, and learn from others. This module
includes testimonials on the use of RDTs and participants
have the opportunity to reflect on and discuss the recom-
mendations in the malaria guidelines. As well as small
group discussions, the module has a card game that 4-6
participants can play. Participants take turn in collecting
cards and achieve a point when they present three cards
that show a patient has received treatment in line with
guidelines. This can be achieved by presenting a ‘patient
with fever’ card accompanied by a ‘RDT positive’ card and
an ‘ACT’ card, or alternatively by presenting a ‘patient
with fever’ card accompanied with an ‘RDT negative’ card
and a ‘further investigation’ card. The game ends when a
participant has treated five patients in line with the guide-
lines and scored five points.
The professionalism module appeals to the providers to
identify and agree what values and behaviours are impor-
tant when providing care. It also emphasises the impor-
tance of working as a team and supporting each other.
The module includes an exercise that considers real-life
scenarios that may interrupt the process of care and parti-
cipants are encouraged to develop strategies for managing
these situations.
The final module focuses on improving the providers’
skills in communicating with patients. It starts by reflect-
ing on what patients think about malaria and malaria
treatment. The module also focuses on managing patient
expectations and allows providers to develop skills and
techniques for explaining to patients why they should be
tested, and also for the situation when the test is negative
and an antimalarial should not be prescribed. Dramas are
developed and acted out by the participants with the sup-
port of the facilitators to help providers understand the
consequences for patients when they are not prescribed
the recommended medicine and what alternative courses
of action may be pursued.
As with the basic training, all participants of the
enhanced training will be strongly encouraged to train
others at their facilities and will only be given a certifi-
cate of completion once this has been undertaken.
Control Arm
The control arm represents current practice. Providers
in these facilities will not receive RDTs or training as
part of the study and are expected to continue to
provide usual medical care for fever patients attending
their facility. Our formative research showed that 90%
of public health facilities and all mission health facilities
in the study sites had microscopy testing, though none
had RDTs.
Objectives
The primary objective is to evaluate the effectiveness
and cost-effectiveness of:
• Basic intervention (i.e. introducing RDTs with
basic provider training) compared to current
practice;
• Enhanced Intervention (i.e. introducing RDTs with
enhanced provider training) compared to current
practice; and
• Enhanced Intervention compared to Basic
Intervention.
Secondary objectives include:
• To describe the process of implementing the inter-
ventions including participant assessment of the
training received;
• To document health worker knowledge and ability
to test and appropriately treat patients with sus-
pected malaria;
• To evaluate patient satisfaction with the quality of
care received at the health facility;
• To calculate the economic and financial costs of
the provider interventions;
• To assess whether the effectiveness and cost-effec-
tiveness of the interventions varies according to
urban/rural residence or socioeconomic status of the
patient.
Hypotheses
• Basic Intervention is more effective in improving
the treatment and diagnosis of malaria (measured by
adherence to malaria treatment guidelines) than cur-
rent practice.
• Enhanced Intervention will be more effective in
improving the treatment and diagnosis of malaria
compared to current practice and compared to Basic
Intervention.
• Basic Intervention is more cost-effective in improv-
ing the treatment and diagnosis of malaria compared
to current practice.
• Enhanced Intervention is more effective and more
costly compared to Basic Intervention.
The relationship between the study hypotheses and
outcomes are summarised in Figure 1.
Wiseman et al. Trials 2012, 13:4
http://www.trialsjournal.com/content/13/1/4
Page 5 of 12
3. STUDY SETTING
111
Outcomes
Primary outcome
The primary outcome is the proportion of patients attend-
ing facilities that report a fever or suspected malaria and
receive treatment according to malaria guidelines. The
corresponding measure of cost-effectiveness is the cost per
febrile patient that receives treatment according to the
malaria guidelines.
Treatment according to the malaria guidelines is a
composite endpoint requiring that:
• Febrile patients should be tested for malaria, using
either microscopy or an RDT
• The patient should receive an ACT if he/she has a
positive malaria test result
• The patient should not receive an antimalarial if
he/she has a negative malaria test result
The outcome measure is summarized in Figure 2.
Secondary outcomes
Secondary outcomes include:
• Proportion of febrile patients that are tested for
malaria
• Proportion of febrile patients receiving an antima-
larial that receive an ACT
• Proportion of febrile patients receiving an ACT
that receive the correct dose for their age
• Proportion of febrile patients receiving an ACT
that accurately report how to take the medicine
• Proportion of febrile patients that report they are
satisfied with the care received
• Proportion of HWs that report they were satisfied
with the training received
• Proportion of HWs that know ACT should be
given if the malaria test is positive and that an anti-
malarial should not be given if the malaria test is
negative
Figure 1 Effect of Provider Interventions on the Treatment Received by Patients.
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• Proportion of HWs that report febrile patients
should be tested for malaria
• Proportion of HWs that know how to identify
positive, negative and invalid malaria RDT results
• Proportion of HWs that know the correct dose of
the first-line ACT in an adult and in a child aged 2
years
• Total cost of the provider interventions and the
cost per HW attending the BT and ET
Secondary outcomes related to patients will also be
reported in terms of their urban/rural residence and
socioeconomic status.
Evaluation design
The evaluation of the intervention will use data col-
lected in a patient exit survey, a register of malaria tests
conducted by the provider during patient consultations,
a provider survey, documentation of the intervention
process, costing of the intervention activities and lastly,
independent testing of malaria by the study team (see
‘quality assurance’). The patient exit survey will be
administered before the provider survey to ensure that
the treatment received by patients is not influenced by
the content of the provider questionnaire. Each of these
is described below.
Patient exit survey
The primary outcome will be measured through an inter-
viewer-administered patient exit survey. Data collection
will commence three months after the intervention has
been implemented. The three-month lag in the data col-
lection is to ensure that the effect measure reflects treat-
ment practices in the medium-term. In the short-term it is
recognised that it is possible that the effect is overstated
because health workers may change practices initially but
revert to past behaviours over time, or that the effect is
understated because it takes time for the training to have
an effect as some health workers are hesitant and want to
learn from the experience of the early-adopters. The sur-
vey data collection will take up to two months and will be
organized such that the data will show the effect of the
intervention over this time period by establishing a maxi-
mum number of patients that can be surveyed each week.
The research team will recruit field workers and pro-
vide training over a week on all aspects of data collec-
tion related to the patient exit survey. The training will
include a practical assessment of their ability to provide
information to respondents about the survey, obtain
consent and administer the questionnaire. The research
team will supervise the field workers and will accom-
pany the field worker at the start of data collection to
obtain consent from the head of the facility and ensure
the fieldworker adheres to the standard operating proce-
dures. Supervisory visits to monitor the performance of
the field workers will take place at least once each week
during the data collection period.
The patient exit questionnaire is designed to collect
information about the patient’s experience of seeking
treatment and has been piloted a selected facilities in
the study site. The questionnaire contains the following
ten modules:
A. Background Information, Consent and Screening
Questions
B. Details of the Respondent and/or Patient
C. Reasons for attendance
D. Consultation and diagnosis
E. Treatment prescribed and received
F. Patient satisfaction and knowledge of malaria
Figure 2 Primary outcome measure.
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G. Costs of seeking treatment
H. Household characteristics
I. Malaria test completed by the study team (in sub-
sample of patients)
J. Malaria test completed by health workers (from reg-
ister of malaria tests at facility)
Register of malaria tests conducted
The patient exit questionnaire will be supplemented by
a register of malaria tests at each participating health
facility because patients may not always know if they
were tested for malaria and the result of the malaria
test. With consent from the head of the facility, health
workers responsible for conducting malaria tests will be
asked to keep a register of all malaria tests undertaken.
The following data will be collected: details of the
patient, availability of microscopy and RDT, method of
test conducted, test result and the provider that con-
ducted the test. At each facility the field workers will
collect the register of malaria tests at least once each
week and will use the patient’s name, gender, age, date
of visit to identify the patients that completed the survey
and record the details in Section J of the questionnaire.
Provider Survey
The research team will administer a provider survey to
all providers responsible for the diagnosis and treatment
of suspected cases of malaria. Providers are eligible to
participate if their responsibilities include any of the fol-
lowing activities: taking patient signs and symptoms,
undertaking diagnostic tests, prescribing or dispensing
medication. Written informed consent will be obtained
before commencing the survey.
The provider survey has been designed to collect data on
the providers’ characteristics, knowledge and preferences
for diagnosing and treating malaria and details of the
resources available at the health facility. The survey will be
piloted with providers at facilities that are not participating
in the study. The questionnaire contains the following
modules (of which A-B are completed by all providers and
C-G are completed once for each facility):
A. Background information, consent and screening
questions
B. Health worker characteristics and treatment
practices
C. Details of the health facility
D. Management and procurement of drugs
E. Availability of RDTs
F. Availability of Antimalarials
G. List of all health workers that are involved in
diagnosis or treatment
Documentation of the Intervention Process
The implementation of the malaria training workshops
delivered to health workers will be documented. Details
of all participants attending the training course will be
recorded. Participants will undertake a pre- and post-
training test to determine the impact of the training on
their knowledge of malaria diagnosis and treatment. All
participants will be invited to complete the training eva-
luation, which assesses the content and delivery of the
training course. In addition, the trainers will complete a
form to record any challenges faced in running the
training workshop. Finally, the process of distributing
the RDTs to health facilities will be monitored and any
problems with the procedures for replenishing RDT
stocks will be documented.
Costing
Direct and indirect costs of each phase of the interven-
tions (i.e. development, implementation, upkeep) will be
assessed from both a provider and societal perspective
using standard economic evaluation methodologies [32].
Cost data will primarily be estimated from health facility
records, project financial accounts and from the provi-
der and patient exit surveys. Any health care savings
will also be included and subtracted from costs.
Quality assurance
Data collection and management There is a quality
assurance officer responsible for ensuring all implementa-
tion and evaluation activities adhere to standard operating
procedures. Quality assurance will include monitoring the
process of obtaining consent, data collection, transfer of
completed survey instruments, data management and the
secure storage of study materials. In addition, field super-
visors will monitor the survey administration undertaken
by field workers and make frequent visits (at least once a
week) to assess the quality of data collection and review
completed questionnaires.
Only authorised staff with appropriate training will
have access to the databases to perform data entry. All
databases will be password protected. Each data form will
be entered by two data entry clerks in a database of the
same structure using two different computers. Entries
will be compared for discrepancies using the Epi info
2000 data compare utility. Any discrepancies will be cor-
rected by crosschecking against the corresponding origi-
nal questionnaire. Checks (validation rules) will be
implemented in different fields of the database. Data will
also be queried electronically to ensure the correct data
is entered under the correct variables for each section of
the form/questionnaire. A log of all data changes will be
kept. Questionnaires will be kept in a locked filing
cabinet.
Independent verification of malaria tests conducted
and test results Reliance on providers register of malaria
tests conducted and their interpretation of the test result
may be a risk for data quality. For example, we are
dependent on the providers’ skills in conducting and
interpreting the test results and the accuracy of their
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record-keeping. We will examine the accuracy of the reg-
ister of malaria tests by comparing the patient reported
data on whether they had a test with the register. We will
also independently conduct RDT tests in a sub-sample of
5% of patients on exit that reported they were tested for
malaria to determine the degree of consistency between
the test result recorded by the provider and the test result
conducted by the fieldworker. In addition, a sample of
cases (both positive and negative) will be tested using
PCR to check the sensitivity and specificity of both RDT
and Microscopy. Quality assurance of the RDTs is
beyond the scope of the study.
Sample size
Patient exit survey
Sample size calculations are based on the primary out-
come, the proportion of patients that receive treatment
according to malaria treatment guidelines. Based on
results from the formative research we expect that this
will be 15% in the control arm (current practice) with a
coefficient of variation (k) within stratum of 0.3.
To evaluate the effect of each of the intervention arms
compared to current practice we have powered the
study to detect a 15% increase over the control, from
15% to 30%, which was deemed to be the minimum
increase for each of the interventions to be worthwhile.
Using methods for stratified cluster randomised trials
[33] and assuming k = 0.25 in the intervention arms, 7
clusters per arm and 100 patients per facility are
required to detect this improvement with 80% power at
a 5% significance level. With allowance for drop outs
from the trial we propose 9 facilities per arm. A lower
coefficient of variation was assumed in the intervention
arms due to the shared training.
If both intervention arms prove to be significantly bet-
ter than the control it is likely that the enhanced inter-
vention will be better than the basic intervention and
we expect a further 10% improvement in the primary
outcome, to 40%. Therefore to determine whether or
not the basic intervention should be recommended we
wish to evaluate whether it is just as effective as (i.e.
non-inferior to) the enhanced intervention. Assuming
that the largest difference between the two intervention
arms that would be considered unimportant is 10% (i.e.
non-inferiority margin) then using methods for equiva-
lence in cluster randomised trials [33] 17 clusters per
intervention arm with 100 patients per cluster are
required to have 80% power to demonstrate that the
limit of a one-sided 95% confidence interval (CI) will be
10% or less. With allowance for drop outs from the trial
we propose 19 clusters per arm.
Provider survey
The sample size calculations for the provider survey
gives the anticipated level of precision for calculating
the proportion of providers that know the treatment
guidelines (i.e. report that parasitological testing is
recommended and that ACTs are for confirmed cases of
malaria). Based on our formative research we can
assume 3-4 providers per facility, an intra-correlation
coefficient (ICC) of 0.1, and an estimate of the primary
outcome in each arm of 90%. With 9 facilities in the
control arm and 19 facilities in each of the intervention
arms this allows us to estimate the true primary out-
come with ± 11.8% precision in the control arm and ±
7.7% precision in each of the intervention arms.
Randomisation
A total of 47 facilities, 23 in Bamenda and 24 in Yaoundé,
will be randomised within stratum to receive current
practice, the basic intervention (RDTs and basic training)
or the enhanced intervention (RDTs with enhanced
training). With cluster randomised trials there is an
increased chance that the study arms are unbalanced
with respect to known and unknown potential confoun-
ders, and therefore undermines the credibility of the trial
results. Stratified randomisation will reduce the likely
imbalance in factors known to be correlated with the
study outcome and the study site. However, the current
availability of microscopy and the type of facility (which
will also capture variation in health worker and patient
characteristics) were assumed to be important correlates
and therefore a process of constrained, or restricted, ran-
domisation [34,35] will also be implemented to balance
these two factors across the study arms using data col-
lected in the formative research.
Using restricted randomisation schemes increases the
risk of producing a design which is biased and not valid.
Moulton [35] describes a design as being biased if there
is any difference across the clusters in their probability of
allocation to any given treatment. A randomised design
is said to be valid if every pair of clusters has the same
probability of being allocated to the same treatment. If
the design is not valid there is a risk that the Type I error
changes from its nominal value of 0.05. We will assess
the validity of the restricted randomisation by producing
a matrix where the rows and columns represent the clus-
ters and the elements of the matrix are the proportion of
times each pair of clusters is allocated to the same study
arm i.e. the probability that the ith cluster is being allo-
cated to the same intervention group as the jth cluster.
The matrix will then be examined for under- and over-
represented pairs that would highlight any potential
causes for concern in the randomisation.
Randomisation of the facilities will be performed by
the study statistician after informed consent has been
sought from the head of the facility to avoid selection
bias. Patients (or caregivers) and fieldworkers adminis-
tering the patient exit survey will be blinded to group
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assignment. The research team involved in implement-
ing the training interventions and supervising data col-
lection will need to be aware of which facilities receive
the different interventions.
Figure 3 shows study eligibility, selection, enrolment
and methods of data collection.
Data analysis
Initially an overall test of the null hypothesis that there
are no differences between either of the intervention
arms and the control will be performed to guard against
over-interpretation of any significant effects from indivi-
dual comparisons of each intervention with the control,
particularly if there is no evidence of a difference for
any of the intervention arms.
The effect of the two interventions compared with
control will be analysed with methods appropriate for
cluster randomised trials. Point estimates of the primary
outcome will be calculated using the unweighted mean
of the cluster summaries in each stratum. If the distri-
bution of the summary measures in each study arm is
skewed, a logarithmic transformation to the proportions
will be considered. An overall estimate of the risk ratio
will be obtained by taking a weighted average of the
stratum-specific risk ratios where the weights are inver-
sely proportional to the stratum-specific variances. 95%
confidence intervals (CI) will be adjusted for observed
between-cluster variance and formal hypothesis testing
will be conducted using stratified t-tests. Adjustment for
covariates, including patient and provider characteristics
and knowledge, contextual factors and process factors,
will be carried out using a two-stage process. In the first
stage, a logistic regression model including stratum as a
fixed effect and the covariates of interest, but excluding
the intervention effect, will be fitted to calculate cluster-
specific expected values. The ratio of observed and
expected values will be computed to give the ratio-resi-
dual for each cluster. In the second stage, the above
methods for estimating the RR and 95% CI and hypoth-
esis testing are carried out with the cluster-level propor-
tions replaced with the covariate-adjusted residuals [35].
Non-inferiority between the two intervention arms will
be assessed using the same methods as described above
but instead of the risk ratio the risk difference will be
estimated. Inference will be based solely on one-sided
95% CIs (or equivalently 2-sided 90% CIs).
Secondary outcomes on treatment received by
patients, and provider knowledge and practice, will be
analysed using the methods described above. To exam-
ine whether secondary outcomes vary according to the
urban/rural residence and socioeconomic status of the
patients methods appropriate for examining an interac-
tion between the intervention and the individual-level
variable will be applied [36]. Differences in coverage
Figure 3 Eligibility, selection, enrolment and methods of data collection.
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estimates between the intervention arms will also be
estimated by calculating the arithmetic mean of the cov-
erage proportions in each cluster and conducting a two-
way analysis of variance, allowing for stratification.
For the economic analysis, cost-effectiveness ratios will
be based on the primary outcome (i.e. the cost per case
of suspected malaria that received treatment as recom-
mended in the malaria guidelines) as well as a range of
secondary outcomes including changes in provider
knowledge. Cost-effectiveness will be calculated for each
comparison and will be expressed as incremental cost-
effectiveness ratios (ICERs). One-way and multi-way
sensitivity analysis will be undertaken to examine the
effects of varying uncertain variables on study findings.
Costs and effects will be presented in both discounted
and undiscounted form.
All data will be double entered using Microsoft Access
2007 (Microsoft Inc., Redmond, Washington) and ana-
lysed using STATA version 11.0 (STATA Corporation,
College Station, Texas). A full analysis plan will be
reviewed and agreed before the data are analysed.
Trial status
Patients and providers are currently being recruited into
the study for the patient exit survey.
Discussion
Results from the study will be reported at local, national
and international levels. At the local and national level,
the Research on the Economics of ACTs (REACT) Pro-
ject (http://www.actconsortium.org/pages/project-5.
html) will continue working with the Ministry of Health
after the trial is completed to adapt the most cost-effec-
tive interventions for national use. At the international
level, we also see an opportunity to support the imple-
mentation of the 2010 WHO malaria treatment guide-
lines which acknowledge the need for provider training
alongside the large-scale deployment of RDTs and
ACTs.
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RDT: Rapid Diagnostic Test; ACT: Artemisinin-based Combination Therapy
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Introduction to the Research Papers 
 
Part II presents the research undertaken for the thesis in five research papers. These 
analyse providers’ stated and revealed preferences for treating febrile patients, when 
providers have imperfect information and are agents in multiple agency relationships, and 
evaluate the cost-effectiveness of interventions that were designed to improve providers’ 
adherence to clinical guidelines. The five papers are: 
I. Treatment of uncomplicated malaria at public health facilities and medicine 
retailers in south-eastern Nigeria.  
II. Malaria prevalence and treatment of febrile patients at health facilities and 
medicine retailers in Cameroon. 
III. What determines providers’ stated preference for the treatment of uncomplicated 
malaria? 
IV. Mind the gap: knowledge and practice of providers treating uncomplicated malaria 
at health facilities and medicine retailers in Cameroon and Nigeria.  
V. Economic evaluation of a cluster randomized trial of interventions to improve 
health workers’ practice in diagnosing and treating uncomplicated malaria in 
Cameroon. 
Papers I and II describe the treatment received by febrile patients and their caregivers 
attending health facilities and medicine retail outlets in Nigeria and Cameroon in 2009, 
before interventions were designed. Exit surveys were conducted to understand how 
patients with symptoms of malaria were diagnosed and treated and identify priorities for 
intervention. The results from both countries indicated problems with the choice of 
antimalarial supplied and a reliance on presumptive treatment based on a symptomatic 
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diagnosis. Few facilities in Nigeria offered malaria testing. In Cameroon most public, 
mission and private health facilities had microscopy available, though malaria testing was 
under-used and the vast majority of patients who tested negative for malaria received an 
antimalarial. The descriptive results contained in Papers I and II suggest a gap between 
providers’ knowledge of the guidelines and their practice, though no conclusions could be 
reached on this since the study population included individuals who had requested a 
specific medicine as well as individuals who had relied on the providers’ advice. 
Papers III and IV focus on providers’ stated and revealed preferences over alternative 
antimalarials. Paper III investigates providers’ stated preference using data from the 
provider survey conducted at the health facilities where the exit survey was undertaken. 
The analysis showed providers’ preference was influenced by their patients, drug 
company representatives, colleagues and other providers working in the locality. The 
findings indicate providers are agents serving multiple principals and constrained by the 
institutional and social context. This suggested it may be valuable to consider the influence 
of different actors when designing interventions.  
Paper IV investigates the determinants of providers’ revealed preference (i.e. their 
practice) and used exit survey data from the subset of patients who relied on the provider 
to select treatment and were supplied an antimalarial. Exit survey responses were linked 
to the individual provider who supplied treatment, and two-level multiple imputation was 
used to impute missing data that arose when identifying the provider responsible for 
selecting treatment. A gap between providers’ knowledge and practice was identified in 
both countries, as providers’ decision to supply ACT was not significantly associated with 
their knowledge of the first-line antimalarial. However, providers’ stated preference was 
important, and this suggested interventions should focus on changing providers’ 
preference rather than their knowledge. The results also showed providers’ practice may 
depend on what they perceive their patients prefer or could afford, information about the 
INTRODUCTION TO THE RESEARCH PAPERS 
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patient’s symptoms and previous treatment seeking, the type of outlet, and the availability 
of ACT. 
As explained in Chapter 3, the formative research contained in Papers I, II, III and IV was 
used to select and develop interventions in Cameroon and Nigeria. In Cameroon, two 
training interventions were designed: one-day ‘basic’ training that sought to ensure 
providers knew how to use malaria RDTs and the recommendations in the national 
malaria treatment guidelines; and three-day ‘enhanced’ training that explicitly focused on 
changing providers’ practice. The training was implemented in public and mission 
facilities and accompanied the introduction of RDTs.  
Paper V presents the cost-effectiveness of introducing RDTs with training interventions at 
public and mission facilities in Cameroon. The results demonstrated it was more cost-
effective to introduce RDTs with enhanced training than with basic training, when each 
was compared to current practice. This finding was consistent with our hypothesis that it 
would be more effective and cost-effective for the intervention to target providers’ 
preference and practice, rather than their knowledge. 
4. RESEARCH PAPER I 
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Chapter 4 
Research Paper I: Treatment of uncomplicated malaria at public health 
facilities and medicine retailers in south-eastern Nigeria 
This research paper describes the treatment received by febrile patients and their 
caregivers attending public health facilities, pharmacies and drug stores in urban and 
rural areas of Enugu State in south-eastern Nigeria.  
At the time the survey was undertaken, ACT had been the first-line treatment for 
uncomplicated malaria for four years, and the national malaria treatment guidelines stated 
that in primary care facilities malaria should be symptomatically diagnosed and treated 
with an ACT. This was the first study in south-eastern Nigeria to use patient exit survey 
data to report on the treatment received by patients presenting with malaria symptoms 
and it highlighted substantial problems: only 23% of febrile patients received an ACT, and 
instead sulphadoxine-pyrimethamine (SP), the former first-line treatment, was frequently 
received. While there were problems with health workers’ knowledge of the 
recommended treatment, consumer demand was an important factor and almost two-
thirds of the exit survey respondents reported they had asked for a specific medicine.  
The findings from this paper showed that interventions to improve malaria diagnosis and 
treatment in south-eastern Nigeria would need to change consumer preferences as well as 
improve health service provision. The results also emphasized the importance of 
distinguishing between retail transactions and interactions that reflect an agency 
relationship.  
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Abstract
Background: At primary care facilities in Nigeria, national treatment guidelines state that malaria should be
symptomatically diagnosed and treated with artemisinin-based combination therapy (ACT). Evidence from
households and health care providers indicates that many patients do not receive the recommended treatment.
This study sought to determine the extent of the problem by collecting data as patients and caregivers leave
health facilities, and determine what influences the treatment received.
Methods: A cross-sectional cluster survey of 2,039 respondents exiting public health centres, pharmacies and
patent medicine dealers was undertaken in urban and rural settings in Enugu State, south-eastern Nigeria.
Results: Although 79% of febrile patients received an anti-malarial, only 23% received an ACT. Many patients (38%)
received sulphadoxine-pyrimethamine (SP). A further 13% of patients received an artemisinin-derivative as a
monotherapy. An estimated 66% of ACT dispensed was in the correct dose. The odds of a patient receiving an
ACT was highly associated with consumer demand (OR: 55.5, p < 0.001).
Conclusion: Few febrile patients attending public health facilities, pharmacies and patent medicine dealers
received an ACT, and the use of artemisinin-monotherapy and less effective anti-malarials is concerning. The results
emphasize the importance of addressing both demand and supply-side influences on malaria treatment and the
need for interventions that target consumer preferences as well as seek to improve health service provision.
Background
Malaria remains a major cause of death and illness in
children and adults in tropical settings. An integrated
strategy is recommended which ensures access to treat-
ment with effective anti-malarials, while also undertak-
ing preventative measures that target vector control [1].
ACT became the recommended treatment for uncom-
plicated malaria, as resistance emerged to conventional
monotherapies, including sulphadoxine-pyrimethamine
(SP), chloroquine and amodiaquine, thereby reducing
their therapeutic efficacy. Over the last decade, countries
have revised their national malaria treatment policies to
adopt ACT as the first-line recommended treatment for
uncomplicated malaria. Although these policies are now
well established, there are persistent problems with their
implementation.
Evidence from several settings on malaria case man-
agement report problems with the choice of treatment,
showing that ACT is often underused and many patients
continue to receive less effective anti-malarials, such as
SP [2-4]. There are also concerns about the availability
and use of artemisinin monotherapy, as drug resistance
is more likely to develop if artemisinin derivatives are
taken without a partner drug [5,6]. Problems with the
dispensing of malaria treatment have also been
observed, with patients frequently receiving inadequate
doses and without advice on how the medicines should
be taken [2,7]. Ensuring accuracy of drug dispensing is
particularly challenging for pharmacies and other drug
retailers which typically stock a multitude of different
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types of ACT and the accurate dosage depends not only
on the patient’s age or weight but varies by brand
depending on the formulation and composition of the
active ingredients [8,9].
In Nigeria, it is estimated that children under five
years of age have between two and four episodes of
malaria each year, and ensuring prompt access to effec-
tive treatment is a key strategy of the Nigerian Federal
Ministry of Health [10]. At the level of primary care, the
national malaria treatment guidelines state that diagno-
sis should be based on symptoms using the Integrated
Management of Childhood Illnesses (IMCI) classification
[10]. Thus, patients presenting with febrile illness at
health facilities without diagnostic testing available
should be presumptively treated for malaria. ACT
became the recommended treatment for uncomplicated
malaria in 2005 and at this time new treatment guide-
lines and training materials were developed [10-12]. The
first-line recommended treatment is artemether-lume-
fantrine (AL), though treatment with artesunate-amodia-
quine (ASAQ), artesunate-mefloquine (ASMQ) and
dihydroartemisinin-piperaquine (DHAPQ) are also con-
sidered acceptable [12]. The policy is also clear that SP
is reserved for intermittent preventive treatment in
pregnancy, and cases of severe malaria should be treated
using quinine injection, artemether injection, or artesu-
nate (either as an injection or suppository); otherwise
the use of monotherapies is no longer recommended.
The provision and utilization of malaria treatment in
south-eastern Nigeria is well researched, with evidence
from household surveys, patient records and from health
care providers at a range of health facilities showing that
many febrile patients do not receive the recommended
anti-malarial [4,13-16]. Much less is known about the
quality of care provided at health facilities, and this
study explores these concerns directly by collecting data
from patients exiting public health facilities and medi-
cine retailers. These types of facilities are the main pro-
viders of malaria treatment at the primary care level
[14]. This paper describes the characteristics of patients
and the health facilities they attend, and their experience
of care, including the nature of the consultation, the
provision of anti-malarial treatments and the quality of
drug dispensing. The paper also investigates whether
patient, health worker or facility factors are associated
with receiving ACT.
Methods
Study area
The study was undertaken in two study sites in Enugu
State in south-eastern Nigeria: Enugu urban (comprising
of Enugu East, Enugu South and Enugu North local gov-
ernment areas (LGAs)) and Udi LGA. Enugu urban is
the largest predominantly urban area in Enugu State,
and Udi LGA is rural. Malaria is endemic in Enugu
State, and occurs all year round. The people of Enugu
are of Igbo ethnicity and speak the Igbo language. The
activities of the majority of the population include farm-
ing, fishing, wine tapping, and poultry keeping and rear-
ing of domestic animals; the main agriculture season
runs from November to February.
ACT was introduced into the study site in 2005 by the
State Malaria Control Programme. The implementation
package consisted of training health workers on sympto-
matic diagnosis, change in antimalarial policy and
rational prescription of antimalarials and was accompa-
nied by a community awareness campaign.
Study setting
The study was undertaken at public primary health
facilities, private sector pharmacies and patent medicine
dealers (PMDs) in Enugu State, south-eastern Nigeria
[17]. The term PMD refers to retail outlets that are
licensed to sell over the counter pharmaceutical pro-
ducts, though often hold a wider range of stock, and
typically have no formal training [18]. Pharmacies and
PMDs are a major source of malaria treatment [14,19].
These facilities are medicine retailers and do not routi-
nely offer clinical care or diagnostic services. At the pri-
mary care level, presumptive treatment of malaria is
recommended in febrile patients, as few public facilities
offer malaria microscopy or RDTs. Primary health cen-
tres are usually staffed by community health officers and
community health extension workers and supported by
registered nurses and midwives [20].
Study design
A stratified multistage cluster survey was conducted
between July and December 2009. The survey sampling
was clustered in 16 randomly selected communities and
stratified by type of facility: i) public facilities including
primary health centres, dispensaries and health posts,
and ii) pharmacies and PMDs. Within each community
all public primary health centres were included due to
their small number. There are a large number of phar-
macies and PMDs, and these were randomly selected
with probability proportionate to size assuming that a
total of 80 (out of 298) medicine retailers could be vis-
ited given the financial resources and time available. All
health workers within each facility responsible for pre-
scribing or dispensing medicines were included in the
study.
A survey sample of 20 patients per public facility was
calculated to estimate the primary outcome, the propor-
tion of febrile patients receiving the recommended treat-
ment for malaria, with a precision of +/- 13%, assuming
that the variability (intra-cluster correlation, ICC) in
treatment between facilities is 0.3 [21]. For pharmacies
Mangham et al. Malaria Journal 2011, 10:155
http://www.malariajournal.com/content/10/1/155
Page 2 of 13
4. RESEARCH PAPER I
127
and PMDs, 14 patients per facility allows the primary
outcome to be calculated with a precision of +/- 6.6%
assuming the same degree of variation. The estimates
assume a prevalence of 50% for the primary outcome
and give the maximum range for precision (if the
observed prevalence by higher or lower than 50% then
greater precision would be achieved). The sampling was
based on an enumeration of health facilities and their
staff conducted in April 2009.
Survey activities
In advance of the survey a field team visited each facility
to explain the purpose of the survey to the head of the
facility and obtain informed written consent. Informed
consent was reconfirmed verbally on the day of the
actual survey. The survey questionnaires were developed
specifically for the study and pretested on a non-random
sample of individuals with characteristics similar to
those of the survey population but not chosen for inclu-
sion in the survey. Survey teams were trained on proce-
dures for conducting the survey and involved in the
pretesting and revision of the questionnaires. Site super-
visors monitored and supervised all aspects of data
collection.
Data were collected using three structured approaches;
a patient exit questionnaire, a health worker survey and
a health facility audit. Written consent from patients
and caregivers (who may or may not be accompanied by
the patient) exiting the health facility was sought before
screening to determine their eligibility to participate in
the survey. An individual was considered eligible if s/he
reported seeking treatment for a fever or if s/he had
received an ACT. Treatment may be sought for them-
selves, a child or another person who is not present (the
latter applies only at medicine retailers). Individuals that
were exiting a health facility were assessed in turn until
the patient quota was reached. All workers that were
involved in prescribing or dispensing malaria treatment
and were available at the time of the survey were invited
to complete the health worker survey and written con-
sent was obtained from all participants.
The patient exit questionnaire collected data on the
patient’s prior treatment seeking and use of anti-malar-
ials, reasons for attendance, the consultation and diagno-
sis, prescriptions and medicines received, the cost of
treatment seeking and the demographic characteristics of
the patient. The health worker questionnaire captured
data on their characteristics, access to in-service training
and national malaria treatment guidelines, malaria
knowledge and treatment practices. The health worker
survey was conducted once all the patient exit question-
naires had been completed to ensure that the treatment
received by patients was not influenced by the content of
the health worker questionnaire and the patient exit data
best reflects current prescribing practices. The health
facility audit was conducted following the health worker
survey and collected data on the characteristics of the
health facility, diagnostic services, management and pro-
curement of medicine, including the availability of ACT.
Definitions
The treatment received by patients was assessed against
the national malaria treatment guidelines, which recom-
mends that patients with a fever are presumptively trea-
ted with an ACT, with the exception of pregnant
women in the first trimester. The accuracy of the ACT
dose provided to patients was assessed in accordance
with dosage recommendations based on the patient’s
age and the type and composition of ACT received.
Thus, the analysis takes into account that the correct
number of tablets (or powder sachets) varies by brand,
the amount of active ingredients contained in each
tablet and whether they are co-formulated or co-blis-
tered. Suspensions were excluded from the analysis on
dosing. As patient age was used as a proxy for weight
[11,22] this may cause some error in estimating the
accuracy of dosing among children, though this would
not apply to adults. Patient knowledge on the dose regi-
men was ascertained by asking the patient or their care-
giver to explain how and when the medicine should be
taken. Knowledge was considered accurate if they
reported the number of tablets (or powder sachets)
which should be taken per day over 3 days that corre-
sponds to the specific brand of ACT received, and the
patient’s age. Suspensions were excluded from the analy-
sis due to the difficulties in accessing the accuracy of the
correct dose.
Statistical analysis
Data were entered and verified using Microsoft Access
2007 (Microsoft Inc., Redmond, Washington) and ana-
lysed using STATA version 11.0 (STATA Corporation,
College Station, Texas) that allows for complex survey
design by identifying different probabilities of selection
(sampling weights), clustering and stratification (applying
the prefix svy) [23]. Thus, all percentages and odds ratios
reported are population-average estimates which have
been adjusted to take into account the stratification, clus-
tering and sampling weights of the study design. The
weights are equal to the inverse probability of being
sampled and took into account the sampling probabilities
at the facility, health worker and patient level. At the
patient level, number of days it took to recruit patients
was used to create a proxy for the volume of patients,
with the less time indicative of a larger facility.
Treatment outcomes by strata were compared using
the Rao and Scott chi-square correction [24]. Survey
logistic regression was used to assess factors associated
Mangham et al. Malaria Journal 2011, 10:155
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with receiving the recommended treatment. The follow-
ing were investigated for their potential association:
characteristics of the patient and health worker, patient
consultation, and the resources available at the health
facility (all factors are listed in Table six). Factors asso-
ciated with receiving the recommended treatment were
investigated in the multivariable model if the univariable
association was statistically significant at the 10 percent
level, or the odds ratio was less than 0.5 or greater than
1.5. Factors were retained in this multivariable model if
they remained significantly associated at the 10% level
of significance or with an adjusted odds ratio less than
0.5 or greater than 1.5. Models were compared using an
adjusted Wald test. Pregnant women and children under
the age of 6 months were excluded from the analysis
because the national malaria treatment guidelines have
alternative recommendations for these groups.
Ethical approval
Ethical approval for this study was obtained from the
ethics committees of University of Nigeria and London
School of Hygiene and Tropical Medicine.
Results
Patient characteristics
Data were collected from 100 health facilities and the
analysis is based on exit data collected from 1,642 febrile
patients attending public facilities and medicine retailers
and 149 health workers (Figure 1). There was notable
variation in the characteristics of patients attending the
different types of health facility (Table 1). More than
half (57%) of the patients treated at public health facil-
ities were children, while 80% of the cases presenting at
pharmacies and PMDs were adults. Treatment-seeking
also varied by education levels and socioeconomic status
(SES), with respondents surveyed at medicine retailers
more likely to have tertiary education and be of a higher
wealth quintile. At medicine retailers81% of patients
reported it was the first time that they had sought treat-
ment for this illness episode, and 43% had sought treat-
ment on the same or day following the onset of
symptoms. While at public facilities 61% of patients at
public facilities were seeking treatment for the first time
and the time before treatment was much longer, with
only 16% seeking treatment on the same or day
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Figure 1 Study population.
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following the onset of symptoms. When asked about
their choice of health facility, many respondents said
that they had sought treatment at this facility for past
illnesses (54%) and it was convenient (55%). In addition,
patients at public health facilities often mentioned the
lower cost of treatment, while the reputation of the pro-
vider and the availability of drugs were more often cited
at medicine retailers.
Table 1 Patient Characteristics by type of facility*
Public Medicine retailer Total
N = 466 % N = 1176 % N = 1642 % P value
Patient genderi
Male 218 45.4 624 56.4 842 55.5 0.006
Female 242 54.6 536 43.6 778 44.5
Patient age
>15 years (adult) 185 42.8 913 79.6 1098 76.7 <0.001
10-15 years 27 6.6 85 7.3 112 7.3
5-9 years 61 12.6 71 4.6 132 5.3
<5 years 193 38.0 107 8.4 300 10.7
Patient socioeconomic statusii
Poorest quintile 223 46.4 343 15.7 566 18.1 <0.001
Second quintile 97 20.4 219 20.0 316 20.1
Third quintile 55 11.8 219 21.3 274 20.6
Fourth quintile 56 13.5 189 21.2 245 20.6
Richest quintile 35 8.0 206 21.8 241 20.7
Education level of patient (or caregiver)iii
No formal education 25 5.8 41 1.3 66 1.6 <0.001
Primary education 116 28.0 198 12.5 314 13.7
Secondary education 213 46.1 469 39.7 682 40.2
Tertiary education 93 20.0 445 46.6 538 44.5
Was first time sought treatmentiv
Yes 269 61.4 896 81.7 1165 81.1 <0.001
No 196 38.7 273 18.3 469 19.9
Number of days since start of symptomsv
None (same day) 14 3.3 234 22.1 248 20.6 <0.001
1 day 71 12.6 259 21.2 330 20.5
2 days 93 19.3 228 21.2 321 21.1
3-5 days 202 45.4 284 23.5 486 25.3
6+ days 85 19.4 169 12.0 254 12.6
Reasons given for choice of health facilityvi
Convenient 229 49.2 617 55.9 846 55.4 0.284
Used previously 243 48.6 732 54.7 975 54.2 0.346
Good reputation 145 30.1 529 49.6 674 48.1 0.002
Availability of drugs 127 23.3 548 48.7 675 46.7 0.001
Inexpensive 206 46.2 178 13.3 384 15.9 <0.001
Qualification of staff 132 24.7 174 12.9 306 13.9 0.011
i missing 22 responses: 6 from public and 16 from medicine retailer
ii Principal components analysis was undertaken to generate a SES index based on household asset ownership [33]. The SES index was disaggregated into wealth
quintiles.
iii missing 42 responses: 19 from public and 23 from medicine retailer
iv missing 8 responses: 1 from public and 7 from medicine retailer
v missing 3 responses: 1 from public and 2 from medicine retailer
vi more than one reason could be given
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Health facility and health worker characteristics
The provision of basic equipment, such as weighing
scales and thermometers was good in public health facil-
ities, though more mixed in pharmacies and PMDs
(Table 2). Very few health facilities offered malaria
microscopy testing and none of the health facilities sur-
veyed used RDTs. At the time of the survey, all health
facilities reported that they had anti-malarials in stock,
and field staff verified that ACT was in stock in 80% of
health facilities. There was some variation by facility
type, with 71% of public health centres and 89% of phar-
macies and PMDs stocking at least one ACT. Two-
thirds of health facilities had artemether-lumefantrine
(AL) available, though other types of ACT were com-
mon in medicine retailers. Artemisinin monotherapy
was available in 96% of medicine retailers while the vast
majority (90%) of facilities also had SP as well as other
types of anti-malarials available; these included less
Table 2 Facility Characteristics
Public Medicine
retailer
Total
HEALTH FACILITIES N = 20 % N = 80 % N = 100 % P value
Equipment and services available
Weighing scale† 19 94.1 36 50.0 55 53.1 <0.001
Thermometer 19 94.2 35 46.5 54 49.8 <0.001
Microscopy services† 3 12.8 0 - 3 0.9 <0.001
RDT 0 - 0 - 0 - -
Availability of anti-malarials
Any anti-malarial 20 100.0 80 100.0 100 100.0 -
Artesunate monotherapy 5 24.6 76 96.1 81 91.1 <0.001
Sulphadoxine Pyrimethamine (SP) † 18 89.8 71 89.9 89 89.9 0.982
Chloroquine 14 71.1 77 96.8 91 95.0 <0.001
Quinine 4 20.3 70 89.1 74 84.3 <0.001
Amodiaquine 3 14.4 60 85.3 63 80.3 <0.001
Any type of ACT 14 71.1 66 89.6 80 88.3 <0.001
Artemether Lumefantrine (AL) 12 65.6 64 79.6 66 78.4 <0.001
Artesunate Amodiaquine (ASAQ) 2 8.6 57 78.8 59 73.9 <0.001
Artesunate Mefloquine (ASMQ) 0 - 35 52.9 35 49.2 <0.001
Artesunate Sulphadoxine-Pyrimethamine (ASSP) 0 - 18 28.4 18 26.4 <0.001
Dihydroartemisinin-Piperaquine (DHAPQ) 0 - 55 78.0 55 72.6 <0.001
Median cost of ACT (& IQ range)
Adult dose of any ACT - 600 (350, 750) 600 (350, 750) -
Child dose of any ACT - 350 (260, 600) 350 (250, 600) -
Adult dose of AL - 750 (650, 835) 750 (650, 820) -
Child dose of AL - 650 (580, 750) 650 (520, 700) -
HEALTH WORKERS N = 50 % N = 99 % N = 149 % P value
Doctor 7 14.0 0 9 1.7 <0.001
Nurse or Midwife 7 14.0 7 7.3 14 8.1
Community Health Officer 14 28.0 1 1.3 15 4.5
Community Health Extension Worker 22 44.0 3 4.1 25 8.9
Pharmacist‡ - 3 3.9 3 3.4
PMD or pharmacy attendant‡ - 85 83.4 85 73.5
HW has attended malaria training in past 3 years 13 24.6 31 33.0 44 31.9 0.011
HW has access to malaria treatment guidelines 15 30.9 4 5.2 19 8.5 <0.001
HW accurately reported ACTs are the recommended treatment for uncomplicated
malaria
38 77.2 44 62.2 82 65.4 <0.001
† missing response from one pharmacy
‡ not applicable in public facilities
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effective conventional treatments such as chloroquine
and amodiaquine.
All the public facilities reported that ACT was avail-
able to patients free of charge. In pharmacies and PMDs
the median price of an ACT was 600 Naira for an adult
dose and 350 Naira for a child dose (which is approxi-
mately equivalent to USD $4.00 and USD $2.30). The
median price of AL was higher at 750 Naira for an adult
dose and 650 Naira for a child dose (equivalent to USD
$6.00 and USD $4.30).
Just under half (44%) of workers in public facilities
were community health extension workers, semi-skilled
health workers trained in primary care, and while junior
to the other cadres listed in Table 2 may prescribe treat-
ment or undertake minor procedures [20]. In the medi-
cine retailers the majority (83%) described themselves as
patent medicine dealers or pharmacy attendants.
Knowledge of malaria treatment was variable, though
better in public facilities, as 80% of workers in public
facilities reported that ACT is the recommended treat-
ment for uncomplicated malaria, compared to 62% of
workers in pharmacies and PMDs. Moreover, less than
one in three health workers surveyed had attended an
in-service malaria training workshop over the past three
years and relatively few (9%) had access to the malaria
treatment guidelines (31% of public health workers and
5% of health workers at pharmacies and PMDs).
Patient consultation, prescription and requests for medicine
The nature of the patient’s consultation differed by type
of health facility (Table 3). In public health facilities 95%
of respondents reported the health workers were told of
the patient’s symptoms, and 90% reported that they had
told the health worker about the patient’s fever. Patients
reported to have been physically examined in 65% of
cases, 50% had their temperature taken, though just 6%
of patients were tested for malaria. At public facilities
with microscopy testing available 21% of patients were
tested for malaria. In pharmacies and PMDs patients
were rarely examined (6%) or tested (<1%), though in
32% of cases health workers were told about the
patient’s symptoms and asked further questions.
The majority of patients attending public facilities had
medicines prescribed and in 78% of cases the prescrip-
tion was for an anti-malarial. ACT was prescribed to
34% of patients seeking treatment, though as many
patients were prescribed SP, which is no longer recom-
mended for treating malaria.
At pharmacies and PMDs, 15% of patients had a pre-
scription and patients often asked for a specific medi-
cine. At these facilities, 58% of patients attending asked
for an anti-malarial. Patients often asked for SP (26%),
though also requested ACT (16%) and artemisinin-
monotherapy (12%). Almost all (96%) of those patients
that asked for an anti-malarial also received the medi-
cine they had requested.
Malaria treatment received by patients
Overall, the majority of patients received an anti-malarial,
though ACT was received by only 22% of all patients
attending health facilities and by 29% of children under
five years of age (Table 4). SP is no longer recommended,
though still frequently used, and 38% of patients had
received this medicine. At public facilities, differences
were observed between the proportion of patients that
were prescribed and received antimalarials at facilities
which had ACT in stock. The proportion of patients that
received an antimalarial at public facilities was also low
compared to the medicine retailers. There were, however,
few differences between the proportions of patients
receiving ACT and SP at public health facilities and med-
icine retailers, though patients were more likely to receive
oral artemisinin monotherapy at medicine retailers than
public facilities (14% compared to 2%, p < 0.001). Other
anti-malarials, such as chloroquine, amodiaquine and
quinine were rarely received by patients. By type of ACT,
AL (44%) was most often dispensed and was widely used
in the public sector. In medicine retailers, AL was regu-
larly dispensed, though patients also received ASAQ and
DHAPQ.
Quality of dispensing of ACT
Two-thirds (66%) of all types of ACT dispensed were
estimated to be in the correct dose, while 58% of ACT
dispensed were in the correct dose and the patient (or
their caregiver) accurately reported how the medicine
should be taken (Table 5). Given the challenges in esti-
mating the accuracy of ACT dosage in children, the
results are also presented for febrile adults receiving
ACT. Overall the results are reasonably similar, with
56% of ACT received in the correct dose and by patients
that had accurate knowledge of how to take the medi-
cine. Very few patients receiving an ACT were told of
any side effects associated with the medicine.
Factors influencing treatment received by patients
The odds of a febrile patient receiving an ACT were
significantly associated with whether the patient had a
prescription, asked for an ACT, the patient’s gender,
and the education level of the patient (or their care-
giver) (Table 6). Patients were also significantly more
likely to receive an ACT at health facilities that were
better equipped, and had one or more health workers
that knew ACT was recommended for uncomplicated
malaria. Patients that chose the health facility because
it was convenient or relatively inexpensive were signifi-
cantly less likely to receive an ACT. Of all the vari-
ables considered in the univariable analysis, patients
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asking for ACT had by far the highest odds ratio of
53.3 (15.9-179.1, p < 0.001). This variable remained
highly significant in the multivariable model with an
odds ratio of 55.5 (15.0-205.6, p < 0.001), though the
other significant variables were the patient’s gender,
the education level of the patient (or caregiver),
whether the facility had a thermometer available, and
whether the facility had health workers that knew ACT
was recommended.
Discussion
There is great need to improve the quality of care for
uncomplicated malaria in south-eastern Nigeria. Parasi-
tological diagnosis was available in only 3% of facilities
and while the national malaria treatment guidelines
recommend presumptive treatment of a fever with ACT
when malaria tests are not available, less than a quarter
(22%) of febrile patients attending facilities received the
recommended treatment. Moreover, the estimates show
that only 58% of patients that received ACT were given
the correct dose and knew how the medicine should be
taken. Inadequate dosing and poor compliance to treat-
ment regimens will reduce the efficacy of the treatment
taken and may contribute to the development of drug
resistance [25].
After four years with ACT as the recommended first-
line antimalarial, these results at public health facilities
are extremely concerning. In Kenya and Zambia poor
Table 3 Patient consultation
Public Medicine retailer Total
N = 466 N = 1176 N = 1642
% (95% CI) % (95% CI) % (95% CI) P value
Patient reported consultation
Told HW about patient symptoms 94.9 (94.4-95.4) 44.3 (36.9-52.0) 48.3 (41.3-55.4) <0.001
Told HW that had a fever 89.8 (87.2-91.9) 40.3 (33.0-48.2) 44.3 (37.1-51.4) <0.001
HW asked follow up questions about patient’s symptoms 79.9 (76.3-83.0) 32.0 (25.0-39.9) 35.7 (29.1-43.1) <0.001
Patient was physically examined 65.1 (48.8-78.5) 6.2 (3.5-10.5) 10.8 (7.8-14.5) <0.001
Patient had temperature taken 49.7 (38.6-60.9) 1.7 (0.6-4.9) 5.5 (3.9-7.8) <0.001
Patient tested for malaria at this facility 5.8 (3.6-9.3) 0.2 (0.0-1.4) 0.7 (0.3-1.3) <0.001
Patient requests for medicine
% of patients that asked for:
any type of medicine 2.8 (1.9-4.2) 65.4 (57.9-72.3) 60.5 (53.7-66.9) <0.001
an anti-malarial 1.2 (0.7-2.1) 58.3 (51.1-65.2) 53.8 (47.3-60.2) <0.001
any ACT 0.9 (0.4-1.9) 16.0 (11.1-22.5) 14.8 (10.3-20.9) <0.001
Artemisinin monotherapy 0 11.5 (8.6-15.3) 10.6 (8.0-14.1) 0.162
Amodiaquine 0 1.6 (0.8-3.4) 1.5 (0.7-3.2) 0.402
Chloroquine 0.1 (0.0-0.4) 1.3 (0.6-2.7) 1.2 (0.6-2.5) <0.001
Quinine 0 0.7 (0.2-2.6) 0.7 (0.2-2.4) 0.631
SP 0.1 (0.1-0.1) 26.2 (21.5-31.5) 24.1 (19.8-29.1) <0.001
Anti-malarial prescriptions
% patients prescription (from any facility) 94.2 (92.4-95.6) 15.4 (10.7-21.5) 21.6 (17.1-26.9) <0.001
% patients that received prescription from this facility 94.2 (92.4-95.6) 1.8 (0.7-4.0) 8.8 (7.3-11.0) <0.001
% patients that were prescribed*: - - -
an anti-malarial† 78.4 (72.6-83.3) - - -
any ACT‡ 34.0 (21.9-48.7) - - -
Artemisinin monotherapy 4.7 (3.1-7.1) - - -
Amodiaquine 1.1 (0.9-1.5) - - -
Chloroquine 3.3 (0.8-11.6) - - -
Quinine 0.2 (0.0-3.1) - - -
SP 34.7 (21.7-50.6) - - -
* Reported only for public health facilities
† At public facilities 73.4% of children under five years were prescribed an antimalarial.
‡ At public facilities 51.5% of children under five years were prescribed an ACT. At public health facilities with ACTs in stock 43.8% of patients (all ages) and
57.9% of children under five years were prescribed an ACT.
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quality treatment practices were observed at public and
mission facilities soon after ACT was introduced as
first-line, though subsequent studies up to five years
later show improvements in the proportion of patients
that are prescribed and receive ACT [3,7,26]. As found
elsewhere, the proportion of patients that were pre-
scribed or received an ACT seems low given the avail-
ability of ACT at health facilities and the proportion of
health workers that knew ACT was recommended
[3,7,27,28]. It was also interesting to note that only half
of patients at public facilities that were prescribed an
ACT also received one, though it is not clear why this
occurred: 34% of patients at public facilities were pre-
scribed an ACT, while 17% received an ACT. The dis-
crepancy is only partially explained by the availability of
ACT and is unlikely to reflect the cost of treatment, as
ACT is provided to patients in public facilities without
charge.
There were some problems with the availability of
ACT: 70% of public facilities and 83% of pharmacies
and PMDs had at least one ACT in stock at the time of
the survey. While the availability of ACT in the public
sector was not as high as has been reported in Angola,
Kenya, or Uganda [7,9,28-30], the availability of ACT in
the study sites was much higher than the Nigerian
national average from 2008, when it was found that 38%
of public health facilities had ACT in stock. The avail-
ability of ACT at private sector outlets was found to be
higher than the Nigerian national average from 2008,
which reported 78% of pharmacies and 19% of PMDs
had ACT in stock [9]. It is concerning to find that arte-
misinin monotherapy is widely available in medicine
Table 4 Anti-malarials received
Public Medicine retailer Total
% (95% CI) % (95% CI) % (95% CI) P value
Anti-malarials received (all ages) N = 466 N = 1176 N = 1642
% of patients (of all ages) that received:
an anti-malarial 54.2 (44.1-63.9) 81.5 (76.2-85.8) 79.3 (74.5-83.4) <0.001
any ACT† 17.3 (9.0-30.5) 22.8 (17.2-29.7) 22.4 (17.0-28.8) 0.378
Artemisinin monotherapy* 2.0 (0.8-5.2) 14.4 (11.4-18.0) 13.4 (10.6-16.7) <0.001
Amodiaquine 0.1 (0.00-1.0) 2.0 (0.9-4.6) 1.9 (0.8-4.2) 0.002
Chloroquine 2.4 (0.5-10.6) 3.3 (2.0-5.4) 3.2 (2.0-5.2) 0.673
Quinine 0 0.9 (0.3-2.2) 0.8 (0.3-2.0) 0.501
SP 33.6 (20.9-49.1) 38.2 (31.8-45.1) 37.9 (31.8-44.3) 0.546
Anti-malarials received (children < 5 yrs only) N = 193 N = 107 N = 300
% of children <5 years that received:
an anti-malarial 33.2 (20.0-49.7) 80.2 (63.6-90.4) 67.1 (53.7-78.1) 0.001
any ACT‡ 21.3 (9.9-39.9) 31.6 (18.2-49.0) 28.7 (18.0-42.6) 0.329
Artemisinin monotherapy* 2.0 (0.2-14.5) 10.2 (3.4-26.8) 7.9 (2.9-20.2) 0.110
Amodiaquine 0.2 (0.0-3.0) 9.3 (2.3-30.6) 6.7 (1.6-23.8) 0.001
Chloroquine 1.5 (0.7-3.2) 12.6 (4.2-32.1) 9.5 (3.5-23.5) 0.001
Quinine 0 4.5 (0.6-26.8) 3.23 (0.5-20.2) 0.497
SP 9.2 (3.7-21.0) 19.9 (8.5-40.0) 16.9 (8.1-32.0) 0.176
Type of ACT received N = 105 N = 210 N = 315
% AL 96.5 (92.5-98.4) 40.2 (26.9-55.1) 43.6 (31.0-57.2) <0.001
% ASAQ 3.0 (1.4-6.2) 28.5 (16.1-45.2) 26.9 (15.3-42.8) <0.001
% DHAPQ 0 24.3 (15.1-36.5) 22.8 (14.3-34.3) 0.074
% ASMQ 0.5 (0.1-1.9) 4.1 (0.9-16.6) 3.9 (0.9-15.5) 0.019
% ASSP 0 2.9 (0.7-11.5) 2.8 (0.7-10.8) 0.648
† At facilities with ACTs in stock 27.0% (20.4-34.7%) of patients at public facilities and 24.2% (17.9-31.9%) of patients at medicine retailers received an ACT
‡ At facilities with ACTs in stock 31.7% (22.0-43.4%) of children under five years at public facilities and 32.5% (18.0-51.3%) of children under five years at
medicine retailers received an ACT
* This was in tablet form at medicine retailers.
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retailers and that many patients request this medicine.
The use of oral artemisinin monotherapy in 13.4% of
patients is also a major concern, since its use without a
combination therapy can lead to the development of
drug resistance [5,6].
Differences observed between the characteristics of
patients by type of health facility are broadly consistent
with evidence from household surveys conducted in
Nigeria on malaria treatment seeking. For example,
rural-urban differences, the education of caregivers, and
socioeconomic status have been found to be important
determinants of where treatment is sought
[14,15,31-33]. Other studies have also shown that urban
residents were more likely to obtain ACT [15] and indi-
viduals of higher levels of education and socioeconomic
status were more likely to have correct knowledge of
malaria treatment [31].
Differences between the facility types in the
resources available and the patient’s consultation were
much as expected, with patients attending public
health facilities more likely to discuss symptoms and
be examined. Similarly, as pharmacies and PMDs are
retail outlets it is not surprising that many lacked
weighing scales and thermometers and that patients
often asked for specific medicines. Moreover, it was
expected that health workers in public facilities would
have better access to the malaria treatment guidelines
and be more likely to know that ACT is recommended
for uncomplicated malaria.
The odds of a febrile patient receiving an ACT were
positively associated with the health workers knowledge
of the treatment guidelines, though there is no evidence
of an association between access to treatment guidelines
and attendance at malaria training. It should be noted
that these variables were defined at the facility-level
because in many cases it was not possible to link
patients to the health worker that prescribed or recom-
mended treatment, either because the health worker was
absent at the time of the survey or because several
health workers attended to the patient.
The treatment received by patients from medicine
retailers was often driven by consumer requests for a
specific medicine, and the odds of a febrile patient
receiving an ACT were extremely high if the patient or
their caregiver had asked for one. Previous studies from
Nigeria have also highlighted the importance of patient
demand. For example, Onwujekwe et al reports that
40% of providers across a range of primary health facil-
ities said requests by patients influenced the type of
drug provided [4]. Qualitative research with patent med-
icine dealers undertaken by Okeke et al also highlighted
that patients often ask for specific medicines and the
doses of anti-malarial drugs can be determined by
patient’s ability to pay [18]. Patients’ requests for specific
medicine at medicine retailers were likely to include
cases for which treatment had been prescribed else-
where, though as only 15% of patients had a prescrip-
tion other factors are likely to be relevant and there
Table 5 Quality of dispensing for patients that received an ACT
Public Medicine retailer Total
% (95% CI) % (95% CI) % (95% CI) P value
All febrile patients that received an ACT* N = 100 N = 176 N = 276
% accurate dose† 75.8 (70.6-80.2) 65.5 (50.1-78.1) 66.2 (51.8-78.0) 0.135
% patient has accurate knowledge of treatment regimen‡ i 68.3 (63.7-72.6) 58.5 (41.6-73.6) 59.2 (43.4-73.3) 0.218
% patients with accurate dose and knowledge of treatment regimenii 66.8 (61.3-71.9) 57.2 (40.3-72.5) 57.8 (41.7-72.4) 0.236
% patients that reported were told of side effectsiii 1.5 (1.2-1.9) 3.0 (0.6-14.0) 3.0 (0.6-12.9) 0.357
Febrile adults that received an ACT* N = 21 N = 125 N = 146
% in accurate dose† 72.8 (68.6-76.6) 62.0 (43.5-77.5) 62.2 (44.2-77.4) 0.165
% patient has accurate knowledge of treatment regimen‡ iv 72.8 (68.6-76.6) 55.4 (36.3-73.0) 55.8 (37.1-73.0) 0.051
% patients with accurate dose and knowledge of treatment regimeniv 72.8 (68.6-76.6) 55.4 (36.3-73.0) 55.8 (37.1-73.0) 0.051
% patients that reported were told of side effectsv 6.2 (5.0-7.7) 4.2 (0.8-18.5) 4.2 (0.9-17.8) 0.570
* excludes suspensions and syrups and limited to cases for which have data on dosage
† defined as dose that is consistent guidance on dosage by patient age.
‡ defined as patient reports treatment regimen is consistent with guidance on dosage by patient age
i missing 10 observations (2 from public and 8 from medicine retailers)
ii missing 12 observations (4 from public and 8 from medicine retailers)
iii missing 6 observations (2 from public and 4 from medicine retailers)
iv missing 2 observations (from medicine retailers)
v missing 3 observations (from medicine retailers)
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Table 6 Factors influencing whether a patient received an ACT
Variable Univariable Analysis Multivariable Analysis
n/N % OR 95% CI P value OR 95% CI P value
Study Site Enugu 211/989 22.7 1.71 (0.81-3.61) 0.148
Udi 71/531 14.7 1.0
Patient characteristics
Gender Male 173/795 25.3 1.63 (1.00-2.65) 0.051 1.91 (1.02-3.55) 0.045
Female 109/725 17.2 1.0 1.0
Age Group >15 yrs 157/1023 19.8 1.0 0.336
10-15 yrs 16/104 20.7 1.06 (0.44-2.53)
5-9 yrs 38/124 37.8 2.46 (0.90-6.74)
<5 yrs 71/269 29.0 1.65 (0.88-3.09)
Quintile Richest 57/230 28.8 2.35 (1.12-4.96) 0.201
Fourth 48/217 26.2 2.07 (0.99-4.35)
Third 48/257 18.7 1.34 (0.58-3.12)
Second 61/297 19.8 1.44 (0.64-3.25)
Poorest 68/519 14.6 1.0
Education Level No formal 3/61 2.1 0.09 (0.02-0.31) 0.001 0.13 (0.03-0.50) 0.045
Primary 45/297 19.9 1.0 1.0
Secondary 113/651 19.1 0.95 (0.47-1.95) 0.81 (0.35-1.85)
Tertiary 121/511 25.4 1.37 (0.70-2.70) 0.84 (0.41-1.73)
First-time go for treatment Yes 207/1091 21.5 0.93 (0.50-1.73) 0.811
No 75/429 22.7 1.0
Time before treatment Same day 30/229 15.5 1.0 0.368
1 day 58/302 17.8 1.17 (0.49-2.83)
2 days 60/307 23.0 1.62 (0.78-3.38)
3-5 days 95/446 28.0 2.11 (0.97-4.58)
6+ days 39/236 23.4 1.66 (0.64-4.29)
Consultation with health worker (HW)
HW told of symptoms Yes 170/1030 18.0 0.65 (0.34-1.22) 0.162
No 112/490 25.4 1.0
HW is told of patient’s fever Yes 165/961 19.2 0.76 (0.41-1.43) 0.373
No 117/559 23.8 1.0
HW asks follow up Qs Yes 139/700 23.6 1.33 (0.68-2.61) 0.376
No 143/819 18.5 1.0
Patient is examined Yes 83/370 19.5 0.88 (0.42-1.87) 0.724
No 199/1150 22.0 1.0
Takes patient temperature Yes 53/251 19.1 0.90 (0.44-1.85) 0.755
No 229/1269 21.9 1.0
Patient has a prescription Yes 99/327 42.1 3.51 (1.77-6.95) 0.001
No 183/1193 17.1 1.0
Asked for ACT Yes 114/138 86.2 53.28 (15.9-179.1) <0.001 55.47 (15.0-205.6) <0.001
No 168/1382 10.6 1.0 1.0
Health facility characteristics
Type of facility Public 94/430 16.6 0.70 (0.29-1.67) 0.385
Retailer 188/1090 22.2 1.0
Weighing scale available Yes 216/892 27.2 2.13 (1.05-4.32) 0.037
No 66/628 14.6 1.0
Thermometer available Yes 198/872 27.5 1.94 (1.01-3.71) 0.046 1.99 (0.94-4.18) 0.068
No 84/648 16.2 1.0 1.0
Offer malaria microscopy Yes 17/70 24.0 1.12 (0.77-1.63) 0.519
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would be merit in further examining the role of patient
demand in influencing the choice of treatment for
uncomplicated malaria in private sector facilities.
Conclusions
ACT became the recommended treatment for uncom-
plicated malaria in 2005, though they remain underused,
and less than a quarter of febrile patients attending
health facilities in this study received ACT. Although
there is increasing emphasis on the parasitological rather
than symptomatic diagnosis of malaria, the study sug-
gests that there is a need for interventions that also
focus on choice of treatment to ensure that patients
with malaria receive the recommended anti-malarial,
irrespective of the diagnostic method. Improving the
provision of health services should also address the
quality of dispensing, and ensure that health workers
can accurately determine the correct dose across a
range of different brands and types of ACT. Concur-
rently attention needs to be given to the high availability
and use of artemisinin monotherapy, as well as the con-
tinued use of less effective treatments, particularly SP.
Consideration should also be given to the role of patient
demand in influencing the treatment received, especially
in medicine retailers, since this was found to be a major
determinant of whether patients received an ACT. Thus,
in developing interventions to improve malaria case
management the results demonstrate the importance of
addressing both demand and supply-side influences on
malaria treatment.
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Chapter 5 
Research Paper II: Malaria prevalence and treatment of febrile patients 
and medicine retailers in Cameroon 
This research paper describes the prevalence of malaria among febrile patients attending 
health facilities and medicine retailers in Cameroon, and the quality of malaria case 
management. The study was undertaken five years after ACT had been adopted as the 
first-line treatment, and made an important contribution to the literature on malaria in 
Cameroon.  
ACT was the type of antimalarial most frequently prescribed or received; it was supplied 
to 51% of febrile patients, though other antimalarials, including quinine, were also used. 
Malaria was confirmed in 29% of febrile patients seeking treatment, and this highlighted 
the importance of testing for malaria before treatment is prescribed. Microscopy was 
available in most public, mission and private health facilities, though less than half of the 
patients at these facilities were tested. Moreover, when patients were tested for malaria 
the findings suggest the test result was ignored: more than 80% of patients who were 
tested during the consultation and found to be malaria negative were prescribed or 
received an antimalarial.  
The findings from this study raised several questions about providers’ knowledge of the 
national malaria treatment guidelines, and their preferences on malaria testing and on the 
type of antimalarial to supply for uncomplicated malaria. This paper was the starting point 
for the subsequent research included in this thesis (Papers III, IV, and V, and Appendices B 
and C). 
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Malaria prevalence and treatment of febrile patients at health
facilities and medicine retailers in Cameroon
Lindsay J. Mangham1, Bonnie Cundill1, Olivia A. Achonduh2, Joel N. Ambebila2, Albertine K. Lele2,
Theresia N. Metoh2, Sarah N. Ndive2, Ignatius C. Ndong2, Rachel L. Nguela2, Akindeh M. Nji2,
Barnabas Orang-Ojong2, Joelle Pamen-Ngako2, Virginia Wiseman1 and Wilfred F. Mbacham2
1 London School of Hygiene and Tropical Medicine, London, UK
2 Laboratory for Public Health Research Biotechnologies, University of Yaounde´ I, Yaounde´, Cameroon
Abstract objective To investigate the quality of malaria case management in Cameroon 5 years after the
adoption of artemisinin-based combination therapy (ACT). Treatment patterns were examined in
different types of facility, and the factors associated with being prescribed or receiving an ACT were
investigated.
methods A cross-sectional cluster survey was conducted among individuals of all ages who left public
and private health facilities and medicine retailers in Cameroon and who reported seeking treatment for
a fever. Prevalence of malaria was determined by rapid diagnostic tests (RDTs) in consenting patients
attending the facilities and medicine retailers.
results Among the patients, 73% were prescribed or received an antimalarial, and 51% were pre-
scribed or received an ACT. Treatment provided to patients significantly differed by type of facility: 65%
of patients at public facilities, 55% of patients at private facilities and 45% of patients at medicine
retailers were prescribed or received an ACT (P = 0.023). The odds of a febrile patient being prescribed
or receiving an ACT were significantly higher for patients who asked for an ACT (OR = 24.1,
P < 0.001), were examined by the health worker (OR = 1.88, P = 0.021), had not previously sought an
antimalarial for the illness (OR = 2.29, P = 0.001) and sought treatment at a public (OR = 3.55) or
private facility (OR = 1.99, P = 0.003). Malaria was confirmed in 29% of patients and 70% of patients
with a negative result were prescribed or received an antimalarial.
conclusions Malaria case management could be improved. Symptomatic diagnosis is inefficient be-
cause two-thirds of febrile patients do not have malaria. Government plans to extend malaria testing
should promote rational use of ACT; though, the introduction of rapid diagnostic testing needs to be
accompanied by updated clinical guidelines that provide clear guidance for the treatment of patients
with negative test results.
keywords fever, malaria, prevalence, treatment, Cameroon
Background
Malaria is a major cause of morbidity and mortality and
places considerable burden on health services in countries
across sub-Saharan Africa. Symptomatic diagnosis of
malaria is a routine practice in malaria endemic settings;
though, recent guidelines from the World Health Organi-
zation recommend parasitological confirmation of sus-
pected malaria cases in all patients before treatment, where
testing facilities are available (WHO 2010a). Rapid diag-
nostic tests (RDTs) have attracted interest in recent years
because of their high specificity and sensitivity and are
suitable for resource-constrained settings as they require
minimal infrastructure and training. Moreover, there is an
economic case for introducing RDTs, compared with
presumptive treatment, given the comparatively high cost
of unnecessary treatment with antimalarials, such as
artemisinin-based combination therapy (ACT), among
those with non-malarial febrile illness (Lubell et al. 2007;
Shillcutt et al. 2008).
The Cameroon government adopted the ACT, artesu-
nate-amodiaquine (ASAQ), as the first-line treatment for
uncomplicated malaria in 2004 and endorsed artemether
lumefantrine (AL) as an alternative ACT in 2006 (Sayang
et al.2009a). The National Malaria Control Programme
(NMCP) organised workshops across all regions in
Cameroon to inform health workers at public, mission
and private health facilities of the policy change. Quinine
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volume 17 no 3 pp 330–342 march 2012
330 ª 2011 Blackwell Publishing Ltd
5. RESEARCH PAPER II
147
and artemether injection are reserved for cases of severe
malaria, and sulfadoxine-pyrimethamine for intermittent
preventive treatment during pregnancy. The 2008 treat-
ment guidelines for suspected cases of uncomplicated
malaria lack coherence: confirmation using microscopy
was advised in patients over 5 years; though, the treat-
ment algorithm did not incorporate parasitological diag-
nosis and there was no advice on what action should be
taken if the microscopy was negative. Moreover, while
the guidelines noted that microscopy is necessary to reveal
the presence of Plasmodium, they also stated that
‘a negative blood film or smear does not rule out the
presence of malaria’ (Ministry of Public Health 2008).
The guidelines note that pregnant women presenting with
signs of malaria should be treated for severe malaria using
quinine (Ministry of Public Health of the Republic of
Cameroon 2008).
In August 2009, the Cameroon government announced
their intention to promote the rational use of ACT using
RDTs or microscopy in all cases of fever in patients over
5 years before treatment (Ministry of Public Health
2009).The NMCP is currently developing plans to pilot the
introduction of RDTs in public health facilities in selected
health districts across Cameroon.
Patterns of malaria treatment have been researched
elsewhere in Africa and shown the extent to which
malaria is over-diagnosed (Reyburn et al. 2007; Rowe
et al. 2009; Juma & Zurovac 2011). Intervention studies
have investigated the effect of improving microscopy and
introducing RDTs on treatment (Ngasala et al. 2008;
Skarbinski et al. 2009; Kyabayinze et al. 2010). Much
less is known about malaria treatment practices in
Cameroon. In the year following the introduction of
ACT, Sayang et al. (2009b,c) found that few health
workers were aware of the change in antimalarial drug
policy, and facility records indicated that quinine was
usually prescribed for adults and amodiaquine for
children <5 years.
This study describes malaria case management in Cam-
eroon 5 years after the adoption of ACT. Diagnosis and
treatment patterns were examined in different types of
facility, and the factors associated with being prescribed or
receiving an ACT were investigated.
Methods
Study setting
The study was conducted in two sites in Cameroon:
Yaounde´ in the Centre region and Bamenda in the North-
West region. In Yaounde´, the capital and predominately
Francophone population, all five health districts were
included. The Bamenda site encompassed urban Bamenda
and five rural health districts within 21 km radius, which
serve an Anglophone population. Facilities included pub-
lic district hospitals and primary health centres; private
health care facilities (including mission hospitals, mission
health centres and private clinics); and medicine retailers
(either pharmacies or drug stores). Many public and
private facilities include a laboratory; though, malaria
microscopy may be limited by the availability of reagents
or trained staff. Pharmacies are present in both study sites
and are licensed to sell prescription and over-the-counter
medicines, although not to provide patient consultations
or malaria testing. Drug stores are informal providers that
typically sell over-the-counter medicines and are peculiar
to the North-West and South-West regions (R. Hughes,
C. I. R. Chandler, L. Mangham, W. Mbacham, unpub-
lished data). Malaria is endemic in both study sites.
Transmission in Yaounde´ is perennial, and in the North-
West region, peak transmission is between March and
October.
Study design
A stratified multistage cluster survey was conducted
between July and November 2009. The survey sampling
was clustered in 20 randomly selected communities,
defined as a natural grouping of health areas, stratified by
site. Facilities were then selected, stratifying by type of
facility: i) public facilities, ii) private facilities and iii)
medicine retailers. Private facilities grouped both mission
and for-profit facilities, which operate with considerable
independence from the government. Within each commu-
nity, all public and private facilities were included, while
medicine retailers were randomly selected with probability
proportionate to size assuming that a total of 100 medicine
retailers could be visited.
The primary outcome was the proportion of
individuals reporting seeking treatment for a fever that
were prescribed or received an ACT. A survey sample of
12 patients per public facility and eight patients per
private facility and medicine retailer was calculated to
estimate the primary outcome with a precision of ±6.2%
(private facility or medicine retailer) and ±8.6% (public
facility), assuming that the intra-cluster correlation in
treatment between facilities is 0.3 (Bennett et al. 1991).
These precision estimates differ given the different
sample sizes per type of facility and assume a prevalence
of 50% for the primary outcome to give the least
amount of precision. The sampling was based on an
enumeration of health facilities conducted in February–
May 2009.
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Survey activities
Afield team visited each facility to explain the purpose of the
survey to the head of the facility or medicine retailer and
obtain informed consent. Data were collected using four
structured approaches: 1) patient exit questionnaire, 2)
malaria testing, 3) healthworker survey and 4) facility audit.
The survey questionnaires were developed specifically for
the study and pretested on a non-random sample of
individuals at facilities not selected for inclusion in the study.
Field teams were trained on procedures for conducting
survey activities, including administering RDTs, and were
involved in the pretesting and revision of the questionnaires.
The field team comprised of researchers without a medical
background but with laboratory expertise and masters’
degrees in public health or microbiology. A quality assur-
ance officer supervised all aspects of data collection.
The primary outcome was measured through the exit
questionnaire which collected data on the patient’s previ-
ous treatment seeking, their consultation and diagnosis,
prescriptions and medicines received, the cost of treatment
seeking, and demographic characteristics. Individuals
exiting the facility or medicine retailer were invited to
participate, asked to give written consent and were
considered eligible if s ⁄he reported seeking treatment for a
fever (for themselves, a child or a patient not present) or if
s ⁄he had received an ACT. Patients with signs of severe
malaria were excluded by the field teams. Patients who
were present at the facility or medicine retailer were also
asked whether they were willing to be tested for malaria
using a RDT (SD Bioline Malaria Ag Pf ⁄pan) to deter-
mine the prevalence of malaria and the proportion of
patients receiving appropriate treatment. Treatment was
considered appropriate if the patient’s test result was
positive and s ⁄he had been prescribed or had received an
ACT, or if the test result was negative and s ⁄he had not
been prescribed and had not received an antimalarial.
Patients were told the test result, and anyone with a
positive result was advised that ACT is the recommended
antimalarial.
The health worker questionnaire asked about access to
in-service training, guidelines, and recommended practices
for treating uncomplicated malaria. The facility audit
recorded data on diagnostic services and antimalarials
available. The health worker and facility data were
collected once the patient exit survey was complete. All
health workers within each facility (including medicine
retailers) responsible for prescribing or dispensing medi-
cines and available at the time of the health worker and
facility audit were included in the survey. Written consent
was obtained from all individuals that participated in the
study.
Statistical analysis
Data were double-entered and verified using Microsoft
Access 2007 (Microsoft Inc., Redmond, Washington) and
analysed using STATA version 11.0 (STATA Corporation,
College Station, Texas) that allows for complex survey
design by identifying different probabilities of selection
(sampling weights), clustering and stratification (StataCorp
2009). Thus, the percentages, 95% confidence intervals
and odds ratios reported are population-average estimates
which have been adjusted to take into account the
stratification, clustering and sampling weights of the study
design.
Treatment outcomes by strata were estimated using the
Rao and Scott chi-square correction (Rao & Scott 1981).
Survey logistic regression was used to assess factors
associated with being provided an ACT (which is defined
as either being prescribed or receiving an ACT). Patient
characteristics, health worker characteristics, details of the
consultation and type of facility were investigated for their
potential association with being provided an ACT (as listed
in Table 4). Factors whose univariable association with
being provided an ACT reached statistical significance at
the 10 per cent level or which were strongly associated with
the outcome (with an odds ratio <0.5 or >1.5) were
included a multivariable model. The multivariable model
was developed using stepwise regression, and all factors
were retained if they remained significantly associated at
the 10% level or with an adjusted odds ratio of <0.5 or
>1.5. Models were compared using an adjusted Wald test.
Pregnant women and children under the age of 6 months
were excluded from the analysis because the guidelines
recommend alternative treatments.
Ethical approval
Ethical approval was obtained from the ethics committees
of the London School of Hygiene and Tropical Medicine
and Cameroon National Ethics Committee. Administrative
clearance was obtained from the Directorate of Opera-
tional Research in Health from the Ministry of Public
Health.
Results
Patient characteristics
In total, 964 eligible patients (or their caregivers) consented
to participate in the exit survey. Of these, 16 pregnant
women and 10 children under 6 months were excluded
from the analysis. Thus, the analysis is based on exit data
collected from 938 febrile patients attending 174 facilities
(Figure 1). The characteristics of patients surveyed at each
Tropical Medicine and International Health volume 17 no 3 pp 330–342 march 2012
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type of facility varied by age, socioeconomic status (SES)
and level of education, with those attending public facilities
of a slightly lower SES and education level (Table 1). In
total 544 (59%) patients reported, it was the first time
treatment was sought for this illness episode and 182
(19%) were seeking treatment on the same day or the day
following onset of symptoms. Of those that had previously
sought treatment, 154 of 386 (43%) recalled receiving an
219 facilities selected to be 
included in the study 11 refused to participate (2 public, 1 private, 8
retailers)
30 had shut down (10 private, 20 retailers)
18 were specialist (1 public, 17 private)
1 was inaccessible (1 public)
15 were replaced (15 retailers)174 facilities participated in the
study
43 public facilities
participated in the study
43 private facilities 
participated in the study
88 retailers participated
in the study
135 HWs 
eligible for
worker survey
337 patients
complete survey
(five refused: 
one unspecified)
294 patients
had RDT for
study (35 were
not present or
refused)
342 patients 
eligible for patient
exit survey
135 HWs
complete survey
(0 refused)
192 HWs eligible
for worker survey
434 patients
complete survey
(21 refused:
12 too busy, five
too ill, four 
unspecified)
290 patients
had RDT for
study (136 were
not present or
refused)
455 patients
eligible for patient
exit survey
184 HWs
complete survey
(seven refused: 
four too busy, 
one trainee staff, 
two unspecified)
133 HWs eligible
for worker survey
193 patients
complete survey
(five refused: 
four too busy, 
one unspecified)
162 patients
had RDT for
study (21 were
not present or
refused)
198 patients 
eligible for patient
exit survey
130 HWs 
complete survey
(three refused:
 three too busy)
329 patients
analyzed (four
were pregnant
and four were
< 6 months)
426 patients
analyzed (five
were pregnant
and three were
< 6 months)
183 patients
analyzed (seven
were pregnant
and three were
< 6 months)
four too busy, 
Figure 1 Survey population in Cameroon.
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antimalarial at the last place they sought treatment and 62
of 386 (18%) recalled receiving an ACT.
Health facility and health worker characteristics
Public and private facilities were well equipped, with
microscopy testing available in 36 (91%) public facilities
and 43 (100%) private facilities (Table 2). ACT was
available in 121 (70%) facilities. Public facilities tended
to stock artesunate-amodiaquine; though, other types of
ACT including artemether-lumefantrine and dihydroarte-
misinin-piperaquine were available at private facilities
and medicine retailers. Most facilities reported quinine
and sulfadoxine-pyrimethamine were available, while
artemisinin-monotherapy was available in 54 (40%)
facilities.
Table 1 Patient characteristics
Public Private Medicine retailer Total
P-valueN = 329 % N = 183 % N = 426 % N = 938 %
Study site
Bamenda 225 69.1 83 39.2 226 58.6 534 57.5 0.148
Yaounde´ 104 30.9 100 60.8 200 41.5 404 42.6
Gender*
Male 157 46.2 81 43.2 228 52.7 466 49.4 0.149
Female 169 53.8 99 56.8 195 47.3 463 50.6
Age
>15 years (adult) 191 57.6 111 59.1 294 69.1 596 64.6 0.090
5–15 years 53 15.2 28 16.3 37 7.6 118 11.0
<5 years 85 27.2 44 24.6 95 23.3 224 24.4
Socioeconomic status (by wealth quintile)
Poorest 104 31.4 30 16.8 55 16.7 189 20.1 0.025
Second 70 21.2 24 11.9 92 22.0 187 20.0
Third 63 19.6 44 26.5 80 18.5 187 20.2
Fourth 51 15.8 48 28.4 89 18.5 188 19.7
Richest 40 12.0 37 16.5 110 24.3 187 20.0
Education (or caregiver education)
None or primary education 143 42.2 69 42.2 129 35.5 341 38.3 0.142
Secondary education 144 46.7 84 41.4 190 42.9 418 43.5
Tertiary education 37 11.1 29 16.4 98 21.6 164 18.2
Number of days since start of
symptoms (n = 938)
£1 day 54 15.0 32 16.4 96 20.7 182 18.6 0.453
2 days 60 18.3 24 13.4 92 21.0 176 19.0
3–5 days 116 35.8 70 38.0 138 33.2 34 34.7
6 days or longer 99 30.9 57 32.2 100 25.1 256 27.8
Was first time sought treatment§
Yes 184 53.5 93 47.6 267 65.4 544 59.3 0.055
No 143 46.5 90 52.4 153 34.7 386 40.7
Recall of treatment received at last
place sought treatment N = 143 % N = 90 % N = 153 % N = 386 %
Any AM 45 30.6 34 42.6 74 49.8 154 42.9 0.048
ACT 14 9.3 10 9.4 38 26.3 62 17.7 0.002
Antibiotic 22 14.7 9 7.3 14 10.3 45 10.8 0.450
Antipyretic 87 61.5 54 54.2 63 41.2 204 49.8 0.025
ACT, artemisinin-based combination therapy; SES, socioeconomic status.
*Missing nine observations (three from public, three from private and three from medicine retailers).
Principal components analysis was undertaken to generate a SES index based on household asset ownership (Filmer & Pritchett 2001) The
SES index was disaggregated into quintiles.
Missing 15 observations (five from public, one from private and nine from medicine retailers).
§Missing eight observations (two from public and six from medicine retailers).
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Across all facilities, 284 (61%) health workers
reported that ACT is the recommended treatment for
uncomplicated malaria, 150 (24%) had access to guide-
lines and 162 (35%) had attended malaria training in the
past 3 years. The knowledge of health workers at public
facilities was higher, with 108 (80%) health workers
aware that ACT is the recommended treatment
compared with 83 (60%) at private facilities and 93
(54%) at medicine retailers.
Prescribed treatment for malaria
Patient-reported consultations differed by type of facility,
with health workers at public and private facilities more
likely to ask about symptoms, examine and test the patient
than health workers at medicine retailers (Table 3).
Patients were more likely to request antimalarials, includ-
ing ACT, at medicine retailers, whilst those attending
private facilities were more likely to be tested for malaria.
Almost three-quarters (73%, 95% CI: 65–80%) of all
patients were prescribed or received an antimalarial.
Antibiotics were prescribed or received by 24% of febrile
patients, and antipyretics were prescribed or received by
56% of febrile patients. Approximately half (51%, 95%
CI: 44–59%) of all patients were prescribed or received an
ACT, the recommended treatment for uncomplicated
malaria; 65% (95% CI: 55–72%) of patients at public
facilities, 55% (95% CI: 40–69%) at private facilities and
45% (95% CI: 35–56%) at medicine retailers (P = 0.023).
This includes 17% (95% CI: 12–23%) of patients who
reported they were tested for malaria during their consul-
tation; though, the results are similar if the sample is
Table 2 Health facility and health worker characteristics
Health facilities
Public Private Medicine retailer Total
P-valueN = 43 % N = 43 % N = 88 % N = 174 %
Study site
Bamenda 32 58.3 20 28.6 59 57.1 111 51.5 0.005
Yaounde´ 11 41.7 23 71.4 29 43.0 63 48.5
Equipment and services available
Weighing scale* 40 93.9 43 100 39 49.0 122 66.5 <0.001
Thermometer* 39 94.6 42 95.4 57 61.2 138 73.4 <0.001
Microscopy services* 36 90.5 43 100 3 3.3 82 36.7 <0.001
RDT in stock* 0 0 5 10.9 1 1.1 6 2.9 <0.001
Availability of antimalarials
Any antimalarial 42 98.2 42 98.0 88 100 172 99.3 0.023
Artesunate monotherapy 9 32.2 15 35.4 30 42.7 54 39.6 0.237
Amodiaquine 3 9.7 7 12.5 36 35.0 46 26.5 <0.001
Quinine 38 91.8 39 95.6 84 96.2 161 95.4 0.774
Sulfadoxine-pyrimethamine (SP) 35 86.2 34 82.8 80 92.5 149 89.6 0.028
Any ACT 34 82.8 27 65.2 60 71.8 121 72.2 0.039
Artemether lumefantrine 5 9.9 18 49.5 37 47.8 60 42.1 <0.001
Artesunate amodiaquine 33 77.0 14 33.7 50 62.6 97 59.0 0.002
Artesunate mefloquine 2 8.5 4 11.7 21 32.9 27 24.7 <0.001
Artesunate sulfadoxine-pyrimethamine 0 0 1 2.0 18 25.9 19 16.9 0.003
Dihydroartemisinin-piperaquine 3 14.3 8 17.5 23 34.9 34 28.1 0.004
Health workers N = 134 % N = 129 % N = 184 % N = 447 % P-value
HW has attended malaria training in
past 3 years
74 49.2 40 33.9 48 29.5 162 34.5 <0.001
HW has access to malaria treatment
guidelines
88 54.8 54 42.2 8 4.6 150 24.1 <0.001
HW accurately reported ACTs are the
recommended treatment for uncomplicated
malaria
108 80.1 83 60.4 93 54.3 284 60.9 <0.001
ACT, artemisinin-based combination therapy.
*Missing one observation (from pharmacy).
Missing two observations (one from public & one from private).
The availability of ACTs was verified by the field staff.
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Table 3 Recommended treatment of malaria
Health facility type
Public Private Medicine retailer Total
P-value
N = 329 N = 183 N = 426 N = 938
% (95% CI) % (95% CI) % (95% CI) % (95% CI)
Patient reported consultation
Told HW about patient symptoms 95.6 (90.8–97.9) 97.6 (90.6–99.4) 62.1 (52.5–70.8) 76.6 (68.6–83.0) <0.001
Told HW that had a fever 66.9 (58.9–74.0) 64.3 (49.2–77.0) 49.5 (39.9–59.2) 56.4 (49.1–63.4) 0.024
HW asked follow up questions about
patient’s symptoms
75.8 (65.8–83.6) 66.9 (53.7–77.8) 32.7 (24.0–42.7) 49.1 (41.2–56.9) <0.001
Patient was examined 60.0 (48.8–70.3) 75.3 (54.7–88.6) 12.3 (7.9–18.7) 35.2 (26.5–44.9) <0.001
Patient had temperature taken 67.9 (54.3–79.0) 55.9 (26.1–82.0) 9.0 (5.0–15.7) 31.4 (23.6–40.4) <0.001
Patient tested for malaria at this facility 35.1 (25.7–45.7) 44.4 (30.0–59.7) 1.0 (0.2–6.1) 17.0 (12.3–23.1) <0.001
% Of patients who requested
Any type of medicine 8.6 (5.0–14.6) 2.2 (0.7–6.3) 53.7 (42.2–64.8) 33.8 (25.3–43.4) <0.001
Antimalarial (any type) 7.5 (4.1–13.4) 1.5 (0.4–5.0) 37.3 (26.8–49.2) 23.8 (16.7–32.7) <0.001
Any ACT 3.7 (1.8–7.3) 1.0 (0.3–3.8) 25.2 (17.2–35.2) 15.7 (10.6–22.6) <0.001
Artemisinin monotherapy 0 0 0.3 (0.0–1.5) 0.1 (0.0–0.9) 0.814
Quinine 3.3 (1.1–9.5) 0.4 (0.1–2.0) 6.7 (3.3–13.0) 4.8 (2.6–8.7) 0.033
SP 0.5 (0.0–6.2) 0 4.4 (2.1–8.8) 2.7 (1.3–5.5) 0.084
% of all patients who were prescribed or received
Antimalarial (any type) 78.3 (71.9–83.6) 84.5 (70.5–92.6) 66.9 (55.5–76.7) 72.8 (64.7–79.7) 0.016
ACT* 64.8 (55.3–72.3) 54.5 (39.5–68.8) 44.9 (34.5–55.7) 51.3 (44.0–58.6) 0.023
Artemisinin monotherapy 1.1 (0.3–4.1) 3.1 (0.3–24.4) 0.1 (0.0–1.1) 0.9 (0.2–3.5) 0.031
Quinine 13.4 (7.6–22.4) 21.1 (11.0–36.8) 15.2 (8.7–25.2) 15.9 (10.9–22.5) 0.477
SP 0.2 (0.0–3.9) 10.7 (4.5–23.2) 4.5 (2.1–9.3) 4.7 (2.6–8.2) 0.008
Antibiotic 41.9 (32.8–51.7) 41.1 (33.3–49.2) 12.0 (8.0–17.5) 24.4 (19.6–29.9) <0.001
Antipyretic 69.4 (60.8–76.8) 71.4 (53.0–84.7) 44.9 (35.0–55.3) 55.6 (46.5–64.2) 0.002
% Of patients who were not tested for malaria and were prescribed or received
Antimalarial (any type) 78.4 (71.1–84.2) 85.1 (67.4–94.0) 67.3 (56.0–76.9) 71.5 (62.6–79.0) 0.046
ACT* 67.6 (56.4–77.1) 63.8 (50.6–75.1) 45.0 (34.7–55.7) 51.4 (43.5–59.3) 0.005
Artemisinin monotherapy 0.8 (0.2–3.0) 0 0.1 (0.0–1.1) 0.2 (0.1–0.7) 0.120
Quinine 10.7 (5.4–20.1) 15.7 (8.5–27.1) 15.3 (8.9–25.0) 14.5 (9.6–21.4) 0.597
SP 0 7.3 (2.2–21.3) 4.6 (2.2–9.2) 4.1 (2.1–7.6) 0.203
Antibiotic 41.2 (31.4–51.6) 45.3 (35.9–55.1) 11.8 (8.0–16.9) 21.3 (16.8–26.6) <0.001
Antipyretic 71.3 (62.3–78.9) 72.1 (50.6–86.7) 45.4 (35.8–55.3) 53.4 (44.3–62.3) 0.002
Dosage and advice given for ACT dispensed
% Of ACTs dispensed that were an accurate
dose
92.4 (84.0–96.6) 98.5 (93.5–99.7) 97.5 (92.3–99.2) 96.5 (93.3–98.1) 0.065
% Patient that has accurate knowledge of
treatment regimen
83.9 (70.7–91.8) 89.0 (74.3–95.7) 85.8 (74.7–92.5) 86.1 (79.8–90.6) 0.781
ACT, artemisinin-based combination therapy.
*61.4% (49.4–72.2%) of children under 5 years that were prescribed or received an ACT. By facility type the percentage of children under
5 years that were prescribed or received an ACT was 79.4% (69.0–87.0%) at public facilities; 50.6% (26.2–74.8%) at private facilities;
and 56.6% (39.7–72.1%) at medicine retailers (P = 0.080).
Defined as dose that is consistent guidance on dosage by patient age (and excludes suspensions and syrups). Based on 306 observations
(112 from public, 68 from private and 126 from medicine retailers).
Defined as patient reports treatment regimen is consistent with guidance on dosage by patient age (and excludes suspensions and syrups).
Based on 283 observations (111 from public, 64 from private and 108 from medicine retailers).
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restricted to those that were diagnosed based on symptoms
alone: 51% (95% CI: 44–59%) of patients were pre-
sumptively prescribed or received an ACT.
The odds of a febrile patient being prescribed or
receiving an ACT were significantly higher for patients
who asked for an ACT (OR = 24.1, P < 0.001), were
examined by the health worker (OR = 1.88, P = 0.021),
had not previously sought an antimalarial for the illness
(OR = 2.29, P = 0.001) and sought treatment at a public
(OR = 3.55) or private facility (OR = 1.99, P = 0.003)
(Table 4). There was no evidence that the treatment
prescribed or received was significantly associated with
the patient’s demographic characteristics or being tested
for malaria. In the univariable analysis, the odds that
febrile patients were prescribed or receiving an ACT
were significantly associated with facilities that had one
or more health workers who had i) attended malaria
training and ii) knew ACT is recommended; though,
these factors did not remain significant in the multivar-
iable model.
Quinine was prescribed or received by 16% (95% CI:
11–22%) of patients and a further 5% (95% CI: 3–9%)
of patients were prescribed or received sulfadoxine-
pyrimethamine (Table 3). Almost all ACTs dispensed were
estimated to be dispensed in the correct dose for the
patient’s age, and 86% (95% CI: 80–91%) of patients
receiving an ACT accurately reported how the medicine
should be taken.
Appropriate treatment for malaria
RDTs were used by the study team to test for malaria in
746 (79%) patients, and malaria was confirmed using
RDTs in 29% (95% CI: 22–36%) of patients tested
(Table 5). Based on these findings, 39% (95% CI: 33–
45%) of patients received appropriate treatment; 43%
(95% CI: 34–52%) in public facilities, 29% (95% CI: 21–
39%) in private facilities and 41% (95% CI: 33–49%) in
medicine retailers (P = 0.08). Of those who were positive
for malaria, 59% (95% CI: 50–66%) received an ACT,
while of those negative for malaria, 48% (95% CI: 40–
57%) received an ACT. Almost three-quarters of patients
(70%, 95% CI: 60–78%) received an antimalarial despite
not having malaria.
Health workers’ choice of treatment was investigated
using patient-reported information on whether a test was
conducted during the consultation, the test result (deter-
mined by the field team) and the treatment prescribed or
received. The test result of the RDT conducted by the field
team was used because patient-reported results were
unreliable as many patients did not know their test result
and routine test data were not accessed. Treatment doesT
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not significantly differ for patients who were tested during
their consultation; 78% (95% CI: 66–86%) of patients
who were tested positive, 82% (95% CI: 71–89%) of
patients who were tested negative and 72% (95% CI:
62–79%) of patients not tested were prescribed or received
an antimalarial (Table 6).
Discussion
Almost three-quarters (73%) of all patients who reported
seeking treatment for a fever were prescribed or received an
antimalarial, and approximately half (51%) were pre-
scribed or received an ACT. These estimates include
patients who were tested for malaria; though, the pre-
scribing patterns were similar for presumptive treatment
(based only on a symptomatic diagnosis). Sixty-one per
cent of children under 5 years with a fever were prescribed
or received an ACT. Studies undertaken in East and
Southern Africa reported similar results: 50% of febrile
children under 5 years were prescribed an ACT in Zambia
in 2006 and 66% in Uganda in 2007 (Zurovac et al. 2007,
2008a).
The results of this study show an improvement of the
situation in Cameroon in 2005, when prescribing records
indicated that less than 15% of antimalarials prescribed
were an ACT (Sayang et al. 2009b,c). The use of quinine in
Table 5 Appropriate treatment of malaria
N
RDT result
% Prescribed or received an
antimalarial % Prescribed or received ACT % Received
appropriate
treatmentYes No Yes No
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
All facilities 746 38.7 (32.9–45.0)
Malaria positive 222 28.6 (22.3–35.9) 82.8 (73.4–89.3) 17.3 (10.7–26.6) 58.8 (50.7–66.4) 41.2 (33.6–49.3)
Malaria negative 524 71.4 (64.1–77.7) 69.5 (60.1–77.4) 30.7 (22.7–40.0) 48.4 (40.0–56.9) 51.7 (43.2–60.1)
Public facilities 294 42.6 (33.9–51.6)
Malaria positive 102 33.0 (22.9–45.0) 89.5 (81.7–94.3) 10.5 (5.7–18.3) 75.6 (64.1–84.3) 24.4 (15.7–35.9)
Malaria negative 192 67.0 (55.0–77.1) 73.8 (65.8–80.6) 26.2 (19.4–34.3) 61.5 (49.7–72.1) 38.9 (28.2–50.7)
Private facilities 162 29.0 (20.5–39.3)
Malaria positive 47 33.6 (18.0–53.9) 79.4 (64.1–89.3) 20.6 (10.7–35.9) 56.7 (39.5–72.4) 43.3 (27.7–60.5)
Malaria negative 115 66.4 (46.1–82.0) 85.0 (69.1–93.5) 15.0 (6.5–30.9) 57.4 (44.6–69.3) 42.6 (30.8–55.5)
Medicine retailers 290 40.8 (33.3–48.8)
Malaria positive 73 24.3 (17.9–32.0) 79.7 (59.8–91.3) 20.3 (8.7–40.2) 47.8 (33.5–62.5) 52.2 (37.5–66.5)
Malaria negative 217 75.7 (68.0–82.1) 61.5 (50.0–71.8) 38.5 (28.2–50.0) 39.0 (28.5–50.7) 61.0 (49.3–71.5)
ACT, artemisinin-based combination therapy.
Table 6 Treatment prescribed to patients tested ⁄ not tested during patient consultation
N
Prescribed or
received an
antimalarial
Prescribed or
received an
ACT
Prescribed or
received quinine
Prescribed or
received an
antibiotic
% (95% CI) % (95% CI) % (95% CI) % (95% CI)
Patient tested during consultation and
malaria positive*
56 77.5 (66.1–85.9) 52.3 (35.3–68.9) 15.8 (61.2–34.8) 38.9 (22.1–58.8)
Patient tested during consultation and
malaria negative*
121 81.9 (71.2–89.2) 56.3 (39.8–71.5) 22.1 (11.2–33.0) 37.9 (25.7–51.9)
Patient was not tested during consultation 730 71.5 (62.5–79.1) 51.5 (43.4–59.5) 14.5 (9.5–21.6) 21.3 (16.7–26.8)
All patients 938 72.8 (64.7–79.7) 51.3 (44.0–58.6) 15.9 (10.9–22.5) 24.3 (19.5–29.9)
ACT, artemisinin-based combination therapy.
*Patient reported data on test results was considered unreliable as more than half of respondents reported that they did not know the result
of the test that was conducted and routine test data was not available to the field team. The malaria test result used here is that from the
RDT conducted by the field team.
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non-severe cases has fallen substantially since 2005
(Sayang et al. 2009b,c); though, it remains a concern: 16%
of patients with symptoms of uncomplicated malaria were
prescribed or received quinine. These improvements over
time may reflect efforts to disseminate the policy change, as
observed in Kenya where the percentage of febrile children
under 5 years that were prescribed an ACT at government
facilities with AL in stock increased from 28% in 2006
to 69% in 2010 (Zurovac et al. 2008b; Juma & Zurovac
2011). In this study, attendance at malaria training and
health worker knowledge of malaria guidelines were no
longer significant in the multivariable model; though, the
association between patients provided an ACT and health
worker attributes may be an underestimate because these
factors were investigated at the facility level.
The odds of a febrile patient being prescribed or receiving
an ACT were significantly associated with patients who
asked for an ACT, were examined, had not previously
obtained an antimalarial and the type of facility at which
treatment was sought. Treatment practices at medicine
retailers were significantly worse than at public and private
facilities, although it is encouraging that patients asking for
an antimalarial most often requested an ACT. Moreover,
the percentage of patients receiving an ACT (45%) was
better thanwas observed at pharmacies and patent medicine
stores in neighbouring Nigeria, where 23% of febrile
patients received an ACT (Mangham et al. 2011).
Reliance on presumptive treatment has led to consider-
able over-diagnosis of malaria. In this survey, malaria was
confirmed in less than a third of suspected cases using
RDTs. The RDTs used have high specificity and sensitivity
(WHO 2010b); though, it is a limitation that their results
were not validated using gold standard microscopy. It was
also beyond the scope of this study to investigate the cause
of non-malarial febrile illness, and we are unable to
comment on the suitability of other medicines received.
Based on the RDT results, the majority of patients (61%)
were prescribed or received antimalarials they did not
need, and thus, many patients received ineffective medi-
cines and incurred unnecessary costs obtaining treatment.
Over-diagnosis also has adverse cost implications for the
Cameroon government, which subsidises ACT at public
facilities.
Microscopy was widely available in public and private
facilities, but underused, with less than half of patients
tested for malaria during their consultation. Similar
findings were reported in an Angolan study, in which
40% of the patients were tested despite the widespread
availability of microscopy and RDTs (Rowe et al. 2009).
Moreover, we observed no significant differences in the
treatment prescribed or received by patients between
those that were tested positive, tested negative and not
tested during their consultation with the health worker.
Poor adherence to test results has been observed in Ghana
and Tanzania, with 50% of patients with negative RDT
test results being prescribed an antimalarial in Ghana
(Ansah et al. 2010) and 54% in Tanzania (Reyburn et al.
2007). Inferences about health workers’ use of the test
result in selecting treatment in this study are limited
because there is some uncertainty whether the RDT result
used for the analysis was consistent with the result of
routine microscopy undertaken at the facility. Health
worker perspectives on malaria testing were subsequently
explored using qualitative methods (C. I. R. Chandler,
L. Mangham, A. N. Njei, O. Achonduh, W. F. Mbacham,
V. Wiseman, unpublished data).
Increasing the use of malaria testing has the potential to
promote the rational use of ACT and appropriate treat-
ment of non-malarial febrile illness (Sayang et al. 2009a).
The government’s plans to introduce RDTs should increase
the proportion of patients tested because RDTs are simple
to use and provide quick results. The study also highlights
the potential benefits of extending the availability of RDTs
to private facilities and medicine retailers. However, the
findings suggest that attention needs to be given to the role
of testing within the therapeutic process to ensure uptake
of RDTs and prescriptions that adhere to the test result.
On a related point, the lack of clear guidance in the
malaria guidelines, which advises confirmation using
microscopy but does not explain what actions to take if the
test is negative, may lead to over-treatment of malaria in
patients with negative test results. The uncertainty over
how to manage febrile patients with a negative malaria test
result is not confined to the Cameroon setting, and there is
currently no consensus on how these cases should be
managed (Bjo¨rkman &Ma˚rtensson 2010). Needless to say,
if the introduction of RDTs is to be cost-effective, it will be
important to revise clinical guidelines and provide health
workers with advice on how to undertake diagnosis and
provide treatment for patients presenting with a fever in
situations when the test is positive and when the test is
negative for malaria.
Conclusion
This study provides timely insight into the quality of
malaria case management at health facilities and medicine
retailers in Cameroon. ACT was prescribed or received by
51% of patients; though, quinine was also provided for
uncomplicated malaria. Symptomatic diagnosis is ineffi-
cient because two-thirds of febrile patients do not have
malaria. Government plans to extend malaria testing
should promote rational use of ACT; though, the
introduction of rapid diagnostic testing needs to be
Tropical Medicine and International Health volume 17 no 3 pp 330–342 march 2012
L. J. Mangham et al. Malaria prevalence and treatment in Cameroon
340 ª 2011 Blackwell Publishing Ltd
5. RESEARCH PAPER II
157
accompanied by updated clinical guidelines that provide
clear guidance on the treatment of patients with negative
test results. Based on these findings and with the support of
the NMCP, the REACT Project has developed provider
training interventions that should improve malaria case
management in public and mission health facilities and
these are currently being evaluated.
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Chapter 6 
Research Paper III: What determines providers’ stated preference for 
the treatment of uncomplicated  
Chapters 4 and 5 described the problems with the treatment received by febrile patients 
attending health facilities and medicine retail outlets in Nigeria and Cameroon.  This 
research paper sets out to explore why, and reports on providers’ knowledge of the 
national malaria treatment guidelines and the determinants of providers’ stated 
preference for treating uncomplicated malaria. The findings from this paper were used to 
select and design interventions to improve the diagnosis and treatment of uncomplicated 
malaria. 
A primary motivation for this analysis was to assess whether an intervention targeting 
providers’ knowledge would be effective, or whether additional effort would be needed to 
ensure providers’ preference over alternative antimalarials was aligned to the national 
guidelines. The paper focuses on providers’ stated preference, since their revealed 
preference (i.e. their practice) may be constrained by the resources and information 
available. The analysis is underpinned by agency theory, and recognises that providers are 
not only agents for their patients, but may also act on behalf of other health sector actors, 
such as their employer, the Ministry of Health and pharmaceutical suppliers. 
Providers’ stated preference was elicited by asking each provider “which antimalarial do 
you think is the best for treating patients with uncomplicated malaria?”. The brand and 
generic names stated were subsequently coded and the analysis was undertaken using a 
binary outcome: whether or not the provider had stated an ACT. As discussed in the paper, 
there is some uncertainty in how providers understood the question used and we 
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acknowledge this is a limitation. The questionnaires were piloted before the full survey 
was administered and no problems were reported. However, this particular question was 
not given specific attention in the piloting since this analysis was not planned a priori and 
the provider questionnaire contained more than a hundred questions. 
The econometric analysis uses a discrete choice model based on random utility theory 
[1-2]. Although utility cannot be directly observed, individuals are assumed to be 
economically rational and make choices that maximize their utility. In this application I 
examine whether providers prefer an ACT and use an multilevel logit regression to assess 
the extent to which providers’ stated preference depends on financial and non-financial 
incentives, subject to information they have available on different antimalarials and the 
underlying institutional environment. 
The analysis uses pooled data from provider surveys conducted at different types of 
facility in Cameroon and Nigeria. This resulted in a heterogeneous study population and 
the opportunity to explore the extent to which providers’ preference reflected their 
institutional and social context. It was straightforward to merge the data from the two 
countries since a standardized questionnaire had been used. Using pooled data also 
increased the sample size, which was restricted because the provider survey was part of a 
larger study that had been designed to examine the treatment supplied to febrile patients. 
As pooled data were used, country-specific effects were examined in the multilevel 
analysis. This included an explanatory variable for the country, and interactions to 
investigate whether any of the provider, facility and area attributes had a country-specific 
effect. Interactions were added to the random-intercept model one at a time and their 
statistical significance was assessed using the Wald test and the likelihood ratio test at a 
10% level of significance. As noted in the paper, model specification was assessed using 
various methods, and none of the interactions were found to significantly improve the fit 
of the model.   
6. RESEARCH PAPER III 
162 
 
The findings confirmed that providers’ stated preference may be influenced by their 
patients, drug company representatives, and other providers who work at the same 
facility or in the same locality. The findings also contributed to a theory-based approach to 
intervention design. Based on these findings, the enhanced training incorporated 
interactive small-group work and sessions on communicating with patients. In addition, 
the enhanced training was intended to build consensus within a facility and all providers 
attending the training workshops were encouraged to hold training and share what they 
had learnt with their colleagues. 
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a b s t r a c t
As agents for their patients, providers often make treatment decisions on behalf of patients, and their
choices can affect health outcomes. However, providers operate within a network of relationships and are
agents not only for their patients, but also other health sector actors, such as their employer, theMinistry of
Health, and pharmaceutical suppliers. Providers’ stated preferences for the treatment of uncomplicated
malaria were examined to determine what factors predict their choice of treatment in the absence of in-
formation and institutional constraints, such as the stock of medicines or the patient’s ability to pay.
518 providers working at non-proﬁt health facilities and for-proﬁt pharmacies and drug stores in
Yaoundé and Bamenda in Cameroon and in Enugu State in Nigeria were surveyed between July and
December 2009 to elicit the antimalarial they prefer to supply for uncomplicated malaria. Multilevel
modelling was used to determine the effect of ﬁnancial and non-ﬁnancial incentives on their preference,
while controlling for information and institutional constraints, and accounting for the clustering of
providers within facilities and geographic areas.
69% of providers stated a preference for artemisinin-combination therapy (ACT), which is the rec-
ommended treatment for uncomplicated malaria in Cameroon and Nigeria. A preference for ACT was
signiﬁcantly associated with working at a for-proﬁt facility, reporting that patients prefer ACT, and
working at facilities that obtain antimalarials from drug company representatives. Preferences were
similar among colleagues within a facility, and among providers working in the same locality. Knowing
the government recommends ACT was a signiﬁcant predictor, though having access to clinical guidelines
was not sufﬁcient.
Providers are agents serving multiple principals and their preferences over alternative antimalarials
were inﬂuenced by patients, drug company representatives, and other providers working at the same
facility and in the local area. Efforts to disseminate drug policy should target the full range of actors
involved in supplying drugs, including providers, employers, suppliers and local communities.
 2014 The Authors. Published by Elsevier Ltd. All rights reserved.
Introduction
The market for health care is characterized by information
asymmetry, as patients delegate decision-making and rely on
providers to select as well as administer treatment (Arrow, 1963).
The performance of providers in low-and-middle-income countries
continues to be scrutinized and there is widespread interest in
strategies to improve their practice (Rowe, de Savigny, Lanata, &
Victora, 2005). In designing interventions to improve the quality
of care it is important to understand what or who inﬂuences pro-
viders’ treatment decisions. Structural factors are often empha-
sized, and providers’ practicemay be constrained by the availability
of essential equipment, supplies and medicines (Peabody,
Taguiwalo, Robalino, & Frenk, 2006), and by shortages of health
professionals, as existing staff care for large volumes of patients and
substitute for more senior cadres (Chen et al., 2004). There is,
q This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-ShareAlike License, which permits non-
commercial use, distribution, and reproduction in any medium, provided the
original author and source are credited.
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however, evidence on providers’ knowledge, competence and
practice demonstrating that poor resource availability and knowl-
edge of clinical guidelines are not the only reasons why patients
receive poor quality care (Das, Hammer, & Leonard, 2008; Willis-
Shattuck et al., 2008).
The literature on medical practice variation examines the
extent to which individual providers affect the quality of patient
care. The notion of ‘practice style’ was introduced to describe the
variation attributed to providers’ preference over alternative forms
of care (Wennberg, Barnes, & Zubkoff, 1982). Early studies focused
on geographic variation, and showed that variations in medical
practice were not fully explained by patients’ health care needs
and demographic characteristics (McPherson, Wennberg, Hovind,
& Clifford, 1982). As the literature grew, studies investigated dif-
ferences between facilities and between individual providers
(Scott & Shiell, 1997a, 1997b). For example, Davis et al. examined
decision-making in primary care facilities and found considerable
variation between doctors in prescribing, referral for diagnostic
tests and follow up having accounted for case-mix, patient, and
practitioner attributes (Davis, Gribben, Scott, & Lay-Yee, 2000).
Although the literature on medical practice variation is reasonably
extensive, it offers limited insight into the extent to which pro-
viders’ preference varies by type of organization. Moreover, most
studies come from high-income countries where facilities are
well-resourced and institutions monitor and regulate the quality
of health care.
Providers’ preference over alternative treatments is said to be
revealed by their actual practice, though the choice of treatment
may be constrained by other factors, such as the stock of medicines,
speciﬁc information about the patient’s condition or the patient’s
ability to pay. Stated preferences are usually used in economic
studies to substitute for revealed preferences under conditions
where it is not possible to capture revealed preferences (because,
for example, the product in question is not available in the market).
However, in some cases it may be useful to focus on stated pref-
erences in their own right, as distinct from revealed preferences.
For instance, focussing on what providers’ state they prefer, rather
than what they know or do, will help to determine whether an
intervention that targets providers’ knowledge is likely to be
effective or whether additional effort is needed to change what
they prefer. In other words, it is acknowledged that changing what
providers prefer may not be sufﬁcient to change actual practice, but
any gap between stated and revealed preference would require
supplementary interventions, such as those that address resource
constraints or reduce the patients’ cost of accessing care.
Providers’ stated preferences for the treatment of uncompli-
cated malaria were examined as part of the formative stages of a
study undertaken to test supply-side interventions to improve
malaria diagnosis and treatment in Cameroon and Nigeria
(Wiseman, Ezeoke, et al., 2012; Wiseman, Mangham, et al., 2012).
Malaria places a considerable burden on the health system in sub-
Saharan Africa, and is treated by providers working at a range of
facilities, including private-sector pharmacies and drug stores. The
clinical guidelines for malaria treatment are unambiguous, and can
be used by providers with limited clinical knowledge or expertise.
Artemisinin-combination therapy (ACT) is the recommended
antimalarial for uncomplicated malaria and should be supplied to
all patients presenting with a fever or history of fever, unless they
have a negative test result or are in the ﬁrst trimester of pregnancy.
ACT has been the ﬁrst-line antimalarial in Cameroon since 2004
and in Nigeria since 2005. In each country, the Malaria Control
Programme of the Ministry of Health, at either national or state
level, is responsible for disseminating malaria policy (Ministry of
Health of the Federal Republic of Nigeria, 2005; Ministry of Public
Health of the Republic of Cameroon, 2008). Their efforts include
distributing clinical guidelines and holding training workshops.
Providers in public and mission facilities have greater access to
information and training, though professional associations may
conduct training for staff at private-sector pharmacies and drug
stores.
In this paper, we report the type of antimalarial that providers in
Cameroon and Nigeria state they prefer to use to treat uncompli-
cated malaria. We assess whether their stated preference is
consistent with their knowledge of the recommended antimalarial,
and investigate who or what inﬂuences their preference over
alternative antimalarials. Previous epidemiological studies from
Cameroon and Nigeria have investigated the factors associatedwith
patients receiving an ACT, though these studies do not focus on
providers’ preference or practice as they include patients at phar-
macies and drug stores that requested speciﬁc treatment
(Mangham et al., 2012, 2011). Studies from elsewhere in sub-
Saharan Africa have examined providers’ actual practice in treat-
ing febrile patients, though these were limited to care provided at
public and mission facilities (Osterholt et al., 2006; Rowe et al.,
2000; Zurovac et al., 2004). This paper complements the existing
literature by investigating providers’ preference using stated pref-
erence data obtained from providers working at non-proﬁt health
facilities and for-proﬁt pharmacies and drug stores in Cameroon
and Nigeria.
Theoretical considerations
Providers’ preference over different types of antimalarials was
examined from an economic perspective founded in agency theory.
An agency relationship occurs when one individual acts on behalf
of another (Shapiro, 2005), and this arises in health care in-
teractions, including those at pharmacies and drug stores, when the
patient relies on the provider to determine their health care needs
(Coast, 2001). It is conventional to focus on the principal-agent
relationship between patients and providers, though providers
may be party to multiple agency relationships (Blomqvist, 1991). In
this study, we acknowledge that providers operate within a
network of relationships, and may be an agent not only for their
patients but also for other actors in the health system, such as their
employer, the Ministry of Health, or antimalarial supplier (Jan,
2005). Agency relationships may have a formal contract, though
will often be an unwritten understanding in which the provider
perceives a responsibility to act on behalf of another.
The economics literature assumes agents are rational and make
choices to maximize their own utility. In standard agency theory it
is assumed that agents are ﬁnancially motivated and would act to
obtain an optimal combination of income and leisure time, or at
least achieve a threshold level of income, irrespective of the prin-
cipal’s preference (Evans, 1974). The provider’s preferred treatment
could, therefore, reﬂect the method of remuneration, whether the
organization has a proﬁt motive, or income from additional sources,
such as secondary employment, sales commission, or ownership of
private businesses (Chaix-Couturier, Durand-Zaleski, Jolly, & Dur-
ieux, 2000; Ferrinho, Van Lerberghe, Fronteria, Hipolito, & Biscaia,
2004). These inﬂuences can be considered from a static or dynamic
perspective, with the latter taking into account reputation effects,
inwhich future income depends on the amount of competition and
the principal’s satisfaction with the agent’s current practice
(Mooney & Ryan, 1993). The theory has also been extended to
recognize that providers have a professional responsibility to act in
the interests of the patient and may derive satisfaction from their
work (Mooney & Ryan, 1993). Thus, providers’ choice of treatment
may reﬂect an intrinsic motivation not only to fulﬁl patients’ ex-
pectations and improve patients’ health, but also to satisfy their
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employer, the Ministry of Health or other principals (Leonard &
Masatu, 2010).
Agents’ choice, and therefore their ability to obtain utility, will
be constrained by the information they have available. Providers
may vary in their access to information from pre- or in-service
training, clinical guidelines, public health campaigns, marketing
materials, and observing colleagues. Institutional, social and psy-
chological factors may also constrain preferences. Formal in-
stitutions, such as regulation, can limit behaviour, though informal
institutions can also have an important effect, as preferences are
embedded within social structures, cultures, values and behav-
ioural norms (Burke, Fournier, & Prasad, 2010; Charles, Gafni,
Whelan, & O’Brien, 2006; Rabin, 1998). For instance, providers
may be inﬂuenced by their colleagues, as social networks not only
affect the ﬂow of information but can be a source of reward and
punishment (Granovetter, 2005).
Methods
Econometric model
The econometric analysis is based on random utility theory.
Although utility cannot be directly observed, individuals are
assumed to be economically rational and make choices that
maximize their utility. The provider’s choice of preferred treatment
can be described as:
U ¼ f ðY ; SÞ
where U is the utility of the provider’s preferred treatment, Y is
income (and other ﬁnancial incentives), S is the satisfaction (and
non-ﬁnancial incentives). Utility is maximized subject to the
information about the treatment options and the underlying
institutional environment. It is assumed that the utility yielded
by mutually exclusive treatment options depends on the
observable factors contained in the provider’s utility function
and unobserved or unknown inﬂuences on individual behaviour.
In its simplest form, the observed sources of utility are deﬁned as
a linear expression in which each explanatory variable is
weighted by a parameter that accounts for that variable’s mar-
ginal utility.
A multilevel model was used to estimate a three-level random
effects model (Hox, 2010). This approach accounts for the clustering
of providers, since some correlation between providers within a
facility or area is possible if they have similar incentives, share in-
formation, and face a common institutional environment (Rice &
Jones, 1997). For a three-level logistic regression the dependent
variable pijk is deﬁned as the probability that the preferred treat-
ment was an ACT for provider i from facility j in area k, where (pijk/
(1-pijk)) is the log odds that the preferred treatment is an ACT. The
model for provider’s preferred treatment is speciﬁed as:
logit

pijk

¼ aþ bYijk þ lSijk þ qIijk þ gFjk þ fAk þ εijk þ ujk
þ vk
εijkwN

0; s2

/ujkwN

0; s2

; vkwN

0;42

;
where:
a is the intercept;
Yijk is the income of provider i at facility j in area k;
Sijk is satisfaction of provider i at facility j in area k;
Iijk are information constraints for provider i at facility j in area k;
Fjk are institutional constraints common to all providers at
facility j in area k;
Ak are institutional constraints common to all providers in
area k;
b, l, q, g and f are the parameters associated with the
explanatory variables;
εijk,, ujk and vk, are the residuals at the level of the provider, fa-
cility and geographical area, respectively, and capture unobserved
variation, measurement and speciﬁcation errors.
Study setting
The study was undertaken in four sites in Cameroon and Nigeria
that had been selected for cluster randomized trials of in-
terventions to support the introduction of malaria rapid diagnostic
testing (Wiseman, Ezeoke, et al., 2012; Wiseman, Mangham, et al.,
2012). This paper analyses provider survey data that were collected
as part of a larger study on malaria diagnosis and treatment at
different types of facility and undertaken to guide the design of
interventions that would accompany the roll-out of malaria rapid
diagnostic tests.
The four sites were Yaoundé and Bamenda in Cameroon, and
Enugu and Udi in Enugu State, south-east Nigeria. Yaoundé is the
capital of Cameroon and has an urban, predominately French-
speaking population. The Bamenda site consisted of one urban
and seven rural districts in the North-West region, where the main
language is English or pidgin-English. The urban sites in Nigeria
were drawn from Enugu town, and the rural areas were located in
Udi local government area. Igbo is the dominant ethnic group and
language in Enugu State. Malaria is endemic and occurs throughout
the year in all four sites, though there is seasonal variation in the
Bamenda site, with peak transmission occurring between March
and November.
Antimalarials, including ACT, have over-the-counter status in
Cameroon and Nigeria and can be obtained from pharmacies and
drug stores as well as public, mission and private facilities. Malaria
treatment may also be sought from mobile medicine vendors,
herbalists and traditional healers. The government supplies public
facilities, and mission facilities receive medicines from a central
agency. Pharmacies and drug stores obtain medicines through
formal and informal channels, including drug company represen-
tatives, wholesalers and the main market in the local area.
In Cameroon, public and mission facilities, and private phar-
macies are the main source of treatment for uncomplicated malaria
(Ongolo-Zogo & Bonono, 2010). Most public and mission hospitals
and health centres in the Cameroon sites have a pharmacy and a
laboratory for simple diagnostic procedures and are staffed by
nurses, pharmacy attendants and laboratory technicians. Some
larger facilities also have a medical doctor. In the private-sector,
pharmacies are legally required to employ a qualiﬁed pharmacist
and licensed to sell prescription and over-the-counter medicines. In
addition, antimalarials are available at drug stores in the North-
West region, which are typically owned and staffed by providers
with no or few qualiﬁcations (Reynolds Whyte, van der Geest, &
Hardon, 2002). In Enugu State, Nigeria, treatment for uncompli-
cated malaria is most frequently obtained at public health centres,
pharmacies and drug stores (known as patent medicine stores)
(Onwujekwe et al., 2005). Malaria diagnostic testing is not widely
available at the primary care level and public facilities are staffed by
nurses, community health ofﬁcers and extension workers. For-
proﬁt pharmacies and drug stores are formally recognised in the
health system and have professional associations. Licensed phar-
macies are required to have a qualiﬁed pharmacist, while patent
medicine dealers are not required to have speciﬁc qualiﬁcations or
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training (Okeke, Uzochukwu, & Okafor, 2006) and are formally
restricted from selling prescription-only medicine.
Survey data
Data on providers’ stated preference for treating uncomplicated
malaria were obtained in stratiﬁed multi-stage cluster surveys
conducted at selected facilities in the study sites between July and
December 2009 (Mangham et al., 2012, 2011). The sampling of
geographic areas and facilities was undertaken separately for each
country, based on an enumeration of facilities conducted inMarche
May 2009. At selected facilities a patient exit survey, a provider
survey and a facility audit were conducted. Sample size calculations
were undertaken for the patient exit survey and sought to deter-
mine the proportion of patients supplied ACT, with a given level of
precision (Mangham et al., 2012, 2011). The primary outcome was
the proportion of individuals reporting seeking treatment for a
fever that were supplied (prescribed or received) an ACT. In
Cameroon a survey sample of 12 patients per public facility was
calculated to estimate the primary outcome with a prevision of þ/
8.6%, and eight patients per mission facility and medicine retailer
was calculated to estimate the primary outcome with a precision
ofþ/ 6.2% (Mangham et al. 2012). In Nigeria, a survey sample of 20
patients per public facility was calculated to estimate the primary
outcome with a precision of þ/ 13%, while 14 patients per med-
icine retailer allows the primary outcome to be calculated with a
precision of þ/ 6.6% (Mangham et al. 2011). All of these calcula-
tions assume the intra-cluster correlation in treatment between
facilities was 0.3. These precision estimates differ given the
different sample sizes per type of facility and assume a prevalence
of 50% for the primary outcome.
In each country, geographic areas were randomly selected,
stratiﬁed by site. Facilities dispensing antimalarials were then
selected based on the number and distribution of facilities in each
area. In both countries, all public primary care facilities were
included and pharmacies and drug stores were randomly selected
with probability proportionate to their number in the local area. In
Cameroon, all district hospitals andmission facilities in the selected
areas were also included since they were an important source of
treatment in Yaoundé and Bamenda (though not a major source of
treatment in the Nigerian study sites). The provider survey was
undertaken at all facilities selected for the patient exit survey and
individually administered by trained ﬁeldworkers to all providers
that prescribe or dispense medicines, were available at the time of
the survey and gave informed consent. Most facilities had two or
three providers who prescribed or dispensed treatment, though the
number ranged from one to twelve. In addition, one provider in
each facility completed the facility survey.
Provider and facility questionnaires were administered to obtain
data on provider and facility characteristics, and the health care
available for febrile illness. Providers were asked about their pre-
service and in-service training, access to guidelines, knowledge of
recommended treatment, and preference over different antima-
larials. Providers were asked to state their preference over alter-
native antimalarials prior to questions on training, guidelines and
malaria treatment policy to avoid framing bias that could arise by
referring ﬁrst to the recommended antimalarial. The question-
naires were developed speciﬁcally for the study and pre-tested at
facilities not selected for the survey. Site co-ordinators monitored
and supervised data collection. Data were independently double-
entered and veriﬁed using Microsoft Access 2007 (Microsoft Inc.,
Redmond, Washington). Data entry errors were corrected to ensure
consistency with the original form.
Dependent and explanatory variables
The dependent variable was a binary outcome derived from the
question “which antimalarial do you think is the best for treating
patients with uncomplicatedmalaria?”. Providers could respond by
stating a generic or brand name. Each response was recorded and
subsequently coded: ACT, artemisinin-monotherapy, chloroquine,
sulphadoxine-pyrimethamine, quinine, other, and don’t know. No
provider refused to answer this question. The dependent variable
was 1 if the provider responded ACT and 0 otherwise.
Explanatory variables occurred at three levels (Table 1). Provider
attributes were at level-1, and included the method of remunera-
tion, based on whether the individual was the owner or an
employee. As providers may yield income from patients obtaining
treatment at a private facility, a variable was included for whether
providers work elsewhere, though we recognized providers may be
unwilling to disclose information relating to their ﬁnancial in-
terests. A binary variable was used to identify providers who re-
ported their patients usually ask for an ACT since providers may
derive satisfaction from fulﬁlling patient expectations. Several
variables indicated providers’ information about ACT, including
whether or not the provider knew ACT was recommended by the
Table 1
Dependent and explanatory variables.
Variable Coding Proportion
Dependent
Stated Preference: ACT is best
type of AM for
uncomplicated malaria
Yes (1)
No (0)
0.69
Explanatory
Level 1: Provider (N[ 518)
Remuneration method: Fixed Salary employee (1)
Sales-related as
owns facility (0)
0.81
Works at other facilities: Yes (1)
No (0)
0.03
Reports patients usually ask for ACT: Yes (1)
No (0)
0.52
Knows ACT is recommended: Yes (1)
No (0)
0.61
Has access to guidelines: Yes (1)
No (0)
0.28
Attended malaria training
in past 3 years:
Yes (1)
No (0)
0.36
Cadre: Doctor (1) 0.06
Nurse or Midwife (2) 0.16
Nurse Assistant (3) 0.05
Health Extension Worker (4) 0.16
Pharmacy or laboratory
technician (5)
0.18
No formal qualiﬁcations
(PMD or attendant) (0)
0.37
Years worked at facility: <1year (0) 0.18
1e4 years (1) 0.34
5e10 years (2) 0.32
11 þ years (3) 0.16
Level 2: Facility (N[ 245)
Facility Ownership: Non-proﬁt Public/
Mission (1)
Private-for-proﬁt
Drug Retailer (0)
0.46
AM supplied by drug
company representative
Yes (1)
No (0)
0.10
Level 3: Area (N[ 36)
Density of facilities: Low (<10 per area) (0) 0.22
Medium (10e19 per
area) (1)
0.37
High (20 þ per area) (2) 0.41
Residence Urban (1)
Rural (0)
0.72
Country: Cameroon (1)
Nigeria (0)
0.71
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government, had access to a copy of the malaria treatment guide-
lines, and attended malaria training in the past three years. Pro-
viders’ cadre was included since pre-service training may have
affected the information they had available, and we controlled for
the number of years worked at a facility.
At the facility level (level-2), a variable indicated whether pro-
viders work in a non-proﬁt organization (owned by the govern-
ment or mission) or in a private-for-proﬁt organization. Facility
ownership may affect the income incentive of providers, or their
employers, though may also reﬂect differences in the information
available and the institutional environment. Whether a facility
received antimalarials from drug company representatives was also
included since they may use ﬁnancial incentives, such as discounts
or commission, to encourage the sale of speciﬁc products, as well as
share information and promotional materials on their products. It
was expected that drug company representatives would promote
ACT over other types of antimalarials.
Area-level (level-3) variables included whether the provider
worked in an urban or rural setting, the density of health facilities
in the locality, and the country. Random effects were used to cap-
ture the degree towhich providers’ preference were clustered since
it was hypothesized that providers working within the same facility
may have similar preferences because they operatewithin the same
institutional context, share information, learn from others and
conform to social norms. Providers’ social network may also extend
to others working in the local area, and for the same reasons may
have similar preferences over different treatments.
Empirical strategy
The ﬁrst step was to analyze stated preference using an
intercept-only model in order to determine the suitability of a
multilevel model over a single-level model and whether to adopt
two or three levels (Hox, 2010). Likelihood ratio tests were used to
compare model ﬁt. The proportion of the total variance that was
attributable to each level of the model was estimated using the
variance partition coefﬁcient (VPC). The VPC is similar to the intra-
cluster correlation, though used when the dependent variable is
discrete. The VPC was calculated as:
VPCfacility ¼

s2facility=s
2
facility þ s2area þ 3:29

and
VPCarea ¼

s2area=s
2
facility þ s2area þ 3:29

where the variance at level 1 was the variance of the standard lo-
gistic distribution (p2/3 ¼ 3.29) (Hox, 2010). Larger values of the
VPC (0 < VPC<1) indicate greater potential for a level to inﬂuence
the value of the dependent variable.
The second step was to estimate a random-interceptmodel with
all explanatory variables at provider, facility and area levels that
were hypothesized may inﬂuence providers’ preference over
alternative antimalarials. The VPC showed the proportion of the
total variance attributable to each level that remained having
incorporated explanatory variables. The third step was to examine
the random-intercept model with interaction terms. Interactions
were investigated for combinations of explanatory variables for
which it was hypothesized there may be a joint effect. Interactions
between facility ownership and information variables were
examined since access to guidelines and training may depend on
the type of facility. Access to guidelines, attendance at training,
cadre, and whether supplies were received from drug company
representatives were each interacted with knowledge that ACT was
the recommended treatment. Finally, interactions were used to
investigate whether provider, facility and area characteristics have
a country-speciﬁc effect. Interactions were added to the random-
intercept model one at a time. The statistical signiﬁcance was
assessed using the Wald test and the likelihood ratio test. Interac-
tion termswere retained in themodel if theywere signiﬁcant at the
10% level.
Multilevel models were estimated using adaptive quadrature to
approximate the marginal likelihood by numerical integration in
Stata 11.2 (StataCorp, 2009). Although computationally demanding,
estimationwith numerical integrationwas the preferredmethod as
there were small cluster sizes at level-2 and quasi-likelihood
methods would be susceptible to bias (Hox, 2010; Rodriguez &
Goldman, 1995). Bootstrap and Bayesian methods are also recom-
mended for small cluster sizes (Hox, 2010), though numerical
integrationwas used as it is well-suited for relatively simplemodels
with binary outcomes (Steele, 2009). Model stability was assessed
by comparing the model estimates from adaptive quadrature with
seven integration points, with those generated by a model using a
higher number of integration points.
Several methods were used to assess model speciﬁcation. The
assumption of normally distributed residuals was examined using
normal plots of standardized level-2 and level-3 residuals. Multi-
collinearity was assessed using the variance inﬂation factor, since
large inﬂation factors show evidence of correlation among
explanatory variables. The deviance, which equals minus two times
the log likelihood, was reported and is an indication of goodness of
ﬁt. The Ramsey RESET test was also used as this is a general test for
problems associated with the functional form (Jones, 2007). It in-
volves taking the square of the predicted value and re-estimating
the model with this as an additional explanatory variable. If the
model is well speciﬁed the new variable will not be signiﬁcant
(Rice, 2000). The RESET test can, therefore, identity speciﬁcation
errors associated with omitted variable bias, simultaneity bias or
measurement error if they lead to nonlinearity in the relationship
between the dependent and explanatory variables. Finally, the
model was estimatedwith andwithout the explanatory variable for
knowing ACT was recommended to investigate the simultaneity
bias that would arise if providers’ preference over alternative an-
timalarials was determined at the same time they acquired
knowledge of the recommended treatment.
The ﬁnal results were validated by re-analysing the ﬁnal model
using Bayesian Markov Chain Monte Carlo (MCMC) estimation
methods in MLwiN 2.25 (Rasbash, Charlton, Browne, Healy, &
Cameron, 2012). The MCMC estimation used uninformative priors
and starting values based on second-order penalized quasi-
likelihood (PQL2) generated using restricted iterative generalized
least-squares (RIGLS) (Browne, 2012). Convergence of the Markov
chain was assessed graphically and by checking that similar pos-
terior distribution summaries were achievedwith different starting
values. Again, goodness of ﬁt was assessed using the RESET Test.
Results
The study was based on a population of 518 providers working
at 245 facilities in 36 geographic areas in Cameroon and Nigeria. Of
the 540 providers invited to participate in the survey, 9 refused to
give consent, and 13 had missing data for at least one of the model
variables. The analysis was conducted on complete cases as bias
from missing responses was expected to be small.
The study population included 240 providers from public and
mission facilities and 278 providers from pharmacies and drug
stores, with providers in Cameroon representing 71% of the study
population (Table 1). The majority (81%) of providers were em-
ployees and less than 3% reported working at other facilities. Just
L. Mangham-Jefferies et al. / Social Science & Medicine 104 (2014) 98e106102
6. RESEARCH PAPER III
169
over half (52%) of the providers reported ACT was the antimalarial
most often requested by patients. Almost two-thirds (61%) of pro-
viders stated ACT was the antimalarial recommended by the gov-
ernment, though only 36% of providers attendedmalaria training in
the past 3 years, and 28% of providers had access to a copy of the
national malaria treatment guidelines. The providers spanned a
range of cadres, though the largest group (37%) were patent med-
icine dealers and sales attendants without formal health qualiﬁ-
cations. The length of time providers had worked at the current
facility ranged from less than one year to more than 11 years.
Overall 69% (359/518) of providers stated ACT was the best
treatment for uncomplicated malaria. Other responses included
quinine and artemisinin-monotherapy, which are recommended
for severe cases of malaria, and sulphadoxine-pyrimethamine,
which was the former ﬁrst-line therapy (Table 2).
Table 3 presents the two-way relationship between providers’
stated preference and their knowledge of the antimalarial recom-
mended by the government for uncomplicated malaria. Overall,
46% (236/518) of all providers surveyed reported ACT was their
preferred treatment and knew it was recommended. There were
24% (123/518) of providers who stated a preference for ACT and did
not know it was the recommended treatment, but also 16% (82/518)
of providers who knew ACT was the recommended treatment and
did not report this was the best treatment.
The degree of variability in providers’ preference that can be
attributed to facility and area levels was examined using intercept-
only models to determine whether to use a two-level and three-
level logistic regression. Signiﬁcant random effects were found at
both levels, and the deviance and likelihood ratio tests indicate that
the three-level model (Model 1 in Table 4) was superior to the two-
level models (Appendix A).
The odds ratios generated by the three-level logistic regression
containing explanatory variables are presented in Table 4. Model 2
included all explanatory variables except the variable “Knows ACT
is the recommended treatment”, while Model 3 included all
explanatory variables. As expected, the introduction of the
explanatory variables reduced the residual variability within facil-
ities and areas (compared to Model 1). Model estimates were stable
to three decimal places. The RESET test indicated Models 2 and 3
were well speciﬁed and there was no evidence of multicollinearity
or simultaneity bias. Model 3 was preferred, based on model di-
agnostics, and was used to investigate interaction terms, though
none were found to signiﬁcantly improve the ﬁt of the model.
The ﬁnal model (Model 3) showed that providers’ stated pref-
erence for an ACT was not signiﬁcantly associated with income
incentives, as measured by the method of remuneration and
whether theyworked elsewhere. Providers were, however, twice as
likely to state a preference for ACT if this was the type of antima-
larial most often requested by their patients. Knowing ACT was the
recommended treatment was also a signiﬁcant determinant, with
the odds of stating a preference for ACT 2.5 times greater amongst
providers who reported ACT was recommended by the govern-
ment. The results also showed the effect of malaria training was of
borderline signiﬁcance, and access to malaria treatment guidelines
did not signiﬁcantly predict a preference for ACT. Providers’ pref-
erence for ACT was signiﬁcantly lower at non-proﬁt facilities, and
the odds of preferring an ACT was 4 times greater if the facility
obtained antimalarials from drug company representatives.
Random effects remained relatively large after the inclusion of
explanatory variables indicating there was unexplained variability
attributable to the facility and local area.
The sensitivity of the results to the estimation method was
investigated by reanalysing the ﬁnal model in MLwiN 2.25 using
PQL2 generated using RIGLS and then by running Bayesian MCMC
using non-informative priors. The results were similar and are
provided in Appendix B.
Discussion
The majority of providers stated a preference over different
types of antimalarials, with just 8% unable or unwilling to state
which antimalarial they prefer for treating uncomplicated malaria.
69% of providers had a preference for ACT, though alternatives
included quinine and artemisinin-monotherapy, which should be
reserved for cases of severe malaria, and sulphadoxine-
pyrimethamine, which was the former ﬁrst-line treatment.
Method of remuneration, access to additional employment in-
come, and facility ownership were used as proxies to investigate
the effect of ﬁnancial incentives on providers’ preference. Of these
variables, facility ownership had a signiﬁcant effect, with providers
at for-proﬁt facilities more likely to prefer an ACT over other anti-
malarials. Further research would be required, however, to ascer-
tain whether the effect of facility ownership reﬂects income
incentives or other institutional characteristics.
We found a positive association between providers who stated a
preference for ACT and providers who reported ACT was the anti-
malarial their patients most often request. This suggests that pro-
viders were more likely to prefer ACT if their patients prefer (or
perceive their patients prefer) ACT, though the interpretation is
Table 2
Providers’ stated preference for treatment of uncomplicated malaria.
Country Type of facility All
Cameroon Nigeria Public/Mission Medicine retailer
N ¼ 369 % N ¼ 149 % N ¼ 240 % N ¼ 278 % N ¼ 518 %
ACT 266 72.1 93 62.4 156 65.0 203 73.0 359 69.3
Artemisinin monotherapy 2 0.5 23 15.4 7 2.9 18 6.5 25 4.8
Chloroquine 0 0.0 10 6.7 8 3.3 2 0.7 10 1.9
Quinine 63 17.1 0 0 44 18.3 19 6.9 63 12.2
Sulphadoxine-pyrimethamine 1 0.3 17 11.4 7 2.9 11 4.0 18 3.5
Other AM 0 0.0 4 2.7 2 0.8 2 0.7 4 0.8
No preference 37 10.0 2 1.4 16 6.7 23 8.3 39 7.5
Table 3
Two-way relationship between knowledge of guidelines and preference for ACT.
Stated ACT was the best treatment for
uncomplicated malaria
Yes No Total
N % N % N %
Knows ACT is
recommended
for uncomplicated
malaria
Yes 236 45.6 82 15.8 318 61.4
No 123 23.8 77 14.9 200 38.6
Total 359 69.3 159 30.7 518 100.0
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uncertain. For example, providers may derive utility from selecting
ACT, either because they have an intrinsicmotivation to satisfy their
patients, or because they want to maintain a good reputation and
secure future income. Local competition would also be expected to
affect the latter, though there was no evidence that the density of
facilities within an area had an effect on providers’ preference.
Alternatively, it could be argued that the association reﬂects an
omitted exogenous factor, such as a public health campaign, that
had an inﬂuence on both providers’ and patients’ preference. Either
way, knowing that preferences were positively associated may be
useful for designing strategies to improve providers’ practice or
inﬂuence patients’ demand.
It was encouraging, and not unexpected, to ﬁnd providers who
knew ACT was the recommended treatment for uncomplicated
malaria were signiﬁcantly more likely to state a preference for ACT.
Moreover, providers that had attended malaria training in the past
three years were more likely to state a preference for ACT (at the
10% level of signiﬁcance) having controlled for their knowledge.
This suggests training can have an effect that goes beyond
informing providers about treatment policy and can inﬂuence their
preferences over different treatments. Access to malaria treatment
guidelines had no signiﬁcant effect on providers’ preference, even
in the model which did not control for their knowledge. This sug-
gests having access to guidelines is not a good predictor that pro-
viders will supply the recommended treatment. The results imply,
therefore, that the nature of communication can have an important
inﬂuence on providers’ preference and further research on this may
help to identify effective strategies for educating providers about
changes in health policy and clinical guidelines.
The results suggest an agency relationship in which drug com-
pany representatives (drug reps) inﬂuence providers’ preference
over antimalarials, though it is also possible that obtaining medi-
cines from drug reps may proxy for unobserved organizational
attributes. If there is a direct effect, then this could reﬂect explicit
incentives, such as sales commission, or an information effect from
marketing strategies that promote the use of ACT. The interaction
between knowledge that ACT is recommended by the government
and use of drug reps did not signiﬁcantly improve themodel, which
suggests drug reps have an effect that is independent of providers’
knowledge of the recommended treatment, though the sample
from which to detect interaction effects was limited. In any case,
there may be merit in exploring the potential to engage drugs reps
Table 4
Factors predicting providers’ stated preference for ACT.
Fixed effects MODEL 1: Intercept-only model MODEL 2: With all explanatory
variables except knowledge
MODEL 3: With all explanatory
variables
OR SE P-value OR SE P-value
Level 1: Provider
Remuneration method: Fixed salary 1.46 0.712 0.434 1.63 0.794 0.320
Sales related Ref Ref
Additional employment: Yes 1.94 1.928 0.507 2.04 2.054 0.477
No Ref Ref
Reports patients usually
ask for ACT:
Yes 2.17 0.737 0.023 2.08 0.710 0.033
No Ref Ref
Has access to guidelines: Yes 2.06 0.901 0.100 2.04 0.900 0.106
No Ref Ref
Has attended malaria training: Yes 1.96 0.662 0.047 1.88 0.638 0.061
No Ref Ref
Knows ACT is recommended: Yes e e e 2.54 0.824 0.004
No Ref
Cadre: Doctor 1.18 0.907 0.127 0.79 0.613 0.147
Nurse or Midwife 2.21 1.308 1.96 1.160
Nurse Assistant 1.37 1.047 1.16 0.888
Extension Worker 0.72 0.392 0.61 0.336
Pharmacist/technician 0.58 0.296 0.55 0.281
No qualiﬁcations Ref Ref
Years worked at facility: <1 year Ref 0.440 Ref 0.406
1e4 years 0.81 0.373 0.74 0.346
5e10 years 0.53 0.257 0.50 0.241
11 þ years 0.95 0.555 0.88 0.517
Level 2: Facility
Ownership: Public/Mission 0.40 0.248 0.140 0.33 0.205 0.075
Drug Retailer Ref Ref
AM supplied by drug
company rep
Yes 5.77 4.858 0.037 4.83 4.048 0.060
No Ref Ref
Level 3: Area
Density of facilities: Low Ref 0.809 Ref 0.872
Medium 0.99 0.800 0.97 0.798
High 1.58 1.514 1.43 1.397
Residence Urban 1.24 1.030 0.793 1.44 1.225 0.666
Rural Ref Ref
Country Cameroon 1.99 1.281 0.283 1.81 1.188 0.366
Nigeria Ref Ref
Random Effects Estimate SE Estimate SE Estimate SE
Residual variance Level-2: s2 (uj) 2.94 1.224 2.64 1.206 2.486 1.170
Level-3: s2 (vjk) 1.66 0.862 1.29 0.768 1.427 0.817
VPC: Level-2: facility 0.377 0.366 0.345
Level-3: area 0.209 0.179 0.198
Diagnostics
Deviance (2*llh) 577.074 536.568 527.868
RESET e 0.249 0.278
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in strategies to change providers’ preference and improve their
practice. There are few examples in the empirical literature, though
a vendor-to-vendor education programme in Kenya, in which
wholesalers were trained to supply providers at drug shops and
kiosks with information and job aids on malaria treatment, was
found to have a moderate effect (Tavrow, Shabahang, & Makama,
2003).
There is evidence that providers’ preference for ACT was similar
among colleagues within a facility and among providers within a
local area. Although the level-2 and level-3 residual variance was
reduced by the inclusion of explanatory variables, it remained
signiﬁcant in the ﬁnal model and the VPC indicated that a sub-
stantial proportion of the unexplained heterogeneity can be
attributed to facility and area factors. This may reﬂect the inﬂuence
of institutional and behavioural factors, such as networks and social
norms, though we are cautious in drawing conclusions since
average cluster size was small and the size of the random effect
depends on the estimation method. Further research would be
beneﬁcial to explore how preferences may be shaped or con-
strained by colleagues, and how strategies to improve providers’
practice could utilize networks or promote social norms.
There are some methodological limitations to our work. First,
there is uncertainty in how providers understood the question used
to elicit their preference over alternative antimalarials. The ques-
tion “which antimalarial do you think is best for treating uncom-
plicated malaria?” followed questions on the type of antimalarial
usually supplied and type of antimalarial patients’ prefer. It is
possible, however, that some providers understood the question to
be asking about the efﬁcacy of different antimalarials, or aspects of
the treatment regimen, such as the number of tablets, or potential
side effects. If this were the case, thenwewould expect the effect of
income and satisfaction on their choice of treatment to be reduced
as providers focus on other attributes. Qualitative methods may be
useful to probe what providers understand by ‘best’ in this context.
Moreover, it is possible that our direct method of eliciting stated
preference encouraged providers to give a socially acceptable
response and report what they know is recommended. More so-
phisticated methods, such as discrete choice experiments, are often
used and designed to overcome this framing bias. The direct
method was, however, practical given that the formative research
sought to examine multiple questions about the treatment of un-
complicated malaria, and was also feasible since ACT was not a new
product.
Second, the sample size was restricted because the provider
survey was conducted as part of a larger study principally designed
to examine the treatment supplied to febrile patients. None of the
interactions included in the model were found to have a signiﬁcant
effect, and this may be due to the limited number of observations.
Furthermore, the average cluster size at level-2 was small since the
survey involved many primary care facilities and medicine retailers
that operate with few, sometimes lone, providers. In this setting,
the small cluster sizes could not have been overcome and theywere
an important consideration for the statistical analysis. Correlation
between providers within a facility was empirically investigated to
determine whether facility should be included as a level in the
model. There remained evidence of clustering at the facility-level
(as well as the area-level) once explanatory variables were added
to the model. In addition, the robustness of the study results to the
estimation method was investigated because of the small cluster
sizes at the facility-level. The alternative methods generated com-
parable results, though the small cluster sizes may have explained
the differences in the magnitude of estimated coefﬁcients. This is
consistent with ﬁndings from a recent study which showed how
the choice of estimation method and software can affect the results
of multilevel logistic regression when the data are limited and the
average cluster size is small (Li, Lingsma, Steyerberg, & Lesaffre,
2011).
Conclusions
Ensuring providers prefer to supply the recommended type of
antimalarial is an important prerequisite for ensuring patients with
uncomplicated malaria receive the most effective treatment. Pro-
viders were asked which antimalarial they think is the best for
treating patients with uncomplicated malaria to elicit which anti-
malarial providers prefer to supply when not constrained by the
resources available or patients’ ability to pay, and we investigated
who or what inﬂuences their preference. The type of antimalarial
providers prefer not only depended on their knowledge of the
clinical guidelines, but also reﬂected their perceptions of what
patients prefer, and the inﬂuence of drug company representatives,
their colleagues and other providers in the locality. These ﬁndings
support the premise that providers are agents serving multiple
principals. Understanding who and what inﬂuences providers’
stated preference over alternative antimalarials is useful for iden-
tifying strategies to encourage providers to supply effective malaria
treatment. The inﬂuence of multiple actors on the providers’ choice
of treatment emphasizes the need to communicate changes in drug
policy not only to providers but also to suppliers and local com-
munities. Moreover, our ﬁndings suggest that public health in-
terventions would be more effective if they target groups of
providers, rather than individuals, and promote a supportive
environment since providers working within a facility or local area
have similar preferences.
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Appendix 
Appendix A: Comparing two-level and three-level intercept-only models 
  Two-level intercept-
only model: facility 
Two-level intercept-
only model: area  
Three-level intercept-
only model:  
facility + area 
(Model 1) 
  Estimate SE Estimate SE Estimate SE 
Random Effects        
Residual variance Level-2: 2 (uj) 4.304*** 1.550 -  2.944*** 1.224 
 Level-3: 2 (vjk) -  1.173** 0.476 1.657** 0.862 
VPC: Level 2: facility 0.567  -  0.377  
 Level 3: area -  0.263  0.209  
Diagnostics        
Deviance (-2*llh)  589.212  599.626  577.074  
*** significant at 1% level, ** significant at 5% level, * significant at 10% level 
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Appendix B: Final model using different estimation methods 
Estimation 
Method 
 Numerical 
Integration 
(Model 3) 
PQL2 (RIGLS)† MCMC‡ 
Fixed Effects  OR SE OR SE OR SE 
Level 1: Provider          
Remuneration 
method: 
Fixed salary  
Sales related  
1.625 
Ref 
0.794 1.607 
Ref 
0.801 1.915 
Ref 
1.182 
Additional 
employment: 
Yes  
No  
2.044 
Ref 
2.054 1.938 
Ref 
2.076 5.052 
Ref 
11.260 
Reports patients 
usually ask for 
ACT: 
Yes  
No  
2.075** 
Ref 
0.710 2.079** 
Ref 
0.749 2.472** 
Ref 
0.985 
Has access to 
guidelines: 
Yes  
No  
2.041 
Ref 
0.900 2.096 
Ref 
0.983 2.596 
Ref 
1.566 
Has attended 
malaria training: 
Yes  
No  
1.884* 
Ref 
0.638 1.881* 
Ref 
0.679 2.116* 
Ref 
0.843 
Knows ACT is 
recommended: 
Yes  
No  
2.543*** 
Ref 
0.824 2.569*** 
Ref 
0.896 3.176*** 
Ref 
1.240 
Cadre:  Doctor  
Nurse or Midwife  
Nurse Assistant  
Extension Worker  
Pharmacist 
/ technician 
No qualifications 
0.787 
1.958 
1.160 
0.612 
0.548 
 
Ref 
0.613 
1.160 
0.888 
0.336 
0.281 
0.742 
1.901 
1.207 
0.579 
0.506 
 
Ref 
0.593 
1.199 
0.971 
0.335 
0.270 
0.860 
2.465 
1.647 
0.619 
0.504 
 
Ref 
0.785 
1.731 
1.673 
0.423 
0.291 
Years worked at 
facility:  
<1 year  
1 – 4 years  
5 – 10 years  
11+ years  
Ref 
0.740 
0.495 
0.879 
 
0.346 
0.241 
0.517 
Ref 
0.652 
0.459 
0.884 
 
0.293 
0.216 
0.495 
Ref 
0.655 
0.467 
1.083 
 
0.334 
0.251 
0.721 
Level 2: Facility          
Ownership: Public/Mission  
Drug Retailer  
0.329* 
Ref 
0.205 0.314* 
Ref 
0.213 
 
0.349* 
Ref 
0.240 
AM supplied by 
drug company rep  
Yes 
No 
4.833* 
Ref 
4.048 4.614* 
Ref 
4.394 17.346** 
Ref 
33.293 
Level 3: Area        
Density of 
facilities: 
Low  
Medium  
High  
Ref 
0.969 
1.429 
 
0.798 
1.397 
Ref 
0.875 
1.156 
 
0.814 
1.272 
Ref 
1.956 
2.398 
 
2.413 
2.925 
Residence Urban 
Rural 
1.443 
Ref 
1.225 1.390 
Ref 
1.373 1.945 
Ref 
1.729 
Country Cameroon  
Nigeria  
1.809 
Ref 
1.188 1.570 
Ref 
1.157 2.354 
Ref 
2.052 
Random Effects  Estimate SE Estimate SE Estimate SE 
Residual variance Level-2: 2 (uj) 2.486** 1.170 3.060*** 0.818 5.346** 2.507 
 Level-3: 2 (vjk) 1.427* 0.817 2.136** 0.903 3.048* 1.779 
VPC: Level 2: facility 0.345  0.361  0.471  
 Level 3: area 0.198  0.252  0.284  
Diagnostics        
RESET  0.278  0.259  0.357  
*** significant at 1% level, ** significant at 5% level, * significant at 10% level 
† Burn-in length=2000, Monitoring chain length=200000, thinning=10  
‡ Difference in random effects is likely to be caused by the estimation technique – MCMC can have a positive bias 
because does not allow negative variances  
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Chapter 7 
Research Paper IV: Mind the Gap: knowledge and practice of providers 
treating uncomplicated malaria at public and mission health facilities, 
pharmacies and drug stores in Cameroon and Nigeria 
The previous chapters have described the problems with malaria diagnosis and treatment 
in Cameroon, and the influences on providers’ stated preferences for treating 
uncomplicated malaria. This research paper examines the determinants of providers’ 
revealed preference (i.e. their practice) for treating patients with symptoms of 
uncomplicated malaria, and focuses on whether providers’ choice of antimalarial adheres 
to the malaria treatment guidelines.  
This paper is one of the first to focus on knowledge-practice gap in the context of malaria 
treatment. The analysis used exit survey data from the subset of patients who relied on the 
provider to select treatment and were supplied an antimalarial. Exit survey responses 
then were linked to the individual provider who supplied treatment. The findings 
demonstrated providers’ decision to supply ACT was not significantly associated with 
their knowledge of the first-line antimalarial in either Cameroon or Nigeria. However, 
stated preferences were important, and I concluded it would be important to design 
interventions that focus on changing providers’ preference in addition to their knowledge. 
Thus, the findings from this study informed the development of interventions in Cameroon 
and resulted in a trial which allowed us to test the hypothesis that interactive training 
targeting providers’ practice would be more cost-effective than conventional approaches 
to training. 
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Abstract  
Background:  
Artemisinin Combination Therapy (ACT) has been the first-line treatment for uncomplicated 
malaria in Cameroon since 2004 and Nigeria since 2005, though many febrile patients receive 
less effective antimalarials. Patients often rely on providers to select treatment, and 
interventions are needed to improve providers’ practice and encourage them to adhere to 
clinical guidelines.  
Methods 
Providers’ adherence to malaria treatment guidelines was examined using data collected in 
Cameroon and Nigeria at public and mission facilities, pharmacies and drug stores. Providers’ 
choice of antimalarial was investigated separately for each country. Multilevel logistic 
regression was used to determine whether providers were more likely to choose ACT if they 
knew it was the first-line antimalarial. Multiple imputation was used to impute missing data 
that arose when linking exit survey responses to details of the provider responsible for 
selecting treatment. 
Results 
There was a gap between providers’ knowledge and their practice in both countries, as 
providers’ decision to supply ACT was not significantly associated with knowledge of the first-
line antimalarial. Providers were, however, more likely to supply ACT if it was the type of 
antimalarial they prefer. Other factors were country-specific, and indicated providers can be 
influenced by what they perceived their patients prefer or could afford, as well as information 
about their symptoms, previous treatment, the type of outlet, and availability of ACT.   
Conclusions 
Public health interventions to improve the treatment of uncomplicated malaria should strive 
to change what providers prefer, rather than focus on what they know. Interventions to 
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improve adherence to malaria treatment guidelines should emphasize that ACT is the 
recommended antimalarial, and it should be used for all patients with uncomplicated malaria. 
Interventions should also be tailored to the local setting, as there were differences between 
the two countries in providers’ choice of antimalarial, and who or what influenced their 
practice.  
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Introduction 
Clinical guidelines are systematically developed statements to assist providers’ decision-
making on the appropriate care for specific clinical conditions (Field et al. 1992). By 
establishing common standards for diagnosis and treatment, they are central to efforts to 
improve the quality of health care and can expedite the introduction of new health 
technologies (Cabana et al. 1999; Woolf et al. 2012). Each year governments invest 
considerable resources in the development and distribution of clinical guidelines to ensure 
providers have access to the latest scientific evidence. Despite these efforts, there are 
challenges translating evidence into practice and patients often receive substandard care (Grol 
& Grimshaw 2003). Moreover, several studies on the performance of health care providers 
have identified a knowledge-practice gap, which suggests that public health interventions to 
disseminate clinical guidelines may not be sufficient to change providers’ practice (Das et al. 
2008; Leonard & Masatu 2010). 
Over the past decade, national malaria treatment policies have been revised in all African 
countries to establish artemisinin combination therapy (ACT) as the first-line treatment for 
uncomplicated malaria. However, uptake of ACT has been slow in some countries and studies 
undertaken in Cameroon and Nigeria in 2009, four years after ACT became the recommended 
first-line treatment, showed that many patients treated for malaria did not receive an ACT 
(Mangham et al. 2012; Mangham et al. 2011). The situation in southeast Nigeria was of 
particular concern as only 22% of febrile patients seeking treatment at primary health centres, 
pharmacies and drugs stores received an ACT (Mangham et al. 2011). These studies also 
showed that providers were routinely responsible for the choice of treatment at the public and 
mission facilities and advised on treatment in more than a third of cases at pharmacies and 
drug stores (Mangham et al. 2012; Mangham et al. 2011).  
Interventions to improve malaria diagnosis and treatment have traditionally focused on 
ensuring providers are informed about policy changes and have used training and job aids to 
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improve their knowledge of the clinical guidelines (Smith et al. 2009). However, evidence from 
intervention and cross-sectional studies show access to in-service training, guidelines and job 
aids often have a limited effect in changing providers’ practice (Osterholt et al. 2006; Rowe et 
al. 2000; Rowe et al. 2003; Smith et al. 2009; Zurovac et al. 2005; Zurovac et al. 2008a; Zurovac 
et al. 2004; Zurovac et al. 2008b).  
It is timely to explore the relationship between providers’ practice in treating uncomplicated 
malaria and their knowledge of the clinical guidelines, as malaria treatment guidelines undergo 
further revision to advise on the use of malaria rapid diagnostic tests (RDTs) and dissemination 
strategies are being developed. Moreover, early evidence suggests that malaria RDTs will only 
be cost-effective if providers adhere to the malaria treatment guidelines: testing before 
treatment should reduce the number of febrile patients consuming antimalarials that they do 
not need, but this requires providers to adhere to the test results when making treatment 
decisions (Lubell et al. 2008).  
In this paper, we examine providers’ adherence to malaria treatment guidelines at public and 
mission facilities, pharmacies and drug stores in urban and rural areas of Cameroon and 
Nigeria prior to the introduction of malaria RDTs. We investigate what influences providers’ 
choice of antimalarial, and assess whether providers were more likely to select an ACT if they 
knew it was the first-line treatment for uncomplicated malaria. This analysis was undertaken 
to guide the design of interventions to support the roll out of malaria RDTs and the 
dissemination of updated clinical guidelines. The effectiveness and cost-effectiveness of the 
interventions are being evaluated in cluster-randomized trials at selected sites in Cameroon 
and Nigeria (Wiseman et al. 2012a; Wiseman et al. 2012b). 
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Methods 
Study Setting 
The study was conducted at public and mission health facilities, pharmacies and drug stores in 
urban and rural areas of Cameroon and Nigeria, where cluster-randomized trials would be 
conducted to evaluate interventions to support the introduction of malaria RDTs. In 
Cameroon, the two sites were Yaoundé in the Centre region, which is urban and 
predominately French-speaking, and Bamenda and seven rural districts in the Northwest 
region where English and pidgin-English are widely spoken (Mangham et al. 2012). In Nigeria, 
both sites were in Enugu State and included urban communities in Enugu, and rural 
communities in Udi (Mangham et al. 2011).   
Malaria is endemic in all four sites and occurs throughout the year. At the time the study was 
conducted, the national malaria treatment guidelines in both countries advised that malaria 
should be suspected in all patients presenting with a fever or history of fever, patients should 
be tested prior to treatment where malaria testing was available, but in the absence of a 
confirmed diagnosis presumptive treatment for uncomplicated malaria was recommended 
(Ministry of Health of the Federal Republic of Nigeria 2005; Ministry of Public Health of the 
Republic of Cameroon 2008). ACT was the first-line treatment for uncomplicated malaria (in all 
patients except pregnant women), and was typically more expensive than other types of 
antimalarial. In all outlets patients pay for the treatment they receive, though there were 
exemptions for children under five and pregnant women attending public facilities. 
In Cameroon and Nigeria, malaria is routinely treated using antimalarials obtained at primary 
care facilities, outpatient departments, pharmacies, and drug stores. In the public and mission 
facilities in Cameroon, malaria cases are treated by doctors, nurses and pharmacists, and some 
facilities have a laboratory technician able to conduct malaria microscopy. In Enugu State, 
malaria is often treated in primary health centres and health posts that do not offer malaria 
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testing and are staffed by nurses, and health extension workers. Medicine retailers were 
present in all study sites. In both countries, pharmacies are legally required to have a trained 
pharmacist in order to sell prescription-only and over-the-counter medicines, and they are 
more prevalent in urban areas. Drug stores, also known as patent medicine dealers, are 
formally recognized in the Nigerian health system and staff are eligible to sell over-the-counter 
medicines (including antimalarials) without any specific qualifications or training. In Cameroon, 
drug stores operate under a business licence in the Anglophone regions (which includes the 
Northwest region) and are staffed by providers with no or few health qualifications (Hughes et 
al. 2013).  
Survey sampling and activities 
Stratified cluster surveys were conducted with patients and caregivers exiting health facilities, 
pharmacies and drug stores and with providers working at these outlets between July and 
December 2009. Sample size calculations were undertaken separately for each country and 
sought to determine the proportion of febrile patients seeking treatment that were supplied 
an ACT, with a given level of precision (Mangham et al. 2012; Mangham et al. 2011). The 
sampling, conducted in March-May 2009, was based on an enumeration of outlets that 
regularly dispense antimalarials. In each country, geographic areas were randomly selected, 
stratified by site. Outlets dispensing antimalarials were then selected based on the number 
and distribution of outlets in each area. In both countries, all public primary care facilities were 
included and pharmacies and drug stores were randomly selected with probability 
proportionate to their number in the local area. In Cameroon, all district hospitals and mission 
facilities in the selected areas were also included because they were also an important source 
of treatment in Yaoundé and Bamenda.  
Questionnaires were developed and pre-tested at outlets that were not included in the survey. 
The exit questionnaire collected data about the patient, previous treatment seeking, the 
consultation or interaction with the health care provider, and the treatment prescribed and 
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received. Individuals were eligible to complete the exit survey if they reported seeking 
treatment for a fever, either for themselves or another (who may or may not be present), the 
patient had no signs of severe malaria, and they gave informed written consent. Providers 
were surveyed to collect data on pre-service and in-service training, their knowledge of the 
national treatment guidelines, and their preference for treating patients with symptoms of 
uncomplicated malaria. All providers that prescribed or dispensed antimalarials, were available 
at the time of the survey, and gave informed written consent were eligible to participate. In 
addition, one provider at each outlet completed a questionnaire which asked about the 
services and medicines available, and the procurement of antimalarials. All questionnaires 
were individually-administered by trained fieldworkers working under the supervision of site 
coordinators. Data were double-entered and verified using Microsoft Access 2007 (Microsoft 
Inc., Redmond Washington) and data entry errors were corrected to ensure consistency with 
the original form.  
Ethical Approval 
Ethical approval was obtained from the ethics committees of the London School of Hygiene 
and Tropical Medicine (5429), Cameroon National Ethics Committee (030/CNE/DNM/09) and 
University of Nigeria (03.11.08). 
Data Sources  
Providers’ choice of antimalarial was investigated using patient exit and provider survey data 
from Cameroon and Nigeria. Data analysis was undertaken separately for each country. Exit 
survey responses that fulfilled the following criteria were included: i) the patient or caregiver 
reported seeking treatment for a fever; ii) the patient was not pregnant or under six months of 
age; iii) the patient or caregiver did not request a specific medicine; iv) the patient had a 
presumptive or confirmed malaria diagnosis (i.e. patients with a negative malaria test result 
were excluded); and v) an antimalarial was prescribed or received (as shown in Figure 1).  
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Multilevel logistic regressions were used to investigate what factors influenced providers’ 
choice of antimalarial. The dependent variable was a binary outcome that indicates whether or 
not the provider supplied an ACT (coded 1 if an ACT was prescribed or received, and 0 
otherwise). This variable was derived from several questions about all medicines that were 
prescribed or received whilst at the health facility, pharmacy or drug store.  
Explanatory variables include attributes of the provider, the patient, their interaction, and also 
the outlet in which the interaction took place (Table 1). To investigate the relationship 
between providers’ knowledge and practice, the following provider attributes were included: 
whether providers knew an ACT was the recommended first-line treatment for uncomplicated 
malaria; their access to national malaria treatment guidelines; whether they had attended in-
service training on malaria in the past three years; their highest level of pre-service health 
training; whether they state ACT to be best treatment for uncomplicated malaria; and whether 
they report ACT is the type of antimalarial their patients most often request. The last two were 
included because there may be a difference between providers’ knowledge of the malaria 
treatment guidelines, the type of antimalarial they state they prefer, and the type of 
antimalarial they perceive their patients prefer.  
It was also assumed that providers may select treatment based on the attributes of the patient 
or information obtained during the interaction. The explanatory variables included the 
following patient attributes: gender; age; household wealth (relative to others who sought 
treatment); the education of the patient or caregiver; whether treatment was sought within 
two days of the onset of fever; and whether previous treatment had been sought for this 
illness episode, including whether an antimalarial had been taken. In addition, relevant aspects 
of the provider-patient interaction were: whether the patient was examined; had a 
presumptive or confirmed malaria diagnosis; and whether the provider was told that the 
patient had diarrhoea or had been vomiting (as these symptoms may affect the suitability of 
different medicines). 
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Attributes of the outlet may also have some bearing on the treatment supplied, as contextual 
factors may constrain the providers’ choice of treatment. Outlet attributes included in the 
model were: outlet type; availability of ACT; whether antimalarials were received from a drug 
company representative (whose promotional activities may be a source of information or 
influence); and whether the outlet was in an urban or rural area. 
Relational Databases 
To investigate the relationship between providers’ knowledge and practice it was necessary to 
prepare a database that linked patient exit responses i) to information about the outlet and ii) 
to the individual provider who was responsible for selecting treatment. The outlet at which the 
exit survey was conducted was known for all patients. Patients and caregivers were asked to 
describe all the providers that were involved in supplying care, and fieldworkers recorded the 
unique code that identified each provider. When care was supplied by a single provider then it 
was straightforward to link the patient and provider data if the provider had completed the 
survey. When care was supplied by two or more providers and the cadre of all providers was 
known, then it was assumed the more senior provider decided which treatment to supply. For 
example, if care was supplied by a registered nurse and a pharmacy attendant, we assume the 
pharmacy attendant dispensed the type of antimalarial prescribed by the registered nurse. In 
the remaining cases, it was not possible to identify the individual provider, and therefore data 
on provider attributes were missing.  
Statistical Analysis 
The statistical analysis involved multiple imputation and multilevel logistic regression 
(Carpenter & Kenward 2013; van Buuren 2010). There were almost complete data on patient, 
and outlet attributes, though up to 26% of cases were missing provider attributes due to 
challenges linking the databases (Table 1). The missing data were binary or categorical 
responses and were non-monotone. The proportion of missing provider data was 
disproportionately greater at public and mission facilities in Cameroon, where ACT was 
7. RESEARCH PAPER IV 
 
190 
 
available, and at outlets located in urban areas. Thus, the missing data were presumed to be 
conditional on attributes of the outlet, which is known as ‘missing at random’ in the statistical 
literature (Sterne et al. 2009).  
Given the scale of missing data and suggested missingness mechanism, multiple imputation 
using chained equations was appropriate since analysis using only complete-cases may be 
biased (White & Carlin 2010). Multiple imputation is a statistical technique for dealing with 
data ‘missing at random’ and is recommended when more than 10% of observations would be 
excluded in a complete-case analysis (Burton & Altman 2004). Multiple imputation allows for 
uncertainty about the missing data by generating multiple copies of datasets in which missing 
values are replaced by imputed values, and then uses standard statistical methods to estimate 
the model of interest using the imputed datasets (Sterne et al. 2009). Rubin’s rules are used to 
take into account of the variability in the results between the imputed datasets, and valid 
inferences are obtained by averaging over the distribution of missing data given the observed 
data (Sterne et al. 2009 White et al. 2011).  
Multiple imputation methods should respect the data structure; ignoring the data hierarchy 
can lead to bias because the variance of the imputation distribution would be underestimated 
(Goldstein et al. 2009). REALCOM-IMPUTE is statistical software that enables multiple 
imputation for a two-level model and fits the specified imputation model using Markov Chain 
Monte Carlo methods (Carpenter et al. 2011). Two-level multiple imputation was used because 
this is the maximum that is possible with currently available software.  
The linked patient-provider data have a hierarchical structure, as patients may be clustered by 
provider and by outlet. For computational reasons it was not possible to take into account all 
possible levels, and a two-level model was specified with patients and provider attributes at 
level-1, and outlet attributes at level-2. Outlet was defined as the level-2 identifier to reflect 
the sampling strategy, the amount of clustering expected at this level, and because it was 
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known for every observation (while it was not always possible to identify which provider 
supplied treatment).  
For a two-level logistic regression the dependent variable ωij is defined as the probability that 
the antimalarial supplied is an ACT for patient i from outlet j, and (ωij /(1- ωij)) is the log odds 
that the antimalarial supplied is an ACT. The model for the providers’ choice of antimalarial 
was specified as: 
logit(ωij)  = α + βVij + λPij + θFj + εij + uj    εij ~N(0,σ2)  uj ~N(0,τ2)  
where: α was the intercept; Vij were attributes of the provider supplying an antimalarial to 
patient i at outlet j; Pij were attributes of patient i receiving an antimalarial at outlet j; Fj were 
attributes of outlet j; β, λ, and θ were the parameters associated with the explanatory 
variables; εij and uj were the residuals at level-1 and level-2 respectively, and capture 
unobserved variation, measurement and specification errors. The statistical significance was 
measured using the Wald test, and assessed at the 10% level. Multicollinearity amongst the 
explanatory variables was assessed in the complete cases using the variance inflation factor. 
We used the Ramsey RESET test to check for misspecification of the regression model (Rice 
2000). This is a general test for problems associated with functional form and can identify 
errors associated with omitted variable bias, measurement error and simultaneity bias if they 
lead to nonlinearity in the relationship between the dependent and explanatory variables 
(Jones 2007). The models were also estimated without the explanatory variable for providers’ 
stated preference to investigate simultaneity bias that would arise if providers’ preference 
over alternative antimalarials was determined at the same time they acquired knowledge of 
the recommended treatment. The proportion of the total variance that was attributable to the 
outlet-level of the model was estimated using the variance partition coefficient (VPC) (Hox 
2010). The VPC is similar to the intra-cluster correlation, though used when the dependent 
variable is discrete, and calculated as:  
7. RESEARCH PAPER IV 
 
192 
 
VPC = τ2 /( τ2 + 3.29)  
where τ2 is the variance at level-2 and the variance at level-1 is the variance of the standard 
logistic distribution (2/3=3.29) . Larger values of the VPC (0<VPC<1) indicate that the level has 
greater potential to influence the value of the dependent variable (Hox 2010).  
Two-level logistic regressions were estimated using adaptive quadrature to approximate the 
marginal likelihood by numerical integration in Stata 12.1 (StataCorp 2009). The model was 
initially estimated with data from each country using listwise deletion, and therefore used only 
those cases that were complete and have no missing data (also known as complete cases). The 
model was subsequently estimated using data from 50 imputations generated by two-level 
multiple imputation using chained equations completed using Stata 12.1 and REALCOM-
IMPUTE with a burn-in of 2000 and 500 further updates between each imputation (White et al. 
2011). To avoid bias the imputation model used all variables that were included the analysis 
model (White et al. 2011). Fifty imputations were used since the number of imputations 
should be at least equal to the percentage of incomplete cases, and also confirmed the 
obtained results were not sensitive to the number of imputations used (White et al. 2011). 
Results 
Description of the Sample 
The linked patient-provider database contained data on 2451 cases of febrile illness that 
sought treatment at public and mission health facilities and medicine retailers, with 871 cases 
from Cameroon and 1634 from Nigeria (Figure 1). The provider was presumed to be 
responsible for diagnosis and treatment when the patient or caregiver reported that they did 
not ask for a specific medicine. There were 516 patients in Cameroon and 942 patients in 
Nigeria eligible for malaria treatment, based on either a symptomatic or confirmed diagnosis 
(having excluded cases which requested a specific medicine and 45 patients from Cameroon 
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that tested negative for malaria). Of the eligible patients, 405 (79%) patients in Cameroon and 
641 (68%) patients in Nigeria were supplied an antimalarial. In Cameroon, providers often 
chose to supply ACT, (74% of antimalarials supplied), though quinine either as a tablet or 
injection was also common (21%) (Table 2). While in Nigeria, providers regularly supplied 
sulphadoxine-pyrimethamine (40%) as well as ACT (37%), and other alternatives included 
artesunate-monotherapy (11%) and chloroquine (10%). 
Linking patients to the provider that supplied treatment 
Across the two countries 1046 patients were supplied an antimalarial (Figure 2). Almost all 
patients and caregivers were able to describe the providers they interacted with whilst at the 
public or mission health facility, pharmacy or drug store (396/405 in Cameroon and 634/641 in 
Nigeria). In Nigeria most cases (527/641) involved interactions with a single provider, while in 
Cameroon the majority of cases (291/405) involved interaction with two or more providers. It 
was possible to link the patient to details about the provider in 75% of cases (304/405) in 
Cameroon and 80% of cases (512/641) in Nigeria (Table 1). In the remaining cases, the 
provider’s details were unknown because the respondent was unable to recall one or more of 
the providers who supplied care (9 in Cameroon and 7 in Nigeria); care was supplied by one or 
more providers who did not complete the survey (74 in Cameroon and 102 in Nigeria); or 
patients received care from multiple providers of the same cadre (18 in Cameroon and 20 in 
Nigeria).   
Provider, outlet and patient attributes 
The febrile patients were linked to 119 providers working at 105 outlets in Cameroon and 107 
providers working at 93 outlets in Nigeria (Table 3). Approximately two-thirds of these 
providers accurately reported ACT was the first-line treatment for uncomplicated malaria, with 
better knowledge of the recommended treatment reported among providers working at public 
facilities.  In Cameroon, 90% of providers at public facilities knew ACT was recommended 
compared to 65% at mission facilities, 50% at pharmacies and 45% at drug stores; while in 
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Nigeria, 79% of providers at public facilities, 73% at pharmacies, and 36% at drug stores 
accurately reported ACT was the recommended first-line treatment. Providers’ access to 
malaria treatment guidelines and training also differed by country and type of outlet, with 
providers at public and mission health facilities more likely to report having access to the 
national malaria treatment guidelines than those working at pharmacies and drug stores. 
Providers’ responses to survey questions on which type of antimalarial their patients usually 
ask for and which antimalarial is best for uncomplicated malaria also varied by setting. It was 
also interesting to note there were 20 providers in Cameroon and 21 providers in Nigeria who 
knew ACT was recommended but did not state it was their preferred treatment for 
uncomplicated malaria. The majority of outlets had ACT available at the time of the survey, 
and almost all pharmacies were located in urban areas.  
The characteristics of febrile patients who relied on the provider to select treatment and were 
supplied an antimalarial are shown in Table 4. The proportions by gender and age group were 
similar across the different types of outlet in Cameroon, though in Nigeria proportionately 
more children under five were treated at public facilities than at pharmacies and drug stores. 
In both countries, there was some variation in the education level of the person seeking 
treatment and household wealth, with individuals at pharmacies having higher levels of 
education and from wealthier quintiles. There were also notable differences in the patient-
provider interaction, as patients at public and mission health facilities were more frequently 
examined. Presumptive diagnosis of malaria was the norm in all outlets, though 23% of 
patients at public and mission facilities in Cameroon had their malaria diagnosis confirmed by 
microscopy. 
Factors influencing the providers’ decision to supply ACT 
The relationship between providers’ knowledge of the malaria treatment guidelines and their 
decision to supply ACT was examined in Cameroon and in Nigeria using univariable and 
multivariable models (Tables 5 and 6).  Analysis was conducted using complete cases and once 
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missing data had been imputed. The specification of the multivariable models was assessed: 
the results for Ramsey RESET tests were not significant and there was no evidence of 
multicollinearity. The variable for providers’ stated preference was included in the final model 
since there was no evidence of simultaneity bias. Also likelihood ratio tests indicated model fit 
was significantly better when providers’ stated preference was included. Multivariable models 
without the variable for providers’ stated preference are available as an appendix (web tables 
A and B). 
There was no evidence of a relationship between providers’ knowledge and practice in the 
univariable analysis in neither Cameroon nor Nigeria. However, the multivariable models 
identified several attributes of providers, patients and outlets that were significant predictors 
of providers supplying an ACT (at the 10% level of significance). Providers in both countries 
were more than twice as likely to supply ACT if they reported ACT was the best type of 
antimalarial for uncomplicated malaria (OR=2.80, p=0.025 in Cameroon and OR=2.54, p=0.044 
in Nigeria). In Nigeria this was the only provider attribute that had a significant effect. In 
Cameroon, however, there was also evidence that providers were more likely to select ACT if 
they had reported it was the type of antimalarial that their patients most often request 
(OR=2.36, p=0.075). In addition, once missing data had been imputed the results suggest that 
pre-service training may have some bearing on their choice (p=0.092), and knowledge of the 
malaria treatment guidelines may be negatively associated with the decision to supply an ACT 
(OR=0.39, p=0.070).  
Providers’ choice of antimalarial was related to several patient attributes, though there were 
notable differences between the two countries. In Cameroon, providers were less likely to 
supply an ACT if the patient had previously taken an antimalarial (OR=0.22, p=0.005) or had 
their diagnosis confirmed using microscopy (OR=0.031, p=0.008). Also, once missing data had 
been imputed there was also some evidence that those from wealthier quintiles were more 
likely to receive an ACT (p=0.048). In Nigeria, there was strong evidence that providers were 
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more likely to supply ACT to patients under five years of age (OR=2.67, p=<0.001) and to male 
patients (OR=1.85, p=0.007), though wealth was not significant. The results also indicate that 
providers in Nigeria were more likely to supply ACT when told the patient had diarrhoea or had 
been vomiting (OR=2.36, p=0.002), though less likely to supply an ACT if it was the first time 
treatment was sought for the illness episode (OR=0.49, p=0.023). As in Cameroon, patients 
with a confirmed malaria diagnosis were less likely to receive an ACT (OR=0.23, p=0.057), 
however it is important to recognise that only 2% of all patients in Nigeria had their diagnosis 
confirmed by a malaria test. 
In both countries, providers’ decision to supply an ACT was correlated with attributes of the 
outlet. In Cameroon, patients were more likely to receive an ACT if treatment was sought at a 
pharmacy or public facility (p<0.001), while in Nigeria providers were three times more likely 
to supply ACT if it was in stock (OR=3.25, p=0.012). Finally, having controlled for a wide range 
of provider, outlet and patient attributes, the variance partition coefficient (VPC) indicates that 
a substantial proportion of the remaining heterogeneity can be attributed to unobserved 
outlet-level factors. 
Discussion 
The analysis focused on the relationship between providers’ knowledge and practice, and was 
motivated by a need to design interventions to support the introduction of malaria RDTs in 
Cameroon and Nigeria. There was no evidence from either country that a provider’s decision 
to supply ACT was determined by their knowledge of the national malaria treatment 
guidelines. There was, however, significant evidence from both countries that providers were 
more likely to supply ACT if they reported it was the best treatment for uncomplicated malaria. 
This positive association between providers’ stated and revealed preferences highlights the 
importance of designing interventions that strive to change what providers’ think and believe  
to be appropriate, not only enhance what they know.  
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The results also showed that having access to a copy of the clinical guidelines and access to 
malaria training was not sufficient to ensure appropriate treatment. Evidence from similar 
studies at public and mission facilities elsewhere in Africa have mixed results: prescribing 
practices were predicted by the providers’ access to in-service training, guidelines or wall 
charts in Benin and Kenya (Rowe et al. 2003; Zurovac et al. 2008a; Zurovac et al. 2004), though 
not in Central African Republic, Malawi, Uganda and Zambia, (Osterholt et al. 2006; Rowe et al. 
2000; Rowe et al. 2003; Zurovac et al. 2005; Zurovac et al. 2008b).  
There was evidence from both countries that providers’ choice of treatment can depend on 
their patients, though which factors were statistically significant differed by setting. It was 
interesting to find providers in Cameroon who reported their patients prefer ACT were more 
likely to supply it and the relative wealth of the patient was also a significant predictor of 
receiving an ACT. These findings were consistent with views expressed during focus group 
discussions, in which providers from public and mission facilities in the Cameroon study sites 
explained how their practice would depend on what they perceive their patients want from 
the consultation and can afford (Chandler et al. 2012).  
Patient attributes were also relevant in Nigeria, where providers’ decision to supply ACT was 
significantly associated with the patient’s age and gender. Age was also found to be a 
significant predictor in other studies, with providers more likely to supply ACT to children than 
adults (Zurovac et al. 2008a; Zurovac et al. 2008b). In-depth interviews conducted at public 
health centres in Kenya described how providers who were concerned about stock outs would 
reserve ACT for young children and patients with more severe symptoms (Wasunna et al. 
2008).  Although we cannot comment on the relative severity of febrile illness among the 
patients in our sample, it was intriguing to find providers were less likely to supply ACT to 
patients seeking treatment for the first time or with a confirmed diagnosis. Given the small 
number of patients that reported having a positive malaria test, we are cautious about 
drawing conclusions on the choice of antimalarial following a confirmed diagnosis, though 
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note that the test-positive patients not supplied ACT were treated with an antimalarial 
recommended for severe malaria, and these cases were clustered in 14 public and mission 
facilities in Cameroon and 3 public facilities in Nigeria. We were also unable to investigate 
whether timing or length of the consultation were important, which were significant predictors 
some studies (Osterholt et al. 2006; Rowe et al. 2003; Zurovac et al. 2005; Zurovac et al. 2004).  
Contextual factors were also associated with providers’ practice, and as there were substantial 
differences between the two countries, the findings highlight the importance of understanding 
the local context when designing public health interventions. It was not surprising that 
providers were more likely to supply ACT if it was in stock, though having ACT available was 
not a prerequisite and providers could prescribe ACT and advise it should be obtained 
elsewhere. It should also be noted that the exit survey would not have captured any cases 
where the provider recommended ACT and the patient or caregiver opted for an alternative.  
Before concluding some limitations are acknowledged. While several factors significantly 
predicted whether a provider supplied an ACT, it is possible others were not identified because 
the sample size was restricted to a subset of exit survey respondents who did not request a 
specific medicine, had a presumptive or confirmed malaria diagnosis, and were supplied an 
antimalarial. Also, two assumptions were made to prepare the data for analysis: the more 
senior cadre selected treatment if patients were seen by more than one provider, and data 
were missing at random. The first assumption was based on the process of care that we 
observed at many health outlets: junior staff record signs and symptoms and direct patients to 
the relevant senior health worker for a consultation, treatment is prescribed during the 
consultation, and prescribed medicines are obtained from a pharmacy attendant. At 
pharmacies and drug stores the process is less structured, though where a pharmacist and a 
sales attendant were involved we observed the   pharmacist giving advice and recommending 
medicines, while the attendant administered the retail transaction. The second assumption 
that data were missing at random (MAR) was critical to the multiple imputation. The observed 
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pattern of missingness was consistent with our expectation that provider attributes were more 
likely to be missing at larger outlets and in urban areas. We acknowledge, however, that it is 
not possible to determine whether data were MAR, as defined in the statistical literature 
(White et al. 2011). Similarly, since the missing data can never be known, we cannot ascertain 
whether differences between the complete case and multiple imputation results, such as 
those observed in Cameroon for the effect of pre-service training and knowledge, arise 
because the complete cases are biased,  because multiple imputation depends on the MAR 
assumption, or because of the specification of the imputation model (White et al. 2011).  
Conclusions 
As governments prepare to introduce malaria RDTs in public and private sectors, clinical 
guidelines will be updated to include guidance on the new type of diagnostic test and 
dissemination strategies will be developed. The introduction of RDTs, with revised guidelines, 
presents an opportunity to improve providers’ practice, not only by increasing the proportion 
of patients that are tested prior to treatment, but also the proportion of patients that receive 
the recommended treatment. The results of this investigation suggest that ensuring providers 
have access to the guidelines, and know the treatment algorithm will not be enough to change 
providers’ practice. The findings highlight that public health interventions to improve the 
treatment of uncomplicated malaria should strive to change what providers prefer, rather than 
focus on what they know. In developing interventions, the differences between the two 
countries highlight the need to understand the local context, as providers’ treatment decisions 
may depend on what they perceive their patients’ prefer or can afford as well as information 
about their symptoms or previous treatment seeking. In addition, the findings suggest it will be 
important to emphasize that the treatment algorithm should not depend on patient attributes, 
such as age or wealth, and that ACT is suitable for patients with a confirmed malaria diagnosis, 
unless they have symptoms of severe malaria or are pregnant. Finally, it should be recognized 
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that working environment can constrain providers’ practice, and providers can only adhere to 
clinical guidelines if essential medicines and supplies are available.  
 
  
7. RESEARCH PAPER IV 
 
201 
 
References 
Burton A, Altman D. 2004. Missing covariate data within cancer prognostic studies: a review of 
current reporting and proposed guidelines. British Journal of Cancer, 91: 4-8. 
Cabana M, Rand C, Rowe N, et al. 1999. Why don't physicians follow clinical practice 
guidelines? A framework for improvement. JAMA, 282: 1458-1465. 
Carpenter J, Goldstein H, Kenward M. 2011. REALCOM-IMPUTE software for multilevel 
multiple imputation with mixed response types. Journal of Statistical Software, 45: 5. 
Carpenter J, Kenward M. 2013. Multiple Imputation and its Application. Wiley, Chichester. 
Chandler C, Mangham L, Njei A, et al. 2012. ‘As a clinician, you are not managing lab results, 
you are managing the patient’: How the enactment of malaria at health facilities in Cameroon 
compares with new WHO guidelines for the use of malaria tests. Social Science & Medicine, 74: 
1528-1535. 
Das J, Hammer J, Leonard K. 2008. The quality of medical advice in low-income countries. 
Journal of Economic Perspectives, 22: 93-114. 
Field M, Lohr K, IOM Committee on Clinical Practice Guidelines. 1992. Guidelines for Clinical 
Practice: From Development to Use. National Academy Press, Washington, DC. 
Goldstein H, Carpenter J, Kenward M, Levin K. 2009. Multilevel models with multivariate mixed 
response types. Statistical Modelling, 9: 173-197. 
Grol R, Grimshaw J. 2003. From best evidence to best practice: effective implementation of 
change in patients' care. Lancet, 362: 1225-30. 
Hox J. 2010. Multilevel analysis: techniques and applications. Routledge, New York. 
Hughes R, Chandler C, Mangham L, Mbacham W. 2013. Providing health care in northeast 
Cameroon: perspectives of medicine sellers. Health Policy and Planning, 28: 636-646. 
Jones A. 2007. Applied Econometrics for Health Economists. A Practical Guide. Second Edition 
edn. Office of Health Economics Oxford. 
Leonard K, Masatu M. 2010. Using the Hawthorne effect to examine the gap between a 
doctor's best possible practice and actual performance. Journal of Development Economics, 93: 
226-234. 
Lubell Y, Reyburn H, Mbakilwa H, et al. 2008. The impact of response to the results of 
diagnostic tests for malaria: cost-benefit analysis. BMJ, 336: 202-205. 
Mangham L, Cundill B, Achonduh O, et al. 2012. Malaria prevalence and treatment of febrile 
patients attending health facilities in Cameroon. Tropical Medicine and International Health, 
17: 330-342. 
Mangham L, Cundill B, Ezeoke O, et al. 2011. Treatment of uncomplicated malaria at public 
health facilities and medicine retailers in south-eastern Nigeria. Malaria Journal, 10: 155. 
Ministry of Health of the Federal Republic of Nigeria. 2005. National Antimalarial Treatment 
Policy. Ministry of Health, Abuja. 
7. RESEARCH PAPER IV 
 
202 
 
Ministry of Public Health of the Republic of Cameroon. 2008. Guidelines for the Management 
of Malaria in Cameroon. Ministry of Public Health, Yaounde. 
Osterholt D, Rowe A, Hamel M, et al. 2006. Predictors of treatment error for children with 
uncomplicated malaria seen as outpatients in Blantyre district, Malawi. Tropical Medicine and 
International Health, 11: 1147-1156. 
Rice N. 2000. Binomial Regression. In: Leyland A, Goldstein H (eds). Multilevel Modelling of 
Health Statistics. Chichester: John Wiley & Sons. 
Rowe A, Hamel M, Flanders D, et al. 2000. Predictors of correct treatment of children with 
fever seen at outpatient health facilities in the Central African Republic. American Journal of 
Epidemiology 151: 1029-1091. 
Rowe A, Onikpo F, Lama M, Deming M. 2003. Risk and protective factors for two types of error 
in the treatment of children with fever at outpatient health facilities in Benin. International 
Journal of Epidemiology, 32. 
Smith L, Jones C, Meek S, Webster J. 2009. Review: Provider Practice and User Behavior 
Interventions to Improve Prompt and Effective Treatment of Malaria: Do we know what 
works? . American Journal of Tropical Medicine and Hygiene, 80: 326-335. 
StataCorp. 2009. Stata Longitudinal-Data / Panel-Data Reference Manual Release 11. 
StataCorp LP, College Station, TX. 
Sterne J, White I, JB C, et al. 2009. Multiple imputation for missing data in epidemiological and 
clinical research: potential and pitfalls. BMJ, 338: b2393. 
van Buuren S. 2010. Multiple Imputation of Multilevel Models. In: Hox J, Roberts J (eds). 
Handbook of Advanced Multivel Analysis. New York: Routledge. 
Wasunna B, Zurovac D, Goodman C, Snow R. 2008. Why don’t health workers prescribe ACT? A 
qualitative study of factors affecting the prescription of artemether-lumefantrine. Malaria 
Journal, 7: 53. 
White I, Carlin J. 2010. Bias and efficiency of multiple imputation compared with complete-
case analysis for missing covariate values. Statistics in Medicine, 29: 2920-2931. 
White I, Royston P, Wood A. 2011. Multiple imputation using chained equations: issues and 
guidance for practice. Statistics in Medicine, 30: 377-399. 
Wiseman V, Ezeoke O, Nwala E, et al. 2012a. A cost-effectiveness analysis of provider and 
community interventions to improve the treatment of uncomplicated malaria in Nigeria: study 
protocol for a randomized controlled trial. Trials, 13: 81. 
Wiseman V, Mangham L, Cundill B, et al. 2012b. A cost-effectiveness analysis of provider 
interventions to improve health worker practice in providing treatment for uncomplicated 
malaria in Cameroon: a study protocol for a randomized controlled trial. Trials, 13: 4. 
Woolf S, Schunemann H, Eccles M, Grimshaw J, Shekelle P. 2012. Developing clinical practice 
guidelines: types of evidence and outcomes; values and economics, synthesis, grading and 
presentation and deriving recommendations. Implementation Science, 7: 61. 
Zurovac D, Ndhlovu M, Rowe A, et al. 2005. Treatment of paediatric malaria during a period of 
drug transition to artemether-lumefantrine in Zambia: cross sectional study. BMJ, 331: 734. 
7. RESEARCH PAPER IV 
 
203 
 
Zurovac D, Njogu J, Akhwale W, Hamer D, Snow R. 2008a. Translation of artemether-
lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya. 
Tropical Medicine and International Health, 13: 99-107. 
Zurovac D, Rowe A, Ochola S, et al. 2004. Predictors of the quality of health worker treatment 
practices for uncomplicated malaria at government health facilities in Kenya. International 
Journal of Epidemiology, 33: 1080-1091. 
Zurovac D, Tibenderana J, Nankabirwa J, et al. 2008b. Malaria case-management under 
artemether-lumefantrine treatment policy in Uganda. Malaria Journal, 7: 181. 
7. RESEARCH PAPER IV 
 
204 
 
Figure 1: Flow chart of patients and caregivers that sought for febrile illness at public and 
mission facilities, pharmacies and drug stores in Cameroon and Nigeria 
 
Febrile patient tested positive for malaria 
Cameroon: n=77, 14%; Nigeria: n=25, 3%  
or had unconfirmed diagnosis  
Cameroon: n=439, 78%; Nigeria: n=917, 97% 
No antimalarial was 
supplied 
Cameroon: n=109, 21% 
Nigeria: n=3--, 32% 
Antimalarial was supplied  
 
Cameroon: n=405, 79%; 
Nigeria: n=641, 68% 
 
ACT was supplied 
 
Cameroon: n=299, 74% 
Nigeria: n=235, 37% 
 Other antimalarial was 
supplied  
Cameroon: n=106, 26% 
Nigeria: n=403, 63% 
  
Febrile patient tested 
negative for malaria  
Cameroon: n=45, 8% 
Nigeria: n=0 
 
Provider determined 
health care needs  
Cameroon: n=562, 69% 
Nigeria: n=947, 58% 
 
Patient asked for specific 
medicine  
Cameroon: n=247, 30% 
Nigeria: n=678, 42% 
Febrile patient sought treatment  
(excluding pregnant women & children <6 months) 
Cameroon: n=871 
Nigeria: n=1634 
 
Missing  
 
Cameroon: n=2, <1% 
Nigeria: n=1, <1% 
 
Missing  
 
Cameroon: n=1, <1% 
Nigeria: n=5, <1% 
 
Missing  
 
Cameroon: n=8, 1% 
Nigeria: n=9, <1% 
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Figure 2: Flow chart showing how patients were linked to providers 
Patient cared for by two 
or more providers 
Cameroon: n=291  
Nigeria: n=107 
Missing 
 
Cameroon: n=71 
Nigeria: n=26 
 
Providers were 
surveyed 
Cameroon: n=220 
 Nigeria: n=81 
Patient was linked to 
provider 
Cameroon: n=102 
Nigeria: n=451 
Patient cared for by 
single provider 
Cameroon: n=105  
Nigeria: n=527 
Patient was able to recall all 
providers who supplied care  
Cameroon: n=396 
Nigeria: n=634 
Febrile patient received 
antimalarial   
Cameroon: n=405 
Nigeria: n=641 
Missing  
 
Cameroon: n=9 
Nigeria: n=7 
Missing 
 
Cameroon: n=3  
Nigeria: n=76 
Providers were 
surveyed 
Cameroon: n=102  
Nigeria: n=451 
 
Patient was linked to 
provider 
Cameroon: n=202 
Nigeria: n=61 
Missing 
 
Cameroon: n=18 
Nigeria: n=20 
Patient was linked to provider 
 
Cameroon: n=304 
Nigeria: n=512 
ACT was supplied 
 
Cameroon: n=299, 74% 
Nigeria: n=235, 37% 
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Table 1: Number of observations with missing data for each explanatory variable, by country and type of outlet 
VARIABLE CAMEROON (N=405) NIGERIA (N=641) 
 
Public Mission Pharmacy Drug Store Public Pharmacy Drug Store 
Number of patients  N=202 N=80 N=52 N=71 N=323 N=60 N=258 
Number of patients that were linked to provider N=165 N=39 N=32 N=68 N=258 N=43 N=211 
Level 1: Patient-Provider Interaction        
Provider knew ACT was first-line antimalarial for uncomplicated malaria 37 41 20 3 83 22 63 
Provider reported having access to malaria treatment guidelines 37 41 20 3 66 18 47 
Provider had attended malaria training in past 3 years 37 41 20 3 65 18 47 
Provider’s pre-service training 37 41 20 3 65 17 47 
Provider stated ACT was best type of antimalarial for uncomplicated 
malaria 
37 41 20 3 65 17 47 
Provider reported the antimalarial that patients’ usually ask for is ACT 37 41 20 3 100 17 47 
Patient’s gender    2 2 - 1 3 1 3 
Patient’s age group (<5years; 5+years) 5 - - - 2 - 3 
Education of person that sought treatment 3 - 1 1 13 1 5 
Wealth quintile of patient (relative to other patients) - - - - - - - 
Treatment was sought within 2 days following onset of fever - - - - - - - 
First time treatment was sought (for this illness episode) - - - - - - - 
Patient had previously taken antimalarial (for this illness episode) - - - - - - - 
Provider was told patient has diarrhoea or been vomiting - - - - - - - 
Patient was examined by provider - - - - - - - 
Patient reported malaria was confirmed using microscopy - - - - - - - 
Level 2: Outlet         
Outlet had ACT in stock - - - - - - - 
Outlet receives antimalarials from drug company representative - - 5 9 - 13 - 
Urban / rural area - - - - - - - 
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Table 2: Providers’ choice of antimalarial, by country and type of outlet 
TYPE OF ANTIMALARIAL CAMEROON (N=405) NIGERIA (N=641) 
 Public Mission Pharmacy Drug Store Public Pharmacy Drug Store 
 N % N % N % N % N % N % N % 
 N=202 N=80 N=52 N=71 N=123 N=323 N=318 
Artemisinin Combination Therapy (ACT) 164 81.2 52 65.0 51 98.1 32 45.1 158 48.9 24 40.0 53 20.5 
Amodiaquine - - - - - - 5 7.0 4 1.2 1 1.7 1 0.4 
Artesunate monotherapy 3 1.5 2 2.5 - - - - 30 9.3 10 16.7 29 11.2 
Chloroquine - - - - - - 1 1.4 16 5.0 - - 51 19.8 
Halofantrine - - - - - - - - 3 1.2 1 1.7 1 0.4 
Quinine 35 17.3 22 27.5 - - 28 39.4 1 0.3 1 1.7 - - 
Sulphadoxine-pyrimethamine (SP) - - 4 5.0 1 1.9 5 7.0 111 34.4 23 38.3 123 47.7 
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Table 3: Provider and Outlet Attributes, by country and type of outlet 
ATTRIBUTES CAMEROON (N=405) NIGERIA (N=641) 
 Public Mission Pharmacy Drug Store Public Pharmacy Drug Store 
 N % N % N % N % N % N % N % 
Provider  N=48 N=20 N=22 N=29 N=38 N=22 N=47 
Knew ACT was first-line antimalarial† 43 89.6 13 65.0 11 50.0 13 44.8 30 78.9 16 72.7 17 36.2 
Reports has access to malaria guidelines† 35 72.9 12 60.0 2 9.1 1 3.4 12 31.6 1 4.5 1 2.1 
Has attended malaria training† 23 47.9 5 25.0 6 27.3 1 3.4 12 31.6 4 18.2 14 29.8 
Pre-service training‡               
    Doctor  10 20.8 6 30.0 - - - - 6 15.8 - - - - 
    Nurse or Midwife 25 52.1 5 25.0 3 13.6 3 10.3 5 13.2 2 9.1 - - 
    Pharmacist 1 2.1 0 0.0 10 45.5 2 6.9 - - 3 13.6 - - 
    Nurse Assistant 7 14.6 6 30.0 2 9.1 15 51.7 - - -  - - 
    CHO or CHEW -  -  -  -  26 68.4 2 9.1 3 6.4 
    None (Attendant or Drug Seller) 5 10.4 3 15.0 7 31.8 9 31.0 1 2.6 15 68.2 44 93.6 
Reported patients usually ask for ACT† 22 45.8 8 40.0 18 81.8 9 31.0 11 28.9 12 54.5 8 17.0 
Stated ACT was best antimalarial for 
uncomplicated malaria† 
38 79.2 9 45.0 15 68.2 23 79.3 22 57.9 19 86.4 24 51.1 
Knew ACT was the first-line antimalarial but 
did not state it was the best antimalarial 
9 18.8 6 30.0 4 18.2 1 3.4 11 28.9 3 13.6 7 14.9 
Outlet  N=35 N=15 N=25 N=30 N=20 N=21 N=52 
Outlet had ACT in stock 28 80.0 13 86.7 23 92.0 17 56.7 14 70.0 21 100.0 38 73.1 
Outlet receives antimalarials from drug 
company representative† 
-  -  1 4.0 2 6.7 -  12 57.1 9 17.3 
Urban / rural area               
     Urban   13 37.1 9 60.0 24 96.0 17 56.7 12 60.0 20 95.2 31 59.6 
     Rural  22 62.9 6 40.0 1 4.0 13 43.3 8 40.0 1 4.8 21 40.4 
† Some observations were missing (see Table 1) 
‡ Categories differ by country. In Cameroon: Doctor; Nurse or Midwife; Pharmacist; Nurse Assistant; None (includes attendants). In Nigeria: Doctor; Nurse or Midwife; Pharmacist; 
Community Health Officer (CHO) or Community Health Extension Worker (CHEW); None (includes patent medicine dealers))  
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Table 4: Patient Attributes by country and type of outlet 
PATIENT ATTRIBUTES CAMEROON (N=405) NIGERIA (N=641) 
 Public Mission Pharmacy Drug Store Public Pharmacy Drug Store 
 N  N  N  N  N  N  N  
 N=202 N=80 N=52 N=71 N=323 N=60 N=258 
Patient’s gender†               
     Male 100 49.5 33 41.3 27 51.9 32 45.1 141 43.7 32 53.3 129 50.0 
     Female 100 49.5 45 56.3 25 48.1 38 53.5 179 55.4 27 45.0 126 48.8 
Patient’s age group†               
     Under 5 years  61 30.2 19 23.8 15 28.8 16 22.5 122 37.8 7 11.7 32 12.4 
     5 years and over 136 67.3 61 76.3 37 71.2 55 77.5 199 61.6 53 88.3 223 86.4 
Education of person who sought treatment†               
     Tertiary 15 7.4 14 17.5 18 34.6 8 11.3 67 20.7 28 46.7 54 20.9 
     Secondary 86 42.6 29 36.3 22 42.3 29 40.8 150 46.4 26 43.3 119 46.1 
     None or Primary 98 48.5 37 46.3 11 21.2 33 46.5 93 28.8 5 8.3 80 31.0 
Patients’ wealth quintile (relative to other 
patients) 
              
     Least poor 21 10.4 9 11.3 19 36.5 5 7.0 46 14.2 19 31.7 25 9.7 
     Fourth 24 11.9 21 26.3 12 23.1 9 12.7 48 14.9 18 30.0 50 19.4 
     Third 40 19.8 18 22.5 11 21.2 13 18.3 72 22.3 9 15.0 55 21.3 
     Second 44 21.8 13 16.3 7 13.5 26 36.6 82 25.4 11 18.3 56 21.7 
     Poorest 73 36.1 19 23.8 3 5.8 18 25.4 75 23.2 3 5.0 72 27.9 
Treatment was sought within 2 days  69 34.2 24 30.0 32 61.5 36 50.7 131 40.6 40 66.7 164 63.6 
First time treatment was sought 125 61.9 39 48.8 39 75.0 57 80.3 220 68.1 48 80.0 194 75.2 
Patient had previously taken antimalarial 19 9.4 20 25.0 6 11.5 4 5.6 34 10.5 4 6.7 14 5.4 
Provider was told patient had diarrhoea or 
been vomiting 
27 13.4 14 17.5 4 7.7 3 4.2 70 21.7 13 21.7 41 15.9 
Patient was examined by provider 175 86.6 73 91.3 14 26.9 21 29.6 228 70.6 7 11.7 39 15.1 
Patient reported malaria was confirmed  47 23.3 18 22.5 2 3.8 - - 16 5.0 - - - - 
† Some observations were missing (see Table 1)  
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Table 5: Factors associated with providers’ decision to supply ACT in Cameroon 
 COMPLETE CASES  MULTIPLE IMPUTATION 
Number of patients 304  281  405  405  
Number of outlets 91  84  105  105  
FIXED EFFECTS OR (95 CI) P-value OR (95 CI) P-value OR (95 CI) P-value OR (95 CI) P-value 
Level 1: Patient-Provider Interaction         
Provider knew ACT is first-line 
antimalarial for uncomplicated malaria 
0.84 (0.33-2.13) 0.709 0.39 (0.11-1.35) 0.138 0.61 (0.28-1.33) 0.216 0.39 (0.14-1.08) 0.070 
Provider had access to malaria guidelines   0.59 (0.20-1.80) 0.354   1.00 (0.37-2.70) 0.992 
Provider had attended malaria training in 
past 3yrs 
  1.31 (0.46-3.74) 0.608   1.73 (0.63-4.76) 0.289 
Provider’s pre-service  
   Doctor  
   Nurse / Midwife  
   Pharmacist 
   Nurse Assistant  
   None (Attendant/drug seller) 
   
0.91 (0.17-5.02) 
0.41 (0.10-1.72) 
0.53 (0.03-9.36) 
1.32 (0.33-5.28) 
1.0 
 
0.458 
   
2.78 (0.53-14.46) 
1.06 (0.26-4.36) 
0.21 (0.03-1.65) 
2.90 (0.70-11.98) 
1.0 
 
0.092 
Provider stated patients usually ask for 
ACT 
  2.60 (0.92-7.31) 0.070   2.36 (0.92-6.06) 0.075 
Provider stated ACT was best antimalarial 
for uncomplicated malaria 
  3.55 (1.28-9.88) 0.015   2.80 (1.14-6.89) 0.025 
Patient was male    1.00 (0.47-2.12) 0.996   1.06 (0.56-1.99) 0.856 
Patient was under 5 years of age    1.87 (0.72-4.77) 0.191   1.45 (0.67-3.13) 0.345 
Education of person seeking treatment 
   Tertiary  
   Secondary  
   None or Primary  
   
0.42 (0.10-1.87) 
0.68 (0.27-1.70) 
1.0 
 
0.490 
   
0.67 (0.21-2.19) 
0.77 (0.36-1.65) 
1.0 
 
0.733 
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Patient’s wealth quintile  
   Least Poor  
   Fourth  
   Third  
   Second  
   Poorest 
   
3.63 (0.68-19.51) 
6.31 (1.23-32.20) 
1.77 (0.53-5.86) 
1.68 (0.63-4.50) 
1.0 
 
0.279 
   
2.62 (0.64-10.71) 
6.46 (1.73-24.13) 
1.63 (0.58-4.60) 
1.10 (0.45-2.69) 
1.0 
 
0.048 
Treatment was sought within 2 days    1.22 (0.53-2.82) 0.635   1.02 (0.51-2.05) 0.956 
First time treatment was sought   0.24 (0.07-0.79) 0.019   0.41 (0.17-1.02) 0.056 
Patient had previously taken an 
antimalarial 
  0.08 (0.02-0.39) 0.002   0.22 (0.07-0.64) 0.005 
Provider was told patient has diarrhoea 
or been vomiting 
  1.07 (0.33-3.47) 0.908   0.77 (0.28-2.08) 0.603 
Patient was examined by provider   0.90 (0.33-2.45) 0.839   1.08 (0.43-2.72) 0.872 
Patient had a confirmed malaria diagnosis   0.33 (0.12-0.91) 0.032   0.31 (0.13-0.74) 0.008 
Level 2: Outlet         
Type of outlet 
   Public 
   Mission 
   Pharmacy 
   Drug Store 
   
22.46 (3.86-130.69) 
7.69 (1.16-50.80) 
72.63 (3.84-1372.3) 
1.0 
 
0.002 
   
7.38 (1.53-35.57) 
2.23 (0.45-11.08) 
203.38 (13.10-3156.3) 
1.0 
 
<0.001 
Outlet had ACT in stock   1.85 (0.67-5.13) 0.238   2.15 (0.74-6.26) 0.160 
Outlet usually receives antimalarial from 
drug company representative 
  1.75 (0.15-19.81) 0.650   1.43 (0.10-20.52) 0.791 
Outlet was in an urban area   0.69 (0.25-1.88) 0.470   0.70 (0.26-1.87) 0.481 
Constant 4.16 (1.76-9.87) 0.001 0.73 (0.10-5.18) 0.753 5.47 (2.63-11.37) <0.001 0.38 (0.06-2.32) 0.296 
RANDOM EFFECTS         
Residual SD 1.42 (0.91-2.21)  0.77 (0.23-2.58)  1.37 (0.92-2.04)  1.12 (0.67-1.86)  
VPC 0.38  0.15  0.36  0.28  
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Table 6: Factors associated with providers’ decision to supply ACT in Nigeria 
 COMPLETE CASES  MULTIPLE IMPUTATION 
Number of patients 473  423  641  641  
Number of outlets 73  71  93  93  
FIXED EFFECTS OR (95 CI) P-value OR (95 CI) P-value OR (95 CI) P-value OR (95 CI) P-value 
Level 1: Patient-Provider Interaction         
Provider knew ACT is first-line 
antimalarial for uncomplicated malaria 
1.66 (0.70-3.90) 0.247 1.08 (0.44-2.66) 0.869 1.69 (0.76-3.75) 0.196 1.08 (0.50-2.33) 0.851 
Provider had access to malaria guidelines   0.83 (0.25-2.76) 0.761   1.54 (0.57-4.18) 0.392 
Provider had attended malaria training in 
past 3yrs 
  0.66 (0.29-1.49) 0.316   0.69 (0.33-1.46) 0.332 
Provider’s pre-service training  
  Doctor or Nurse/Midwife or Pharmacist‡ 
  CHO or CHEW  
  None (Attendant/drug seller) 
   
2.18 (0.39-12.22) 
2.66 (0.58-12.16 
1.0 
 
0.453 
   
1.75 (0.41-7.48) 
1.62 (0.41-6.34) 
1.0 
 
0.717 
Provider stated patients usually ask for 
ACT 
  1.41 (0.29-1.49) 0.458   1.38 (0.62-3.07) 0.429 
Provider stated ACT was best antimalarial 
for uncomplicated malaria 
  2.54 (0.92-7.00) 0.071   2.54 (1.02-6.32) 0.044 
Patient was male    1.61 (0.92-2.82) 0.093   1.85 (1.19-2.89) 0.007 
Patient was under 5 years of age    3.84 (1.91-7.73) <0.001   2.67 (1.54-4.63) <0.001 
Education of person seeking treatment 
  Tertiary  
  Secondary  
  None or Primary  
   
0.91 (0.37-2.26) 
0.84 (0.39-1.80) 
1.0 
 
0.903 
   
1.37 (0.67-2.78) 
1.08 (0.60-1.96) 
1.0 
 
0.643 
 
Patient’s wealth quintile  
  Least Poor  
  Fourth  
  Third  
  Second  
  Poorest 
   
1.35 (0.40-4.62) 
1.40 (0.43-4.58) 
1.57 (0.52-4.80) 
1.36 (0.64-3.45) 
1.0 
 
0.951 
   
1.39 (0.54-3.60) 
1.32 (0.54-3.25) 
1.30 (0.55-3.09) 
1.30 (0.62-2.73) 
1.0 
 
0.962 
Treatment was sought within 2 days    1.75 (0.91-3.39) 0.095   1.45 (0.87-2.40) 0.151 
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First time treatment was sought   0.56 (0.25-1.25) 0.155   0.49 (0.26-0.90) 0.023 
Patient had previously taken an 
antimalarial 
  1.80 (0.59-5.51) 0.300   1.01 (0.43-2.41) 0.976 
Provider was told patient has diarrhoea 
or been vomiting 
  2.39 (1.18-4.82) 0.015   2.36 (1.38-4.04) 0.002 
Patient was examined by provider   1.06 (0.49-2.27) 0.885   1.29 (0.71-2.35) 0.408 
Patient had a confirmed malaria diagnosis   0.06 (0.00-0.79) 0.033   0.23 (0.05-1.04) 0.057 
Level 2: Outlet         
Type of outlet 
  Public 
  Pharmacy 
  Drug Store 
   
2.83 (0.51-15.80) 
0.78 (0.13-4.51) 
1.0 
 
0.380 
   
2.22 (0.50-9.94) 
1.25 (0.36-4.33) 
1.0 
 
0.558 
Outlet had ACT in stock   3.24 (1.05-9.96) 0.040   3.25 (1.30-8.14) 0.012 
Outlet usually receives antimalarial from 
drug company representative 
  1.93 (0.44-8.55) 0.386   1.04 (0.34-3.14) 0.947 
Outlet was in an urban area   1.70 (0.50-5.72) 0.393   1.49 (0.54-4.09) 0.442 
Constant 0.21 (0.10-0.46) <0.001 0.01 (0.00-0.06) <0.001 0.23 (0.12-0.45) <0.001 0.02 (0.00-0.06) <0.001 
RANDOM EFFECTS         
Residual SD 1.73 (1.23-2.42)  1.06 (0.65-1.73)  1.68 (1.25-2.25)  0.99 (0.66-1.48)  
VPC 0.48  0.26  0.46  0.23  
‡ Categories
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Appendix A: Factors associated with providers’ decision to supply ACT in Cameroon 
(model does not include providers’ stated preference for ACT) 
 COMPLETE CASES  MULTIPLE IMPUTATION 
Number of patients 281  405  
Number of outlets 84  105  
FIXED EFFECTS OR (95 CI) P-value OR (95 CI) P-value 
Level 1: Patient-Provider Interaction     
Provider knew ACT is first-line 
antimalarial for uncomplicated 
malaria 
0.47 (0.13-1.70) 0.252 0.46 (0.17-1.27) 0.135 
Provider had access to malaria 
guidelines 
0.56 (0.17-1.79) 0.327 0.98 (0.35-2.70) 0.961 
Provider had attended malaria 
training in past 3yrs 
1.40 (0.47-4.23) 0.546 1.75 (0.63-4.90) 0.279 
Provider’s pre-service  
   Doctor  
   Nurse / Midwife  
   Pharmacist 
   Nurse Assistant  
   None (Attendant/drug seller) 
 
1.22 (0.21-7.15) 
0.61 (0.14-2.66) 
0.72 (0.03-15.06) 
1.39 (0.32-6.01) 
1.0 
 
0.763 
 
3.07 (0.58-16.22) 
1.39 (0.34-5.79) 
0.20 (0.03-1.60) 
2.85 (0.68-11.97) 
1.0 
 
0.097 
Provider stated patients usually ask 
for ACT 
3.02 (1.00-9.12) 0.051 2.56 (0.98-6.69) 0.054 
Patient was male  0.96 (0.44-2.07) 0.912 1.06 (0.57-2.00) 0.845 
Patient was under 5 years of age  2.07 (0.79-5.44) 0.141 1.50 (0.70-3.24) 0.301 
Education of person seeking 
treatment 
   Tertiary  
   Secondary  
   None or Primary  
 
0.45 (0.10-2.04) 
0.66 (0.26-1.68) 
1.0 
 
0.522 
 
0.74 (0.23-2.38) 
0.81 (0.38-1.72) 
1.0 
 
0.818 
Patient’s wealth quintile  
   Least Poor  
   Fourth  
   Third  
   Second  
   Poorest 
 
4.02 (0.71-22.58) 
7.03 (1.34-36.88) 
2.33 (0.69-7.90) 
1.83 (0.66-5.02) 
1.0 
 
0.238 
 
2.72 (0.67-11.17) 
6.34 (1.68-23.89) 
1.77 (0.63-5.00) 
1.15 (0.47-2.83) 
1.0 
 
0.061 
Treatment was sought within 2 days  1.39 (0.59-3.25) 0.448 1.10 (0.55-2.21) 0.781 
First time treatment was sought 0.28 (0.08-0.93) 0.037 0.46 (0.19-1.13) 0.089 
Patient had previously taken an 
antimalarial 
0.09 (0.02-0.42) 0.002 0.23 (0.08-0.66) 0.007 
Provider was told patient has 
diarrhoea or been vomiting 
1.07 (0.32-3.62) 0.907 0.78 (0.29-2.13) 0.630 
Patient was examined by provider 0.88 (0.32-2.43) 0.809 1.11 (0.44-2.79) 0.826 
Patient had a confirmed malaria 
diagnosis 
0.28 (0.10-0.79) 0.017 0.30 (0.12-0.70) 0.006 
Level 2: Outlet     
Type of outlet 
   Public 
   Mission 
   Pharmacy 
   Drug Store 
 
17.08 (2.68-108.73) 
4.21 (0.62-28.82) 
42.41 (2.22-808.51) 
1.0 
 
0.006 
 
148.44 (9.59-2297.3) 
1.48 (0.30-7.35) 
6.09 (1.24-29.69) 
1.0 
 
0.001 
Outlet had ACT in stock 2.24 (0.74-6.79) 0.155 2.45 (0.82-7.35) 0.109 
Outlet usually receives antimalarial 
from drug company representative 
1.79 (0.12-25.91) 0.668 1.51 (0.10-23.38) 0.767 
Outlet was in an urban area 0.74 (0.25-2.18) 0.586 0.73 (0.26-1.98) 0.536 
Constant 1.12 (0.14-8.69) 0.914 0.55 (0.09-3.31) 0.514 
RANDOM EFFECTS     
Residual SD 1.02 (0.45-2.29)  1.20 (0.74-1.96)  
VPC 0.24  0.30  
  
7. RESEARCH PAPER IV 
 
215 
 
Appendix B: Factors associated with providers’ decision to supply ACT in Nigeria (model does 
not include providers’ stated preference for ACT) 
 COMPLETE CASES MULTIPLE IMPUTATION 
Number of patients 423  641  
Number of outlets 71  93  
FIXED EFFECTS OR (95 CI) P-value OR (95 CI) P-value 
Level 1: Patient-Provider Interaction     
Provider knew ACT is first-line 
antimalarial for uncomplicated 
malaria 
0.98 (0.40-2.43) 0.970 0.94 (0.46-2.20) 0.985 
Provider had access to malaria 
guidelines 
0.91 (0.27-3.09) 0.882 1.73 (0.62-4.76) 0.288 
Provider had attended malaria 
training in past 3yrs 
0.63 (0.27-1.42) 0.264 0.65 (0.31-1.38) 0.264 
Provider’s pre-service training  
   Doctor or Nurse/Midwife or 
Pharmacist‡ 
   CHO or CHEW  
   None (Attendant/drug seller) 
 
2.47 (0.45-13.66) 
2.79 (0.60-12.87) 
1.0 
 
0.417 
 
1.97 (0.45-8.58) 
1.63 (0.41-6.57) 
1.0 
 
0.646 
Provider stated patients usually ask 
for ACT 
1.30 (0.52-3.26) 0.576 1.34 (0.60-3.00) 0.476 
Patient was male  1.64 (0.94-2.86) 0.084 1.87 (1.20-2.93) 0.006 
Patient was under 5 years of age  3.98 (1.97-8.04) <0.001 2.77 (1.59-4.82) <0.001 
Education of person seeking 
treatment 
   Tertiary  
   Secondary  
   None or Primary  
 
0.97 (0.39-2.39) 
0.82 (0.38-1.76) 
1.0 
 
0.842 
 
1.43 (0.71-2.90) 
1.07 (0.59-1.94) 
1.0 
 
0.539 
Patient’s wealth quintile  
   Least Poor  
   Fourth  
   Third  
   Second  
   Poorest 
 
1.37 (0.40-4.68) 
1.43 (0.44-4.64) 
1.56 (0.51-4.77) 
1.29 (0.51-3.29) 
1.0 
 
0.960 
 
1.41 (0.55-3.65) 
1.33 (0.54-3.27) 
1.30 (0.55-3.09) 
1.27 (0.61-2.68) 
1.0 
 
0.963 
Treatment was sought within 2 days  1.76 (0.91-3.40) 0.091 1.43 (0.87-2.37) 0.162 
First time treatment was sought 0.54 (0.24-1.21) 0.136 0.48 (0.26-0.89) 0.020 
Patient had previously taken an 
antimalarial 
1.86 (0.61-5.65) 0.273 1.04 (0.44-2.46) 0.936 
Provider was told patient has 
diarrhoea or been vomiting 
2.36 (1.17-4.75) 0.016 2.36 (1.38-4.05) 0.002 
Patient was examined by provider 1.13 (0.53-2.40) 0.754 1.35 (0.74-2.45) 0.323 
Patient had a confirmed malaria 
diagnosis 
0.06 (0.00-0.87) 0.039 0.24 (0.05-1.10) 0.066 
Level 2: Outlet     
Type of outlet 
   Public 
   Pharmacy 
   Drug Store 
 
2.50 (0.44-14.29) 
0.68 (0.12-3.85) 
1.0 
 
0.414 
 
1.22 (0.35-4.28) 
2.00 (0.43-9.22) 
1.0 
 
0.655 
Outlet had ACT in stock 3.54 (1.14-10.95) 0.029 3.67 (1.45-9.25) 0.006 
Outlet usually receives antimalarial 
from drug company representative 
2.44 (0.56-10.62) 0.234 1.21 (0.40-3.65) 0.733 
Outlet was in an urban area 2.50 (0.78-8.00) 0.122 2.18 (0.84-5.64) 0.110 
Constant 0.01 (0.00-0.08) <0.001 0.02 (0.00-0.08) <0.001 
RANDOM EFFECTS     
Residual SD 1.09 (0.66-1.79)  1.03 (0.68-1.54)  
VPC 0.26  0.24  
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Chapter 8  
Research Paper V: Economic evaluation of a cluster-randomized trial of 
interventions to improve health workers' practice in diagnosing and 
treating uncomplicated malaria in Cameroon 
In Chapter 5 I described problems with malaria diagnosis and treatment in Cameroon. 
Although microscopy was available in most public and mission facilities it was often 
under-used, and many febrile patients who were tested and found to be negative received 
an antimalarial they did not need.  
The economic argument for introducing RDTs critically depends on providers’ practice, 
and whether the treatment prescribed is consistent with the malaria test result. Having 
identified a gap between providers’ knowledge and their practice, I hypothesized that 
interventions would be needed to support the introduction of RDTs and that training 
would be more effective and cost-effective if it focused on providers’ practice, not only 
their knowledge of the malaria treatment guidelines. 
This research paper reports the economic evaluation of a trial, developed on the basis of 
work the work reported in Chapters 5 through 7, which introduced of RDTs with either 
basic or enhanced health worker training at public and mission health facilities in 
Cameroon. While the basic training took a conventional approach, with lectures on the 
revised malaria treatment guidelines and a practical session on how to use RDTs, the 
enhanced training incorporated participatory methods that sought to change providers’ 
preference and encourage them to adapt their practice and adhere to the treatment 
guidelines.  
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The results from this paper demonstrated it was more cost-effective to introduce RDTs 
with enhanced training, when each intervention was compared to current practice. The 
paper may also be useful for other researchers, as it is one of the first examples to apply 
the recent methodological guidance on analysing individual patient level data on costs and 
effects from a cluster randomized trial.  
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ABSTRACT  
Background 
Malaria rapid diagnostic tests (RDTs) are a valid alternative to malaria testing with microscopy 
and are recommended for testing of febrile patients before prescribing an antimalarial. There is 
the need for interventions to support the uptake of RDTs by health workers.  
Objective 
To evaluate the cost-effectiveness of introducing RDTs with basic or enhanced training in health 
facilities where microscopy was available, compared to current practice.  
Methods 
A three-arm cluster randomized trial was conducted in 46 facilities in Centre and North-west 
Cameroon. Basic training had a practical session on RDTs and lectures on malaria treatment 
guidelines. Enhanced training included small-group activities designed to change health 
workers’ practice and reduce consumption of antimalarials among test-negative patients. The 
primary outcome was the proportion of febrile patients correctly treated: febrile patients should 
be tested for malaria, artemisinin combination therapy should be prescribed for confirmed 
cases, and no antimalarial should be prescribed for patients who are test-negative. Individual 
patient data were obtained from facility records and an exit survey. Costs were estimated from a 
societal perspective using project reports and patient exit data. The analysis used bivariate 
multilevel modelling and adjusted for imbalance in baseline covariates.  
Results 
Incremental cost per febrile patient correctly treated was $8.40 for basic and $3.71 for 
enhanced arms. Upon scale-up it was estimated RDTs with enhanced training would save 
$0.75 per additional febrile patient correctly treated.  
Conclusion 
Introducing RDTs with enhanced training was more cost-effective than RDTs with basic training, 
when each was compared to current practice.    
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INTRODUCTION 
In 2010 the World Health Organization (WHO) updated malaria treatment guidelines to confirm 
that rapid diagnostic tests (RDTs) are a valid alternative to testing using microscopy and to 
recommend parasitological testing in all patients before prescribing an antimalarial (1). Interest 
in RDTs has intensified and governments across sub-Saharan Africa are now deciding how to 
expand access to malaria testing, and whether to introduce RDTs in health facilities that already 
offer malaria testing using microscopy. These policy decisions will require revisions to national 
malaria treatment guidelines and supporting interventions that ensure the policy change is 
accompanied by a change in health workers’ practice. 
In malaria endemic areas, cases of uncomplicated malaria are routinely treated in primary 
health facilities and hospital outpatient departments, and clinical guidelines advise that in high 
transmission settings malaria should be suspected in patients who present with a fever or report 
having a fever in the past 24 hours (1). Malaria testing is advised, since malaria symptoms are 
non-specific and the fever may have other causes. However, microscopy requires a laboratory 
and technicians able to prepare and read blood slides and these are often limited in low-income 
settings. Consequently, it has become common for health workers to make treatment decisions 
based on symptoms alone and for antimalarials to be presumptively prescribed to febrile 
patients.  
RDTs offer considerable potential to transform malaria diagnosis and treatment since they do 
not require a laboratory and can be used with minimal training. However, this potential will only 
be realized if health workers’ prescribe treatment based on the test result. Evidence from 
several countries, including Cameroon, suggests the reliance on a presumptive malaria 
diagnosis has created a mindset among health workers and patients that febrile illness should 
be treated with an antimalarial and it is not uncommon for antimalarials to be prescribed to 
patients who tested negative for malaria (2-6).  
The economic argument for introducing RDTs critically depends on health workers’ practice (7, 
8). This assumption has been emphasized in several studies (7, 9, 10) and the sensitivity of the 
cost-effectiveness results to health workers’ practice has been illustrated using trial data from 
Tanzania (8). Results were also sensitive to the prevalence of malaria in febrile patients, 
specificity and sensitivity of the test, cost of testing and medicines, whether non-malaria febrile 
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illness were bacterial or self-resolving viral infections, the efficacy of antimalarials and antibiotics 
taken, and whether patients take medicines as advised (9). The literature shows that RDTs tend 
to be more cost-effective than microscopy, when each are compared to a presumptive 
diagnosis (7, 11, 12), while the cost-effectiveness of RDTs compared to microscopy depends on 
the relative cost of the tests, as well as their specificity and sensitivity in routine use (10, 13-15).  
In order to improve malaria diagnosis and treatment using RDTs in Cameroon, interventions 
were designed following formative research with patients and health workers in two regions of 
Cameroon (3, 6, 16). The formative research showed microscopy was available in the majority 
of public and mission facilities, but was under-used and less than 50% of febrile patients were 
tested for malaria (6).Malaria was over-diagnosed: 73% of febrile patients received an 
antimalarial yet malaria was present in only 30% of febrile patients tested by the study team (6). 
Moreover, patients often received an antimalarial regardless of the test result: 82% of patients 
who reported they tested negative for malaria were prescribed an antimalarial (6). Qualitative 
research also provided insight on health workers’ practice and highlighted both a mistrust of 
malaria test results and challenges in managing patient expectations (3).  
In collaboration with the National Malaria Control Programme (NMCP) of Cameroon, training 
modules were developed to support the introduction of RDTs in public and mission facilities. 
The basic training was intended to equip health workers with the knowledge and practical skills 
needed to diagnose and treat uncomplicated malaria, including how to conduct a RDT. As 
improving health workers’ adherence to the malaria treatment guidelines was a key objective, 
additional training was designed that used interactive methods and sought to address the gap 
between health workers’ knowledge and practice, and change prescribing behaviour. 
This paper reports the incremental cost per febrile patient correctly treated (according to the 
malaria treatment guidelines) of each intervention compared to current practice. Cost-
effectiveness was assessed from both a provider and a societal perspective. The analysis uses 
statistical methods suitable for individual patient data on costs and effects obtained from a 
cluster-randomized trial (17, 18). 
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METHODS 
Trial Design & Intervention 
A cluster randomized trial was designed to evaluate effectiveness and cost-effectiveness of 
introducing RDTs with basic or enhanced training in facilities where microscopy was available, 
compared to current practice. The three-arm cluster randomized trial was conducted at 46 
public and mission health facilities, which offered malaria microscopy testing, and were located 
in Centre and Northwest regions of Cameroon where malaria is endemic. The trial design and 
interventions are summarized here, and further details are available elsewhere (19, 20). The 
trial was registered (clinicaltrials.gov: NCT01350752), the study protocol is available (19), and 
the main trial paper has been published (20). The effect of the interventions on the proportion of 
febrile patients correctly treated according to the malaria treatment guidelines was measured by 
surveying febrile patients exiting health facilities.  
Facilities were stratified by site, randomly selected and allocated to one of three arms: control, 
basic and enhanced. There was no intervention at facilities in the control arm. Each facility in 
the two intervention arms was supplied 100 RDTs (SD Bioline Malaria Ag Pf/Pan, Standard 
Diagnostics, Yongin, South Korea) per month without charge. The brand and number of RDTs 
supplied was selected based on advice from the NMCP, and the test is reported to have a 
minimum detection rate of 97.5% for P. falciparum malaria, even at low levels of parasitemia 
(200 parasites/µl) (21).  
Each facility in the basic arm was invited to send three health workers to the one-day training 
course that was organised by the study team in each study site. The one-day training had three 
lectures on the revised malaria clinical guidelines and a practical session on how to use RDTs. 
In addition, three-day enhanced training workshops were held in each study site. The enhanced 
intervention replicated the basic intervention, but also contained an additional two days of 
training. The additional training used participatory methods to reinforce material covered in the 
basic training, whist also encouraging health workers to adapt to change, communicate 
effectively and support each other. For instance, trainers facilitated small-group work, and used 
problem-solving exercises, a treatment algorithm game, self-developed participatory drama and 
role-playing. The training courses were delivered by representatives from the NMCP and 
members of the study team. Copies of the training materials can be downloaded from the ACT 
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Consortium website (http://www.actconsortium.org/resources.php/82/training-manuals-from-
react-study-in-cameroon).  
Health workers that attended the basic and enhanced training courses were encouraged to hold 
training sessions at their facility (hereafter referred to as in-facility training) and inform their 
colleagues about RDTs and the revised malaria treatment guidelines. Members of the REACT 
team were invited to attend the in-facility training but they did not have a role in leading or 
facilitating the training. The trial was designed to approximate ‘real-world’ rather than controlled 
conditions, and it was possible, for example, that a facility encountered stock-outs of RDTs and 
artemisinin combination therapies (ACTs) during the evaluation. 
Effectiveness of Interventions 
The effect of the interventions was measured by the proportion of the febrile patients attending 
facilities who were correctly treated according to the revised malaria treatment guidelines. This 
was a composite measure which required all febrile patients to be tested for malaria using 
microscopy or RDT, patients to receive an ACT if they have a positive malaria test result, and 
patients not to receive an antimalarial if they have a negative malaria test result. Patients were 
invited to participate in an exit survey if they sought treatment for a fever at one of the facilities 
participating in the trial, were over six months old, not pregnant and did not have symptoms of 
severe malaria. With informed consent, the exit survey was administered by trained fieldworkers 
to the patient or their caregiver. A copy of the malaria test register in each facility was also 
obtained. Data collection took place between October and December 2011 and commenced 
three months after interventions were implemented. The effectiveness results have been 
submitted for peer-reviewed publication in an academic journal (20). 
Cost Measurement and Valuation 
The health care costs for each patient in the exit survey was estimated taking into account the 
direct and indirect costs incurred by the patient and caregivers to obtain care, net costs to the 
facility (adjusting for user fees) and the intervention cost. All costs were estimated in 2011 in 
Central African Francs (CFA) and converted to US dollars (USD) at 2011 prices, using a 
conversion rate of USD1 = CFA 471.87 (the official exchange rate for 2011, 
http://wdi.worldbank.org/table/4.16 accessed on 23 August 2013). 
8. RESEARCH PAPER V 
 
227 
 
Intervention cost 
Financial and economic costs of the training interventions were estimated from project reports 
and interviews with staff, using an ingredients-based approach (Table 3 and Appendix A). For 
the costing, the intervention was separated into the following activities: i) development of the 
training materials; ii) engaging with stakeholders; iii) training facilitators; iv) administration and 
implementation of the basic training; v) administration and implementation of the enhanced 
training; vi) in-facility training in which health workers train colleagues with support from project 
staff. For each of these activities, the amount of resources uses and their unit cost of was 
determined by referring to time sheets completed by staff members or project reports that 
documented either the number of items procured (e.g. stationery or refreshments) or the 
number of participants (e.g. per diems). Cost of transport and communications were also 
logged. The cost categories were: personnel, venue; intervention materials; stationery, 
refreshments; transport; communications; per diems, equipment and overheads. The cost of the 
equipment used was estimated based on the useful life of the equipment, a 3% discount rate, 
and the number of days the equipment was used. Overheads were estimated based on the cost 
of running the REACT office, taking into account rent and utilities. 
Start-up costs were incurred to develop the training materials and to engage national and local 
stakeholders on the training programme and revisions to the malaria treatment guidelines. One-
off implementation costs were incurred to train the trainers, administer and implement the 
training workshops, and hold in-facility training. The base-case scenario assumed one-off 
implementation costs would be incurred annually. Many activities to prepare for the basic and 
enhanced training were conducted simultaneously, and the cost that corresponds to each arm 
has been determined by estimating which costs would have been incurred if the interventions 
were independent (Appendix A). For example, the time spent developing training materials for 
the basic training workshop was assumed to be one third of the total cost since the basic 
training last a third of the length of the enhanced training. The cost of the in-facility training was 
estimated separately for each facility, based on the length of the training and number of health 
workers attending. RDTs were not included in the cost of the intervention, but were captured 
elsewhere. 
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The total annual economic cost of the intervention was estimated for each facility. Start-up costs 
of the training interventions were annualized over 4 years using a 3% discount rate, based on 
the assumption that the training materials would remain relevant for a minimum of 4 years (22). 
The economic costing also incorporated the time health workers spent at the in-facility training, 
for which there was no financial cost. The cost of the intervention per febrile patient was 
estimated by apportioning the total annual economic cost across all febrile patients who attend 
the facility each year, based on an estimate obtained from facility records. 
Cost of febrile illness 
Costs incurred by patients to diagnose and treat febrile illness were estimated for each 
individual participating in the exit survey and the mean cost per febrile patient was calculated. 
Exit survey respondents described the care received during the facility visit; and reported direct 
costs incurred for the consultation, tests undertaken and medicines received; direct cost of 
travel and other out-of-pocket expenses; and the time spent at the facility and for travel. The 
time of patients and caregivers was valued at the wage of an unskilled worker (CFA 1200 per 
day). 
The costs incurred by facilities to diagnose and treat each febrile patient were also estimated. 
The facility cost was estimated for each febrile patient using patient-reported information on the 
consultation, such as the cadre of health worker, malaria tests conducted (by microscopy or 
RDT), and medicines prescribed and dispensed. These data were combined with detailed unit 
cost data collected at selected facilities on the average health worker time and resource use per 
activity plus portion of overhead costs. The net facility cost per febrile patient was estimated by 
deducting the amount paid by the patient. In some cases the amount paid by the patient 
exceeded the cost to the facility (i.e. net facility cost was zero) though in other cases (often 
when the patient was under five years of age) the cost to the facility exceeded the fees paid. 
Cost-Effectiveness Analysis 
Incremental cost-effectiveness ratios (ICERs) for the basic and enhanced interventions, with 
each intervention compared to control, were calculated for the primary outcome (correctly 
treated according to guidelines) in an intention-to-treat analysis from both a provider and a 
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societal perspective. The ICERs represent the incremental cost for each additional febrile 
patient correctly treated.  
The cost-effectiveness analysis used individual patient-level data on costs and effects from the 
cluster-randomized trial, according to the latest methods (17, 18, 23). An initial examination of 
the data found correlation between costs and effects at the individual-level and cluster-level; 
and intra-cluster correlation in both costs and effects. In addition, although randomization of 
clusters to trial arms should negate the need to include individual-level and cluster-level 
covariates, there was imbalance in selected patient and facility characteristics across the three 
arms. For instance, there was a larger percentage of public facilities in the control arm (85.3%) 
than in basic (61.3%) and enhanced (56.7%) arms, and the control arm (36.7%) contained a 
larger percentage of patients and caregivers who had asked for a blood test than the basic 
(22.4%) and enhanced (21.3%) (Table 1). The incremental costs and effects were estimated 
using a bivariate multilevel model with covariates. This method simultaneously estimates the 
multilevel model for cost, cij, and the multilevel model for effect, eij: 
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where aj is the arm of the trial, xij are the individual-level covariates, zj are the cluster-level 
covariates, β1, β2, and β3 are the corresponding parameter for these variables, β0 is the 
constant, and eij and uj capture the individual-level and cluster-level variation. The individual-
level covariates were: the patient’s age; whether previous treatment had been sought for the 
illness episode, and whether the patient (or their caregiver) requested a blood test. The cluster-
level covariates were: study site; type of facility; the average number of patients that attend the 
facility per day; whether the facility had any stock outs of ACT in the past 4 weeks and the 
cluster size. By including covariates in the model (and thereby controlling for differences in 
individual and cluster characteristics by arm) the results report the incremental costs and effects 
that are associated with the arm of the trial. The assumption of normality was investigated for 
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costs and effects. The distribution of the costs was close to a normal distribution. We assumed 
a normal distribution for effects having considered the alternative specifications, and having 
confirmed the predicted probabilities from the linear probability model lay within the 0 to 1 
interval, and were similar to those from a logit model (24, 25). Statistical analysis was completed 
by running MLwiN 2.28 from Stata 12.1 (26). 
Confidence intervals for the ICERs cannot be interpreted because there were some 
observations with worse outcomes and higher costs and some with better outcomes and lower 
costs, and hence not reported. This is shown on a cost-effectiveness plane when bootstrap 
replications occurring in more than one quadrant.  
Cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs) were generated 
by bootstrapping the residuals from the bivariate multilevel models (17, 27). Bootstrapping is a 
well-established method for estimating uncertainty of parameter estimates in statistical models 
(27). For each costing perspective (provider and societal) and scenario (base-case and scale-
up), incremental costs and effects were obtained for 5000 bootstrap replications, both with and 
without adjustment for imbalance in patient and facility characteristics across the study arms 
(Figures 1-4). CEACs were generated to illustrate the probability that each intervention was 
optimal for a range of willingness-to-pay values, where the willingness to pay is the value placed 
on an additional person treated according to the malaria treatment guidelines (28). CEACs were 
obtained using the bootstrap replications of cost and effect (with adjustment for imbalance in 
patient and facility characteristics across the study arms). For each willingness to pay value (λ) 
the percentage of bootstrap replications for which the net monetary benefit (NMB = λ * effect – 
cost) is less than the willingness to pay value was estimated. This determines the probability 
that the intervention is cost-effective at a given willingness to pay threshold. CEACs have been 
presented in Figure 5, and this shows the incremental cost effectiveness of the two 
interventions compared to current practice for a given costing perspective and scenario. 
The base-case analysis estimated the cost-effectiveness of the interventions compared to 
current practice as implemented for the trial. The base-case included all start-up costs and 
implementation costs, assuming the training materials would remain useful for four years and 
the training would be held annually. The cost-effectiveness of the interventions were also 
considered in a ‘scale-up scenario’ in which the start-up costs were excluded because they 
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were a sunk cost, and it was assumed the training would be held every two years. These 
estimates should be useful for the Government of Cameroon in deciding whether to scale-up 
the introduction of RDTs with health worker training. 
Ethics Statement 
Ethical approval was obtained from the ethics committees of the London School of Hygiene and 
Tropical Medicine (No.5429) and Cameroon National Ethics Committee (No 030/CNE/DNM/09). 
Administrative clearance was obtained from the Ministry of Public Health (No. D30-
343/AAR/MINSANTE/SG/DROS/CRC/JA).  The trial is registered with clinicaltrials.gov 
NCT01350752. 
 
RESULTS 
The study took place between June and December 2011 and 46 facilities participated in the 
study. The basic and enhanced training was successfully delivered to 37 facilities in the 
intervention arms, and in-facility training was held in 34 facilities (15 of 18 in the basic arm, and 
all 19 in the enhanced arm) (Appendix A). Each month 100 RDTs were supplied to all facilities 
in the intervention groups for a period six months, which commenced at the end of the training 
and continued until all data collection was complete. Although facilities were asked not to 
charge more than 100 CFA ($0.20) per test, most facilities charged substantially more, with a 
mean charge of $3.10 in the basic arm and $2.43 in the enhanced arm. ACT was supplied by 
the government or mission central medical stores and availability was reasonably good through 
the study period. One of the 9 facilities in the control arm reported they offered rapid diagnostic 
testing, but they also reported stock outs of RDTs in the past month. We were told they had 
received RDTs as a donation and not part of the intervention and they did not receive any 
training in the use of RDTs. Additional information on the implementation and fidelity of the 
interventions has been described elsewhere (20). 
Study Population 
The effectiveness and cost-effectiveness of the basic and enhanced interventions were 
evaluated using 3982 eligible patients that completed the exit survey (Table 1). Patient 
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characteristics across the three arms of the trial show some differences in the age distribution of 
patients, and in the proportion that had previously sought treatment and asked for a blood test. 
Similarly, while facilities were randomly allocated to the trial arm, there were also some 
differences across the arms in the type of facility, the average number of febrile patients per day 
and percent of facilities that encountered stock-outs of ACT in the past 4 weeks. In other 
respects the facilities were comparable (Appendix B). 
Effects 
The proportion of febrile patients who were correctly treated according to the clinical guidelines 
was 42% in the basic arm and 55% in the enhanced arm, compared to 37% in the control arm 
(Table 2). This is a composite indicator, which requires febrile patients to be tested for malaria 
and for their treatment to be consistent with the malaria test result. Breaking down this indicator 
shows that the difference between the arms is largely in the treatment prescribed and received 
by patients who tested negative for malaria: 47% of patients in the basic arm and 68% in the 
enhanced arm were correctly treated compared to 14% in the control arm. There were also 
some differences in the malaria positivity rates across the arms, and the percent of patients with 
a positive result was higher when patients were tested using microscopy rather than RDT. It 
should be noted that all these results are unadjusted, and do not take into account the 
clustering or the imbalance in the baseline covariates, and more detailed analyses are 
presented elsewhere (20). 
Costs 
The financial cost of the basic training was $28,392 and the enhanced training was $63,127. A 
description of the resources used is provided in Appendix A. The start-up costs constitute a 
large proportion of the total financial costs (73% and 74% of the basic and enhanced 
interventions, respectively), which largely reflects the amount of time staff spent designing, 
piloting and refining the training materials.   
On the assumption that the training materials would remain useful for four years, the total 
annual economic cost was $14,481 for the basic training and $30,976 for the enhanced training 
(Table 3). The annual economic cost of the training workshops held by the NMCP and study 
team (including the training of facilitators) was $5,497 for two basic workshops that trained 50 
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health workers from 18 facilities, and was $12,100 for two enhanced workshops that trained 48 
health workers from 19 facilities. The economic cost of the in-facility training was on average 
$190 per facility in the basic arm and $328 per facility in the enhanced arm, and included the 
value of in-kind items and time of participating health workers. It was estimated that the total 
annual economic cost of the training interventions in a ‘scale-up’ scenario would be $4,662 for 
basic and $9,585 for enhanced training.  
The mean cost per febrile patient was estimated from a provider and societal perspective, and 
presented by study arm for both the base-case and scale-up scenarios (Table 4). The mean 
cost of the training per febrile patient in the base-case scenario was $0.52 in the basic and 
$1.12 in the enhanced arm (and falls to $0.16 and $0.35 respectively for the scale-up scenario). 
In the base-case scenario, the total cost per febrile patient in the base-case scenario was $1.28 
in the basic and $1.88 in the enhanced arm from a provider perspective and $13.47 in the basic 
and $13.69 from a societal perspective. The substantial difference between the provider and 
societal costs arises because patients pay user fees to access health care, which vary by facility 
and depend on the care received.  The average out-of-pocket costs relating to the consultation, 
tests conducted and treatment received was reported to be $8-10 per febrile patient. 
Cost-Effectiveness 
In the base-case scenario, the interventions were more costly but also more effective than 
current practice. From a provider perspective, the incremental cost per patient correctly treated 
was $10.13 for the basic and $6.70 for the enhanced intervention (Table 5). From a societal 
perspective, which includes any costs incurred by patients, the incremental cost per patient 
correctly treated was $8.40 for the basic and $3.71 for the enhanced intervention. Thus, it was 
more cost-effective to introduce RDTs with enhanced training, than basic training, when each 
intervention was compared to current practice.  
The cost of the intervention is reduced in the scale-up scenario, and the interventions become 
more cost-effective. From a provider perspective, incremental cost per patient correctly treated 
was $4.39 for the basic and $2.45 for the enhanced arm. From a societal perspective, 
incremental cost was $2.46 per patient correctly treated in the basic arm, while the enhanced 
had a net saving of $0.75 per additional patient correctly treated. 
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It is not appropriate to report confidence intervals for these incremental cost-effectiveness ratios 
because there are some instances were some observations with worse outcomes and higher 
costs and others with higher costs and worse outcomes. This is shown on the cost-
effectiveness planes with bootstrap estimates in all multiple quadrants. The cost-effectiveness 
planes are useful for illustrating the degree of uncertainty around the point estimate. 
An alternative approach is to estimate the net benefit of an intervention, though this depends on 
the willingness to pay threshold and there is no agreed willingness to pay threshold in 
Cameroon. Instead, CEACs are often used to illustrate the probability than an intervention is 
cost-effective at a range of willingness to pay thresholds. The probabilities that each 
intervention was cost-effective at different levels of the cost-effectiveness threshold, compared 
to current practice, are illustrated using CEACs (Figure 5). These graphs show that the basic 
intervention has the lowest probability of being cost-effective at all values from both a provider 
perspective and a societal perspective. Current practice has the highest probability of being 
cost-effective at very low threshold levels (less than $5), though as the threshold increases so 
does the probability that the enhanced intervention is cost-effective. The CEACs for the scale-
up scenario lie to the left of the base-case scenario, and in the scale-up scenario from a societal 
perspective the enhanced intervention has the highest probability of being cost-effective at all 
threshold values. The CEACs in the scale-up scenario lie to the left of the CEACs in the base-
case because the start-up costs associated with developing the intervention were treated as a 
sunk cost leading to a lower incremental cost in the scale-up scenario. As a result for each 
willingness to pay value the probability that the intervention is cost-effective is higher in the 
scale-up scenario than it is in the base-case. 
 
DISCUSSION 
The cluster randomized trial evaluated the introduction of RDTs at health facilities where 
microscopy was available with either basic or enhanced training. The interventions had a 
positive effect on health workers’ practice in the diagnosis and treatment of febrile illness, 
though were also more costly than current practice. The enhanced intervention was more cost-
effective than the basic intervention, when each intervention was compared to current practice, 
which indicates the additional two days of training represent good value for money. However, 
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since there is no established cost-effectiveness threshold in Cameroon, the question of whether 
it is cost-effective to introduce RDTs (with training) in health facilities where microscopy is 
already available will depend on the government’s willingness to pay for improvements in the 
diagnosis and treatment of febrile patients. The incremental cost of introducing RDTs with 
enhanced training for the trial was $3.71 per patient correctly treated from a societal perspective 
(2011 prices). Similar ICERs have been reported elsewhere (7, 10, 11, 13, 29). For instance, 
the incremental cost per patient correctly treated of replacing microscopy with RDTs in public 
health facilities was $3.6 in Ghana (2009 prices) (13), and in Uganda was $1.78 in low and $8.9 
in high malaria transmission areas (2011 prices) (11).  
Differences in study design should be noted, however, when comparing results, and our study 
was distinctive for several reasons. First, RDTs were introduced to complement rather than 
replace malaria microscopy, since existing laboratory services were expected to continue in 
Cameroon. Second, we included the costs of training health workers and distributing revised 
guidelines since the NMCP indicated changes in policy would need to be disseminated. The 
need for interventions that improve health workers’ adherence clinical guidelines was also 
identified in formative research and highlighted in the cost-effectiveness literature (3, 6, 8). 
Third, the study used individual patient-level data collected in a ‘real-world’ setting which meant 
the availability, use and quality of malaria testing was not controlled and there was variation 
among febrile patients in whether they were tested for malaria, the type of test used, the 
treatment prescribed and the prices charged. Finally, the analysis applied statistical methods 
that took into account the cluster randomized design, correlation between costs and effects, and 
imbalance between arms in baseline characteristics (17, 18). Several aspects of the study 
design should be noted when interpreting the effectiveness and cost-effectiveness results. The 
NMCP considered training as integral to the introduction of RDTs, and the evaluation was 
designed to focus on whether health workers’ adhered to the malaria treatment guidelines. As a 
result, it is not possible to distinguish the effect of introducing RDTs from the effect of the 
training, though the observed differences between the basic and enhanced arms suggest 
training alone can change health workers’ practice.  
Moreover, the study was not designed to assess specificity and sensitivity of the tests 
conducted and the primary outcome was measured using the test result recorded by health 
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workers. Disaggregating this outcome indicated there were similar results across the study arms 
in the proportion of febrile patients tested for malaria. This countered our expectations, as we 
had expected the interventions would encourage malaria testing but we also noted there had 
been a substantial increase in the use of testing since 2009 (6). 
The decision to focus on the treatment supplied in a single consultation, rather than the health 
outcome of the illness episode, also has limitations for the cost-effectiveness analysis and it 
would not have been possible to estimate the number of deaths (or disability-adjusted life-years) 
averted without making several assumptions about the specificity and sensitivity of each 
diagnostic methods, causes of non-malaria febrile illness, patient adherence to medication, or 
the costs and effects of subsequent treatment seeking. There are, however, plans to synthesize 
findings from this and other cost-effectiveness studies undertaken within the ACT Consortium 
(www.actconsortium.org), and the synthesis will include data on the accuracy of microscopy and 
RDT in routine use and data from following up febrile patients. 
The study was designed to approximate the ‘real world’, though the extent to which this can be 
achieved in the context of a trial could be questioned. For example, while the number and 
distribution of RDTs supplied was based on advice from the NMCP and sought to replicate the 
existing supply management systems, some modifications may be needed for nationwide 
implementation. The timing of the evaluation is a further consideration. The results reflect the 
situation three months post-implementation, but we do not know whether the effect of the 
interventions on health workers’ practice will be sustained.  
We considered a scale-up scenario to facilitate the governments’ decision on whether to roll out 
RDTs beyond the study sites. In this analysis the start-up costs incurred to develop the training 
were considered a sunk cost. Excluding start-up costs not only substantially reduces the cost of 
the intervention, but also increases the probability interventions were cost-effective. Moreover, 
from a societal perspective the results indicate it would be net saving to introduce RDTs with 
enhanced training, though there is uncertainty surrounding the point estimates.  
Finally, the findings highlight two areas for further research. First, differences in the malaria 
positivity rates by type of test should be explored as data from a limited sample of patients re-
tested by the study team indicated there were more false positives with microscopy than RDT. 
The observed differences are unlikely to affect the findings of this study, which assesses 
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whether the treatment prescribed was consistent with the test result recorded by the provider, 
however it would be valuable to understand the implications for health outcomes and the 
incremental cost-effectiveness of each diagnostic method in routine use. If there are more false 
positives when malaria is diagnosed using microscopy then the case for introducing RDTs with 
provider training may be strengthened, though the economic analysis would need to take into 
account the costs of treating non-malaria febrile illness as well as the cost savings from the 
overuse of ACT. 
Second, the patient cost of testing and treatment warrants further investigation. There was 
considerable variation in the cost of malaria diagnosis and treatment and the cost reported by 
patients was often high compared to the amount we estimated it cost health facilities to provide 
these services. It will be important to understand the extent to which cost is a barrier to 
treatment seeking. 
 
CONCLUSION 
It was more cost-effective to introduce RDTs with enhanced training than RDTs with basic 
training, when each was compared to current practice. The supplementary training improved 
health workers practice, especially in terms of reducing the consumption of antimalarials among 
test-negative patients. Since the trial concluded, the Government of Cameroon has revised the 
national malaria treatment guidelines to support the use of RDT and recommend all febrile 
patients are tested for malaria using microscopy or RDT. The NMCP has incorporated the 
enhanced training in their efforts to disseminate the policy change and health worker training is 
due to commence in January 2014.  
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Table 1: Patient and facility characteristics 
 
CURRENT 
PRACTICE 
BASIC ENHANCED 
 N=681 N=1632 N=1669 
PATIENT CHARACTERISTICS    
Patient’s gender    
   Male 45.8% 45.0% 44.0% 
   Female 54.2% 55.0% 56.0% 
Patient’s age    
   6-12 month 5.7% 7.7% 6.8% 
   1-4 years 28.9% 29.1% 29.8% 
   5-19 years 28.5% 22.7% 22.1% 
   20-39 years 19.2% 26.4% 26.2% 
   40+ years 17.3% 14.2% 15.2% 
Previously sought treatment for this illness 
episode 
   
   Yes 73.1% 59.5% 64.8% 
   No 26.9% 40.5% 35.2% 
Patient or caregiver asked for a blood test    
   Yes 36.7% 22.4% 21.3% 
   No 63.3% 77.7% 78.7% 
FACILITY CHARACTERISTICS    
Type of facility    
   Public 85.3% 61.3% 56.7% 
   Mission 14.7% 38.7% 43.3% 
Average number of patients at facility per day    
   Mean (Range) 20.5 (5-80) 45.1 (6-300) 51.3 (4-200) 
Facility had stock outs of artemisinin 
combination therapy (ACT) in past 4 weeks 
   
   Yes 14.8% 12.3% 6.0% 
   No 85.2% 87.7% 94.0% 
Study Site    
   Bamenda, Northwest region 58.7% 42.8% 46.6% 
   Yaoundé, Centre region 41.3% 57.2% 53.4% 
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Table 2: Summary of effects*  
 
CURRENT 
PRACTICE 
BASIC ENHANCED 
 N=681 N=1632 N=1669 
PRIMARY OUTCOME    
% of febrile patients who were correctly treated 
according to malaria guidelines 
36.8% 42.0% 55.0% 
Components of Primary Outcome:    
     % tested for malaria 79.2% 76.6% 78.6% 
     If malaria test-positive, % with ACT 75.6% 74.3% 75.8% 
     If malaria test-negative, % without an 
antimalarial 
13.7% 46.6% 68.2% 
MALARIA TEST TYPE AND RESULT†     
If tested for malaria, % tested using microscopy 100% 63.4% 57.3% 
     % positive if tested using microscopy 53.2% 39.7% 46.0% 
     % negative if tested using microscopy 45.9% 60.3% 54.0% 
If tested for malaria, % tested using RDT - 36.6% 42.7% 
     % positive if tested using RDT - 23.2% 30.6% 
     % negative if tested using RDT - 76.9% 69.4% 
TREATMENT PRESCRIBED OR RECEIVED    
Of those not tested: N=274 N=385 N=479 
     % with any antimalarial 90.4% 62.1% 55.3% 
     % with an ACT 75.6% 48.3% 47.8% 
     % with an antibiotic 69.6% 56.4% 52.8% 
Of those who tested positive for malaria: N=235 N=773 N=730 
     % with any antimalarial 96.7% 92.5% 94.4% 
     % with an ACT 75.6% 74.3% 75.8% 
     % with an antibiotic 39.1% 44.9% 42.6% 
Of those who tested negative for malaria: N=135 N=351 N=320 
     % with any antimalarial 86.3% 53.4% 31.8% 
     % with an ACT 81.3% 41.9% 22.9% 
     % with an antibiotic 71.5% 62.5% 63.4% 
 
RDT = rapid diagnostic test; ACT = artemisinin combination therapy 
* The results are unadjusted and do not take into account the clustering or the imbalance in the baseline 
covariates across the study arms. 
† From facility records. Across the three arms 144 patients were retested by the study team, with 92 
patients previously tested using microscopy and 52 tested using RDT. Of the 92 patients previously tested 
using microscopy, we found 18 (20%) were true positive, 51 (55%) were true negative, 22 (24%) were 
false positives and 1 (1%) was false negative. Of the 52 patients previously tested using RDT, we found 10 
(19%) were true positive, 37 (71%) were true negative, 4 (8%) were false positives and 1 (2%) was false 
negative. 
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Table 3: Financial and economic costs of the basic and enhanced training (USD, 2011 
prices) 
 FINANCIAL COST* ANNUAL ECONOMIC COST 
  BASE-CASE† SCALE UP‡ 
 BASIC ENHANCED BASIC ENHANCED BASIC ENHANCED 
START-UP       
Develop training 
(including 
stakeholder 
engagement) 
20,670 46,970 5,561 12,636 0 0 
TRAINING 
WORKSHOP 
      
Train facilitators & 
hold workshops 
5,497 12,100 5,497 12,100 2,873 6,324 
IN-FACILITY 
TRAINING 
      
Health workers’ 
train colleagues 
2,225 4,057 3,423 6,240 1,789 3,261 
TOTAL COST 28,392 63,127 14,481 30,976 4,662 9,585 
 
* Financial costs incurred to design and implement training. 
† Start-up costs are treated as investment & annualized over 4 years. Assumes health workers are trained 
annually. Cost of in-facility training takes into account in-kind items and health workers’ time 
‡ Excludes start-up costs. Assumes health workers are trained every two years, thus implementation costs 
treated as investment & annualized over 2 years. Cost of in-facility training takes into account in-kind items 
and health workers’ time  
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Table 4: Mean cost per febrile patient (USD 2011 prices) 
 CURRENT PRACTICE BASIC ENHANCED 
 N=681 N=1632 N=1669 
 Mean (Min, Max) Mean (Min, Max) Mean (Min, Max) 
COST OF TRAINING a 
Base case - - 0.52 (0.04, 1.57) 1.12 (0.11, 5.44) 
Scale-up scenario - - 0.16 (0.01, 0.50) 0.35 (0.04, 1.73) 
COST OF FEBRILE ILLNESS INCURRED BY PATIENTS AND CAREGIVERS b 
Consultation b 1.10 (0.00, 16.11) 1.14 (0.00, 12.72) 1.55 (0.00, 8.48) 
Microscopy  b 3.97 (0.00, 20.13) 4.11 (0.00, 19.50) 3.42 (0.00, 20.13) 
Rapid Diagnostic 
Test (RDT) b 
-  3.10 (0.00, 19.50) 2.43 (0.00, 18.65) 
Treatment  b 3.77 (0.00, 20.66) 4.70 (0.00, 20.98) 4.16 (0.00, 20.98) 
Travel b 0.34 (0.00, 12.72) 0.51 (0.00, 10.60) 0.56 (0.00, 10.60) 
Other  
(including food) b 
0.20 (0.00, 14.83) 0.32 (0.00, 17.17) 0.23 (0.00, 11.23) 
Travel Time  
(return journey) c 
0.35 (0.00, 2.80) 0.30 (0.00, 4.77) 0.36 (0.00, 9.66) 
Time at Facility c 1.48 (0.04, 11.44) 2.07 (0.00, 6.48) 2.13 (0.00, 36.62) 
Total Costs to 
Patient 
10.49 (0.51, 41.96 12.18 (0.17, 45.99 11.80 (0.08, 41.07) 
COST OF FEBRILE ILLNESS INCURRED BY THE FACILITY d 
Consultation 1.51 (0.78, 2.48) 1.60 (0.78, 2.48) 1.56 (0.78, 2.48) 
Microscopy  
(if applicable)  
1.38 (1.38, 1.38) 1.38 (1.38, 1.38) 1.38 (1.38, 1.38) 
RDT (if applicable) -  1.71 (1.71, 1.71) 1.71 (1.71, 1.71) 
Treatment  
(if received) 
2.58 (0.38, 9.92) 2.22 (0.38, 16.91) 2.37 (0.38, 16.17) 
Total Cost to 
Facility 
4.82 (0.88, 12.61) 4.85 (0.78, 21.10) 4.88 (0.78, 19.19) 
Net Cost to 
Facility e 
0.77 (0.00, 9.11) 0.77 (0.00, 19.65) 0.76 (0.00, 16.86) 
TOTAL COST: PROVIDER PERSPECTIVE f 
Base case 0.77 (0.00, 9.11) 1.28 (0.04, 20.62) 1.88 (0.11, 18.68) 
Scale-up scenario 0.77 (0.00, 9.11) 0.93 (0.01, 19.96) 1.11 (0.04, 17.36) 
TOTAL COST: SOCIETAL PERSPECTIVE g 
Base case 11.27 (1.89, 41.96) 13.47 (2.32, 46.40) 13.69 (2.01, 44.21) 
Scale-up scenario 11.27 (1.89, 41.96) 13.11 (1.78, 46.12) 12.91 (1.81, 43.05) 
 
a) Total cost of intervention per facility (obtained from project reports, interviews with staff) divided by the 
number of febrile patients per facility per year (estimated from facility records) 
b) From patient exit survey. Patients reported the amount, including zero costs if the category was 
applicable. 
c) Time of patient (& caregiver if applicable). Amount of time, as reported in exit survey. Time valued at 
wage of an unskilled worker (Central African Franc, CFA 1200 per day or US $2.54). 
d) From facility costing undertaken at 9 facilities. Facility unit cost per activity was estimated taking into 
account use of HW time, equipment and supplies. Cost to facility per febrile patient was estimated exit 
survey data on resource use (e.g. if tested, type of test, medicines received) and average unit costs from 
facility costing. Cost per-patient takes into account the cadre of HW (as reported by the patient) for each 
activity, where possible. 
e) Total cost to facility less amount patient reported for consultation, test and treatment.  
f) Sum of Training Cost & Net Cost to Facility 
g) Sum of Training Cost, Patient Cost & Net Cost to Facility
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Table 5: Total and incremental costs and effects* 
 TOTAL COSTS AND EFFECTS 
INCREMENTAL COSTS AND 
EFFECTS 
 
Current 
Practice 
Basic Enhanced 
Basic vs. Current 
Practice 
Enhanced vs. 
Current Practice 
Effect  
(proportion of patients 
correctly treated) 
0.25 0.35 0.50 0.10 (0.03, 0.32) 0.25 (0.17, 0.47) 
PROVIDER PERSPECTIVE 
Cost (USD 2011)      
Base-case 0.56 1.62 2.24 1.06 (0.67, 2.08) 1.67 (1.24, 2.74) 
Scale-up 0.08 0.55 0.65 0.46 (0.10, 1.36) 0.56 (0.22, 1.43) 
Incremental cost per febrile patient correctly treated † 
Base-case - - - 10.13 6.70 
Scale-up - - - 4.39 2.25 
SOCIETAL PERSPECTIVE 
Cost (USD 2011)      
Base-case 9.83 10.68 10.76 0.85 (-0.12, 3.62) 0.92 (0.17-3.89) 
Scale-up 10.30 10.55 10.12 0.25 (0.77, 2.90) -0.19 (-1.31, 2.40) 
Incremental cost per febrile patient correctly treated † 
Base-case - - - 8.40 3.71 
Scale-up - - - 2.46 -0.75 
 
* Estimates from bivariate multilevel model, having adjusted for clustering, correlation between costs and 
effects and imbalance in patient and facility characteristics. The following covariates were included: 
patient’s age; whether previous treatment had been sought for the illness episode, and whether the patient 
(or their caregiver) requested a blood test; study site; type of facility; the average number of patients that 
attend the facility per day; whether the facility had any stock outs of ACT in the past 4 weeks and the 
cluster size. Full regression results are reported in Appendices C and D. 
† Confidence intervals for the ICERs were not reported because there were some observations with worse 
outcomes and higher costs and some with better outcomes and lower costs and they cannot be 
interpreted. 
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Figure 1: Cost-effectiveness Planes for the base-case from a provider perspective (with and without covariates to adjust for imbalance in patient and 
facility characteristics) 
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Figure 2: Cost-effectiveness Planes for the base-case from a societal perspective (with and without covariates to adjust for imbalance in patient and 
facility characteristics) 
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Figure 3: Cost-effectiveness Planes for the scale-up scenario from a provider perspective (with and without covariates to adjust for imbalance in patient 
and facility characteristics) 
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Figure 4: Cost-effectiveness Planes for the scale-up scenario from a societal perspective (with and without covariates to adjust for imbalance in patient 
and facility characteristics) 
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Figure 5: Cost Effectiveness Acceptability Curves 
 
 
  
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 5 10 15 20 25 30 35 40 45 50
P
ro
b
ab
il
it
y 
In
te
rv
en
ti
o
n
 is
 C
o
st
 E
ff
e
ct
iv
e
Willingness to Pay for an additional febrile patient treated according to malaria treatment guidelines 
(USD 2011 prices)
Cost-Effectiveness Acceptability Curve 
(Provider Perspective)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 5 10 15 20 25 30 35 40 45 50
P
ro
b
ab
il
it
y 
In
te
rv
en
ti
o
n
 is
 C
o
st
 E
ff
e
ct
iv
e
Willingness to Pay for an additional febrile patient treated according to malaria treatment guidelines 
(USD 2011 prices)
Cost-Effectiveness Acceptability Curve 
(Societal Perspective)
8. RESEARCH PAPER V 
 
251 
 
Appendix A: Financial Cost of Training Interventions (USD, 2011 prices) 
CATEGORY RESOURCES USED 
TOTAL 
COST 
ALLOCATION BY ARM 
BASIC ENHANCED  
START UP   46,970 20,670 46,970 
Development of training 
(including all materials) * 
Development and piloting of training materials took place over 6 months. In total used 2 months of 
senior staff; 38 months of project staff & 45 days of health worker (HW) time. Costs incurred for 3 
design workshops, commissioned artwork, travel and accommodation for pilot in Buea, intervention 
materials, stationery, office equipment and overheads 
39,450 13,150 39,450 
Engaging with 
stakeholders * 
Two workshops with 33 stakeholders were held in Yaoundé and Bamenda. To prepare and hold 
workshops used 3 days of senior staff time, 100 days of junior staff time & 33 days of stakeholder time. 
Costs incurred to invite participants, venue hire, intervention materials, refreshments, travel, stationery, 
office equipment and overheads 
7,520 7,520 7,520 
TRAINING WORKSHOP  16,461 5,497 12,100 
Training of Facilitators * 
Training workshop held with National Malaria Control Programme (NMCP) staff who would deliver 
training alongside project staff. In total used 2 days of senior staff; 78 days of project staff time & 4 days 
of NMCP staff time. Costs incurred for venue hire, intervention materials, refreshments, travel, 
stationery, office equipment and overheads 
3,409 1,136 3,409 
Administration and 
Implementation of Basic 
Training 
Two 1-day workshops were held in Yaoundé and Bamenda. 57 HWs from 19 facilities were invited and 
50 attended. To prepare and hold training used 50 days of project staff & 2 days of NMCP staff time. 
Costs also incurred for venue, intervention materials, refreshments, travel, stationery, office equipment 
and overheads. HWs received per diems to cover transport costs. 
4,361 4,361 - 
Administration and 
Implementation of 
Enhanced Training 
Two 3-day workshops were held in Yaoundé and Bamenda. 57 HWs from 19 facilities were invited and 
48 attended. To prepare and hold training used 66 days of project staff & 6 days of NMCP staff time. 
Costs incurred for venue, intervention materials, refreshments, travel, stationery, office equipment and 
overheads. HWs received per diems to cover transport costs. 
8,691 - 8,691 
IN-FACILITY TRAINING  6,282 2,225 4,057 
Health workers train their 
colleagues (with support 
from project staff) ‡ 
In-facility training occurred in15 of 18 (84%) facilities in the basic arm (totalling 8.5 days) and in all 19 
(100%) facilities in the enhanced arm (totalling 15.5 days). Resources used varied by facility with each 
training lasting between 0.5 and 2 days. 2 project staff attended each in-facility training. On average 20 
HWs attended each in-facility training. Costs were incurred for intervention materials, refreshments, 
stationery and travel. 
6,282 2,225 4,057 
TOTAL FINANCIAL 
COST  
 69,713 28,392 63,127 
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* Joint costs were incurred for these activities as they were undertaken simultaneously. For these activities, costs have been apportioned to the basic and enhanced arm on the basis 
of what costs would have been incurred if the interventions were independently developed and implemented. One-third of the costs incurred to i) develop the training materials and ii) 
train facilitators has been allocated to the basic arm since the training was one-third of the length of the enhanced training; while the total cost of these activities have been allocated to 
the enhanced arm. The total cost of engaging with stakeholders has been allocated to each arm since this cost would have been incurred if the training programmes were developed 
separately. 
‡ Estimated per facility based on uptake and length of in-facility training
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Appendix B: Characteristics of facilities (clusters) across the study arms 
 
Characteristics 
Control 
Nc=9† 
Basic 
Nc=18 
Enhanced 
Nc=19 
Stratum    
Bamenda 5 (56%) 8 (44%) 9 (47%) 
Yaoundé 4 (44%) 10 (56%) 10 (53%) 
Type of facility    
Public District Hospital 1 (11%) 6 (33%) 4 (21%) 
Public Health Centre 7 (78%) 5 (28%) 6 (32%) 
Mission Hospital 0 (0%) 0 (0%) 1 (5%) 
Mission Health Centre 1 (11%) 7 (39%) 8 (42%) 
Time established‡    
≤5 years 1 (11%) 2 (12%) 2 (12%) 
> 5 years 8 (89%) 15 (88%) 15 (88%) 
Number of patients per day    
Median (Inter-quartile range) 8 (5 – 10) 20 (15 – 30) 30 (10 – 75) 
Number of clinicians (median, range)    
Who regularly work at the facility 17 (4, 32) 16 (4, 35) 11 (4, 61) 
Who are involved in treatment of malaria# 8 (2, 14) 8 (4, 18) 9 (4, 20) 
Cadre of clinician#    
Doctor 4 (44%) 9 (50%) 9 (47%) 
Nurse or midwife 8 (89%) 16 (89%) 14 (74%) 
Nurse or midwife assistant 5 (56%) 11 (61%) 12 (63%) 
Lab technician or assistant 8 (89%) 16 (89%) 19 (100%) 
Pharmacist 2 (22%) 1 (6%) 3 (16%) 
Pharmacy technician or assistant 7 (78%) 15 (83%) 14 (74%) 
Services available    
Weighing scale 8 (89%) 18 (100%) 18 (95%) 
Functioning thermometer 8 (89%) 17 (94%) 15 (79%) 
Functioning microscope## 9 (100%) 18 (100%) 18 (95%) 
Malaria microscopy testing## 9 (100%) 18 (100%) 19 (100%) 
RDT, ACT & antibiotic availability    
ACTs currently in stock 8 (89%) 18 (100%) 19 (100%) 
Stock-outs of ACTs in past 4 weeks 1 (11%) 2 (11%) 1 (5%) 
ACT supply problems in past year 2 (22%) 3 (17%) 3 (17%) 
RDTs currently in stock§ 1 (13%) 8 (47%) 13 (72%) 
Stock-outs of RDTs in past 4 weeks§ 1 (13%) 10 (59%) 10 (56%) 
Antibiotics currently in stock 8 (89%) 16 (89%) 18 (95%) 
Notes:  Numbers and percentages are presented unless stated otherwise. Percentages may not add to 
100 due to rounding. 
† Nc represents the number of clusters (facilities).   
‡ All facilities had been established for a minimum of 3 years. The number of years ago the facility was 
established was not known for one facility in the basic arm and two facilities in the enhanced arm.   
# Clinicians who diagnose, prescribe or dispense malaria treatment at the facility.  
## One facility noted that they provided microscopy testing but they did not have a functioning microscope.  
All facilities that offered malaria microscopy testing had at least one laboratory technician or assistant who 
regularly worked at the facility, except four facilities in the enhanced arm for whom this information is not 
known. 
§ The facility/provider questionnaire (PQ) was conducted after the last delivery of RDTs by the research 
team.  Information missing for one facility in the basic and one facility in the enhanced arm.  One facility in 
the control arm received RDTs as a donation and not as part of the REACT intervention.  They did not 
receive any training associated with using the RDTs. 
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Appendix C: Bivariate multilevel regression results for the base-case 
  Base-case from provider perspective Base-case from societal perspective 
  coefficient standard error p-value coefficient standard error p-value 
COSTS (USD)        
Arm Basic 1.06 0.53 0.048 0.85 1.38 0.539 
 Enhanced 1.67 0.54 0.002 0.92 1.40 0.510 
Age group 6-12 month 0.24 0.11 0.029 -0.33 0.37 0.374 
 1-4 years 0.42 0.11 0.000 0.78 0.38 0.040 
 5-19 years 0.21 0.11 0.068 0.77 0.38 0.042 
 20-30 years 0.12 0.12 0.327 1.40 0.41 0.001 
First time sought treatment Yes 0.04 0.06 0.491 0.00 0.21 0.988 
Asked for blood test Yes 0.04 0.07 0.617 0.73 0.25 0.003 
Study site Bamenda 0.35 0.40 0.381 0.76 1.04 0.465 
Facility type Public 0.59 0.45 0.183 2.95 1.15 0.010 
Stock outs of ACT in past 4 weeks Yes -0.13 0.68 0.849 -0.07 1.76 0.967 
Patients per facility Mean -0.01 0.00 0.011 0.01 0.01 0.582 
Cluster size Cluster size 0.00 0.02 0.844 0.11 0.05 0.045 
 Cluster size squared 0.00 0.00 0.022 0.00 0.00 0.047 
Constant constant 0.56 0.52 0.279 9.83 1.37 0.000 
EFFECTS        
Arm Basic 0.10 0.11 0.345 0.10 0.11 0.361 
 Enhanced 0.25 0.11 0.026 0.25 0.11 0.027 
Age group 6-12 month 0.06 0.03 0.049 0.06 0.03 0.050 
 1-4 years 0.04 0.03 0.174 0.04 0.03 0.178 
 5-19 years 0.04 0.03 0.193 0.04 0.03 0.196 
 20-30 years 0.00 0.03 0.910 0.00 0.03 0.981 
First time sought treatment Yes 0.04 0.02 0.040 0.04 0.02 0.041 
Asked for blood test Yes 0.07 0.02 0.001 0.07 0.02 0.001 
Study site Bamenda -0.09 0.08 0.307 -0.09 0.08 0.305 
Facility type Public -0.03 0.09 0.782 -0.03 0.09 0.742 
Stock outs of ACT in past 4 weeks Yes 0.12 0.14 0.399 0.12 0.14 0.398 
Patients per facility Mean 0.00 0.00 0.068 0.00 0.00 0.072 
Cluster size Cluster size 0.00 0.00 0.548 0.00 0.00 0.549 
 Cluster size squared 0.00 0.00 0.100 0.00 0.00 0.102 
Constant constant 0.24 0.11 0.026 0.25 0.11 0.025 
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Appendix D: Bivariate multilevel regression results for the scale-up scenario 
  Scale-up scenario from provider perspective Scale-up scenario from societal perspective 
  coefficient standard error p-value coefficient standard error p-value 
COSTS (USD)        
Arm Basic 0.46 0.48 0.340 0.25 1.39 0.858 
 Enhanced 0.56 0.49 0.250 -0.19 1.41 0.894 
Age group 6-12 month 0.24 0.11 0.030 -0.33 0.37 0.374 
 1-4 years 0.42 0.11 0.000 0.78 0.38 0.040 
 5-19 years 0.21 0.11 0.068 0.77 0.38 0.041 
 20-30 years 0.12 0.12 0.325 1.41 0.41 0.001 
First time sought treatment Yes 0.05 0.06 0.468 0.01 0.21 0.969 
Asked for blood test Yes 0.04 0.07 0.597 0.74 0.25 0.003 
Study site Bamenda -0.03 0.36 0.944 0.38 1.05 0.713 
Facility type Public 0.51 0.40 0.200 2.88 1.16 0.013 
Stock outs of ACT in past 4 weeks Yes -0.16 0.61 0.795 -0.10 1.77 0.955 
Patients per facility Mean -0.01 0.00 0.085 0.01 0.01 0.350 
Cluster size Cluster size 0.00 0.02 0.959 0.11 0.05 0.037 
 Cluster size squared 0.00 0.00 0.023 0.00 0.00 0.059 
Constant constant 0.09 0.47 0.853 10.30 1.38 0.000 
EFFECTS        
Arm Basic 0.10 0.11 0.346 0.10 0.11 0.360 
 Enhanced 0.25 0.11 0.026 0.25 0.11 0.027 
Age group 6-12 month 0.06 0.03 0.050 0.06 0.03 0.050 
 1-4 years 0.04 0.03 0.175 0.04 0.03 0.178 
 5-19 years 0.04 0.03 0.195 0.04 0.03 0.196 
 20-30 years 0.00 0.03 0.916 0.00 0.03 0.979 
First time sought treatment Yes 0.04 0.02 0.041 0.04 0.02 0.041 
Asked for blood test Yes 0.07 0.02 0.001 0.07 0.02 0.001 
Study site Bamenda -0.09 0.08 0.306 -0.09 0.08 0.305 
Facility type Public -0.03 0.09 0.778 -0.03 0.09 0.742 
Stock outs of ACT in past 4 weeks Yes 0.12 0.14 0.400 0.12 0.14 0.398 
Patients per facility Mean 0.00 0.00 0.068 0.00 0.00 0.072 
Cluster size Cluster size 0.00 0.00 0.548 0.00 0.00 0.548 
 Cluster size squared 0.00 0.00 0.101 0.00 0.00 0.102 
Constant constant 0.24 0.11 0.026 0.25 0.11 0.025 
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9.  Discussion and Conclusion 
 
This Chapter summarises the overall findings of the thesis and describes the contribution 
of the research. The limitations of the thesis are acknowledged and areas for further 
research are outlined. The Chapter concludes by considering the implications of the 
research for the design and evaluation of interventions to encourage providers to adhere 
to malaria treatment guidelines and on malaria treatment policy in Cameroon and the 
generalizability of the findings to other settings. 
9.1. Introduction 
Working as agents for their patients, health care providers are often responsible for 
diagnosing the illness and selecting treatment. Clinical guidelines establish standards for 
patient care and can expedite the introduction of new technologies or changes in policy. 
Conventional public health interventions typically focus on ensuring providers are 
informed about changes to clinical guidelines, though studies that have evaluated their 
effect suggest they may have a limited impact in changing providers’ practice and patient 
care often falls short of the required standard. 
The thesis is on the knowledge, preference and practice of providers treating febrile 
patients with suspected malaria in Cameroon and Nigeria. In this setting uncomplicated 
malaria is routinely diagnosed and treated by health workers in outpatient departments 
and primary health centres, or treated using antimalarials purchased from pharmacies 
and drug stores. Drawing on economic theory, research was undertaken to design and 
evaluate interventions to support the roll out malaria RDTs and train providers on revised 
malaria treatment guidelines. Providers’ stated and revealed preferences were analysed, 
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when providers have imperfect information and are agents in multiple agency 
relationships. The cost-effectiveness of interventions designed to improve providers’ 
adherence to clinical guidelines was evaluated. 
The specific objectives were: 
 To describe the treatment supplied to febrile patients at health facilities and 
medicine retailers in Cameroon and Nigeria. 
 To assess providers’ knowledge of the national malaria treatment guidelines and 
investigate the determinants of providers’ stated preference for treating 
uncomplicated malaria. 
 To examine the determinants of providers’ revealed preference (i.e. their practice) 
for treating patients with malaria symptoms. 
 To evaluate the cost-effectiveness of interventions to improve providers’ practice 
in diagnosing and treating uncomplicated malaria at public and mission facilities in 
Cameroon. 
9.2 Summary of the research findings 
Research Papers I and II report the main findings from exit surveys with febrile patients 
and their caregivers conducted at different types of facility in Nigeria and Cameroon [1, 2]. 
These papers highlight considerable problems with the treatment supplied. Although ACT 
had been the first-line treatment for uncomplicated malaria for more than four years, ACT 
was under-used in both settings. In Nigeria less than a quarter of febrile patients were 
presumptively supplied an ACT and most patients received sulphadoxine-pyrimethamine 
(SP), which is much less effective. The situation was more favourable in Cameroon and 
ACT was the dominant choice, though only 51% of febrile patients eligible for malaria 
treatment were supplied ACT. Malaria testing had limited availability in Nigeria, and while 
microscopy testing was available at most public, mission and private health facilities in 
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Cameroon, it was under-used. Moreover, when patients were tested there appeared to be 
no relationship between the test result and the treatment prescribed. Independent malaria 
testing conducted by the Cameroon study team indicated malaria was prevalent in less 
than one in three febrile patients, yet 82% of patients who were tested during their 
consultation and did not have malaria, received an antimalarial. 
As patients often rely on providers to select as well as dispense treatment, I was interested 
in the relationship between providers’ knowledge of the malaria treatment guidelines, 
their preference over alternative antimalarials, and their actual practice. The descriptive 
statistics suggested a knowledge-practice gap, since the proportion of patients receiving 
an ACT appeared low when compared to the proportion of providers who correctly 
identified ACT as the recommended treatment for uncomplicated malaria. However, no 
conclusions could be drawn from these initial analyses because the study population 
included individuals who requested a specific medicine, as well as individuals who relied 
on the providers’ advice. Also, exit survey responses had not been linked to the details of 
the specific provider who selected treatment and provider attributes were aggregated at 
the facility level in the regression analysis. 
To explore providers’ stated and revealed preferences over alternative antimalarials, 
secondary analyses of the provider and exit survey data were undertaken (Research 
Papers III and IV) [3, 4]. I wanted to understand what treatment providers’ prefer to 
supply when they are not constrained by the resources available or patient-specific 
factors. This would indicate whether an intervention targeting providers’ knowledge 
would be likely to achieve a change in providers’ practice, or whether additional 
intervention would be needed to first change what they prefer. Hence, I decided to focus 
on their stated preference over alternative antimalarials as well as the treatment actually 
supplied. Research Paper III presents multilevel analysis on influences over providers’ 
stated preferences, and showed that the type of antimalarial they prefer not only 
depended on their knowledge of clinical guidelines, but also their perceptions of what 
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patients’ prefer, and on drug company representatives, colleagues and other providers 
working in the locality [3]. These findings suggested interventions to disseminate changes 
in drug policy should acknowledge that providers are agents serving multiple principals 
and involve a wide range of actors, including employers, suppliers and local communities. 
Research Paper IV focused on the relationship between providers’ knowledge and practice 
in Cameroon and Nigeria [4]. Providers’ adherence to malaria treatment guidelines was 
examined using exit survey data from the subset of patients who relied on the provider to 
select treatment and were supplied an antimalarial. For this analysis exit survey responses 
were linked to the individual provider who supplied treatment, and two-level multiple 
imputation was used to impute missing data that arose when identifying the provider 
responsible for selecting treatment. In both countries, there was a gap between providers’ 
knowledge and practice, since providers’ decision to supply ACT was not significantly 
associated with their knowledge of the first-line antimalarial. Providers were, however, 
more likely to supply an ACT if they stated a preference for treating uncomplicated 
malaria with ACT (rather than other antimalarials). Other factors were country-specific, 
and indicated that providers can be influenced by what they perceived their patients’ 
prefer or can afford, as well as information about their symptoms, previous treatment 
seeking, the type of outlet, and the availability of ACT. 
Interventions were developed to improve providers’ practice in diagnosing and treating 
uncomplicated malaria in both countries, though the remainder of the thesis focused on 
developments in Cameroon. Policy-makers in Cameroon were interested in malaria RDTs, 
and it was agreed interventions should be developed to support their introduction at 
public and mission health facilities.  The interventions for Cameroon were selected and 
designed based on formative research, which included Research Papers II, III and IV, 
qualitative research (Appendix B) and a literature review (Section 2.2) [1, 3-5]. The 
findings emphasized the need to improve providers’ practice when diagnosing and 
treating uncomplicated malaria, and suggested that conventional approaches, such as a 
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training workshop to inform providers of the change in malaria treatment guidelines may 
have a limited effect on the treatment prescribed following a negative malaria test result. 
The interventions developed to improve providers’ practice in diagnosing and treating 
malaria were evaluated using a cluster-randomized trial (Appendix C).  Public and mission 
health facilities in the study sites were randomly allocated to one of three arms: basic, 
enhanced and control. Facilities in the basic and enhanced arms were supplied RDTs each 
month and up to three providers per facility were trained on the basic knowledge and 
practical skills needed to effectively diagnose and treat malaria. Providers in the enhanced 
arm also received two-days of supplementary training using participatory methods that 
explicitly sought to change providers’ practice. The proportion of patients who were 
tested for malaria and the proportion of patients with a positive test result who were 
prescribed or received an ACT were similar across the study arms. However, the 
proportion of patients with a negative test result who were prescribed or received an 
antimalarial was significantly reduced in the enhanced arm, and non-significantly reduced 
in the basic arm. Stratum-specific relative risk results indicate the interventions were 
more effective in Bamenda than in Yaoundé in reducing over-treatment with antimalarials 
among those who tested negative for malaria (as shown in Table 3 of Appendix C), though 
as the sample size in some clusters was too small to do an adjusted analysis we are 
cautious about drawing conclusions.  
The economic evaluation of interventions to improve providers’ practice in diagnosing and 
treating patients with malaria symptoms presenting at public and mission health facilities 
in Cameroon was presented in Research Paper V [6]. This paper considers the economic 
argument for introducing RDTs with training in a setting where microscopy testing was 
already available. The analysis used individual patient data on costs and effects and took 
into account the cluster-randomized study design. The incremental cost per febrile patient 
correctly treated was US$ 8.40 for the basic arm and US$ 3.71 for the enhanced arm (in 
2011 prices), which demonstrated that introducing RDTs with enhanced training was 
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more cost-effective than RDTs with basic training, when each was compared to current 
practice. Moreover, in a ‘scale-up’ scenario, which excluded the costs of intervention 
design, it was estimated the enhanced intervention would save US$ 0.75 per additional 
febrile patient correctly treated if the government adopted and implemented the training 
in Cameroon.  
9.3 Overall contribution of the thesis 
9.3.1 Economics perspective on a public health problem 
This thesis approached a common public health problem, how to improve providers’ 
performance and encourage adherence to malaria treatment guidelines, from an 
economics perspective. Approaching the problem from this perspective led me to question 
whether providers would always act in the patient’s interest and supply the treatment 
recommended in the clinical guidelines, which is an assumption that underpins many 
public health interventions. Agency theory was the starting point for examining the 
knowledge-practice gap, as the theory emphasizes how provider behaviour may depend 
on financial incentives and intrinsic motivation as well as information and structural 
constraints, such as access to clinical guidelines or the medicines available. Thinking from 
behavioural economics and new institutional economics was also valuable, as it indicates 
that individuals may be bounded in their ability to make rational utility-maximizing 
decisions and constrained by the institutional and social context. Although the extent to 
which these theories could be tested was limited by the data available, I was able to 
demonstrate that there was no significant relationship between providers’ knowledge and 
their practice, and that preferences were similar among providers working in the same 
facility or locality.  
These findings complement the existing literature on the behaviour of providers 
diagnosing and treating uncomplicated malaria. Existing studies focused on the treatment 
prescribed at public and mission facilities, and investigated the effect of pre-service 
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training, in-service training, and access to clinical guidelines rather than directly assessing 
whether knowledge predicts practice [7-18]. In addition, most studies used generalised 
estimating equations to account for the hierarchical data structure and potential 
correlation among patients treated by the same provider. This method generates 
population-averaged estimates, rather than subject-specific effects, and so the extent to 
which unexplained variation reflected differences between providers or facilities was 
unknown.  
Variation in providers’ practice has, however, been studied in the context of other illnesses 
and health conditions. Wennberg coined the term ‘practice style’ to describe the variation 
in prescribing practices attributed to providers’ preference over alternative forms of care 
[19], and economists have previously used multilevel modelling to assess, among other 
things, the effect of competition and remuneration systems on doctors’ behaviour [20-22]. 
Moreover, the distinction between providers’ competence and practice has been 
highlighted in work undertaken on quality of care in low-income settings by Das, Leonard 
and others [23-25]. I also recognise that this thesis contributes to a much larger body of 
work on patient-provider interactions, which has a long history and has been approached 
from many different disciplines. For example, there are anthropological models of 
behaviour change, such as social learning theory in which behaviour change results from 
observing and imitating others [26], and literature on the role of social expectations and 
trust within patient-provider relationships [27-29]. 
9.3.2  Theory-based intervention design 
The research undertaken for this thesis made a substantial contribution to the selection 
and design of interventions to improve the diagnosis and treatment of uncomplicated 
malaria in both countries, though especially in Cameroon. The analysis of providers’ 
revealed preference showed that an intervention should focus on ensuring that providers’ 
preferences are consistent with the treatment guidelines, rather than simply informing 
them about recommended practice. The analysis of providers’ stated preference over 
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alternative antimalarials highlighted the influence of multiple principals, including 
patients, suppliers and other providers. These findings led me to hypothesize that 
conventional educational interventions, which typically involve training providers to 
inform them about revisions to the malaria treatment guidelines, would have a limited 
effect on prescribing practice in Cameroon. 
In early discussions, representatives from the National Malaria Control Programme in 
Cameroon indicated they were considering introducing malaria RDTs in public and 
mission facilities. It was agreed this could be explored by REACT, and that the intervention 
should train providers in how to use the new type of test and interpret the result, and 
should be easy to replicate and suitable for implementation on a national scale. 
Given the findings from the formative research, a three-arm cluster randomized trial was 
proposed, in which two interventions: i) supplying RDTs with ‘basic’ training, and ii) 
supplying RDTs with ‘enhanced’ training, would be compared to current practice in health 
facilities where microscopy was available. The proposal to evaluate two types of training 
interventions arose from the hypothesis that the intervention would be more effective, 
and more cost-effective, if it sought to change providers’ preference, rather than enhance 
their knowledge. 
The activities included in the two supplementary days of enhanced training were chosen 
to reinforce the key messages about malaria diagnosis and treatment, but also based on 
the insights on who or what influenced providers’ preference. For example, a testimonial 
on rapid diagnostic testing from a senior medical doctor was included since providers may 
be influenced by other health workers. Similarly, many of the activities used small-group 
exercises in which providers worked together to discuss challenges and identify possible 
solutions, while a module on communicating effectively with patients was included as 
providers can be influenced by their perception of what their patients prefer. The 
communications module included an activity in which providers had the opportunity to 
reflect and discuss patient perceptions about malaria, and also a series of role-playing 
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activities to generate ideas on how they could better manage patient expectations, 
especially when the patient tested negative for malaria. 
Providers who had attended the training were encouraged to conduct ‘in-facility’ training 
and run training workshops with their colleagues using the knowledge and skills they had 
obtained and the training materials provided by REACT. This peer-to-peer learning was a 
relatively inexpensive method of extending the dissemination efforts, but also sought to 
build consensus within a facility on appropriate treatment of malaria. This was thought to 
be important because stated and revealed preferences were similar among providers 
within a facility, and the economics literature emphasized the importance on behavioural 
norms within an institutional environment. 
Finally, having interventions founded on economic theory and extensive empirical analysis 
was important for generating specific hypotheses for how the intervention would lead to a 
change in providers’ practice. These hypotheses were illustrated in a logic model (Section 
3.2, Figure 3). This depicts the mechanisms by which the training interventions were 
expected to change providers’ knowledge, preference and practice. The logic model 
proved to be a powerful communication tool, and was used within the research team, with 
colleagues in the ACT Consortium, and stakeholders at the NMCP. The logic model also 
facilitated a theory-based approach to the evaluation. It was used to map the evaluation 
data that would be needed to assess the intermediate as well as output indicators, and in 
the development of research instruments.  
9.3.3 Demonstrating the explanatory potential of multilevel modelling 
Multilevel modelling was used in three research papers: to analyse providers’ stated 
preferences, to assess the knowledge-practice gap, and to determine the cost-effectiveness 
of training interventions in improving providers’ practice. Multilevel modelling readily 
applies to economic and social research in which individual behaviour may depend on the 
influence of social groups or the social context in which they belong [30]. This can be 
conceptualized as a hierarchical system of individuals nested within groups, and 
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multilevel analysis examines the relationship between variables that characterize 
individuals and variables that characterize groups. Thus, multilevel models are suitable for 
examining variations in medical practice since they account for correlation between 
providers within a facility or area that may arise because they have similar incentives, 
share information and face a common institutional environment [31]. The intra-class 
correlation coefficients from Research Papers I-V are summarized in Appendix D. 
Alternative statistical methods can be used to account for data that have a hierarchical 
structure, and to ensure the point estimates and standard errors reflect the sampling 
design.  If the hierarchical structure was ignored, then standard errors are likely to be 
under-estimated, which may lead to results that appear statistically significant when in 
fact they are not. The first two research papers used the survey prefix (svy) in Stata 11.0 to 
account for the multistage sampling. This approach allowed me to obtain population-
representative estimates using survey data collected from a sample of the population. In 
each paper results were generated having specified the geographic areas that constituted 
the primary sampling unit, indicated that stratification was by study site, and using 
sampling weights to correct for unequal probability of selection. While this approach is 
widely used for analysing survey data and provides unbiased esimates of standard errors, 
it has limitations when compared to multilevel modelling. For example, multilevel models 
allow the analyst to ascertain the extent to which observed variation is attributable to 
different levels of the data hierarchy [30]. Multilevel models also explicitly model 
dependencies and cope well with unbalanced data structures [30, 31].  Moreover, 
multilevel models have been shown to generate robust estimates for cost-effectiveness 
analysis of cluster randomized trials in a wide range of simulated scenarios when 
compared to alternative methods, including seemingly unrelated regressions and 
generalized estimating equations [32].  
Multilevel modelling was used for the secondary analyses contained in Research Papers III 
and IV because I wanted to investigate subject-specific effects, between-group variability, 
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and the effects of group-level characteristics on individual outcomes. For example, 
multilevel modelling enabled me to determine the extent to which the variation in 
providers’ practice was explained by facility-level and patient-level factors, and the extent 
to which unexplained variation was partitioned among different levels of the hierarchy 
[33]. Thus, using a multilevel model allowed me to gain additional insights that were of 
relevance to the research questions in those chapters. In addition to the differences in the 
modelling approach adopted, the results from Research Papers III and IV cannot be 
directly compared to Research Papers I and II because of differences in the study sample.  
Each application of multilevel modelling raised different methodological considerations. 
Small cluster size was an important consideration in the analysis of providers’ stated 
preferences because some facilities were staffed by sole or very few providers. In building 
the model the degree of variability attributed to facility and area levels was assessed using 
the variance partition coefficient. In addition, the deviance and the likelihood ratio tests 
indicated that the three-level model was superior and the results were not sensitive to the 
estimation method. This analysis highlighted the value in estimating the variance partition 
coefficient and the importance of taking into account clustering, even when the average 
cluster size is small. 
Missing data was a feature of the analysis on providers’ knowledge and practice, since it 
was not possible to identify the individual provider who selected treatment for all exit 
survey responses. The missing data were presumed to be conditional on attributes of the 
facility or outlet, which is known as ‘missing at random’ in the statistical literature. 
Multiple imputation is recommended when data are missing at random, and it allows for 
uncertainty by generating multiple copies of datasets in which missing values are imputed. 
Multiple imputation methods are well established, though only relatively recently has 
statistical software become available that allows the multiple imputation to respect the 
data structure. Consequently, there are relatively few empirical examples demonstrating 
the use of two-level multiple imputation, and Research Paper IV should be a useful case 
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study for others facing similar challenges. It is also relatively unusual to use multiple 
imputation for missing survey data, and this application demonstrates the role for 
multiple imputation alongside multilevel modelling in the context of relational databases.  
The final application of multilevel modelling was for the cost-effectiveness analysis of the 
cluster randomized trial. This is also an area where there have been recent methodological 
developments, and there are relatively few empirical examples. Bivariate multilevel 
modelling is recommended for cost-effectiveness analysis when individual patient data 
are available and there may be intra-cluster correlation, correlation between individual-
level and cluster-level effects, and imbalance between the trial arms [32, 34]. Other 
considerations include the distribution of costs and effects, the number of clusters, cluster 
size, and imbalance in the number of observations per cluster. As an initial analysis of the 
data indicated intra-cluster correlation, correlation between costs and effects and 
imbalance in selected baseline characteristics across the three arms of the trial, the 
incremental costs and effects were estimated using a bivariate model with individual-level 
and cluster-level covariates. Given the paucity of examples using individual patient data 
from cluster randomized trials, particularly from low-income settings, Research Paper V 
may prove to be a useful example for other researchers. 
9.3.4 Evidence-based policy-making in Cameroon 
The REACT project worked closely with the National Malaria Control Programme (NMCP) 
throughout the project, and the research presented in this thesis has had a direct effect on 
malaria treatment policy in Cameroon.  
The interest in rapid diagnostic testing arose in early discussions with policy makers, as 
representatives of the NMCP explained they were considering whether to introduce RDTs 
in public and mission health facilities where microscopy testing was already available. 
Economic modelling studies had suggested it would be cost-effective to introduce RDTs 
where microscopy was already available in areas of low-to-medium malaria transmission, 
though also highlighted that the results required providers adhere to the test result when 
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prescribing treatment [35, 36]. The formative research was instrumental in highlighting 
the need for interventions to support the roll-out of RDTs that focused on changing 
providers’ practice, and as already discussed, the research findings contributed to the 
selection and design of the training interventions.  
NMCP representatives participated in intervention design and endorsed the training 
materials. NMCP representatives also worked hand-in-hand with the REACT research 
team to facilitate the basic and enhanced provider training workshops held in Yaoundé 
and Bamenda. This close collaboration with the NMCP helped to ensure the training 
interventions would be suitable for implementation on a large scale. 
Since the trial concluded in 2013, the Government of Cameroon has revised malaria 
treatment guidelines to recommend that all febrile patients are tested for malaria using 
either microscopy or RDTs. The evaluation demonstrated that the enhanced intervention 
was both more effective and more cost-effective than the basic intervention, when each 
was compared to the control arm (Research Paper V). Based on these findings, the 
Government of Cameroon has incorporated the enhanced training in their plans to roll out 
RDTs and disseminate the policy change. Nationwide training of providers at public health 
facilities commenced in January 2014. 
9.3.5 Generalizability 
While the research undertaken for this thesis was focused on improving malaria diagnosis 
and treatment in Cameroon and Nigeria, many of the findings have implications that will 
be relevant elsewhere. Taking a theory-based approach to intervention design had a 
number of advantages, as discussed earlier, and these would readily applicable to other 
settings. I would encourage researchers to ensure interventions are selected and 
developed based on a comprehensive understanding of the prevailing context, particularly 
when the intervention involves some aspect of behaviour change. Similarly, I believe it is 
good practice to clearly articulate the rationale for intervention and ensure assumptions 
about the causal mechanisms are explicit. 
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The problems identified in the diagnosis and treatment of malaria are not unique to 
Cameroon and Nigeria, and the lessons from this study should be useful for researchers 
and policy makers in other countries who want to expand access to malaria testing and 
improve patient care. The findings highlight the value of understanding the relationship 
between providers’ knowledge, preference and practice, and they demonstrate the 
economic rationale for introducing RDTs together with interventions that focus on 
changing prescribing behaviour. 
Finally, many of the ideas incorporated in the development of the enhanced training could 
be adapted in other geographic settings, or for training on other health topics. For 
instance, it would be conceivable to use participatory methods to reinforce the clinical 
guidelines in other applications. Similarly, the small-group sessions that encourage 
providers to adapt to change, communicate effectively and support each other could be 
tailored to another setting. In fact, some of the ideas developed in Cameroon were adapted 
and used in Nigeria to train providers from pharmacies and drug stores. The examples 
included the treatment algorithm game, and the exercises that used drama and role-
playing to improve providers’ communication with their clients. 
9.4 Limitations  
The research for the thesis was undertaken in the context of the REACT project. This had a 
number of benefits, not least an ability to undertake policy-orientated research and 
contribute to improvements in malaria diagnosis and treatment in Cameroon, though it 
also had some constraints. From the outset I knew I wanted to study for a PhD and that my 
research interests related to the behaviour and actions of health care providers, and the 
institutional environment in which they work. However, the focus on providers’ 
knowledge and preferences for treating uncomplicated malaria emerged following the 
primary analysis of the survey data from each country. While the findings suggested there 
may be a gap between providers’ knowledge of the guidelines and their practice, inference 
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was limited by the study population, which included patients and caregivers who 
requested a specific medicine, and because exit survey responses were not linked to the 
individual provider that supplied treatment.  
Secondary analysis of the survey data was undertaken to investigate some of the 
limitations of the primary analyses, however there were also some challenges with the 
data available. For example, it was necessary to use a subset of the exit survey responses 
for the analysis conducted on the knowledge-practice gap, and the sample size was limited 
to individuals who did not ask for a specific medicine and received an antimalarial. There 
were also challenges linking exit survey responses to individual providers since it was 
common for patients to interact with multiple providers during their visit, and the survey 
did not ask respondents to specify which provider had prescribed or recommended the 
treatment they received. Similarly, the analysis on providers’ stated preferences used the 
sample of providers surveyed at facilities where the exit survey was conducted, but the 
sample size was limited by the number of providers available at the time of the survey. In 
addition, their preference over alternative antimalarials was obtained from the single 
question “which antimalarial do you think is best for treating uncomplicated malaria?” 
rather than elicited using more extensive stated preference techniques, such as a discrete 
choice experiment. 
There were also challenges in examining whether providers’ practice was motivated by 
financial incentives. Individual providers at public and mission facilities and employees in 
medicine retail outlets should not, in principle, derive any financial benefit from the health 
care interaction beyond their salary, however in practice it is not uncommon for providers 
to receive ‘under-the-counter’ payments, or for providers to encourage patients to obtain 
medicines from retail outlets in which they have an ownership interest [37-39]. We sought 
to collect data from providers on alternative sources of income and employment, though 
we recognise that providers may not disclose this information. Similarly we were unable 
to ascertain whether under-the-counter payments were received. Thus, questions remain 
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about the extent to which the over-treatment of antimalarials in test-negative patients that 
was observed in both the formative research and during the evaluation reflects providers’ 
financial incentives. 
Other limitations reflect the evaluation design. A cluster-randomized trial was a rigorous 
study design for determining whether the basic and enhanced interventions were effective 
and cost-effective. However, within each arm of the trial it was not possible to identify the 
relative contribution of specific activities within the training package or ‘in-facility’ 
training. Moreover, given the resources available for the study, it was not feasible to follow 
up patients and ascertain whether they recovered or whether additional treatment was 
sought. Nor was it possible to independently verify for all cases whether the cause of the 
fever was malaria and there are also outstanding research questions about non-malaria 
causes of febrile illness. A decision was made not to independently re-test all patients due 
to ethical concerns about testing patients twice and because we wanted minimize any 
Hawthorne effect associated with the data collection activities. Consequently, the primary 
outcome for the trial was an output indicator: the proportion of patients who received the 
correct treatment according to the malaria treatment guidelines. This measure was also 
used for the economic evaluation, which reported the incremental cost per patient 
correctly treated. This measure has been used in several studies to report the cost-
effectiveness of RDTs, relative to presumptive treatment and microscopy [35, 40-43], 
though otherwise has limited comparability. Extrapolating to health outcomes was 
considered but not undertaken because there was substantial uncertainty relating to 
patient adherence to treatment, non-malaria causes of febrile illness, and the extent to 
which subsequent treatment would be sought. 
9.5 Future research 
The research demonstrated the advantages of examining providers’ practice from an 
economics perspective, and there is a rich body of theory from which to draw when 
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considering provider behaviour. The extent to which some of these theories could be 
tested in this thesis was, however, limited by the data available, and further research 
would be beneficial. In recent years there has been a growth in studies exploring the effect 
of financial incentives on provider performance and the quality of care, either using pay-
for-performance or results-based financing schemes [44-46]. In comparison, non-
monetary incentives have received much less attention, though they were highlighted in 
selected studies and I found them to be important in previous work on the employment 
preferences of registered nurses in Malawi [47, 48]. There is also considerable scope to 
undertake empirical work to further investigate the role of the institutional and social 
context on providers’ practice and concepts from behavioural economics.  
Behavioural economics is a relatively new area of economic thinking, though there is 
growing interest in how it can be applied to public health problems. There are some 
empirical examples that focus on lifestyle choices of individuals, such as healthy eating or 
smoking cessation [49], though as yet few examples that focus on provider behaviour. For 
instance, it would be interesting to use experimental methods to explore concepts such as 
status quo bias and risk aversion in the context of malaria diagnosis and treatment, to 
understand why many providers continue to knowingly supply non-recommended 
antimalarials and supply antimalarials to patients who test negative for malaria. 
The study was not designed to assess the specificity and sensitivity of microscopy and 
RDTs, and the primary outcome measure assesses whether the treatment prescribed was 
consistent with the test result recorded by providers in the malaria test register. A sub-
sample of patients, approximately 5%, were independently re-tested using RDTs by the 
study team and these results suggested there may be some false positive results among 
those tested using microscopy. Further research on the accuracy of the microscopy and 
RDTs in routine use would be beneficial and the case for introducing RDTs would be 
strengthened if diagnostic testing with RDT was found to be more accurate than with 
microscopy.    
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Further research on the cost-effectiveness of malaria RDTs would also be useful. The 
arguments for testing febrile patients for malaria before prescribing treatment are 
primarily economic. Knowing whether the fever was malaria or had other causes should 
reduce the unnecessary consumption of antimalarials, assuming providers use the test 
result when selecting treatment [35, 50]. Guidance from the World Health Organization 
(WHO) was predominately based on studies that applied the specificity and sensitivity of 
RDTs in trial conditions [51] and on economic modelling studies that incorporated 
assumptions about the relative cost of testing and treatment, the extent to which non-
malaria febrile illnesses were bacterial or self-resolving viral infections, the efficacy of 
antimalarials and antibiotics taken, and whether patients take medicines as advised [35, 
50]. Since these first economic evaluations were undertaken the market for RDTs and ACT 
has developed and competition between different brands has reduced prices. There have 
also been negotiations with pharmaceutical manufacturers for the Affordable Medicines 
Facility – malaria (AMFm) led by the Clinton Health Access Initiative (CHAI) and these 
have also reduced the price of ACT purchased by first-line buyers 
(www.theglobalfund.org/en/amfm). Moreover, there is also growing clinical research on 
the causes of non-malaria febrile illness which could replace assumptions based on expert 
opinion. It would be valuable, therefore, to update the economic modelling studies with 
the latest information.  
I would also like to evaluate the cost-effectiveness of RDTs with respect to health 
outcomes. This was a limitation of the REACT study, and having data on the specificity and 
sensitivity of both microscopy and RDTs in routine settings, subsequent treatment seeking 
behaviour and final health outcomes would strengthen the work I have undertaken. In 
addition, I would like to extend the economic modelling studies to take into account the 
cost of interventions that support the introduction of RDTs. The cost of these interventions 
will be particularly important for policy decisions in settings where uptake of malaria 
testing is low, or where providers persist in supplying antimalarials to test-negative 
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patients. This includes policy questions about the potential for making RDTs available in 
the private sector, where medicine retailers are a major source of malaria treatment.  
9.6 Conclusion 
The research in this thesis examined providers’ knowledge, preference and practice in 
treating febrile patients with suspected malaria in Cameroon and Nigeria. Drawing on 
economic theory, research was undertaken to inform the design and evaluation of 
interventions to support the roll out of malaria RDTs and train providers on revised 
malaria treatment guidelines.  
In formative research, findings from exit surveys undertaken at public health facilities and 
private retail outlets indicated considerable problems with malaria diagnosis and 
treatment. Malaria testing had limited availability in Nigeria, and while microscopy testing 
was available at most public, mission and private health facilities in Cameroon, it was 
under-used. There were also problems with the choice of treatment. Many febrile patients 
did not receive the recommended antimalarial, and when patients were tested for malaria, 
the test result was often ignored when providers were prescribing treatment. 
By approaching these public health problems from an economics perspective I questioned 
the conventional assumption that providers prefer to act in the best interest of their 
patients, and I analysed their stated and revealed preferences over different antimalarials. 
The research recognized that providers make decisions in an institutional and social 
context and often act as agents in multiple agency relationships. I was able to demonstrate 
that there was no significant relationship between providers’ knowledge and their 
practice, and that preferences over alternative antimalarials were similar among 
providers working in the same facility or locality, and therefore constrained by 
institutional and social factors.  
9. DISCUSSION AND CONCLUSION 
276 
 
The research contributed to the selection and design of interventions to improve the 
diagnosis and treatment of uncomplicated malaria in Cameroon. Specifically, we 
hypothesized that informing providers about revisions to the malaria treatment guidelines 
would have a limited effect on prescribing practice unless the intervention also sought to 
change how providers’ prefer to diagnose and treat uncomplicated malaria.  
Evidence on the effectiveness and cost-effectiveness of the enhanced intervention, which 
introduced RDTs with training that explicitly sought to change providers’ practice, has 
contributed to malaria treatment policy in Cameroon. Since the trial concluded, the 
Ministry of Health has incorporated the enhanced training in the roll out of RDTs and 
nationwide training of providers at public health facilities commenced in January 2014. 
The findings also have relevance for policy makers in other settings, and highlight the 
value in developing strategies to improve providers’ adherence to malaria treatment 
guidelines when expanding access to malaria testing. 
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Introduction to the Appendix 
 
The thesis has three appendices: 
A. A review of interventions to improve providers’ ability to diagnose and treat 
uncomplicated malaria: Appendix 
B. Research Paper VI: ‘As a clinician you are not managing lab results, you are 
managing the patient’: How enactment of malaria at health facilities in Cameroon 
compares with new WHO guidelines for the use of malaria tests. 
C. Research Paper VII: What does it take to improve diagnosis and treatment for 
uncomplicated malaria? A three-arm cluster randomised trial in two areas of 
Cameroon. 
Appendix A is the appendix to the Empircal Literature Review from Section 2.2. 
Appendix B is a qualitiative study on the preferences of providers’ at public and mission 
health facilities in Cameroon. It explores the role of malaria testing in the therpeutic 
process and reasons why providers prescribe an antimalarial when the malaria test was 
negative. 
Appendix C is the main trial paper and contains information about the implementation 
and effectiveness of the introducing RDTs with basic and enhanced training at public and 
mission facilities in Cameroon. This paper complements Research Paper V, which reports 
the cost-effectiveness analysis.
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Appendix A 
A review of interventions to improve providers’ ability to 
diagnose and treat uncomplicated malaria: Appendix  
The appendix to the empirical literature review in Section 2.2 has been included as 
Appendix A. This contains information on publications that were rejected following the full 
text review, and detail of the different types of intervention that were included in the 
review. 
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Appendix A. Reasons for rejection of publications based on full text review 
Country Intervention Reference 
Intervention did not seek to improve the ability of health workers: involves introduction of community 
agent 
Ghana, 
Nigeria, 
Uganda 
Recruit & train 
community medicine 
distributors 
Ajayi IO, Browne EN, Garshong B, et al. 2008. Feasibility and 
acceptability of artemisinin-based combination therapy for the 
home management of malaria in four African sites. Malaria 
Journal 7:6. 
Nigeria Recruit & train 
community medicine 
distributors to sell pre-
packaged drugs 
Brieger WR, Salako LA, Umeh RE, et al. 2002-2003. Promoting 
prepackaged drugs for prompt and appropriate treatment of 
febrile illnesses in rural Nigerian communities. International 
Quarterly of Community Health Education 21(1):19-40. 
Ghana Recruit & train 
community medicine 
distributors 
Chinbuah AM, Gyapong JO, Pagnoni F, et al. 2006. Feasibility and 
acceptability of the use of artemether-lumefantrine in the home 
management of uncomplicated malaria in children 6-59 months 
old in Ghana. Tropical Medicine and International Health 
11(7):1003-1006. 
Zaire Recruit & train 
community health 
workers 
Delacollette C, Van der Stuyfy, P, Molima K. 1996. Using 
community health workers for malaria control in Zaire. Bulletin of 
the World Health Organization 74(4):423-430 
Sudan Recruit & train malaria 
control assistants to 
use RDTs and treat 
malaria 
Elmardi KA, Malik EM, Abdelgadir T, et al. 2009. Feasibility and 
acceptability of home-based management of malaria strategy 
adapted to Sudan’s conditions using artemisinin-based 
combination therapy and rapid diagnostic test. Malaria Journal 
8:39. 
Sri Lanka 
(refugee 
camp) 
Compares treatment 
by community health 
workers to Field 
Laboratory 
Hoek WVD, Premasiri DAR, Wickremasinghe AR. 1997. Early 
diagnosis and treatment of malaria in a refugee population in Sri 
Lanka. Southeast Asian Journal of Tropical Medicine and Public 
Health. 28(1):12-17. 
Nigeria Introduction of 
community health 
workers to provide 
malaria treatment 
Onwujekwe O, Uzochukwu B, Ojukwu J, et al. 2007. Feasibility of a 
community health workers strategy for providing near and 
appropriate treatment of malaria in southeast Nigeria: An analysis 
of activities, costs and outcomes. Acta Tropica 101(2):95-105. 
Kenya Selection, training and 
job aids for community 
health workers 
Rowe SY, Kelly JM, Olewe MA, et al. 2007. Effect of multiple 
interventions on community health workers’ adherence to clinical 
guidelines in Siaya district, Kenya. Transactions of the Royal 
Society of Tropical Medicine and Hygiene 101(2):188-202. 
Burkina Faso Home management of 
malaria using 
community health 
workers /key opinion 
leaders 
Tiono AB, Kabore Y, Traore A, et al. 2008. Implementation of 
home-based management of malaria in children reduces the 
workload for peripheral health facilities in a rural district of 
Burkina Faso. Malaria Journal 7:201. 
Intervention did not seek to improve the ability of health workers: Assesses efficacy of clinical algorithm 
India Clinical algorithm for 
malaria diagnosis 
Chandramohan D, Carneiro I, Kavishwar A, et al. 2001. A clinical 
algorithm for the diagnosis of malaria: results of an evaluation in 
an area of low endemicity. Tropical Medicine and International 
Health 6(7):505-510. 
Kenya Clinical algorithm for 
IMCI 
Perkins BA, Zucker JR, Otieno J, et al. 1997. Evaluation of an 
algorithm for integrated management of childhood illness in an 
area of Kenya with high malaria transmission. Bulletin of the 
World Health Organization 75(S1):33-42. 
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Gambia Clinical algorithm for 
IMCI 
Weber MW, Mulholland EK, Jaffar S, et al. 1997. Evaluation of an 
algorithm for the integrated management of childhood illness in 
an area with seasonal malaria in the Gambia. Bulletin of the World 
Health Organization 75(S1):25-32. 
Intervention did not seek to improve the ability of health workers: Assesses efficacy of diagnostic tests 
Philippines Compares symptom-
based diagnosis, RDTs 
and microscopy 
Bell D, Go R, Miguel C, Walker J, et al. 2001. Diagnosis of malaria 
in a remote area of the Philippines: comparison of techniques and 
their acceptance by health workers and the community. Bulletin 
of the World Health Organization 79(10):933-941. 
Intervention did not seek to improve the ability of health workers: Assesses patient response to drug 
formulation 
Ghana Pre-packaged 
chloroquine tablets 
and syrup 
Ansah EK, Gyapong JO, Agyepong et al. 2001. Improving 
adherence to malaria treatment for children: the use of pre-
packaged chloroquine tablets vs chloroquine syrup. Tropical 
Medicine and International Health 6(7):496-504. 
Myanmar Introduces blister 
packaging 
Shwe T, Lwin M, Aung S. 1998. Influence of blister packaging on 
the efficacy of artesunate + mefloquine over artesunate alone in 
community based treatment of non-severe falciparum malaria in 
Myanmar. Bulletin of the World Health Organization 76(S1):35-41 
Intervention did not seek to improve the ability of health workers: Assesses patient response to national 
malaria programme 
Vietnam Malaria programme on 
prevention, early 
diagnosis and 
treatment 
Giao PT, Vries PJ, Binh TQ, et al. 2005. Early diagnosis and 
treatment of uncomplicated malaria and patterns of health 
seeking in Vietnam. Tropical Medicine and International Health 
10(9):919-925. 
Descriptive study without intervention 
Zambia Descriptive study 
reporting on treatment 
in health centres with 
microscopy available 
Barat L, Chipipa J, Kolczak M, et al. 1999. Does the availability of 
blood slide microscopy for malaria at health centers improve the 
management of persons with fever in Zambia?  American Journal 
of Tropical Medicine and Hygiene 60(6):1024-1030. 
Cambodia Descriptive study of 
rational drug use 
Chareonkul C, Khun VL, Boohshuyar C. Rational drug use in 
Cambodia: study of three pilot health centers in Kampong Thom 
Province. Southeast Asian Journal of Tropical Medicine and Public 
Health 33(2):418-424. 
Intervention, but without comparison group 
Madagascar Training course open 
to international 
participation 
Domarle O, Randrianarivelojosia M, Duchemin JB, et al.. Atelier 
paludisme: an international malaria training course held in 
Madagascar. Malaria Journal 7:80. 
International Online training course 
in microscopy 
Icke G, Davis R, McConnell W. 2005. Teaching health workers 
malaria diagnosis. PLoS Medicine. 2(2):108-110. 
Uganda Provider Training 
(IMCI) 
Karamagi CAS, Lubanga RGN, Kiguli S, et al.. 2004. Health 
providers’ counselling of caregivers in the integrated 
management of childhood illnesses (IMCI) programme in Uganda. 
African Health Sciences 4(1):31-39. 
Burkina Faso Training of community 
health workers 
Sirima SB, Konate A, Tiono AB, et al.. 2003. Early treatment of 
childhood fevers with pre-packaged antimalarial drugs in the 
home reduces severe malaria morbidity in Burkina Faso. Tropical 
Medicine and International Health 8(2):133-139. 
Do not report on malaria-related outcomes 
Bangladesh Provider Training 
(IMCI) 
Arifeen Se, Hoque DE, Akter T, et al.. 2009. Effect of the 
Integrated Management of Childhood Illness strategy on 
childhood mortality and nutrition in a rural area of Bangladesh: a 
cluster randomised trial. Lancet 374(9687):393-403. 
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India Quality improvement 
intervention (feedback  
to providers on case 
management) 
Chakraborty A, D’Souza SA, Northrup RS. 2000. Improving private 
practitioner care of sick children: testing new approaches in rural 
Bihar. Health Policy and Planning 15(4):400-407. 
Peru Provider Training 
(IMCI) 
Huicho L, Davila M, Gonzales F, et al. 2005. Implementation of the 
Integrated Management of Childhood Illness strategy in Peru and 
its association with health indicators: an ecological analysis. 
Health Policy and Planning 20(S1):i32-i41. 
Pakistan Provider Training 
(IMCI) 
Luby S, Zaidi N, Rehman S, et al. 2002. Improving private 
practitioner sick-child case management in two urban 
communities in Pakistan. Tropical Medicine and International 
Health 7(3):210-219. 
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Appendix B: Detail of the different types of interventions 
Intervention Detail of Intervention Malaria 
Specific 
Facility or 
Outlet 
Country,  
Year 
Study 
Provider 
Training 
(malaria) 
Provider Training:  
2-day workshop on malaria. Covered symptoms, treatment, prevention, drug resistance, referral, 
storage and expiry of drugs, and communication skills 
Printed Educational Materials: 
Training booklets. Posters. 
Supervision: 
Local monitoring by public health officers 
Consumer Education: 
Widespread public information campaigns 
National policy or initiative: 
MoH training programme during change from SP to ACT. Though as ACT were not OTC then were 
promoting AQ in drug retailers. 
Yes 60 Private 
sector drug 
retailers 
Kenya,  
2005 
[1] 
Provider 
Training 
(IMCI) 
Provider Training: 
11-day training on IMCI, tailored to country context. Covered assessing signs, symptoms, classifying 
the illness based on treatment needs and providing appropriate treatment and education of the 
child’s caregiver. 
Printed Educational Materials: 
Training materials in local language 
No, 
childhood 
illnesses 
20 Primary 
health 
facilities 
Tanzania, 
2000 
[2, 3] 
Provider 
Training 
(laboratory 
tests) 
Provider Training: 
Workshops and workplace training covering 7 common tests including microscopy 
National Policy or Initiative: 
Assess feasibility of nationwide system for quality assurance of laboratory testing 
No, training 
on several 
laboratory 
tests 
205 Public 
sector 
peripheral 
laboratories  
Ghana, 
2000 
[4] 
Educational 
Process  
(self- 
assessment) 
Provider Educational Process: 
2-3 day workshop to initiate participatory approach. Followed by self-assessment to reflect on service 
quality and planning. Also, i) a client exit interview tool to encourage staff to talk with and listen to 
their clients about quality of services offered; ii) a client flow analysis tool to measure how long clients 
wait for services and how much contact time they have with service providers; and iii) an action 
planning tool to help identify root causes of problems and to develop a realistic, time bound plan. 
Printed Educational Materials: 
Self-administered guides with questions on client rights and health care needs. 
No quality 
improvemen
t approach 
8 Primary care 
clinics in each 
country 
Guinea 
and 
Kenya, 
2001 
[5] 
APPENDIX A
289
 
Review of Interventions to improve providers’ ability to diagnose & treat uncomplicated malaria 
 
33 
 
Intervention Detail of Intervention Malaria 
Specific 
Facility or 
Outlet 
Country,  
Year 
Study 
Provider 
Training & 
Pre-
packaged 
AMs 
Pre-packaged antimalarials 
Age-specific packs of CQ and SP 
Provider Training 
2-day training for peer educators, who then conducted 1-day training for drug retailers.  
Printed Educational Materials: 
Training manual. Materials, such as flip charts, were developed by the peer educators to use in their 
training workshops 
Consumer Education: 
Retailers were provided with caregiver manuals, and logos and stock to show completed malaria 
training. Also mass media (including radio, billboards) to encourage prompt treatment of malaria. 
Yes 200+ Private 
drug retailers 
Nigeria, 
2003 
[6] 
A) Provider 
Training 
(RDT) & Job 
Aid 
B) Job Aid 
Provider Training: 
3-hour training course in preparing RDTs, including practical and an assessment of skills in conducting 
the test and interpreting the results. 
Printed Educational Materials: 
Job aid developed and tested with focus groups 
Yes 79 Community 
health 
workers 
Zambia [7] 
Educational 
Process  
(self- 
assessment 
& peer 
feedback) 
Provider Educational Process: 
Self-monitoring tool and peer feedback mechanism to improve the quality of care for fever and to 
improve aspects of structural quality, such as cleanliness and drug availability.  
Self-assessment contained questions to the provider on care of fever and was used weekly for 3 
months. Providers would ask colleague to observe consultation and assess compliance to fever care 
standards.  
Head of the facility completed a monthly questionnaire on the facility: services offered; supervision 
and oversight; drug commodities and vaccine availability; quality of physical space and equipment; 
and cleanliness and hygiene.   
No, all 
febrile 
illness 
Public health 
facilities 
Mali, 
2001 
[8] 
Provider 
Training 
(IMCI) 
Provider Training: 
5-day training on IMNCI, tailored to country context. Covered assessing signs, symptoms, classifying 
the illness based on treatment needs and providing appropriate treatment and education of the 
child’s caregiver. 
Printed Educational Materials: 
Training materials in local language 
No, neonatal 
and 
childhood 
illnesses 
Public health 
facilities (85 
health 
workers) 
India [9] 
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Intervention Detail of Intervention Malaria 
Specific 
Facility or 
Outlet 
Country,  
Year 
Study 
Provider 
Training 
(malaria) 
Provider Training: 
3-day training, that encouraged active participation, provides practical training. Covered brand name 
drugs frequently stocked. Trained to use dosage charts for CQ and rubber-stamps that depict correct 
CQ regimen in children of different ages. Also trained on symptoms that require referral to a trained 
HW. 
Printed Educational Materials: 
Training materials, including dosage charts 
Supervision: 
1-2 hour individual sessions to observe retailers’ skills in his/her normal workplace.  
Refresher training: 
2-day refresher workshop after 6 months. 
Consumer Education: 
Information on regimen using rubber-stamps. 
Yes 23 Private 
sector drug 
retailers 
Kenya, 
1995-
1997 
[10] 
Provider 
Training 
(malaria) 
Provider Training: 
4-day malaria training using participatory methods, including role-play, practicals, small group 
discussions and exercises. Covered causes; symptoms; treatment; drug resistance; stock management; 
referral; and communication skills. In 1999 trained on CQ, from 2000 trained on SP as it became first-
line OTC AM.  
Printed Educational Materials: 
Training materials. Accreditation certificates. 
Supervision: Two annual supervisory visits 
Refresher Training: 1-day workshops each year 
Consumer Education: 
Raised awareness on trained retailers and importance of prompt and effective treatment, changes in 
first-line AM and when to consult health professional. 
Yes  Private sector 
drug retailers 
Kenya 
1999-
2000 
[11, 
12] 
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Intervention Detail of Intervention Malaria 
Specific 
Facility or 
Outlet 
Country,  
Year 
Study 
A) Provider 
Training 
(microscopy 
+ clinical 
diagnosis)  
B) Provider 
Training 
(clinical 
diagnosis) 
Provider Training: (both arms) 
5-day training on clinical diagnosis and malaria treatment malaria. Used presentations and practicals. 
Covered signs and symptoms, history taking, physical examination, referral, appropriate treatment 
and counselling patients on use of drugs.  
Malaria Diagnostic Testing: (one arm) 
5-day training on malaria microscopy (in intervention arm). Covered how to prepare thick blood 
smears, identify and count malaria parasites, maintain microscope and store blood slides. 
Printed Educational Materials: 
Clinical algorithm (both arms) 
Malaria microscopy training manual (one arm). 
Supervision: Weekly supervision 
Yes 16 public 
health centres 
& 13 
dispensaries 
Tanzania 
2003-
2004 
[13] 
Provider 
Training 
(childhood 
illness) 
 
Provider Training: 
1-hour individual training to improve retailers’ adherence to national guidelines for malaria and 
common childhood illnesses (diarrhoea, ARI). Covered rational prescribing, dispensing, correct 
labelling, correct information or instructions on how to use or administer AM, antibiotics, anti-
diarrhoea. 
Printed Educational Materials: 
Included wall charts on approved brands, and dosage charts of SP and antipyretics. 
Posters on how to dispense drugs given to both arms.  
Yes 40 private 
sector drug 
retailers 
Tanzania, 
2004 
[14] 
Provider 
Training 
(rational 
drug use) 
Provider Training: 
1-day workshop: presentations on rational use of drugs, & national treatment policy. Also opportunity 
to discuss findings from baseline surveys to reinforce importance of good prescribing. 
Printed Educational Materials: 
Copies of WHO guidelines on Good Prescribing and other printed materials on treatment of ARI, 
malaria and diarrhoeal diseases were distributed. 
No, several 
illnesses 
private 
providers 
Uganda, 
Not 
specified 
[15] 
Provider 
Training 
(malaria) 
 
Provider Training: 
In-service training for medical assistants. 2-hour lecture on malaria. Covered clinical features, 
diagnosis and treatment, severe and un complicated malaria, chemoprophylaxis and AM side-effects 
of drugs. Followed by workplace training. 
Yes Medical 
assistants 
from 40 public 
health centres 
Ghana, 
Not 
specified 
[16] 
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Intervention Detail of Intervention Malaria 
Specific 
Facility or 
Outlet 
Country,  
Year 
Study 
Provider 
Training 
(microscopy) 
+ 
Refresher 
Training 
(microscopy) 
Provider Training: 
12-day course on malaria microscopy. Involved laboratory practical, lectures, group discussions, 
demonstrations, and take home assignments. 
Printed Educational Materials: 
Training materials including microscopy slides 
Refresher Training: 
4-day course on malaria microscopy offered to those that had previously completed the 12-day 
course. 
Yes Kenyan & 
international 
microscopists 
Kenya [17] 
Provider 
Training 
(childhood 
illnesses) 
Provider Training: 
8 weekly 2-hour sessions on malaria, diarrhoea, guinea worm, gonorrhoea, cough, malnutrition, 
medication counselling and reading prescriptions. Used a participatory approach with cultural 
appropriate methods such as storytelling, role play and use of proverbs. 
Printed Educational Materials: 
Written and pictorial hand out materials based on lesson plans. 
No, several 
illnesses 
28 private 
sector drug 
retailers 
Nigeria [18] 
Provider 
Training 
(IMCI) 
 Provider Training: 
11-day training on IMCI, tailored to country context. Covered assessing signs, symptoms, classifying 
the illness based on treatment needs and providing appropriate treatment and education of the 
child’s caregiver.  
Printed educational materials: 
Training materials in local language 
No, 
childhood 
illnesses 
public and 
NGO facilities 
Uganda, 
2000, 
2001, 
2002 
[19]  
[3] 
Economic 
Incentive  
A) Price 
subsidy, BCC, 
training, & 
suggested 
retail price 
B) Price 
subsidy, BCC 
& training 
C) No 
intervention 
Economic incentives to providers: 
Pilot ACT subsidy: AL is sold to private wholesalers at subsidized prices in intervention areas using the 
supply chain. Then uses existing distribution channels to deliver AL to private drug retailers.  
Provider Training: 
Shopkeeper training 
Printed Educational Materials / Pre-packaged drugs: 
Simplified dosing instructions in local language. Drugs and behaviour change materials with a 
suggested retail price (in one of two intervention areas) 
Consumer Education: 
Behaviour change campaign (BCC)  
Yes private sector 
drug retailers 
Tanzania, 
2007-08 
[20, 
21] 
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Intervention Detail of Intervention Malaria 
Specific 
Facility or 
Outlet 
Country,  
Year 
Study 
Economic 
Incentive 
(Franchise 
scheme) 
Economic incentives to providers: 
ACTs made available through private shops in targeted rural areas. Shops operate via franchise and 
provide a range of services. Participating shops were upgraded to private clinics by recruiting a 
qualified nurse. AL distributed by government central medical stores and administered free of charge 
to patients with malaria after confirmation with RDT. Patients pay for consultation and RDT. 
Yes 9 Community 
& family 
wellness 
shops that 
joined 
franchise  
Kenya, 
2007 
[21]  
Provider 
Training 
(IMCI) 
Provider Training: 
9-day training using pre-tested IMCI course. Covered assessment and classification, identification of 
treatment, treat the child, counsel the mother. Involved written exercises, role plays, group 
discussions and drills, & practice sessions in the clinic. 
Printed Educational Materials: 
3 case management wall charts, booklets of the wall charts, recording forms for the assessment of the 
sick child, draft video and photo booklet 
No, 
childhood 
illnesses 
3 public health 
facilities 
without 
laboratories (6 
nurses) 
Ethiopia [22] 
A) RDT 
provision vs 
No RDTs 
B) Pre vs 
post training, 
guidelines, 
supervision 
Provider Training: (both arms) 
3-day training course on malarial guidelines, use of AL and diagnostic tests (microscopy and RDTs) for 
at least one provider per facility. 
Provision of RDTs: (intervention arm) 
Provided RDTs and supplies for safe use and disposal.  
Printed Educational Materials: (both arms) 
Copy of the revised national malaria treatment guidelines and supervision. 
Supervision: 
Half-day on-site interactive discussion on RDT use, revised national malaria treatment guidelines for 
outpatients >=5yrs, dosing and administration of AL, management of severe malaria. 
National Policy or Initiative: 
MoH supplied AL. Training was part of the national implementation of new antimalarial policy.  
Yes 60 
government 
health 
facilities 
(hospitals, 
health 
centres, 
dispensaries)  
Kenya, 
2006 
[23] 
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Intervention Detail of Intervention Malaria 
Specific 
Facility or 
Outlet 
Country,  
Year 
Study 
Provider 
Training 
(microscopy)  
Provider Training: 
6-day training on malaria for medical officers, clinical officers, nurses, midwives, laboratory staff and 
records clerks. Involved didactic and practical sessions. Covered malaria epidemiology, national 
malaria policy, medical ethics, clinical management of malaria, management of patients with fever 
and a negative blood slide, and medical record keeping.  
Malaria Diagnostic Testing: 
Training on preparation of blood slides and microscopy skills. 
Printed Educational Materials: 
Training materials 
Supervision:  
Supervisory visits were held after 6 and 12 weeks 
Yes 8 public 
facilities with 
microscopy 
services (also  
malaria 
surveillance 
sites) 
Uganda 
2006 
[24] 
Provider 
Educational 
Process 
(peer 
educators) 
 
Provider Educational Process: 
Train and equip drug wholesalers to be unpaid outreach educators of new malaria guidelines (SP now 
OTC). Following 3-hour orientation wholesalers offered, 1-day training for wholesaler attendants and 
retailers. Supervision after 3 months. 
Provider Training: 
1-day training with wholesalers, with role play on using posters as communicate tool. Wholesalers 
distributed the job aids at the point of sale to vendors from wholesale and retail outlet. 
Printed Educational Materials: 
Poster for a retailer on AMs: listing malaria symptoms, dosage chart of approved brands of SP and 
antipyretics, and treatment advice 
Consumer Education: 
Poster at retailer to generate demand for 5 approved brands of SP and to communicate SP was now 
available OTC.  
Yes Private sector 
wholesalers 
and drug retail 
outlets 
Kenya, 
2000 
[25] 
Provider 
Training 
(childhood 
illness) 
Provider Training: 
3-day negotiation participatory sessions intended to improve private practitioners’ quality of 
management of childhood illness. Baseline survey results were used to stimulate participants to 
consider their own practice compared to desired practice.  
Printed Educational Materials: 
Illustrative materials such as posters were used to explain correct malaria treatment doses.  
Supervision: 
Support visit after 1-2 months. 
No, 
childhood 
illnesses 
Private clinics 
and drug 
shops 
Uganda, 
2002-
2003 
[26] 
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Intervention Detail of Intervention Malaria 
Specific 
Facility or 
Outlet 
Country,  
Year 
Study 
Provider 
Training 
(IMCI) 
Provider Training: 
4-day IMCI training (not recommended 11 days). Training on case malaria management, diarrhoeal 
disease, pneumonia and measles. Covered signs and symptoms, classifying the illness, appropriate 
treatment, counselling to caregiver about how to administer medicines and appropriate home care, 
and when caregiver should return to facility 
Printed Educational Materials: 
Training materials 
Supervision: 
Supervision visit after 4 weeks 
No, 
childhood 
illnesses 
4 urban public 
health centres 
(32 health 
workers) 
Nigeria, 
Not 
specified 
[27] 
Provision of 
RDTs 
(including 
training) 
 
Provider Training: 
2-day training and practical on RDTs for dispensary staff (in intervention arm). Covered diagnosis and 
treatment algorithms, and RDT (including how to perform and interpret the test, and storage and 
disposal). Providers instructed to prescribe per national guidelines (negative result = no AM and 
investigate other causes of febrile illnesses).  
Provision of RDTs: 
RDT training and sufficient supplies of RDTs (Paracheck) were distributed to each dispensary. 
Printed Educational Materials: 
Training guides 
Yes 6 rural public 
dispensaries 
(without 
microscopy 
services) 
Tanzania, 
2005 
[28] 
Pre-
packaged 
AMs 
(compared 
to routine 
prescription) 
Pre-packaging of drugs: 
Pre-packaged CQ and paracetamol available in seven weight-specific regimens. Packs of CQ tablets 
were divided into three compartments, each containing a daily dose. Syrups pre-packaged in plastic 
bottles purchased by the district health management team.  
Patients charged for medicines. Intervention facilities charged for cost of pre-packaging, while control 
charged for prescribing envelopes, CQ syrup included small fee to cover the cost of the bottles. 
Yes 6 public health 
facilities  
Ghana, 
Not 
specified 
[29] 
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Research Paper VI: ‘As a clinician, you are not managing lab results, 
you are managing the patient’: How the enactment of malaria at health 
facilities in Cameroon compares with new WHO guidelines for the use 
of malaria tests 
This research paper is a qualitiative study on the preferences of providers at public and 
mission health facilities in Cameroon. It complements the formative research using 
quantitative methods that is included in the  main body of the thesis (Papers II, III and IV). 
This paper explores the role of malaria testing in the therpeutic process and reasons why 
providers prescribe an antimalarial when the malaria test was negative. The findings from 
this paper were usedto inform the design of enhanced training intervention in Cameroon. 
 
Authors: Clare Chandler(1), Lindsay Mangham(1), Abanda Ngu Njei(2), Olivia 
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Abstract 
In response to widespread overuse of antimalarial drugs, the World Health Organisation changed 
guidelines in 2010 to restrict the use of antimalarials to parasitologically confirmed malaria cases. 
Malaria rapid diagnostic tests (RDTs) have been presented as a means to realize the new guidelines, and 
National Malaria Control Programmes, including that of Cameroon, are developing plans to introduce 
the tests to replace microscopy or clinical diagnosis at public health facilities across the country.  
We aimed to understand how malaria tests and antimalarial drugs are currently used as part of social 
interactions between health workers and patients at public and mission health facilities in Yaoundé and 
Bamenda and surrounding districts in the Northwest region of Cameroon. In May to June 2010, we held 
17 focus group discussions with 146 health workers involved in clinical care from 49 health facilities.  
Clinicians enacted malaria as a ‘juggling’ exercise, involving attention to pathophysiology of the patient 
as well as their desires and medical reputations, utilising tests and medicines for their therapeutic 
effects as symbols in the process of care. Parasites were rarely mentioned in describing diagnostic 
decisions.  
These enactments of malaria contrast with evidence-based guidelines emanating from WHO, which 
assume the parasite is the central driver of practice. If RDTs are to be taken up in practice, public health 
practitioners need to pay careful attention to the values and priorities of health workers and patients if 
they are to work with them to improve diagnosis and treatment of febrile illnesses.
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Background 
In response to the recognition of widespread overuse of antimalarial drugs, and the consequent 
potential for unnecessary expenditure on subsidised antimalarial drugs, the WHO revised its guidelines 
in 2010 to restrict the use of ACT to parasitologically confirmed malaria cases, where diagnostics are 
available (World Health Organisation, 2010). This change intends new technologies to be adapted into 
the everyday practice of malaria. 
 
Although microscopy is considered to be the gold standard for malaria diagnosis (World Health 
Organisation, 2010), it has been found to be impractical in many remote and resource-poor settings due 
to its requirements for trained personnel, equipment, regular supply of reagents and continued quality 
assurance supervision (Bell & Peeling, 2006; Moody, 2002; Zikusooka et al., 2008). Rapid Diagnostic 
Tests (RDTs) are being promoted as a solution to these diagnostic challenges in settings with no or poor 
quality microscopy. Malaria RDTs have been found to be accurate under controlled conditions, easy to 
use and interpret and can be performed with basic training and equipment (Nankabirwa et al., 2009; 
Zikusooka et al., 2008). Several studies have also suggested RDTs can be cost-effective when compared 
with no testing or microscopy although this depends on the prevalence of malaria, costs of testing and 
treatment and critically whether the treatment prescribed is consistent with the outcome of the malaria 
test (Lubell et al., 2008; Shillcutt et al., 2008; Zikusooka et al., 2008; Zurovac et al., 2008).  
 
This  kind of evidence has encouraged the global procurement of malaria RDTs which rose from 
approximately 2.9 million tests in 2000 to an estimated 80 – 90 million in 2008 (Baik & Bell, 2007). 
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Unfortunately many of the perceived benefits to malaria management are yet to be realized. In many 
settings where RDTs have been introduced, the tests have been underused and the overuse of 
antimalarial drugs has remained high. Even when tests are carried out, findings are accumulating from 
studies in different countries that show between 35 and 85% of RDT negative patients have been 
prescribed antimalarials (Ansah et al., 2010; Bisoffi et al., 2009; Chinkhumba et al., 2010; Elmardi et al., 
2009; Hamer et al., 2007; Kyabayinze et al., 2010; Reyburn et al., 2007; Skarbinski et al., 2009). By 
contrast, other studies have found a reduction in overdiagnosis, down to between 4% and 16% RDT 
negative patients receiving antimalarials after the introduction of RDTs with various supporting 
interventions (Bastiaens et al., 2011; D'Acremont et al., 2009; Hopkins, 2008; Masanja et al., 2010; 
Mawili-Mboumba et al., 2009; Msellem et al., 2009; Thiam et al., 2011; Williams et al., 2008). In spite of 
this mixed evidence over the effect of introducing RDTs, and in the absence of good information about 
the best way to support their introduction for effective adoption, scale-up of the tests is being promoted 
(World Health Organisation, 2010), and many countries including Cameroon have included the tests in 
their Global Fund grant applications (Ministry of Public Health, 2009). 
 
An understanding of how testing is conceptualised is needed in order to maximise investment in the 
scale-up of RDTs. In spite of the high quality of many RDTs (World Health Organisation et al., 2008), 
studies have suggested that providers are unsure about the accuracy of tests, especially negative results. 
This persists even when they perform the test themselves and particularly when the results clash with 
observed signs and symptoms (Kyabayinze et al., 2010; Moonasar et al., 2007; Rowe et al., 2009; 
Uzochukwu et al., 2010). Results from a recent survey of health facilities in Cameroon in 2009 indicate 
malaria is significantly overdiagnosed and mistreated (Mangham et al., 2011). The Ministry of Public 
Health in Cameroon promotes the rational use of ACTs using microscopy before providing treatment in 
all cases of fever in patients over five years (Ministry of Public Health, 2008).The survey, a baseline to 
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the current qualitative study and precursor to a randomised controlled trial to introduce RDTs, found 
that 81% of febrile patients on exit from public and mission health facilities were prescribed 
antimalarials, though only 35% of febrile patients on exit had malaria parasites according to the results 
of RDTs conducted by the study team.  
 
Social relationships have been underscored as important in diagnostic decision making and are shown to 
have an important bearing on whether negative test results are adhered to. Social relationships are 
often based on a perceived or real demand from patients for antimalarials (Chandler et al., 2008b; 
Onwujekwe et al., 2009) as well as habitual practice built on observation and expectations from 
colleagues within communities of practice (Chandler et al., 2008a; Chandler et al., 2010). Undertaking 
qualitative studies to understand local conceptualisations of malaria treatment and diagnosis is essential 
in order to design supporting interventions for the introduction of new technologies such as RDTs in 
different settings. In this study qualitative methods were used to understand how new diagnostic 
guidelines to restrict antimalarials to patients with malaria parasites on blood testing could be 
implemented, alongside the introduction of RDTs, in an upcoming cluster randomised controlled trial 
(clinicaltrials.gov NCT01350752). 
 
Theoretical orientation 
In this work, we adopt a meaning-based, interpretive approach to understanding malaria in practice, 
well established in the field of medical anthropology (Nichter, 2008). We see ‘malaria’ as a term with 
multiple meanings, held by and communicated between health workers and their patients as well as 
other communities of stakeholders across educational, economic and geographic boundaries (Beisel, 
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2010). We conceive that constructions such as ‘malaria’ become apparent as such diseases are ‘enacted’ 
or practiced, following Mol (2002) who presented an ethnography or ‘praxiography’ of arthrosclerosis as 
a disease, showing how medical technologies, arteries, doctors and patients enact different versions of 
the disease through coordination, interference and contradiction in medical practices. 
We have problematised the enactment of malaria by health workers through analysis of the roles of 
different processes and paraphernalia.  To do this, we draw on long-standing work on symbolism in 
medical practice (Kleinman, 1973) and the role of tangibles such as medicines that can facilitate 
communication about experiences that may be difficult to express (Van der Geest & Whyte, 1989). In 
the case of artefacts involved in diagnostic procedures, we are sentient to the arguments of the 
‘technological imperative’ of medicine as practiced in Northern societies (Koenig, 1988), with diagnostic 
technologies representing reductionist notions of health as localised and identifiable within the body, 
privileged over clinical information gathered from listening, looking and feeling patients, as ‘paraclinical’ 
information (Feinstein, 1975).  
We view the introduction of new guidelines and technologies for diagnosing ‘malaria’ that have 
emerged from outside of Cameroon through the analytical lens of evidence based medicine (EBM) as a 
social movement, following Pope (2003). Emerging within the medical profession in Northern countries, 
EBM has been observed to have shifted notions of ‘evidence’ from clinical reason, based on experience 
of what worked, and rooted in pathophysiology together with social and cultural knowledge of the 
individual patient, to probabilistic rationality based on the results of clinical trials (Armstrong, 2002; 
Mykhalovskiy & Weir, 2004). In this paper, we analyse how malaria and its treatment are enacted by 
health workers and consider how this relates to emergent evidence based guidelines. 
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Methods 
We carried out focus group discussions (FGDs) with health care providers and with community members 
in two areas of Cameroon. This paper presents analysis drawn from the provider side. Findings from the 
community FGDs will be presented elsewhere in order to allow sufficient space to present each 
perspective. The two areas were chosen by the broader study team to represent Anglophone and 
Francophone areas in which an upcoming trial of different supporting interventions for the introduction 
of RDTs would take place. This qualitative research aimed to contribute to the design of supporting 
interventions by identifying factors important to consider across different areas, cadres and 
administrative types of providers. 
 
Study area 
The study areas were Yaoundé, the bustling capital city of Cameroon, situated in the Central region in 
the Francophone area of the country, and Bamenda and surrounding area in the Northwest region in the 
Anglophone area of the country. Yaoundé has 8 health districts within the urban capital, five of which 
were included in our study. In the Bamenda study area, we included the urban district plus seven 
neighbouring rural districts: Tubah, Batibo, Ndop, Santa, Bafut, Mbengwi and Bali. Both areas have a mix 
of formal health facilities and medicine retailers. Public and mission hospitals and health centres form 
the bulk of the formal health system, although there are many more private pharmacies and others 
selling medicines privately. Malaria is endemic in both study areas.  
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Participant selection 
Potential recipients for future introduction of malaria RDTs at health facilities were invited to participate 
in the FGDs. All health workers who had a role of prescribing or dispensing and administering medicines 
at public or mission health facilities in the study areas were therefore eligible. We separated the 
participants into different cadres of medical doctors or nurses/midwives/nurse assistants in order to 
foster more openness amongst participants. We identified potential participants from an earlier census 
survey of health facilities in the two study areas and from lists provided by the person in charge of the 
health facilities. We aimed for 8-12 participants per FGD, and if there were too few eligible to participate 
from one health facility, we grouped together participants from neighbouring health facilities. Health 
workers were invited to attend the FGD in a meeting area that was convenient for participants and 
provided a private space to discuss. No incentives were provided, other than transport refund for those 
health workers travelling to attend the discussion. 
  
Focus group discussions   
We chose to carry out FGDs rather than one-to-one interviews in order to stimulate and observe 
discussion amongst participants about the research topics. Health workers were given information 
sheets and consent forms which were explained and discussed in the group. Those choosing to 
participate were asked to sign consent forms prior to the start of the FGD and were given identification 
numbers for anonymity. The FGDs were facilitated by one member of the study team, accompanied by a 
note taker and a co-ordinator. The facilitator followed a topic guide to stimulate discussion with open-
ended questions on the role of antimalarial drugs and tests in participants’ practice, perceived reliability 
and logistics of existing tests, perceptions of community preferences, and their relationships with 
practice. Discussions were held in French in Yaoundé and Pidgin English in Bamenda, although 
APPENDIX B
316
 9 
 
facilitators were flexible to the preferences of participants to use different languages. The note taker 
recorded the discussion with a digital recording device and made detailed notes to record participants’ 
contributions, non-verbal communication and the atmosphere of the FGD. The coordinator collected 
demographic and work history information and provided refreshments after the discussion. After each 
FGD, the study team reflected on the discussion held and any challenges faced in facilitation, or new 
ideas arising, and circulated a summary for further discussion with investigators.  
The study team consisted of five facilitators, all of whom were researchers at the University of Yaoundé 
in biomedical departments, although none were health care providers, and eight note 
takers/coordinators. The team completed an intensive 7-day training carried out by CC, an experienced 
social researcher, to orient them to the study’s objectives and methods and to practice skills in carrying 
out FGDs, following exercises for communication skills development (Haaland et al., 2006). Fieldwork 
took place after a period of pretesting and revision of tools, in May and June 2010. 
 
Data handling and analysis 
Audio recordings and notes were transcribed using a word processor. The transcription was then 
checked and edited by another member of the study team before it was translated into English. 
Translations were then cross-checked and finalised by the study coordinator.  
FGD summaries, translations and enrolment form information were imported into NVivo 8 (QSR 
International). They were read carefully for the overall flow of the discussion and then coded line-by-
line, labelling ideas described or implied by participants. These ideas were then grouped together into 
themes in a continuous revision process as more transcripts were reviewed. A coding template was set 
up by CC and two social science research assistants completed the coding, with agreements on coding 
reached through close communication and frequent reviews and revisions to the template. Higher level 
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concepts were interpreted from the themes together with review of literature and theory relevant to 
the themes emerging. Findings in the paper represent a narrative of the central conceptualisations 
developed through this analysis process. 
 
Ethics 
The study was approved by the National Ethics Committee, Cameroon (reference: 030/CNE/DNM/09) 
and ethics review board of the London School of Hygiene & Tropical Medicine, UK (reference: 5885). 
 
Study participants 
We held 17 focus group discussions with health workers from public and mission facilities across the two 
study areas in Bamenda and Yaoundé. A total of 146 health workers participated in focus groups, with a 
median FGD size of 9 participants. Eight health worker FGDs were held in the Bamenda study area and 9 
in Yaoundé and each site included FGDs with medical doctors and with nurses of different cadres, the 
majority (90%) of whom reported their responsibilities currently included prescribing treatment (Table 
1). In Yaoundé, nurses who prescribed were of a higher cadre, including staff nurses and registered 
nurses. In Bamenda, nurses also included nurse assistants. Otherwise, characteristics of health workers 
were similar between sites (Table 2). Most of the health workers were female, although the medical 
doctors were predominantly male. The median age was 39 and around a third of the participants were 
originally from the region in which they were now working. Most had at least a secondary school 
education, and 34 held medical degrees. Most health workers had undergone at least 3 years of 
professional training, although Yaoundé participants had undergone more years of training than staff in 
Bamenda. Overall, almost half had graduated in the past 10 years. Many (56% overall) had never 
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received malaria related in-service training, while a small minority had attended more than three 
malaria trainings. None had used a rapid diagnostic test for malaria, whilst almost all facilities did have 
microscopy available.  
 
Results 
We identified key themes that were important across the different sub-groups in the study. We found 
antimalarial prescriptions, antimalairal drugs and malaria tests to have multiple functions in the practice 
of health care, including but not limited to pathophysiological functions. Malaria drugs and tests also 
performed psychological and social functions. Drugs, prescriptions and testing procedures were imbued 
with different meanings, based on an understanding of what is required by patients in general, and each 
patient in particular. Underlying the varied use of malaria drugs and tests was flexibility in the category 
of ‘malaria’ that allowed various ailments to be incorporated within its socially acceptable label. This 
flexibility is assisted by the ambiguity of malaria in local clinical guidelines, with presumptive malaria 
treatment recommended as the default course of action.  
 
Enacting malaria: pathophysiology 
Foremost amongst reasons given by health workers in all groups for antimalarial prescription was to 
treat particular signs and symptoms, particularly fever, headache, vomiting and body or joint pains. Such 
symptoms were ‘clearly’ malaria, a diagnosis that overshadowed all potential others in the narratives of 
participants. Health workers talked about how their clinical experience shaped their recognition of 
malaria symptoms, particularly observing positive responses to antimalarial drugs: 
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‘From my day to day experience, the patients to whom I had prescribed, they got well. So, that 
one can also influence me to go on with the sign and symptoms that they are giving, so that I 
know that the other one had it and I gave this drug and the patient is well, so I can continue with 
it to the others.’ (P5, FGD104 Bamenda, mission facility midwives/nurses) 
Health workers described tests as important and desirable, but their results were overshadowed by the 
role of clinical judgement when it came to prescribing, 
‘There are clinical and biological reasons [to prescribe antimalarials]. Biologically, the thick blood 
smear, or a previous history. Priority is always given to the clinical despite the results of the thick 
blood smear. But at least, the malaria test is an important stage.’ (P4, FGD307 Yaoundé, mission 
facility medical doctors) 
The importance of treating cases as malaria presumptively was highlighted by many respondents who 
discussed their personal experiences of the risks of malaria – both in its frequency and its dangers,  
‘I would also like to say, we are in an endemic zone. That is, in particular, in Cameroon, the 
species of malaria is the Plasmodium falciparum ... It is the most devastating species which has 
after effects. There are some children who remain paralysed ... I saw children at the Central 
Hospital who were completely in a vegetative state because of malaria ... And for us, the first 
thought is that it is malaria. When we fall ill we think it is malaria’ (P10, FGD300, Yaoundé public 
facility nurses). 
In contrast with the strong feeling that malaria is well known, common and serious and therefore must 
be treated presumptively, feelings about testing were ambivalent. When asked about practice with 
negative malaria test results, respondents in all 17 FGDs stated that results do not change their 
treatment with antimalarials. In most cases, what health workers saw and heard from patients (‘signs 
and symptoms’) dictated treatment regardless of test results,  
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‘When we do the malaria test and it comes out negative, it does not prevent the patient from 
having his malaria ... We continue with the antimalarial treatment.’ (P11, FGD305 Yaoundé, 
mission facility midwives/nurses) 
Malaria as a clinical entity was thus defined beyond the boundaries of laboratory diagnosis. Clinical 
judgement of the health worker was most important, especially as the quality of laboratory staff and 
resources was sometimes questioned. Notable was the absence of statements of the reason for 
prescribing antimalarials being related to killing parasites, mentioned in only one focus group. 
 
Enacting malaria: psychology 
Health workers in both regions and across cadres repeatedly emphasised the importance of 
‘psychological treatment’ for patients as central to their healing and satisfaction, 
 ‘In the definition of medicine, we say the doctor treats the body and the soul, isn’t it? It implies 
that when a patient comes to you, if he is uncomfortable in his head, even if you give him the 
best drug, he would not be healed, isn’t it? So, a patient who comes, the psychological 
treatment is the first thing.’ (P3, FGD306 Yaoundé, public facility medical doctors) 
Health workers related that it was the welcome they gave to patients (at 15 FGDs) and the good 
interpersonal skills of the staff (at 13 FGDs) that satisfied patients. In only four FGDs did health workers 
discuss the availability of testing services as important to patients.  
In this context, where psychological treatment of patients was apparently so central to practice, it is 
perhaps unsurprising that medicines were sometimes given to patients as a ‘placebo,’ including 
antimalarials, other medicines and the mode of delivery. For example, drips were often symbols of care 
for patients,  
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‘We can just put an IV line and some B-complex inside just for placebo to flatter them. Because 
when they see that thing they think that it is malaria, but we are giving our antibiotic!’ (P8, 
FGD100 Bamenda, public facility nurses). 
However, health workers also described diagnostic tests as psychological, or ‘placebo’ treatment. Health 
workers from different cadres and in both areas said they felt that most patients liked to have tests 
performed, although there are some who did not ‘know the lab.’ Respondents made it clear that a key 
reason tests were done was for the psychological rather than diagnostic benefits,  
‘Some patients when they come, they already have in mind that they must do a laboratory test. 
So even when you observe that they do not necessarily need the test, we simply request the 
test because they want it to be done. We also request the test because they also require some 
psychological treatment. If you observe the symptoms they present, we simply prescribe them 
drugs, and to boost their psychological treatment we prescribe the test.’ (P8, FGD301 Yaoundé, 
mission facility nurses) 
‘According to me, most of the times I will send the patient for a malaria test just for the 
psychology of the patient, just to please the patient... but if I have to decide, the lab test will not 
count. Clinically I take my decision to treat my patients.’ (P4, FGD107 Bamenda, mission facility 
medical doctors) 
 
Enacting malaria: social context 
In addition to responding to clinical and psychological needs of patients, health workers across different 
sub-groups recognised the importance of considering other aspects of the backgrounds and needs of 
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their patients, including their educational background, their financial capabilities and the beliefs of the 
patient about their illness.  
Considering education and economics 
Health workers identified differences amongst their patients in expectations for malaria treatment and 
laboratory investigations. Broadly, those considered better educated and more able to pay would ask 
more questions and expect laboratory tests in order to know what their disease was. For others, who 
were described as ‘not knowing’ the lab, or who could not afford it, health workers reported that they 
would usually not test but move straight to treatment. For context, our baseline survey suggests 
patients pay on average 1 USD for a consultation, 2-3 USD for a malaria test and around 6 USD for all 
medicines received. 
‘When a patient comes in and then you see that the patient hasn’t money you just go straight to 
giving the treatment rather than sending the patient to the lab, while when coming back from 
the lab he will not be able to buy drugs.’ (P6 FGD103 Bamenda, public facility nurses)  
This may be partly based on fears that patients may be dissatisfied upon receiving negative results, 
‘Yes, we have already had a lot of problems with patients as regards the results. Because some 
patients, when you tell them it is negative, he puts in his mind that he has lost his money 
whereas when it is positive, he is happy.’ (P3 FGD302 Yaoundé, public facility nurses)  
Some health workers in Bamenda also expressed fears that they may be left to pay the expenses for 
very poor patients, leading to decisions for a less expensive consultation.  
Considering the patient’s concerns 
Aside from the patient’s educational and financial status, health workers described that for a patient to 
feel properly ‘treated,’ their concerns needed to be recognised and responded to. In some cases, this 
meant treating their malaria, even if it wasn’t strictly what the health worker would define as malaria,  
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‘So they come in saying “I have malaria,” so they consider all fevers to be malaria. So if you do 
not prescribe what treats their malaria, you have not prescribed what treats their illness. So, 
they feel well. They feel satisfied because you have responded to their concerns.’ (P6, FGD301, 
Yaoundé Mission facility nurses) 
Proper management of patients also meant giving confidence to the patient in the ability of the health 
worker. This involved specific processes of care and the use of particular artefacts such as drips and 
tests, and the declaration of ‘malaria’ if this was suspected to be the patient’s expectation. Health 
workers in all groups noted malaria as a more acceptable diagnosis than others. The acceptability of 
malaria was demonstrated by the ownership participants attributed to the disease, as ‘my malaria’, 
‘Patients prefer malaria because, when they have malaria, they already conclude that it is “their 
malaria.” They even come to the hospital and say: “no, I know that it is malaria that has been 
troubling me. It is my illness.” And when you confirm to them that it is malaria, he is happy.’ (P9 
FGD100 Bamenda, public facility nurses) 
Health workers identified that patients were generally relieved to receive malaria treatment or 
diagnoses because it is a disease that is common and well known, possible to cure, with simple 
treatment, and a less distressing diagnosis overall than others such as diabetes, hypertension, TB or HIV, 
which health workers found far harder to deliver to patients.  
‘I usually say that it [malaria] is an elegant sickness. “What do you have?” “I have malaria!” So 
when they get to the hospital and it is truly confirmed that they have malaria, they are happy. 
They say to themselves “No, it’s ok.” It means he knows that malaria is easy. It is a sickness 
which can be easily treated. (P3 FGD301 Yaoundé, mission facility nurses)  
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Juggling patient concerns and clinical reputation 
The many reasons for malaria acceptability meant that health workers found it hard to give non-malaria 
diagnoses and treatments, with an array of difficult patient responses to navigate. In the case of 
negative results, some health workers reported the need to emphasise their knowledge of malaria over 
that of the patient in order to persuade them of another diagnosis. However, this was not always easy, 
particularly with ‘those who have been to school and believe that they know all in all the domains’ who 
would not accept a negative malaria diagnosis. For fear of their competence being undermined, 
participants, particularly the medical doctors, said they often made the malaria diagnosis anyway, 
‘Yes as a clinician ... you are not managing lab results you are managing the patient ... when the 
lab results come back you are not going to tell the patient that you don’t have malaria. You are 
going to explain to the patient that “this test is negative but it doesn’t mean that you don’t have 
malaria,” so you still go ahead and treat. So it depends on how you disclose the information to 
the patient because if you just sit back and tell the patient that you don’t have malaria then the 
patient will even have the impression that you don’t know what you are doing.’ (P3 FGD107 
Bamenda, mission facility medical doctors) 
‘What could we also say to the patients who comes with a negative malaria test whereas we are 
suspecting malaria? We could only tell him that it is a drop of blood that was taken for analysis. 
If we had taken a good quantity of blood we could find malaria, we could find the parasites. So, 
it is just a drop of blood, he needs not worry, yes he has malaria.’ (P6 FGD306, Yaoundé public 
facility medical doctors) 
 
This left health workers to juggle patient expectations alongside the need to maintain professional and 
institutional authority, sometimes through bending realities in explanations to patients and contributing 
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to malaria overdiagnosis, 
‘If the test is negative whereas we suspect malaria in a patient, I try to, it would first of all 
depend on the attitude that I had with the patient at the start, the degree of confidence that I 
did have with him. I would not try to explain him the things of the hospital, like to tell him the 
laboratory things. I just try to tell him “it could happen that the thick blood smear, your blood 
that was taken, the parasitaemia was not high, but you are supposed to have malaria.” I tell him 
like that and I put him on treatment. So, I try to reassure him that it is just as a result of the 
blood that was collected, in order not to incriminate the hospital.’ (P2 FGD306, Yaoundé public 
facility medical doctors) 
 
Enacting malaria: ‘evidence’ 
In around half of the FGDs, across the participant sub-groups, discussions of malaria diagnosis included 
citation of guidelines, mostly noting that presumptive treatment was the malaria policy, 
‘To respect the standard policy for the management of malaria, once there is a fever, you have 
to put an antimalarial treatment.’ (P3, FGD306 Yaounde, public facility medical doctors). 
Indeed, the 2008 guidelines promote presumptive treatment of fevers with antimalarial drugs (Ministry 
of Public Health, 2008) by stating:  
‘Fever is the most frequent symptom and the most reliable criterion in the diagnosis, treatment 
and follow-up of malaria.’ (emphasis in original) 
Then, 
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‘Malaria diagnosis is based on the identification of plasmodium with the microscope either on a 
blood film and/or a thick blood smear. However, a negative result does not rule out the 
presence of malaria.’ 
And, as a ‘hint’ on the last page, 
‘Malaria is a costly disease to the household and to society. The importance of an appropriate 
treatment cannot therefore be overemphasized.’  
The word ‘evidence’ does not appear in the guidelines at all, and their style conveys authoritative 
information, based on objective knowledge. It also carries an implicit assumption that clinicians can 
identify malaria in spite of laboratory results that may be negative. Respondents, particularly medical 
doctors, did show awareness of an apparent paradox in this practice, but this awareness was not 
sufficient for most to challenge its premise, 
‘*sending patients for tests] allows them to be reassured but it is a little bit paradoxical because 
there are patients who come, who would do the malaria test which would turn out negative, but 
you would nonetheless put him on antimalarial treatment.’ (P1, FGD307, Yaoundé, mission 
facility medical doctors)  
Uniquely, one medical doctor did use the term ‘evidence based medicine’ to account for his decisions to 
restrict antimalarial drugs to those with parasites,  
‘As I said earlier, I believe in evidence-based medicine. If I have a patient who has not taken 
antimalarial drug before coming to me and the malaria parasite is negative. I know that you 
people will disagree with me but I am not tempted in treating that patient for malaria. I know that 
you disagree with me. But I will look for other causes. Because we have the tendency of treating 
everybody in Africa for malaria, when we have many other pathologies who can present the 
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commonest symptoms which is fever. So I believe in evidence based medicine. I don’t treat [by] 
giving malaria drugs [P1 and P5 and start smiling] just like that.’ (P2 FGD307 Yaoundé, mission 
medical doctors) 
However, in the main, malaria diagnosis and treatment at health facilities could be described as based 
on ‘evidence’ that could be captured from observation and listening to the patient. This is in line with 
existing guidelines. However, in line with the international move towards evidence-based medicine, the 
country’s 2009 Global Fund application declared promotion of the ‘rational use’ of ACTs by using RDTs 
or microscopy before providing treatment in all cases of fever in patients over five years (Ministry of 
Public Health, 2009).  
APPENDIX B
328
 21 
 
Discussion 
Antimalarials are overprescribed in Cameroon. This practice appears to be embedded in the social 
enactment of malaria, a wider concept than Plasmodium parasites. The richness of medical decision 
making is not usually targeted by evidence-based guidelines, but is crucial for understanding the context 
within which guidelines are enacted. This paper highlights three areas that are downplayed in such 
guidelines: individual experiences of clinicians, perceived psychological responses of patients and the 
social context of the patient and clinician; each reflecting what is valued as ‘evidence’ in local schools of 
medical thought.  
 
The clinical rather than ‘paraclinical’ mode of diagnosis described here is in line with observations from 
elsewhere that clinicians often practice with a more ‘interpretive’ than ‘probabilistic’ model, whereby 
interpretation seeks to make sense of ‘the whole story’ of a patient’s condition, and is ‘therefore 
irreducible to probabilities, no matter how rigorously derived’ (Tanenbaum, 1994)(p31). In this 
interpretive line of practice, based on a realist rather than empiricist school of medical thought, 
diagnosis is not limited to the black-and-white ideal of restricting treatment as dictated by a laboratory. 
The use of ‘psychological’ treatment – in the form of medicines but also procedures such as tests or 
drips – also demonstrates a more interpretive, as well as paternalistic approach, providing what is 
perceived as needed for that patient. Malaria test results may have been largely ignored in the face of 
clinical symptoms, but they served an important function in providing care to patients. This extends the 
idea of the ‘placebo’ beyond the idea of the accompanying therapeutic effect of giving a drug to a 
patient from a specific prescriber in a specific context (Claridge, 1970), to the therapeutic effect of 
entering a diagnostic process. The belief of health workers in this study that processes of care play a role 
in therapy mirrors findings of trials that various processes, including the use of instruments and labels 
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for diagnoses, affect health outcomes (Moerman, 2000), reflecting the power of their symbolic value. It 
is interesting to ask why the health workers in this study use these concepts of ‘placebo’ and 
‘psychological’ treatment.  This can be interpreted within the paternalistic paradigm of medicine, 
whereby the clinician is making decisions they believe are best for patients, including concealing certain 
truths, on their behalf (Lynoe et al., 1993). This presents a particular challenge for the expectation for 
clinicians to follow evidence solely based on laboratory data. Together with clinicians’ consideration of 
the whole person, including their capacity for appreciating and/or paying for tests, this points to a 
broader interpretation of the role of clinician that is often neglected in simplified clinical algorithms and 
epidemiology based targets for ‘rational drug use.’  These findings, of broader context and expectations 
affecting diagnostic practice for malaria, are in line with the theory that clinicians operate with 
‘mindlines’ rather than guidelines, as previously described in Tanzania (Chandler et al., 2008a) and 
Ghana (Chandler et al., 2010).  
 
The ‘juggling’ that clinicians conveyed, between patients’ desires, clinical guidelines and protecting 
medical reputations, was most commonly described by medical doctors, who perhaps feel in a stronger 
position to blame tests or ‘quantity of blood’ than lower cadre colleagues. This diversion of blame away 
from individuals and institutions may reflect difficulties with dealing with not knowing, and the primacy 
of the ‘art’ of medicine. The challenge of integrating new technologies and probabilistic-oriented 
guidelines into medicine is long standing and well described in Europe and the USA, where such 
‘evidence’ has been doubted, reinterpreted, used as a starting point, added as one part of a tool-kit, or 
cast out in favour of other better established knowledges (Gordon, 1988; Kassirer, 1992; Tanenbaum, 
1994). The introduction of parasite-based guidelines and equipment represents the same challenge, 
instigated by the evidence-based movement in the North, but expected to be played out far more 
rapidly in the South. Lessons from the adoption of evidence-based approaches elsewhere suggests 
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expectations for rapid scale-up of RDTs may need to be reined-in. In addition, those aiming for targets 
for all patients to be tested for malaria and treated in line with results may need to accept that while the 
strategy of appealing to ‘the evidence’ as the bottom line is attractive as a rationalisation project, this 
may be fought for at the expense of other aspects of the complex social process of health care 
(Goldenberg, 2006). 
 
We recommend that the interpretive style of medicine should be valued and maintained rather than 
attempting to overwrite this with a probabilistic approach. Clinicians should be supported in continuing 
to respond to the complex social context of their work including crucially to the patient as a whole. 
Change towards improved clinical care and better use of resources may be achieved within this 
approach through different means that go beyond training in case management. Firstly, raising 
consciousness amongst clinicians of the reasons for and consequences of certain practices, such as 
providing ‘placebo’ tests or drugs, and stimulating problem-solving to achieve desired results without 
compromising clinical outcomes could enable change (Freire, 1975). Secondly, encouraging clinicians to 
experiment with their new tools in practice, including assessing the responses of patients, may also help 
to shift behaviour (Armstrong & Ogden, 2006). Thirdly, equipping clinicians with skills to communicate 
with patients in order to elicit their specific needs, for example to understand the meaning of a negative 
malaria test result, and to respond to these without reliance on the use of commodities could provide a 
channel through which to implement change. Findings from elsewhere in Cameroon suggest that there 
is still significant room for improvement in patient-centred care from biomedical providers (Labhardt et 
al., 2010). Such clinician-oriented interventions have been successful elsewhere when carried out at a 
local level through participatory workshops (Fonn et al., 2001). We have designed a supporting 
intervention for providers based on these principles, which will be compared with standard introduction 
of RDTs in a cluster randomised controlled trial in 2011-12 (clinicaltrials.gov NCT01350752) (Wiseman et 
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al., 2012). Our results also suggest that the role of probabilistic guidelines in routine case management 
needs to be debated amongst the wider community of clinicians in the professions of medicine and 
nursing.  
 
In this paper, we have attempted to outline the ‘reality’ of malaria from the perspective of health 
workers. We know that the enactment of malaria is also different from the perspective of patients, 
researchers of varying disciplines and those involved in public health enterprises (Beisel, 2010). We 
therefore only present our partial interpretation, and these other perspectives will also be important to 
explore when considering the uptake of RDTs. Our interpretation is also only partial because of the 
perspectives of those asking questions in FGDs and the set-up of the project as part of a biomedical 
research organisation. Participants may have aligned their responses with expected biomedical norms, 
although this could strengthen our conclusion that malaria is constructed as paramount amongst 
diseases. The study could have been strengthened further with the use of observational methods such 
as ethnography, particularly given our focus on the praxis of malaria. The use of FGDs rather than 
interviews reduces our ability to analyse findings across different health worker characteristics, such as 
length of professional experience. However, our intention was to understand factors in common 
between different groups, and although the study was only in two areas of Cameroon, we suggest the 
common ground between the sub-groups and with findings elsewhere does provide some transferable 
concepts, such as the important place of the social roles of health workers, tests and medicines in health 
care. 
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Conclusion 
Few would dispute that rapid diagnostic tests have a potentially useful role to play in limiting malaria 
over-diagnosis and over-treatment. This study illustrates the divide between parasite-based guidelines 
initiated in Geneva and patient-based practice in Cameroon for the diagnosis and treatment of malaria. 
Careful attention must be paid to the values and priorities of health workers and patients if they are to 
be partners in improving diagnosis and treatment of febrile illnesses.  
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Tables 
TABLE 1. SUB-GROUP CHARACTERISTICS OF HEALTH WORKER FGDS 
 Number of FGDs 
 Bamenda Yaoundé 
Health facility type   
Public 5 5 
Mission 3 4 
Cadre   
Medical Doctors only 2 3 
Staff nurses/registered nurses only 0 6 
Nurses and nursing assistants mixed 6 0 
 
Total 
 
8 
 
9 
 
.
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TABLE 2. DEMOGRAPHIC AND WORK HISTORY CHARACTERISTICS OF HW FGD PARTICIPANTS 
 Number of participants (%) 
 Bamenda Yaoundé 
Gender   
Female 56 (82%) 55 (71%) 
Male 12 (18%) 23 (29%) 
Age   
30 and younger 15 (22%) 13 (17%) 
31-45 39 (57%) 40 (51%) 
46 and older 14 (21%) 25 (32%) 
Originally from region   
Yes 24 (35%) 24 (31%) 
No 44 (65%) 54 (69%) 
Highest education level   
Primary School 7 (10%) 1 (1%) 
Secondary School 18 (27%) 35 (45%) 
High School 28 (41%) 22 (28%) 
Bachelor’s Degree/diploma 15 (22%) 20 (26%) 
Number of years health profession training   
1 year 26 (38%) 1 (1%) 
2 years 7 (10%) 23 (30%) 
3 years 16 (24%) 32 (41%) 
4 + years 19 (28%) 22 (28%) 
Health profession graduation year    
1990 and before 14 (21%) 20 (25%) 
1991-2000 18 (26%) 27 (35%) 
2001-2010 36 (53%) 31 (40%) 
Number of malaria trainings attended   
None 42 (62%) 40 (51%) 
1 13 (19%) 24 (31%) 
2 7 (10%) 7 (9%) 
3+ 6 (9%) 7 (9%) 
 
Total 
 
68 
 
78 
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Appendix C 
Research Paper VII: What does it take to improve diagnosis and 
treatment for uncomplicated malaria? A three-arm cluster randomised 
trial in two areas of Cameroon 
This research paper contains information about the implementation and effectiveness of 
the introducing RDTs with basic and enhanced training at public and mission facilities in 
Cameroon. It complements Research Paper V, which reports the cost-effectiveness 
analysis.  
The interventions developed to improve providers’ practice in diagnosing and treating 
malaria were evaluated using a cluster-randomized trial. Public and mission health 
facilities in the study sites were randomly allocated to one of three arms: basic, enhanced 
and control. Facilities in the basic and enhanced arms were supplied RDTs each month and 
up to three providers per facility were trained on the basic knowledge and practical skills 
needed to effectively diagnose and treat malaria. Providers in the enhanced arm also 
received two-days of supplementary training using participatory methods that explicitly 
sought to change providers’ practice.  
The proportion of patients who were tested for malaria and the proportion of patients 
with a positive test result who were prescribed or received an ACT were similar across the 
study arms. However, the proportion of patients with a negative test result who were 
prescribed or received an antimalarial was significantly reduced in the enhanced arm, and 
non-significantly reduced in the basic arm.  
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Articles
Basic or enhanced clinician training to improve adherence to 
malaria treatment guidelines: a cluster-randomised trial in 
two areas of Cameroon
Wilfred F Mbacham, Lindsay Mangham-Jeﬀ eries, Bonnie Cundill, Olivia A Achonduh, Clare I R Chandler, Joel N Ambebila, Armand Nkwescheu, 
Dorothy Forsah-Achu, Victor Ndiforchu, Odile Tchekountouo, Mbuh Akindeh-Nji, Pierre Ongolo-Zogo, Virginia Wiseman
Summary
Background The scale-up of malaria rapid diagnostic tests (RDTs) is intended to improve case management of fever 
and targeting of artemisinin-based combination therapy. Habitual presumptive treatment has hampered these 
intentions, suggesting a need for strategies to support behaviour change. We aimed to assess the introduction of 
RDTs when packaged with basic or enhanced clinician training interventions in Cameroon.
Methods We did a three-arm, stratiﬁ ed, cluster-randomised trial at 46 public and mission health facilities at two study 
sites in Cameroon to compare three approaches to malaria diagnosis. Facilities were randomly assigned by a computer 
program in a 9:19:19 ratio to current practice with microscopy (widely available, used as a control group); RDTs with a 
basic (1 day) clinician training intervention; or RDTs with an enhanced (3 days) clinician training intervention. 
Patients (or their carers) and ﬁ eldworkers who administered surveys to obtain outcome data were masked to study 
group assignment. The primary outcome was the proportion of patients treated in accordance with WHO malaria 
treatment guidelines, which is a composite indicator of whether patients were tested for malaria and given appropriate 
treatment consistent with the test result. All analyses were by intention to treat. This study is registered at ClinicalTrials.
gov, number NCT01350752.
Findings The study took place between June 7 and Dec 14, 2011. The analysis included 681 patients from nine facilities 
in the control group, 1632 patients from 18 facilities in the basic-training group, and 1669 from 19 facilities in the 
enhanced-training group. The proportion of patients treated in accordance with malaria guidelines did not improve 
with either intervention; the adjusted risk ratio (RR) for basic training compared with control was 1·04 (95% 
CI 0·53–2·07; p=0·90), and for enhanced training compared with control was 1·17 (0·61–2·25; p=0·62). Inappropriate 
use of antimalarial drugs after a negative test was reduced from 84% (201/239) in the control group to 52% (413/796) 
in the basic-training group (unadjusted RR 0·63, 0·28–1·43; p=0·25) and to 31% (232/759) in the enhanced-training 
group (0·29, 0·11–0·77; p=0·02).
Interpretation Enhanced clinician training, designed to translate knowledge into prescribing practice and improve 
quality of care, has the potential to halve overtreatment in public and mission health facilities in Cameroon. Basic 
training is unlikely to be suﬃ  cient to support the behaviour change required for the introduction of RDTs.
Funding ACT Consortium (Bill & Melinda Gates Foundation).
Copyright © Mbacham et al. Open Access article distributed under the terms of CC BY-NC-SA.
Introduction
Presumptive treatment of fever as malaria is entrenched 
in medical practice in malaria-endemic countries. In 
many African countries, fewer than 20% of suspected 
malaria cases were conﬁ rmed through parasitological 
testing in 2009.1 Increased awareness of the 
overdiagnosis of malaria and concerns about 
inappropriate treatment of fevers, drug wastage, and 
the potential for drug resistance have led WHO to 
recommend universal parasitological conﬁ rmation 
before the use of artemisinin-based combination 
therapy.2 Malaria rapid diagnostic tests (RDTs) oﬀ er the 
potential for improved targeting of artemisinin-based 
combination therapy in settings where microscopy is 
absent or of uncertain quality.3–5
Studies of malaria diagnosis in public health facilities 
have shown that clinicians rely on clinical judgment over 
the results of diagnostic tests.6–9 Challenges faced by 
clinicians in the diagnostic process include insuﬃ  cient 
training in the use of tests,10 a distrust of negative test 
results,11–13 little conﬁ dence or resources to treat alternative 
causes of fever,10,12 and the perception of patient demand 
for antimalarial drugs.14,15 These challenges seem to 
persist even when highly sensitive and speciﬁ c RDTs are 
used12 and when the evidence suggests that adhering to 
RDT results does not have a negative eﬀ ect on health 
outcomes.16 Interventions are urgently needed to address 
such problems in routine health-care settings.
Few studies have assessed interventions intended to 
change clinician practice when introducing RDTs, and 
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those that have investigated such interventions have 
produced mixed results, have often used weak study 
designs, and have provided little information about the 
interventions used.17 Policy makers therefore remain 
uncertain about the types of intervention needed and 
about which interventions can be implemented within 
a realistic budget. This study, Research on the 
Economics of Artemisinin-based Combination Therapy 
(REACT), was done in two phases and was undertaken 
to identify interventions that could be adopted by the 
National Malaria Control Programme to support the 
distribution of RDTs in Cameroon. In the ﬁ rst phase,18 
formative research showed that microscopy was 
available at 90% of public health facilities and all 
mission and private health facilities, and that 35% of 
patients at public and 44% at mission facilities were 
tested. Of patients tested during their consultation, 
78% of those who had a positive test result were 
prescribed or received an antimalarial drug (52% 
artemisinin-based com bination therapy), but so 
were 82% of those who had a negative test result (56% 
artemisinin-based com bination therapy).18 We therefore 
recognised a need for changes in clinician knowledge, 
skills, and mindset to make test-driven diagnoses the 
norm in this setting.9,18 The second phase, the results of 
which are reported here, was a stratiﬁ ed cluster-
randomised trial done in a real-world setting to compare 
the introduction of RDTs in two intervention packages 
(involving diﬀ erent content and modes of clinician 
training) to routine care where microscopy is widely 
available. The overall aim of the study was assess how 
to improve the targeted use of antimalarial treatment 
and to optimise the imple mentation of malaria 
treatment guidelines.2
Methods
Study setting and population
We did a stratiﬁ ed, cluster-randomised trial at 46 public 
and mission health facilities (clusters) in two study sites 
(strata) in Cameroon (Yaoundé in the Centre region and 
Bamenda in the Northwest region). Facilities were 
eligible for inclusion if they were not included in the 
Government’s pilot rollout of RDTs,19 did not oﬀ er 
specialist services, received more than four febrile 
patients per day on average, and were more than 2 km 
(1 km in Yaoundé) away from another facility. All patients 
(or their carers) who attended the health facilities 
between Oct 3 and Dec 14, 2011, were approached on exit 
for consent to participate in the study and screened for 
their eligibility. Patients were eligible for inclusion in the 
exit survey if they reported seeking treatment for fever or 
suspected malaria, but were excluded if they were 
pregnant, younger than 6 months, or had signs of severe 
malaria. Individuals were also excluded if the patient was 
not present (when a carer was the respondent). Medical 
doctors, nurses, laboratory technicians, and pharmacy 
attendants were eligible for the clinician training, and all 
clinicians responsible for the diagnosis and treatment of 
malaria were eligible for participation in the assessment 
of provider knowledge. The nature and purpose of the 
trial was explained to the participants, all of whom 
provided written informed consent (consent for child 
participants was obtained from parents or carers).
Ethics approval was obtained from the London School 
of Hygiene & Tropical Medicine (number 5885) and the 
Cameroon National Ethics Committee (number 030/
CNE/DNM/09). Administrative clearance was obtained 
from the Cameroon Ministry of Public Health (number 
D30-343/AAR/MINSANTE/SG/DROS/CRC/JA). An 
independent data safety monitoring board monitored the 
trial and approved the analysis plan.
Randomisation and masking
Within each study site, facilities were randomly selected 
from those that met the eligibility criteria and had agreed 
to participate in the study, and were randomly allocated 
in a 9:19:19 ratio to the control, basic-training inter-
vention, or enhanced-training intervention groups by a 
process of constrained or restricted randomisation (to 
improve the balance across the study groups).20 The study 
statistician (BC), who had no involvement in the delivery 
or assessment of the interventions, did the random 
assignment using a program written in R statistical 
software version 2.13.0 (R Foundation for Statistical 
Computing, Vienna, Austria). Patients (or their carers) 
and ﬁ eldworkers who administered the surveys were 
masked to study group assignment.
Procedures
Clinicians in the control facilities did not receive RDTs or 
training as part of the study. Facilities in both intervention 
groups were supplied with 100 RDTs (SD Bioline Malaria 
Ag Pf/Pan, Standard Diagnostics, Yongin, South Korea) 
each month without charge. Facilities could charge 
patients for the use of RDTs, but, in line with national 
policy, facilities were asked not to charge for their use in 
children younger than 5 years, and 100 CFA francs 
(US$0·20) was the recommended price per test for other 
patients. The availability of artemisinin-based com-
bination therapy was not controlled.
The training interventions were designed to be suitable 
for implementation on a large scale. Clinicians working at 
facilities assigned to the basic-training intervention group 
were invited to a 1-day training course with three separate 
modules. These modules covered malaria diagnosis, 
RDTs, and malaria treatment. Together these modules 
explained to participants that all febrile patients should be 
tested for malaria using microscopy or an RDT, described 
the procedures for using an RDT, and explained that 
conﬁ rmed cases of uncomplicated malaria should be 
treated with artemisinin-based combination therapy, 
whereas patients with a negative malaria test should not be 
given antimalarial drugs. The training also included advice 
about other causes of febrile illness. The training was 
For more on the REACT study 
see www.actconsortium.org/
REACTCameroon
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provided by representatives of the National Malaria Control 
Programme and members of the research team who had 
been trained to deliver the material. Information was 
disseminated through lectures, and a practical session was 
run to show participants how to use an RDT.
Clinicians working at facilities in the enhanced-training 
intervention group received 3 days of training. The ﬁ rst 
day was identical to that attended by those in the basic-
training group, and the remainder of the course covered 
three additional modules targeting improvements in 
quality of care. These modules covered adapting to 
change, professionalism, and eﬀ ective communication. 
The module on adapting to change sought to provide 
clinicians with the opportunity to reﬂ ect and discuss the 
WHO malaria treatment guidelines2 and to learn from 
others. It included testimonials about the use of RDTs, 
and participants reﬂ ected on and discussed recom-
mendations in the malaria guidelines.2 As well as 
discussions in small groups, the module included a card 
game for four to six players designed to reinforce the 
treatment algorithm.
In the professionalism module, clinicians were asked to 
identify and agree on the values and behaviours that are 
important when providing care. The module included an 
exercise in which participants considered real-life scenarios 
that often interrupt the process of care and were 
encouraged to develop strategies for managing these 
situations. The ﬁ nal module focused on improving the 
clinicians’ skills in communicating with patients. It began 
by reﬂ ecting on what patients think about malaria and its 
treatment. The module also looked at diﬀ erent ways of 
managing patients’ expectations and allowed participants 
to develop skills and techniques for explaining to patients 
why they should be tested for malaria and for dealing with 
the situation in which the test is negative and an 
antimalarial should not be prescribed. Participants 
developed and acted out dramas to help them to understand 
the consequences for patients of not being prescribed an 
antimalarial drug and the alternative courses of action that 
could be pursued. These additional modules were designed 
to reinforce material contained in the malaria treatment 
guidelines and to address challenges brought by RDTs for 
the interactions between health workers and patients.9,18
In both intervention groups, participants received 
copies of training materials and job aids (including 
posters and table-top ﬂ ip charts) and were strongly 
encouraged to train other clinicians at their facilities. We 
used this form of in-facility cascade training because it 
seemed to be the most feasible approach for this 
resource-constrained setting. The training materials 
used are available from the ACT Consortium website.
Data were collected on the process of implementing 
the interventions: the research team kept records of 
RDTs supplied to each facility; clinician satisfaction and 
understanding of training materials was assessed by use 
of a structured questionnaire at the start and end of the 
training workshops; and the training facilitators 
completed an assessment form recording details of the 
running of the workshops.
Outcomes
The primary outcome was the proportion of patients 
attending study facilities that reported a fever or 
suspected malaria and received treatment in accordance 
with the WHO malaria treatment guidelines.2 This 
outcome is a composite measure that requires febrile 
patients to be tested for malaria (with either microscopy 
or an RDT), patients with a positive malaria test result to 
be given artemisinin-based combination therapy, and 
patients with a negative malaria test result not to receive 
an antimalarial drug.
The primary outcome was assessed through an 
interviewer-administered patient exit survey to all eligible 
and consenting patients (or carers) exiting the study 
facilities. The survey started 3 months after the 
interventions were implemented and ran for 3 months. 
The exit survey asked about the patient’s previous 
treatment seeking, whether the patient was tested, what 
treatment was prescribed and received, and whether the 
patient was satisﬁ ed with the visit (with options ranging 
from completely satisﬁ ed to not at all satisﬁ ed).
Clinicians were asked to complete a register of all 
malaria tests done by microscopy or RDTs to supplement 
the exit survey, since patients might not always know 
whether they were tested for malaria or the result of the 
malaria test. The register data included facility code, 
date, patient name, age, sex, type of test done (microscopy 
or RDT), test result, and the name of the health worker 
who did the test. A ﬁ eldworker collected the register at 
the end of every week and combined this information 
with the exit survey results. A subsample of patients 
(roughly 5%) was independently tested by the research 
team to determine the degree of consistency between the 
test results reported by the patients, clinicians, and 
research team. A facility audit was done once the exit 
survey was complete to collect details about the health 
facility (such as type of facility, how long it had been in 
operation, and the average number of patients treated 
per day), available resources (such as number and type of 
staﬀ , testing equipment, and drugs), and management 
procedures (such as stocking and procurement). 
Fieldworkers obtained these data by interviewing the 
head of the facility with a structured questionnaire.
On the basis of our formative research,18 we assumed 
that the proportion of patients treated in accordance with 
malaria treatment guidelines (the primary outcome) 
would be 15% in the control group and that the coeﬃ  cient 
of variation between clusters within each stratum would 
be 0·25. On the basis of these assumptions, we estimated 
that a sample size of nine facilities per group 
with 100 patients per facility would be needed (with 
allowance for facility withdrawals) to provide 80% power 
at the 5% signiﬁ cance level to detect a 15 percentage 
point increase in the primary outcome (ie, increasing the 
For the study training materials 
see http://www.actconsortium.
org/REACTCameroonmanuals
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proportion to at least 30%) in either of the intervention 
groups.19 To test whether the basic training was as 
eﬀ ective as the enhanced training, we estimated that a 
sample size of 19 clusters per group would have 80% 
power to show that the basic intervention is non-inferior 
(with a margin of 10%) to the enhanced intervention at 
the 5% signiﬁ cance level (two-sided). Thus, the number 
needed for the non-inferiority comparison was greater, 
and the ﬁ nal sample size was set at nine for the control 
group and 19 for each intervention groups.20
All clinicians responsible for diagnosis and treatment of 
suspected cases of malaria were asked to take part in a 
clinician survey. This survey was done after completion of 
the patient exit survey and measured changes in secondary 
outcomes between study groups including changes in 
clinicians’ knowledge and preferences for treating patients 
presenting with symptoms of uncomplicated malaria. The 
assessment of clinicians’ knowledge included a mean 
score for how to use an RDT, which was derived from the 
correct identiﬁ cation of 11 steps required to do the test. The 
logic model in ﬁ gure 1 shows the expected eﬀ ect of the 
provider interventions on primary and secondary 
outcomes.
Further information about the design of the trial and 
the interventions is reported in the study protocol.20
Statistical analysis
All data were double-entered in Microsoft Access 2007 
(Microsoft, Redmond, WA, USA), veriﬁ ed with the data 
compare utility in Epi Info 2000 (Centers for Disease 
Control and Prevention, Atlanta, GA, USA), and 
analysed with Stata version 12.0 (Stata Corporation, 
College Station, TX, USA). All analyses were by 
intention to treat. We used methods suitable for 
stratiﬁ ed, cluster-randomised trials with fewer 
than 20 clusters per group21 to assess the eﬀ ect of each 
intervention compared with control. Within each 
stratum, we calculated the risk ratio (RR) from the mean 
risks across facilities in each intervention group. We 
calculated an overall estimate of the RR as the geometric 
weighted average of the stratum-speciﬁ c RRs, with the 
weights inversely proportional to the stratum-speciﬁ c 
variances. We calculated 95% CIs taking into account 
the observed between-cluster variation21 and did formal 
hypothesis testing by use of a stratiﬁ ed t test on the 
logarithm of the RR.
We adjusted for covariates by ﬁ tting a logistic 
regression model to data for individual patients, 
including terms for stratum and the covariates of 
interest, but excluding the intervention eﬀ ect. We 
estimated ratio-residuals for each facility by comparing 
expected and observed values, and we applied the same 
methods for estimating the RRs and 95% CIs and for 
hypothesis testing as we used in the main analysis, but 
with the residuals replacing facility-speciﬁ c risks. We 
assessed non-inferiority between the two intervention 
groups using the same methods used for the main 
analysis to calculate an overall estimate of the risk 
diﬀ erence and a corresponding one-sided 95% CI.
The trial is registered with ClinicalTrials.gov, number 
NCT01350752.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
The study took place between June 7 and Dec 14, 2011. 
122 facilities were assessed for eligibility (50 in Yaoundé 
and 72 in Bamenda); after exclusions, 46 facilities were 
included in the analyses (24 in Yaoundé and 22 in 
Bamenda), with nine randomly allocated to the control 
group, 18 to the basic-training intervention, and 19 to the 
enhanced-training intervention (ﬁ gure 2).
The basic and enhanced training workshops were 
successfully delivered across both study sites, with 
all 37 intervention facilities represented and the 
Figure 1: Logic model for the eﬀ ect of provider interventions on treatment received by patients
RDTs=rapid diagnostic tests. Reproduced from reference 20.
Provider 
intervention
Control Basic intervention Enhanced intervention
Current practice
(no intervention)
RDTs supplied 
to facilities
Training on:
• how to do RDTs and 
interpret results
• treatment 
recommended 
in malaria guidelines
RDTs supplied 
to facilities
Training on:
• how to do RDTs and 
interpret results
• treatment 
recommended 
in malaria guidelines
Additional training to:
• encourage adherence 
to guidelines through 
supportive interactive 
activities
• develop 
communication skills 
with patients 
and colleagues
Improved knowledge
Large change in willingness 
to do malaria tests and
treat on the basis of test 
results
Improved communication
with patients
Large increase in the 
proportion of febrile 
patients treated in 
accordance with 
malaria guidelines
Improved knowledge
Moderate change in 
willingness to do malaria
tests and treat 
on the basis of test results
Moderate increase in the 
proportion of febrile 
patients treated in 
accordance with 
malaria guidelines
No change in knowledge 
or practice
No change
Eﬀect of 
intervention 
on provider
Eﬀect on the 
treatment 
received by 
febrile patients
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training materials delivered as planned. Participant 
satisfaction was high in both intervention groups, with 
more than three-quarters of participants (77% [37/48] in 
the basic-training group and 83% [40/48] in the 
enhanced-training group) strongly agreeing that they 
were satisﬁ ed with the training (as deﬁ ned by 
knowledge gained and the relevance and acceptability 
of the material). Seven of eight facilitators responsible 
for delivering the training also strongly agreed that the 
learning objectives for each module had been achieved 
successfully. Three facilities in Yaoundé assigned to the 
basic-training intervention did not do any in-facility 
cascade training for clinicians who did not attend the 
workshops (ﬁ gure 2).
Each month 100 RDTs were supplied to all facilities in 
the intervention groups, from the end of the training 
until all assessments were complete (6 months). Despite 
requests not to charge more than 100 CFA francs 
(US$0·20) per test, most facilities charged substantially 
more, with a mean charge of 611 CFA francs ($1·28) per 
test in facilities in the basic-training group and 997 CFA 
francs ($2·09) in the enhanced-training group. Facilities 
were supplied with artemisinin-based combination 
therapy by the Government or mission authorities, and 
availability was reasonably good; four public facilities 
reported stock-outs in the 4 weeks before the facility 
audit, and eight reported problems obtaining stock in the 
previous year.
Characteristics of the facilities and patients were 
generally similar across the groups (tables 1, 2), but with 
some exceptions: there were disproportionately more 
public than mission facilities in the control group; 
Figure 2: Study proﬁ le
Flow of facilities (clusters), clinicians, and patients through the study.
122 facilities assessed for eligibility
72 in Bamenda stratum
50 in Yaoundé stratum 58 facilities excluded 
10 were specialist facilities
24 had too few patients
12 were included in pilot rollout of RDTs
6 were too close (for contamination reasons)
6 were inaccessible
17 facilities were not selected for inclusion in 
the study
64 facilities eligible
32 in Bamenda stratum
32 in Yaoundé stratum
47 randomly assigned 
23 in Bamenda
24 in Yaoundé
1 facility (in Bamenda) withdrew consent after 
random assignment to the basic-training group
(excluded from analysis)
9 facilities in control group 
(5 in Bamenda, 4 in Yaoundé)
39 clinicians invited to take part in 
clinician survey
729 patients invited to take part in the 
patient exit survey
18 facilities in the basic-training group 
(8 in Bamenda, 10 in Yaoundé)
18 received workshop training
15 did in-facility training
18 received RDTs
95 clinicians invited to take part in 
clinician survey
1879 patients invited to take part in the 
patient exit survey
19 facilities in the enhanced-training group
(9 in Bamenda, 10 in Yaoundé)
19 received workshop training
19 did in-facility training
19 received RDTs
103 clinicians invited to take part in 
clinician survey
2021 patients invited to take part in the
patient exit survey
0 facilities lost to follow-up
0 clinicians did not complete survey
48 (7%) patients were not eligible
0 facilities lost to follow-up
0 clinicians did not complete survey
247 (13%) patients were not eligible
0 facilities lost to follow-up
0 clinicians did not complete survey
352 (17%) patients were not eligible
Included in primary analysis
9 facilities
39 clinicians in clinician survey
681 (93%) patients in patient exit survey
Included in primary analysis
18 facilities
95 clinicians in clinician survey
1632 (87%) patients in patient exit survey
Included in primary analysis
19 facilities
103 clinicians in clinician survey
1669 (83%) patients in patient exit survey
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intervention facilities treated a larger number of patients 
per day; and patients seeking treatment at control 
facilities were of a higher socioeconomic status than 
those at intervention facilities. Concordance between 
RDT reporting in registers and exit-poll information was 
high (sensitivity 96%, speciﬁ city 94%, observed 
agreement 95%, κ=0·89).
Neither training intervention had a signiﬁ cant eﬀ ect 
on the proportion of febrile patients treated in 
accordance with malaria treatment guidelines (table 3). 
The proportion of patients tested for malaria was high 
across all groups. Compared with the control group, the 
proportion of patients with a negative test result who 
were prescribed or received an antimalarial drug was 
signiﬁ cantly reduced in the enhanced-training group 
and non-signiﬁ cantly reduced in the basic-training 
group (table 3). The proportion of patients with a 
positive test result who were prescribed or received 
Control (n=9) Basic training (n=18) Enhanced training 
(n=19)
Stratum
Bamenda 5 (56%) 8 (44%) 9 (47%)
Yaoundé 4 (44%) 10 (56%) 10 (53%)
Type of facility
Public district hospital 1 (11%) 6 (33%) 4 (21%)
Public health centre 7 (78%) 5 (28%) 6 (32%)
Mission hospital 0 (0%) 0 (0%) 1 (5%)
Mission health centre 1 (11%) 7 (39%) 8 (42%)
Time established*
≤5 years (at time of facility audit) 1 (11%) 2 (11%) 2 (11%)
>5 years (at time of facility audit) 8 (89%) 15 (83%) 15 (79%)
Unknown 0 1 (6%) 2 (11%)
Median number of patients per day (IQR) 8 (5–10) 20 (15–30) 30 (10–75)
Median number of clinicians (range)
Who regularly work at the facility 17 (4–32) 16 (4–35) 11 (4–61)
Who are involved in the treatment of patients with malaria† 8 (2–14) 8 (4–18) 9 (4–20)
Types of clinician†
Doctor 4 (44%) 9 (50%) 9 (47%)
Nurse or midwife 8 (89%) 16 (89%) 14 (74%)
Nurse assistant or midwife assistant 5 (56%) 11 (61%) 12 (63%)
Laboratory technician or assistant 8 (89%) 16 (89%) 19 (100%)
Pharmacist 2 (22%) 1 (6%) 3 (16%)
Pharmacy technician or assistant 7 (78%) 15 (83%) 14 (74%)
Services available
Weighing scale 8 (89%) 18 (100%) 18 (95%)
Functioning thermometer 8 (89%) 17 (94%) 15 (79%)
Functioning microscope‡ 9 (100%) 18 (100%) 18 (95%)
Malaria microscopy testing‡ 9 (100%) 18 (100%) 19 (100%)
RDT, ACT, and antibiotic availability
ACTs currently in stock 8 (89%) 18 (100%) 19 (100%)
Stock-outs of ACTs in past 4 weeks 1 (11%) 2 (11%) 1 (5%)
ACT supply problems in past year 2 (22%) 3 (17%) 3 (17%)
RDTs currently in stock§ 1 (11%)¶ 8 (47%)|| 13 (72%)||
Stock-outs of RDTs in past 4 weeks§ 1 (11%)¶ 10 (59%)|| 10 (56%)||
Antibiotics currently in stock 8 (89%) 16 (89%) 18 (95%)
Data are number of facilities (%), unless otherwise indicated. RDT=rapid diagnostic test. ACT=artemisinin-based combination therapy. *All facilities had been established for a 
minimum of 3 years. †Clinicians who diagnose, prescribe, or dispense malaria treatment at the facility. ‡One facility in the enhanced-training group noted that it provided 
microscopy testing, but it did not have a functioning microscope ; all facilities that oﬀ ered malaria microscopy testing had at least one laboratory technician or assistant who 
regularly worked at the facility, apart from four facilities in the enhanced-training group for which this information is unavailable. §The facility audit was done after the exit 
survey was complete. ¶One facility in the control group received RDTs as a donation and not as part of the intervention; they did not receive any training associated with the 
use of RDTs. ||Information was unavailable for one facility in the basic-training group and one facility in the e nhanced-training group (these facilities were excluded from the 
percentage calculations).
Table 1: Characteristics of facilities (clusters), by study group
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artemisinin-based combination therapy was similar 
across the study groups at 72–75% (table 3); most of the 
remaining patients with a positive test result received 
either another antimalarial treatment or an antibiotic 
(ﬁ gure 3). The proportion of febrile patients who were 
prescribed or received an antimalarial receiving 
artemisinin-based combination therapy was similar 
across the study groups: 508 (85%) of 598 in the control 
group, 790 (79%) of 997 in the basic-training group, and 
694 (79%) of 873 in the enhanced-training group; the 
unadjusted RR was 0·91 (95% CI 0·74–1·13; p=0.38) for 
basic training compared with control and 0·81 
(0·51–1·28; p=0.35) for enhanced training compared 
with control.
The study was powered to assess non-inferiority 
between the two intervention groups, and the crude risk 
diﬀ erence between the two groups was 0·15 
(90% CI –0·29 to 0·60); since the diﬀ erence and the 
upper bound of the CI is more than 10%, non-inferiority 
is not shown in the analysis.
Control (n=681) Basic training (n=1632) Enhanced training 
(n=1669)
Median number of patients per facility (range) 80 (28–101) 100 (49–102) 98 (17–114)
Sex
Male 312 (46%) 735 (45%) 733 (44%)
Female 369 (54%) 897 (55%) 934 (56%)
Missing data 0 0 2 (<1%)
Age 
<5 years 236 (35%) 600 (37%) 610 (37%)
5–19 years 194 (28%) 370 (23%) 368 (22%)
20–40 years 131 (19%) 431 (26%) 438 (26%)
≥40 years 120 (18%) 231 (14%) 253 (15%)
Main activity of patient
Paid work or self-employed 141 (21%) 294 (18%) 352 (21%)
Domestic work 55 (8%) 159 (10%) 146 (9%)
Looking for work 7 (1%) 27 (2%) 37 (2%)
At school, college, or university 293 (43%) 687 (42%) 606 (36%)
At leisure 22 (3%) 35 (2%) 51 (3%)
Child and does not go to school 158 (%) 401 (25%) 438 (26%)
Other or missing data 5 (1%) 29 (2%) 39 (2%)
Education of respondent
None 49 (7%) 140 (9%) 141 (8%)
Primary 206 (30%) 426 (26%) 409 (25%)
Secondary 314 (46%) 705 (43%) 731 (44%)
Tertiary 104 (15%) 338 (21%) 371 (22%)
Missing data 8 (1%) 23 (1%) 17 (1%)
Wealth index*
Poorest 160 (23%) 553 (34%) 548 (33%)
Less poor 232 (34%) 537 (33%) 492 (29%)
Least poor 263 (39%) 460 (28%) 537 (32%)
Missing data 26 (4%) 82 (5%) 92 (6%)
(Continued from previous page)
Median days of illness (range) 3 (0–14) 3 (0–30) 3 (0–60)
Seeking treatment for ﬁ rst time
No† 181 (27%) 656 (40%) 582 (35%)
Yes 492 (72%) 962 (59%) 1071 (64%)
Missing data 8 (1%) 14 (1%) 16 (1%)
Previous treatment seeking‡
Public facility 81 (45%) 133 (20%) 122 (21%)
Mission facility 16 (9%) 82 (13%) 39 (7%)
Private facility 55 (30%) 263 (40%) 244 (42%)
Other§ 24 (13%) 164 (25%) 156 (27%)
Missing data 5 (3%) 14 (2%) 21 (4%)
(Table 2 continues on next page)
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A higher proportion of patients tested by microscopy 
had positive test results than those tested by RDT. For 
microscopy, 53% of cases in the control group, 40% in 
the basic-training group, and 45% in the enhanced-
training group had positive test results. For RDT, 53% of 
cases in the control group, 23% in the basic-training 
group, and 31% in the enhanced-training group had 
positive test results.
With the possible exception of how to use an RDT, 
there were no signiﬁ cant diﬀ erences between study 
groups in clinicians’ responses to knowledge questions 
and treatment preferences (table 4). This ﬁ nding was 
consistent with the treatment of such patients during the 
study. With respect to patient satisfaction, 616 (90%) of 
681 febrile patients in the control group, 1393 (85%) of 
1632 in the basic-training group, and 1478 (89%) of 1669 
in the enhanced-training group were satisﬁ ed with the 
care received. Thus, no signiﬁ cant diﬀ erences from 
control were seen in either the basic-training group 
(unadjusted RR 1·01, 95% CI 0·95–1·07; p=0·70) or the 
enhanced-training group (0·99, 0·93–1·04; p=0·59).
Discussion
Although the two training interventions did not lead to a 
signiﬁ cant increase in the proportion of patients treated 
in accordance with malaria treatment guidelines (the 
primary outcome), we did note a substantial and 
signiﬁ cant reduction in the unnecessary use of 
antimalarial drugs in patients with a negative test result 
in the enhanced-training group compared with control. 
Use of this intervention could potentially halve 
overtreatment in public and mission health facilities in 
Cameroon. However, further studies are necessary to 
substantiate this ﬁ nding.
We also noted improvements in two other key 
indicators compared with our ﬁ ndings from the 
formative research in 2009.18 First, nearly 80% of febrile 
patients were tested for malaria across all study groups, 
representing a substantial improvement from 
the 35–44% noted in 2009. Second, about 75% of 
patients who tested positive for malaria across all study 
groups were prescribed or received artemisinin-based 
combination therapy, compared with 59% during the 
formative research period. Both of these practices had 
been targeted by an extensive malaria communication 
campaign.
Changing established clinical behaviours can be 
diﬃ  cult.24,25 We undertook this study in response to calls 
for more evidence and for theory-driven approaches to 
intervention design.26,27 We compared a conventional, 
knowledge-based and skills-oriented, didactic training 
approach (the basic-training intervention) with a 
mindset-oriented, interactive training approach (the 
enhanced-training intervention). The interventions 
were designed in conjunction with the National Malaria 
Control Programme and the enhanced-training 
intervention was carefully designed and piloted to tackle 
issues raised by clinicians in their communities of 
Control (n=681) Basic training (n=1632) Enhanced training
(n=1669)
(Continued from previous page)
Previous treatment received¶
Had RDT or microscopy‡
Yes 67 (37%) 92 (14%) 127 (22%)
No 99 (55%) 536 (82%) 431 (74%)
Missing data 15 (89%) 28 (4%) 24 (4%)
Received ACT‡
Yes 46 (25%) 152 (23%) 148 (25%)
No 116 (64%) 474 (72%) 387 (66%)
Missing data 19 (10%) 30 (5%) 47 (8%)
Received appropriate treatment||
Yes 23 (34%) 47 (51%) 75 (59%)
No 18 (27%) 29 (32%) 19 b(15%)
Missing data 26 (39%) 16 (17%) 33 (26%)
Data are n (%), unless otherwise indicated. RDT=rapid diagnostic test. ACT=artemisinin-based combination therapy. *Generated through principal component analysis and 
based on ownership of household possessions (eg, electricity, radio, mobile telephone, generator, bicycle, and car), access to utilities (toilet type and source of drinking 
water), and housing characteristics (ﬂ oor type, fuel, people per sleeping room), in line with the Demographic and Health Survey wealth index22 and the technique described by 
Vyas and colleagues;23 tertiles were used for tabular analysis of the wealth index. †For patients who had previously sought treatment for this illness episode across all groups, 
562 (40%) of 1419 had sought treatment once before, 503 (35%) twice before, and 211 (15%) three or more times before (data were missing for 143 [10%])). ‡Patients not 
seeking treatment for the ﬁ rst time used as totals for percentage calculations. §Other places patients sought treatment include non-specified hospitals, at home, from 
friends, and from traditional healers. ¶Treatment received at the last place the patient previously sought treatment for this illness, as reported by the patient. ||Appropriate 
treatment is deﬁ ned as receiving an ACT if RDT or microscopy was positive for malaria, and not receiving an antimalarial drug if RDT or microscopy was negative for malaria; 
patients who had RDT or microscopy used as totals for percentage calculations.
Table 2: Characteristics of patients who participated in the exit survey, by study group
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practice and to use best-practice methods for adult 
learning.
In making choices about our interventions and 
methods for assessment, we sought to investigate the 
eﬀ ectiveness of the interventions in a real-world setting, 
rather than their eﬃ  cacy in a highly controlled 
environment. For example, RDTs were supplied on a 
monthly basis and the quantity set in consultation with 
the National Malaria Control Programme to represent a 
realistic disbursement schedule. Despite this forward 
planning, stock-outs of RDTs in the past 4 weeks were 
still reported across all study groups during the 
Number of 
clusters
Number of patients 
(n/N [%]) 
Stratum-speciﬁ c RR 
(95% CI)
Unadjusted RR
(95% CI)*
Adjusted RR 
(95% CI)†
p value k
Treatment in accordance with malaria treatment guidelines (composite outcome)
Control 9 246/659 (37%) ·· 1·00 ·· ·· ··
Bamenda 5 86/388 (22%) 1·00 ·· ·· ·· ··
Yaoundé 4 160/271 (59%) 1·00 ·· ·· ·· ··
Basic training 18 670/1576 (42%) ·· 1·18 (0·56–2·49) 1·04 (0·53–2·07) 0·90 0·15
Bamenda 8 265/678 (39%) 2·01 (1·27–3·16) ·· ·· ·· ··
Yaoundé 10 405/898 (45%) 0·66 (0·41–1·06) ·· ·· ·· ··
Enhanced training 19 890/1613 (55%) ·· 1·76 (0·83–3·70) 1·17 (0·61–2·25) 0·62 0·16
Bamenda 9 427/754 (57%) 3·61 (2·33–5·59) ·· ·· ·· ··
Yaoundé 10 463/859 (54%) 0·78 (0·49–1·24) ·· ·· ·· ··
Febrile patients tested for malaria
Control 9 539/681 (79%) ·· 1·00 ·· ·· ··
Bamenda 5 313/400 (78%) 1·00 ·· ·· ·· ··
Yaoundé 4 226/281 (80%) 1·00 ·· ·· ·· ··
Basic training 18 1250/1632 (77%) ·· 0·97 (0·76–1·23) 0·95 (0·76–1·18) 0·62 0·05
Bamenda 8 494/699 (71%) 0·92 (0·79–1·07)  ··  ·· ·· ··
Yaoundé 10 756/933 (81%) 1·02 (0·88–1·19) ·· ·· ·· ··
Enhanced training 19 1309/1665 (79%) ·· 1·01 (0·74–1·37) 0·96 (0·72–1·28) 0·78 0·06
Bamenda 9 617/776 (80%) 1·08 (0·90–1·30)  ··  ·· ·· ··
Yaoundé 10 692/889 (78%) 0·94 (0·77–1·13) ·· ·· ·· ··
Patients with positive test results received ACT
Control 8 208/278 (75%) ·· 1·00 ·· ·· ··
Bamenda 4 56/75 (75%) 1·00 ·· ·· ·· ··
Yaoundé 4 152/203 (75%) 1·00 ·· ·· ·· ··
Basic training 17 287/398 (72%) ·· 1·01 (0·67–1·52) 1·09 (0·76–1·56) 0·61 0·06
Bamenda 7 33/47 (70%) 1·14 (0·86–1·51)  ··  ·· ·· ··
Yaoundé 10 254/351 (72%) 0·91 (0·70–1·17) ·· ·· ·· ··
Enhanced training 19 363/498 (73%) ·· 0·87 (0·52–1·44) 0·89 (0·55–1·44) 0·62 0·11
Bamenda 9 117/147 (80%) 0·85 (0·71–1·01)  ··  ·· ·· ··
Yaoundé 10 246/351 (70%) 0·88 (0·74–1·05) ·· ·· ·· ··
Patients with negative test results received an antimalarial drug‡
Control 8 201/239 (84%) ·· 1·00 ·· ·· ··
Bamenda 5 196/226 (87%) 1·00 ·· ·· ·· ··
Yaoundé 3 5/13 (38%) 1·00 ·· ·· ·· ··
Basic training 18 413/796 (52%) ·· 0·63 (0·28–1·43) ·· 0·25 0·15
Bamenda 8 194/426 (46%) 0·43 (0·26–0·70) ·· ·· ··
Yaoundé 10 219/370 (59%) 1·04 (0·59–1·86) ·· ·· ·· ··
Enhanced training 19 232/759 (31%) ·· 0·29 (0·11–0·77) ·· 0·02 0·20
Bamenda 9 138/448 (31%) 0·14 (0·08–0·26) ·· ·· ··
Yaoundé 10 94/311 (30%) 0·74 (0·37–1·48) ·· ·· ·· ··
RR=risk ratio. ACT=artemisinin-based combination therapy. *Crude analysis adjusted for stratum only, based on geometric means of cluster summaries; overall F-test of the 
null hypothesis that there are no diﬀ erences between any of the treatment arms provides p value of 0·08. †Adjusted for the following facility and patient characteristics: 
stratum; facility type; stock-outs of ACTs in past 4 weeks; average number of patients per day; patients’ sex, age, job or main activity, and socioeconomic status; whether 
patient had previously sought treatment for this illness; and whether they asked for a blood test at the facility. ‡The sample size in some clusters within the strata was too 
small to do an adjusted analysis for this outcome.
Table 3: Unadjusted and adjusted eﬀ ects of the training interventions on treatment in accordance with malaria guidelines, compared with control
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assessment. Moreover, cascade training was used to limit 
the direct costs of the interventions, making them more 
aﬀ ordable for large-scale implementation.
The independent veriﬁ cation of malaria test results 
lends support to the internal validity of outcomes that 
relied on patients’ recall and clinicians’ ability to do the 
diagnostic tests and accurately interpret their results. 
However, two methodological constraints limit the 
external application of the ﬁ ndings from this study. First, 
many of the clinicians surveyed did not attend the 
training workshops and therefore the knowledge and 
practice of those treating patients in whom the outcomes 
were measured was most likely informed by in-facility 
training, or no training. This issue limits our ability to 
estimate the eﬀ ect of attending workshops compared 
with participating in in-facility training. Second, the 
assessment was done 3 months after the workshops took 
place, and we do not know the long-term eﬀ ects of 
intervention on clinicians’ practice.
The Government of Cameroon, along with those of other 
malaria-endemic countries, is preparing for the national 
scale-up of RDTs. Our results suggest that supporting 
interventions should be employed alongside RDT rollout if 
presumptive practices are to be changed (panel). This 
study, the ﬁ rst of its kind in Cameroon, provides timely 
evidence about the eﬀ ects of diﬀ erent types of intervention, 
Treatment in accordance 
with guidelines 
Treatment in accordance 
with guidelines 
Treatment not in 
accordance with guidelines
Treatment not in 
accordance with guidelines
Treatment not in 
accordance with guidelines
Any antimalarial drug¶ 
not prescribed or 
received||
38 (16%) in the control 
group
383 (48%) in the basic-
training group
527 (69%) in the enhanced-
training group
ACT not prescribed or 
received‡§
70 (25%) in the control 
group
111 (28%) in the basic-
training group
135 (27%) in the enhanced-
training group
ACT prescribed
or received‡
208 (75%) in the control 
group
287 (72%) in the basic-
training group
363 (73%) in the enhanced-
training group
Any antimalarial drug¶  
prescribed or received||
201 (84%) in the control 
group
413 (52%) in the basic-
training group
232 (31%) in the enhanced-
training group
Negative test result†
245 (46%) in the control group
815 (66%) in the basic-training group
778 (61%) in the enhanced-training group
Positive test result†
280 (53%) in the control group
415 (34%) in the basic-training group
502 (39%) in the enhanced-training group
Facility oﬀers malaria testing
681 patients in the control group 
(n=9 facilities)
1632 patients in the basic-training group 
(n=18 facilities)
1669 patients in the enhanced-training 
group (n=19 facilities)
Patient is tested*
539 (79%) in the control group
1250 (77%) in the basic-training group
1309 (79%) in the enhanced-training group
Patient is not tested*
142 (21%) in the control group
382 (23%) in the basic-training group
356 (21%) in the enhanced-training group
Figure 3: Flow chart for the deﬁ nition of the primary outcome
Missing data were excluded from percentage calculations. ACT=artemisinin-based combination therapy. *Testing could not be established from malaria registers for 
eight (1%) patients in the control group, 69 (4%) in the basic-training group, and 83 (5%) in the enhanced-training group (in these cases testing was established as 
reported by the patient); whether or not a patient was tested was not known for four of 1669 (<1%) patients in the enhanced-training group (treated as missing 
data). †Among patients who were tested, test result could not be established from malaria registers for 18 (3%) in the control group, 89 (7%) in the basic-training 
group, and 79 (6%) in the enhanced-training group; of these, 14 (3%) in the control group, 20 (2%) in the basic-training group, and 29 (2%) in the enhanced-training 
group did not have a test result reported by the patient or had an invalid result (treated as missing data). ‡Among patients with a positive test result, whether a 
treatment was prescribed or received was not known for two (1%) in the control group, 17 (4%) in the basic-training group, and four (1%) in the enhanced-training 
group (treated as missing data). §Among patients with a positive test result who were not prescribed or receiving ACT, 58 (83%) in the control group, 69 (62%) in the 
basic-training group, and 89 (66%) in the enhanced-training group were prescribed or received an antimalarial drug; of those not prescribed or receiving any 
antimalarial drug (including ACT), six (50%) in the control group, 19 (45%) in the basic-training group, and 17 (37%) in the enhanced-training group were prescribed 
or received either paracetamol or an antibiotic, with the remainder being prescribed or receiving either vitamins, iron, or nothing. ¶Any antimalarial drug includes 
ACT. ||Among patients with a negative test result, whether a treatment was prescribed or received was not known for six (2%) in the control group, 19 (2%) in the 
basic-training group, and 19 (2%) in the enhanced-training group (treated as missing data).
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Control 
(n=39)
Basic training
(n=95)
Enhanced 
training
(n=103)
Crude RR*
(95% CI)
Adjusted RR† 
(95% CI)
p value
Clinician knowledge
Fever is a symptom of uncomplicated malaria 38/39 (97%) 89/95 (94%) 99/103 (96%) ·· ·· ··
Basic training vs control ·· ·· ·· 0·93 (0·81–1·08) 0·97 (0·83–1·12) 0·63
Enhanced training vs control ·· ·· ·· 0·95 (0·86–1·05) 0·97 (0·87–1·07) 0·53
Febrile patients should be tested for malaria 37/38 (97%) 90/91 (99%) 100/101 (99%) ·· ·· ··
Basic training vs control ·· ·· ·· 1·01 (0·97–1·06) 1·00 (0·95–1·05) 0·91
Enhanced training vs control ·· ·· ·· 1·01 (0·97–1·06) 1·00 (0·96–1·04) 0·97
How to use an RDT‡§ 4·3 (4·1) 6·2 (3·7) 6·7 (3·5) ·· ·· ··
Basic training vs control ·· ·· ·· 1·95 (0·42–4·32) ·· 0·10
Enhanced training vs control ·· ·· ·· 2·55 (0·23–4·86) ·· 0·03
How to interpret an RDT result‡ 11/13 (85%) 56/73 (77%) 53/77 (69%) ·· ·· ··
Basic training vs control ·· ·· ·· 0·86 (0·59–1·26) ·· 0·84
Enhanced training vs control ·· ·· ·· 0·76 (0·46–1·24) ·· 0·83
Patients with a positive test results should receive an ACT 35/38 (92%) 79/87 (91%) 76/91 (83%) ·· ·· ··
Basic training vs control ·· ·· ·· 0·96 (0·85–1·08) 1·01 (0·87–1·17) 0·91
Enhanced training vs control ·· ·· ·· 0·89 (0·74–1·07) 1·08 (0·93–1·25) 0·31
Patients with a negative test results should not receive an antimalarial drug 19/35 (54%) 57/83 (69%) 66/95 (69%) ·· ·· ··
Basic training vs control ·· ·· ·· 1·15 (0·86–1·54) 1·06 (0·73–1·54) 0·73
Enhanced training vs control ·· ·· ·· 1·26 (0·88–1·79) 1·28 (0·80–2·06) 0·29
First-line treatment as recommended by the Government 21/35 (60%) 60/77 (78%) 67/90 (74%) ·· ·· ··
Basic training vs control ·· ·· ·· 1·25 (0·75–2·11) 0·97 (0·59–1·60) 0·91
Enhanced training vs control ·· ·· ·· 1·12 (0·74–1·69) 1·11 (0·73–1·67) 0·61
Clinician treatment preferences
Believes that using a patient’s symptoms to diagnose malaria is reliable 25/39 (64%) 29/94 (31%) 21/102 (21%) ·· ·· ··
Basic training vs control ·· ·· ·· 0·50 (0·30–0·83) 0·72 (0·39–1·33) 0·28
Enhanced training vs control ·· ·· ·· 0·33 (0·21–0·53) 0·94 (0·49–2·50) 0·10
Takes history,  signs and symptoms,  examination, or temperature 33/39 (85%) 70/95 (74%) 71/103 (69%) ·· ·· ··
Basic training vs control ·· ·· ·· 0·83 (0·58–1·19) 0·97 (0·68–1·38) 0·85
Enhanced training vs control ·· ·· ·· 0·78 (0·59–1·02) 0·96 (0·74–1·25) 0·76
Uses RDT or microscopy to diagnose malaria 34/39 (87%) 88/95 (93%) 90/102 (88%) ·· ·· ··
Basic training vs control ·· ·· ·· 1·04 (0·91–1·18) 0·99 (0·86–1·13) 0·83
Enhanced training vs control ·· ·· ·· 0·95 (0·76–1·19) 0·95 (0·77–1·18) 0·63
Believes that test results are reliable 16/37 (43%) 49/89 (55%) 69/100 (69%) ·· ·· ··
Basic training vs control ·· ·· ·· 1·39 (0·73–2·68) 1·06 (0·57–1·95) 0·85
Enhanced training vs control ·· ·· ·· 1·93 (1·22–3·03) 1·22 (0·76–1·95) 0·39
Believes that ACT is the best treatment for malaria in adults 34/37 (92%) 69/88 (78%) 72/95 (76%) ·· ·· ··
Basic training vs control ·· ·· ·· 0·88 (0·71–1·09) 1·01 (0·80–1·28) 0·92
Enhanced training vs control ·· ·· ·· 0·73 (0·44–1·21) 0·94 (0·58–1·54) 0·81
Believes that ACT is the best treatment for malaria in children 37/38 (97%) 73/88 (83%) 80/96 (83%) ·· ·· ··
Basic training vs control ·· ·· ·· 0·87 (0·74–1·02) 1·00 (0·87–1·15) 0·98
Enhanced training vs control ·· ·· ·· 0·79 (0·58–1·09) 0·96 (0·71–1·30) 0·77
Thinks that it is good to give antimalarial drugs to patients with negative test 
results
34/39 (87%) 50/91 (55%) 39/101 (39%) ·· ·· ··
Basic training vs control ·· ·· ·· 0·52 (0·34–0·81) 0·89 (0·58–1·37) 0·60
Enhanced training vs control ·· ·· ·· 0·33 (0·19–0·56) 0·91 (0·55–1·52) 0·71
Data are n/N (%), unless otherwise indicated. Missing data were excluded from percentage calculations. Clinician knowledge was measured through speciﬁ c knowledge-based questions in the clinician survey; 
clinician treatment preferences were based on questions in the clinician survey about what the clinician thinks and would do in speciﬁ c circumstance. RDT=rapid diagnostic test. ACT=artemisinin-based 
combination therapy. *Crude analysis adjusted for stratum only; data are risk diﬀ erence for continuous outcomes. †Adjusted for the following facility and clinician characteristics: stratum, facility type, and 
clinician sex, education, and type (for some outcomes only stratum and facility type were included because of multicollinearity and perfect prediction of the clinician characteristics). ‡Adjusted analysis could not 
be done for these outcomes because the the sample sizes were too small to provide robust estimates. §Data are mean (SD); based on a score (out of 11) derived from correct identiﬁ cation of several steps taken in 
the use of an RDT; only measured in 23 clinicians in the control group, 85 in the basic-training group, and 93 in the enhanced-training group.
Table 4: Eﬀ ect of the intervention on clinician knowledge and treatment preferences
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with potentially substantial eﬀ ects on the overuse of 
antimalarial drugs. Speciﬁ cally, we have shown that an 
enhanced training programme, designed to translate 
knowledge into prescribing practice and improve quality 
of care, has the potential to signiﬁ cantly reduce the 
unnecessary use of antimalarial drugs in patients who 
have tested negative for malaria. Basic training that focuses 
only on how to use RDTs and the content of malaria 
treatment guidelines is unlikely to bring about the 
behaviour change needed to support the national rollout of 
RDTs.
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Panel: Research in context 
Systematic review 
We sought to identify studies that have assessed interventions intended to improve the 
ability of health workers to diagnose and treat patients with uncomplicated malaria. We 
systematically searched Medline, Embase, the CABI Global Health database, the 
International Bibliography of Social Sciences, CAB Abstracts, and the International 
Network for the Rational Use of Drugs for reports published in English between Jan 1, 
1990, and Nov 26, 2009, using a list of truncated synonyms for the search terms 
“malaria” AND “treatment” AND “intervention” AND “provider”. Studies were regarded as 
eligible irrespective of the type of health provider so long as the eﬀ ect of the intervention 
included a malaria-related outcome. Eligibility was restricted to studies that took a 
comparative approach, using either a before-and-after study design or comparing an 
intervention with a comparison group. 28 studies (assessing 33 diﬀ erent interventions) 
met the eligibility criteria. 20 of the interventions focused on provider training and used 
learning techniques to improve diagnosis and treatment of malaria. Only six provider-
training interventions included malaria diagnostic tests. Although the results showed 
that these interventions led to improvements in the appropriate treatment of malaria, 
the proportion of patients receiving an antimalarial drug after a negative test result 
remained fairly high. Recent reviews of interventions designed to improve clinician 
management of malaria have had similar ﬁ ndings,16,28 showing that the links between 
staﬀ  training and clinical performance remain mixed and in short supply. A recent 
systematic review16 that assessed the introduction of rapid diagnostic tests (RDTs) into 
diagnostic algorithms for patients with fever showed that health-worker adherence to 
test results was highly variable—between 0% and 80% of patients with a negative test 
result received an antimalarial drug. Notably, all the reports included in these reviews16,28 
included little detail of the interventions used, limiting the extent to which these studies 
can usefully guide policy makers and programme managers in the selection of methods to 
support a shift in practice towards appropriate use of antimalarial drugs alongside RDTs. 
Interpretation 
Governments of many malaria-endemic countries are preparing to scale up the use of 
RDTs nationally. WHO malaria treatment guidelines2 acknowledge the need for provider 
training alongside the deployment of RDTs and artemisinin-based combination therapy 
to address key problems such as the habitual presumptive treatment of malaria. Our 
study provides timely evidence about the eﬀ ects of diﬀ erent types of supporting 
interventions. Our results show that enhanced training, designed to translate knowledge 
into prescribing practice and improve quality of care, has the potential to substantially 
improve adherence to negative RDT results, which in Cameroon could halve 
overtreatment in public and mission health facilities. Basic training is unlikely to be 
suﬃ  cient to support the behaviour change required for the introduction of RDTs.
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Appendix D 
Intra-class correlation coefficients and variance partition coefficients 
from Research Papers I-V 
All of the data analysed in this thesis had a hierarchical data structure. Thus, it could not 
be assumed that the observations in a sample were independent from each other. The 
statistical methods used acknowledge that observations within a cluster tend to be more 
similar to each other, than to individuals in the rest of the sample. In Research Papers I-IV 
this clustering arose because the survey design used multi-stage cluster sampling 
(communities were selected, then facilities were selected, and then patients and providers 
were surveyed at the selected facility). In Research Paper V the clustering arose because 
the evaluation used a cluster-randomized design, in which facilities were allocated to one 
of three arms and the primary outcome was measured using data from patients seeking 
treatment at the facilities participating in the trial. 
The amount of clustering can be measured using the intra-class correlation coefficient 
(ICC), and this determines the proportion of the total variance that was attributable to the 
each level of the data hierarchy. Thus, the ICC can be calculated as:  
ICC at level 2 = (variance at level 2 / total variance) 
ICC at level 3 = (variance at level 3 / total variance) 
The variance partition coefficient (VPC) is similar to the ICC, though it is used when the 
dependent variable is discrete. The key distinction is that when the analysis uses logistic 
regression, the variance at level 1 is the variance of the standard logistic regression (π2/3 
= 3.29). 
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The following tables summarize the data used in Research Papers I-V and lists the ICC or 
VPC for each level of the hierarchy included in the analysis (before the inclusion of any 
covariates). For example, in Research Paper I the VPC shows that 27.9% of the total 
variance was attributable to variation at the facility level. 
Research Paper I 
Country Nigeria 
Data source Formative phase: Patient exit data  
Study population Patients were eligible if they:  
 Reported having a fever in the past 24 hours AND were not 
pregnant AND not less than 6 months AND had no signs of 
severe malaria 
OR 
 had received an ACT 
Data structure Level 1: 1642 eligible patients 
Level 2: 100 facilities (public facilities, medicine retailers) 
Level 3: 16 communities 
Primary outcome  % of patients who received an ACT 
ICC / VPC at level 2 0.279 
ICC / VPC at level 3 0.095 
 
Research Paper II 
Country Cameroon 
Data source Formative phase: Patient exit data  
Study population Patients were eligible if they:  
 reported having a fever in the past 24 hours AND were not 
pregnant AND not less than 6 months AND had no signs of 
severe malaria 
OR 
 had been prescribed or received an ACT 
Data structure Level 1: 938 eligible patients 
Level 2: 174 facilities (public facilities, mission/private clinics, 
medicine retailers) 
Level 3: 20 communities 
Primary outcome  % of patients who were prescribed or received an ACT 
ICC / VPC at level 2 0.367 
ICC / VPC at level 3 <0.001 
  
APPENDIX D 
359 
 
Research Paper III 
Country Pooled analysis for Cameroon and Nigeria 
Data source Formative phase: Provider data  
Study population Providers were eligible if:  
 their responsibilities included prescribed or dispensing of 
medicines  
 they worked at a facility where the patient exit survey had 
been conducted  
 they were available on the day of the survey  
Data structure Pooled data for Cameroon and Nigeria 
Level 1: 518 providers 
Level 2: 245 facilities (public, mission, pharmacies and drug stores) 
Level 3: 36 geographic areas 
Primary outcome  % of providers who stated a preference for ACT when asked which 
antimalarial do you think is the best drug for treating patients with 
uncomplicated malaria 
ICC / VPC at level 2 0.377 
ICC / VPC at level 3 0.209 
 
Research Paper IV 
Country Separate analyses for Cameroon and Nigeria 
Data source Formative phase: Patient exit data  
Study population Patients were eligible if they:  
 reported having a fever in the past 24 hours  
 were not pregnant 
 not less than 6 months 
 had no signs of severe malaria 
 had been prescribed or received an antimalarial 
Data structure Cameroon: 
Level 1: 304 eligible patients 
Level 2: 91 facilities (public facilities, mission facilities, pharmacies 
& drug stores) 
Nigeria: 
Level 1: 473 eligible patients  
Level 2: 73 facilities (public facilities, pharmacies & drug stores) 
Primary outcome  % of patients who received an ACT (of those who were prescribed 
or received an antimalarial) 
ICC / VPC at level 2 For Cameroon (complete cases): 0.380 
For Nigeria (complete cases): 0.476 
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Research Paper V 
Country Cameroon 
Data source Evaluation: Patient exit data 
Data structure Level 1: 3982 eligible patients 
Level 2: 46 public and mission facilities 
Study population Patients were eligible if they:  
 reported having a fever in the past 24 hours  
 were not pregnant 
 not less than 6 months 
 had no signs of severe malaria 
 were present at the facility 
Primary outcome  % of patients who were correctly treated according to the malaria 
treatment guidelines* 
* which is a composite measure that requires:  
i) the patient to be tested for malaria,  
ii) to be prescribed or receive an ACT if the malaria test was 
positive, and  
iii) not to be prescribed or receive an antimalarial if the malaria 
test was negative 
ICC / VPC at level 2 For effects: 0.302 
For societal costs in base case: 0.293 
For provider costs in base case: 0.545 
 
